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Zusammenfassung 
Einleitung 
Beschreibung der Technologie und der Komparatoren 
Infektionsmarker können ergänzend zur klinischen Diagnose einer Infekti-
onskrankheit eingesetzt werden. Das C-reaktive Protein (CRP) ist ein „Aku-
te-Phase-Protein“, das von der Leber als Reaktion auf eine Infektion oder 
Gewebsentzündung gebildet wird. Der normale Serum- oder Plasma-CRP-
Spiegel liegt bei maximal 5 mg/L, steigt nach einer akuten Entzündungsreak-
tion rasch an und erreicht nach 48 Stunden einen Höchststand von 20 bis 
500 mg/L. Die Serum-CRP-Werte sind bei bakteriellen Infektionen (insbe-
sondere bei schweren Infektionen) häufig erhöht, bei Virusinfektionen hin-
gegen wird üblicherweise nur ein geringer Anstieg beobachtet. Bisher wur-
den CRP-Tests im Labor durchgeführt; CRP „point-of-care-testing“ (patien-
tennahe Diagnostik; POCT) bezieht sich auf patientennahe Messungen in der 
Primärversorgung. Das Ergebnis steht innerhalb von Minuten zur Verfügung. 
Bei PatientInnen in der Primärversorgung, die mit akuten Atemwegsinfekti-
onen (RTIs) vorstellig werden, besteht das Ziel von CRP POCT darin, zuver-
lässige Testergebnisse zu liefern, welche 
b den/die Arzt/Ärztin unterstützen, eine schwere bakterielle Infektion 
auszuschließen und  
b eine Entscheidung unterstützen, jenen PatientInnen, die wahrschein-
lich nicht von der Behandlung profitieren würden, kein Antibiotikum 
zu verschreiben.  
Der Test ist nach der klinischen Beurteilung der PatintInnen indiziert, falls 
Unsicherheiten bezüglich einer Antibiotikaverschreibung bestehen. 
Es wurden 15 CRP POCT-Systeme mit CE-Kennzeichnung identifiziert. Diese 
lassen sich grob in quantitative (mit einem Analysator zur quantitativen 
CRP-Messung) und semi-quantitative Geräte (mit Streifen, Messstäbchen 
oder Einweg-Tests) unterteilen und sind für die Messung von CRP im 
menschlichen (Voll-)Blut sowie im Serum und Plasma indiziert.  
 
Quantitative CRP POCT-Systeme: 
b QuikRead go® CRP assay and QuikRead go® instrument  
(Orion Diagnostica Oy) 
b QuikRead go® CRP+Hb assay and QuikRead go® instrument  
(Orion Diagnostica Oy) 
b QuikRead go® CRP assay and QuikRead® 101 instrument  
(Orion Diagnostica Oy) 
b Alere Afinion™ CRP assay and Alere Afinion™ AS100* or Alere Af-
inion™ 2** (Abbott Diagnostic Technologies AS) 
b NycoCard™ CRP assay and NycoCard™ Reader II  
(Abbott Diagnostic Technologies AS) 
b Eurolyser CRP assay and Cube S Analyser (Eurolyser Diagnostica) 
b iChroma™ CRP test cartridge and iChroma™ Reader (Boditech Med) 
b AFIAS™ CRP test cartridge and AFIAS 1™ (Boditech Med) 
b AQT90 Flex CRP assay and AQT90 Flex analyser  
(Radiometer Medical ApS) 
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b Microsemi CRP reagent unit and Microsemi (Horiba Ltd) 
b spinit® CRP disposable disc and spinit® instrument (Biosurfit ) 
b CRP IS™ test kits and Innovastar™analyser (DiaSys Diagnostic) 
 
Semi-quantitative CRP POCT-Systeme: 
b Actim® CRP dip sticks (Medix Biochemica) 
b Cleartest® CRP strips (Servoprax) 
b FebriDx® (RPS Diagnostics) 
 
CRP POCT kann von medizinischem Fachpersonal (ohne Laborschulung) in 
der Primärversorgung verwendet werden. Eine Grundschulung des medizi-
nischen Fachpersonals in der Anwendung von CRP POCT ist aber erforder-
lich. Unterschiede in der Größe, Format, Handhabung und Testdurchfüh-
rungszeit der Geräte tragen möglicherweise zu Unterschieden in ihrer Ak-
zeptanz und Leistung bei. 
Für diesen Bericht dient die übliche Versorgung („standard care“) als Kom-
parator. 
 
Gesundheitsproblem 
 
RTIs sind die häufigsten Infektionen, die in der Primärversorgung auftreten; 
die meisten sind viral, aber ein kleiner Teil davon wird durch Bakterien ver-
ursacht und kann auf Antibiotika ansprechen. Je nach Infektionsort, kann 
man zwischen oberen (Pharyngitis, Tonsillitis, Laryngitis, Rhinosinusitis, Oti-
tis Media und Erkältung) und unteren (Pneumonie, Bronchitis, Tracheitis und 
akute infektiöse Exazerbationen der chronisch obstruktiven Lungenerkran-
kung[COPD]) RTIs unterscheiden. Die Influenza kann sowohl die oberen als 
auch die unteren Atemwege betreffen. 
Die meisten RTIs sind selbstlimitierend, wobei der natürliche Verlauf von In-
fektionen der oberen Atemwege (URTIs) typischerweise kürzer (von vier 
Tagen bei akuter Otitis Media bis 2,5 Wochen bei akuter Rhinosinusitis) als 
von Infektionen der unteren Atemwege (LRTIs) (von drei Wochen bei akuter 
Bronchitis/Husten bis zu drei bis sechs Monaten [zur vollständigen Gene-
sung] bei ambulant erworbener Pneumonie [CAP]) ist.  
Zu den PatientInnengruppen, die allgemein das höchste Risiko für akute 
RTIs aufweisen, gehören: pädiatrische (<5 Jahre) und geriatrische (>70 Jah-
re) PatientInnen, PatientInnen mit einer bereits bestehenden Lungener-
krankung (wie COPD oder Asthma), immungeschwächte PatientInnen und 
BewohnerInnen von Pflegeheimen mit Langzeitpflege (LTC). Für diesen Be-
richt sind PatientInnen jeden Alters, die Symptome einer akuten RTI aufwei-
sen und in der Primärversorgung erscheinen, interessant. Es wird geschätzt, 
dass RTIs 15% aller Konsultationen in der Primärversorgung ausmachen, 
wobei Konsultationen für URTI-bezogene Krankheiten mehr als doppelt so 
häufig sind als jene für LRTIs.  
Die Antibiotikaresistenz stellt eine wachsende und erhebliche Bedrohung für 
die öffentliche Gesundheit dar. Es gibt einen klaren Zusammenhang zwi-
schen der Dosis und der Dauer der Antibiotikaeinnahme und dem Auftreten 
von Antibiotikaresistenzen. Auch gibt es Hinweise darauf, dass PatientInnen, 
die häufig mit Antibiotika behandelt wurden, einem höheren Antibiotikare-
sistenz-Risiko ausgesetzt sind. Die Antibiotikaresistenz führt zu einer erhöh-
ten Morbidität und Mortalität durch bakterielle Infektionen. Sie trug im Jahr 
2015 zu schätzungsweise 33.000 Todesfällen in der EU bei, wobei der höchs-
te Anteil bei Säuglingen (im Alter von < einem Jahr) und bei Personen im Al-
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ter von 65 Jahren oder älter lag.  
 
Dementsprechend setzen alle europäischen Länder Antibiotikastrategien 
ein, um deren Einsatz zu reduzieren. Da Antibiotika-bedingte unerwünschte 
Ereignisse häufig sind, muss die Behandlung immer im Verhältnis zum Scha-
denspotenzial betrachtet werden. Eine zu hohe Antibiotika-
Verschreibungsrate für RTIs in der Primärversorgung ist üblich, wobei ein 
hohes Maß an unangemessener Verschreibung in Beobachtungsstudien do-
kumentiert ist. 
Für die URTIs empfehlen die Guidelines eine klinische Beurteilung, die eine 
detaillierte Krankengeschichte und eine körperliche Untersuchung der Pati-
entInnen beinhalten sollte. Für einige Arten von URTI werden klinische Vor-
hersageregeln („clinical prediction rules“) verwendet, um jene PatientInnen 
zu identifizieren, die am ehesten von einer Antibiotikatherapie profitieren. 
In unkomplizierten Fällen von URTIs, welche die erwartete Dauer der Er-
krankung nicht überschreiten, gibt es generell die Empfehlung, kein Antibio-
tikum zu verschreiben oder eine verzögerte Antibiotikatherapie zu erwägen.  
Für die LRTI wird die Verwendung von Antibiotika bei PatientInnen mit 
Pneumonie und bei PatientInnen mit erhöhtem Komplikationsrisiko emp-
fohlen. Ansonsten werden Antibiotika nicht zur Behandlung der akuten 
Bronchitis empfohlen. Einige klinische Guidelines empfehlen die CRP-
Messung, wenn nach der klinischen Beurteilung keine Pneumonie diagnosti-
ziert wurde und eine Unsicherheit darüber besteht, ob ein Antibiotikum ver-
schrieben werden soll.  
Der Einsatz von CRP POCT ist in Europa sehr unterschiedlich. Obwohl CRP 
POCT in vielen europäischen Ländern verfügbar ist, gibt es keine zuverlässi-
gen Daten über den aktuellen und/oder erwarteten jährlichen Gebrauch von 
CRP POC-Tests in europäischen Ländern. 
 
Methoden 
Der Bericht wurde im EUnetHTA HTA Core Model® REA Version 4.2 (mit 
ausgewählten Elementen vom HTA Core Model® „Application for Diagnostic 
Technologies“ Version 3.0) – erstellt. Die Beschreibung der Technologie und 
des Gesundheitsproblems basierte auf deskriptiven Analysen von Informati-
onen aus verschiedenen Quellen. Die bekannten Hersteller von kommerziell 
verfügbaren CRP POC-Tests wurden kontaktiert und ersucht, das EUnetHTA 
Dossier auszufüllen. Dieses wurde zusammen mit Informationen von Fir-
men-Websites als Ausgangspunkt für die Beschreibung der Technologie und 
des Gesundheitsproblems verwendet. Die bereitgestellte Dokumentation 
wurde zusätzlich zu der in der Literaturrecherche identifizierten Literatur 
verwendet. 
Es wurden drei systematische Literatursuchen in verschiedenen Datenban-
ken durchgeführt: 
b Klinische Wirksamkeit und Sicherheit (SR1),  
b Genauigkeit der diagnostischen Tests (SR2) und  
b Leistungsfähigkeit der Analytik (SR3).  
Es gab keine Einschränkungen in Bezug auf das Studiendesign oder die Spra-
che. Klinische Studienregister wurden durchsucht, um laufende klinische 
Studien oder Beobachtungsstudien zu identifizieren. Zwei AutorInnen von 
HIQA überprüften unabhängig voneinander Titel, Abstracts und Volltexte 
der systematischen Literatursuchen. Studien, die keine Daten über relevante 
Endpunkte lieferten, wurden ausgeschlossen. Eventuelle Meinungsverschie-
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denheiten wurden durch Diskussion gelöst. Für die Bereiche klinische Wirk-
samkeit und Sicherheit wurden die relevanten Daten von zwei AutorInnen 
unabhängig voneinander extrahiert und in Evidenztabellen erfasst. Diese 
Schritte wurden auch von den Ko-AutorInnen überprüft. 
Für die Bewertung der klinischen Wirksamkeit und Sicherheit wurden Stu-
dien, die in Bezug auf die Population, die Intervention und die Endpunkte als 
klinisch homogen angesehen wurden, für eine Meta-Analyse mit der Soft-
ware RevMan5.3 gepoolt. Für dichotome Variablen wurde das relative Risiko 
berechnet. Die Heterogenität wurde mit der I2-Statistik untersucht. Aufgrund 
der erheblichen Heterogenität zwischen den Studien in der systematischen 
Übersicht 2 (SR2) als auch in der systematischen Übersicht 3 (SR3), war eine 
Meta-Analyse der Daten nicht angemessen. Die Ergebnisse wurden qualitativ 
beschrieben.  
Zwei AutorInnen bewerteten unabhängig voneinander das Bias-Risiko der 
eingeschlossenen Studien: 
b Das Cochrane Risk of Bias Tool wurde zur Bewertung von randomi-
sierten, kontrollierten Studien (RCTs) und Cluster-RCTs verwendet 
(SR1).  
b Für nicht-randomisierte, kontrollierte Studien und Beobachtungs-
studien wurde die Newcastle Ottawa Qualitätsbewertungsskala ver-
wendet (SR1).  
b Für die Qualitätsbewertung von diagnostischen Genauigkeitsstudien 
(SR2) wurde das QUADAS-2 Tool angewendet um das Bias-Risiko 
und die Anwendbarkeit von diagnostischen Genauigkeitsstudien zu 
beurteilen. Ein modifiziertes QUADAS-2-Tool wurde verwendet, um 
das Bias-Risiko von Studien bezüglich Leistungsfähigkeit der Analy-
tik (SR3) zu bewerten.  
b Für die Bewertung der Qualität der Evidenz wurde GRADE (Grading 
of Recommendations, Assessment, Development and Evaluation) 
verwendet.  
b Für die Informationen zur Beschreibung der Technologie und des 
Gesundheitsproblems wurde kein Qualitätssicherungsinstrument 
verwendet; es wurden jedoch mehrere Quellen herangezogen (z.B. 
nationale und europäische klinische Guidelines, graue Literatur), um 
einzelne, möglicherweise voreingenommene Quellen, zu validieren.  
Während der Scoping-Phase wurden potenziell relevante PatientInnenorga-
nisationen kontaktiert, um die Perspektive der PatientInnen zu verstehen, 
mögliche zusätzliche Endpunkte zu identifizieren und mehr über die bereits 
identifizierten Endpunkte zu erfahren. Eine PatientInnenorganisation, Pati-
ent Focus (Irland), hat Feedback zur Forschungsfrage und zum Entwurf des 
Projektplans gegeben. Der PatientInneninvolvierungs-Fragebogen der HTAi 
wurde als Grundlage für ein semi-strukturiertes Telefoninterview verwen-
det. Das Feedback wurde im Rahmen des Scoping E-Meetings besprochen 
und von den AutorInnen in die Bewertung der Endpunkte mittels GradePRO 
miteinbezogen. 
 
Ergebnisse 
Die primären Endpunkte bezüglich klinischer Wirksamkeit und Sicherheit in 
diesem Bericht waren:  
b Antibiotikaverschreibung: Anzahl der PatientInnen, die ein Rezept 
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gegen akute RTIs (bei der Erstberatung und bei einem 28-tägigen 
Follow-Up) erhalten 
b Anzahl der PatientInnen mit wesentlicher Verbesserung oder einer 
vollständigen Genesung bei einem 7 und 28-tägigen Follow-Up 
b Mortalität bei einem 28-tägigen Follow-Up 
Sekundäre Endpunkte: 
b Anzahl der PatientInnen, die ein Rezept für ein Antibiotikum zur so-
fortigen Einnahme erhalten versus verzögerter Antibiotikatherapie 
b Anzahl der PatientInnen, die ein Rezept für ein Antibiotikum einlö-
sen 
b Zeitspanne bis zum Verschwinden akuter RTI-Symptome 
b Antibiotika-bedingte Nebenwirkungen (inklusive erneuter Beratun-
gen oder Krankenhausaufenthalte aufgrund Antibiotika-bedingter 
Nebenwirkungen) 
b Anzahl der PatientInnen mit RTI-Komplikationen, die zu erneuten 
Beratungen führen 
b Anzahl der PatientInnen mit RTI-Komplikationen, die zu Kranken-
hausaufenthalten führen 
b Gesundheitsbezogene Lebensqualität 
b PatientInnenzufriedenheit 
b Zufriedenheit der ÄrztInnen 
 
Klinische Wirksamkeit 
Die systematische Übersicht der klinischen Wirksamkeit und Sicherheit 
(SR1) umfasste 12 Studien, von denen vier individuelle RCTs, drei Cluster-
RCTs und fünf nicht-randomisierte Studien waren. Zehn dieser Studien wur-
den in Europa durchgeführt. Alle Studien berichteten über mindestens einen 
primären Endpunkt. Die im Rahmen dieser systematischen Übersicht identi-
fizierten Studien bezogen sich nur auf drei von 15 CE-gekennzeichneten CRP 
POC-Tests. Die meisten Studien umfassten lediglich Erwachsene, wobei in 
drei Studien auch Kinder berücksichtigt wurden.  
b Es wurden sieben RCTs mit 5.320 PatientInnen in die Meta-Analyse 
für den primären Endpunkt bzgl. Verschreibung (Antibiotikaver-
schreibung bei Erstberatung d.h. „index consultation“) einbezogen. 
b Die gepoolte Schätzung der RCTs zeigte eine statistisch signifikante 
Reduktion der Antibiotika-Verschreibung bei der Erstberatung in 
der CRP POCT-Gruppe im Vergleich zur üblichen Versorgung (relati-
ves Risiko [RR] 0,76, 95% CI: 0,67-0,86, I2= 70%).  
b Insgesamt war die Qualität der mit GRADE bewerteten Evidenz für 
diesen Endpunkt moderat.  
b Nicht-randomisierte Studien (n= 4.839 PatientInnen) zeigten einen 
ähnlichen Effekt von CRP POCT auf die Antibiotikaverschreibung mit 
einer gepoolten RR von 0,61 (95% CI: 0,54-0,69, I2= 74%); die Quali-
tät der mit GRADE bewerteten Evidenz war sehr gering.  
b Fünf RCTs (2.744 PatientInnen) berichteten über die Anzahl der Pa-
tientInnen, denen bei einem Follow-Up von innerhalb 28 Tagen, An-
tibiotika verschrieben wurde. Alle Studien und die gepoolte Schät-
zung zeigten Punktschätzer zugunsten von CRP POCT zur Reduzie-
rung der Antibiotikaverschreibung innerhalb von 28 Tagen (RR 0,81, 
95% CI: 0,74-0,88, I2= 21%); in drei der Studien war der Unter-
schied jedoch nicht statistisch signifikant. 
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Die Subgruppenanalyse wurde für den Endpunkt Antibiotikaverschreibung 
bei der Erstkonsultation für obere (URTI) im Vergleich zu untere RTIs 
(LRTI) durchgeführt.  
b Die gepoolten Daten aus den RCTs deuteten auf eine statistisch signi-
fikante Reduktion der Verschreibung bei PatientInnen mit URTI hin 
(RR 0,72, 95% CI: 0,58-0,90, I2= 0%); die Ergebnisse basieren jedoch 
auf nur zwei Studien.  
b Vier RCTs berichteten über LRTI. Die gepoolte RR deutete darauf hin, 
dass die Verwendung von CRP POCT die Antibiotikaverschreibung 
bei PatientInnen mit LRTI senkt (RR 0,76, 95% CI: 0,61-0,94); es gibt 
allerdings eine erhebliche Heterogenität (I2= 59%), wobei nur eine 
Studie eine statistisch signifikante Reduktion im Vergleich zur übli-
chen Versorgung zeigt. Diese Ergebnisse werden durch ähnliche Re-
sultate in nicht-randomisierten Studien gestützt. 
Zwei Studien (ein RCT und eine nicht-randomisierte Studie; n=378) gaben 
Aufschluss darüber, ob Antibiotika für die verzögerte oder sofortige Anwen-
dung verschrieben wurden. Es wurde kein Unterschied in der Anzahl der Pa-
tientInnen mit einer verzögerten Antibiotikatherapie in der CRP POCT und 
den üblichen Versorgungsgruppen festgestellt. Eine der Studien ergab je-
doch, dass deutlich mehr Antibiotikaverschreibungen in der üblichen Ver-
sorgungsgruppe eingelöst wurden (72% gegenüber 23%). 
Drei RCTs (n=1.264 PatientInnen) berichteten über die Anzahl der Patien-
tInnen, die bis zum siebten Tag wesentlich oder vollständig genesen waren. 
Die gepoolte Schätzung für die RCTs zeigte keinen signifikanten Unterschied 
in der Anzahl der PatientInnen, bei denen es nach sieben Tagen zu einer we-
sentlichen Verbesserung oder einer vollständigen Genesung kam (RR 1,03, 
95% CI: 0,93-1,14; I2= 0%). In Studien, die Daten über die Genesung der Pa-
tientInnen über sieben Tage hinaus lieferten, wurde kein statistisch signifi-
kanter Unterschied zwischen dem CRP POCT und den üblichen Versorgungs-
gruppen festgestellt. Studien, die über Daten bis zum Zeitpunkt des Ver-
schwindens akuter RTI-Symptome berichteten (n=4), zeigten keinen statis-
tisch signifikanten Unterschied zwischen der CRP POCT und den üblichen 
Versorgungsgruppen.  
Wenn man die Anzahl der PatientInnen betrachtet, die zu einer erneuten Be-
ratung kamen, zeigten die Studien Punktschätzer zugunsten der üblichen 
Versorgung; der Unterschied in der Rate der erneuten Beratungen war je-
doch weder in den Studien noch in der gepoolten Metaanalyse statistisch 
signifikant (RCTs: n=4.524, RR 1.09, 95% CI: 0,93-1,27;  I2= 0%). 
Keine der eingeschlossenen Studien berichtete über die Zufriedenheit der 
ÄrztInnen mit CRP POCT. Vier Studien berichteten über die PatientInnenzu-
friedenheit (n=1.885). Die PatientInnen waren im Allgemeinen zufrieden 
mit der Betreuung im Rahmen des Arztbesuchs. Die Ergebnisse der gepool-
ten Analyse zeigten keinen statistisch signifikanten Unterschied zwischen 
der Intervention (CRP POCT) und den Kontrollgruppen (RCTs: RR 0,82, 95% 
CI: 0,55-1,21; I2= 48%). Diese Ergebnisse wurden durch die Resultate einer 
nicht-randomisierten Studie gestützt. 
Drei Studien umfassten neben Erwachsenen auch Kinder (n=1; Alter >1 
Jahr; n=2 alle Altersgruppen). In den beiden Studien, welche in die Meta-
Analyse eingeschlossen werden konnten, war der Effekt von CRP POCT auf 
die Antibiotikaverschreibung bei Erwachsenen und Kindern ähnlich. Aller-
dings fand eine Studie einen signifikanten Effekt in beiden Gruppen, wäh-
rend die andere über keinen Effekt in beiden Gruppen berichtete. Es war 
nicht möglich eine geplante Subgruppenanalyse für ältere Erwachsene (≥65 
Jahre) durchzuführen. 
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Sicherheit 
Für die Bewertung der Sicherheit wurden alle zwölf Studien berücksichtigt, 
die auch in der SR1 (klinische Wirksamkeit und Sicherheit) eingeschlossen 
wurden. 
b Keiner der eingeschlossenen RCTs oder nicht-randomisierten Stu-
dien berichtete über den Tod eines/einer PatientIn. Fünf der einge-
schlossenen RCTs gaben ausdrücklich an, dass es während des Stu-
dienzeitraums keine Todesfälle gab. 
b Keine Studie berichtete ausdrücklich über erneute Arztkonsultatio-
nen oder Krankenhausaufenthalte aufgrund einer Antibiotika-
bedingten Nebenwirkung. Fünf RCTs gaben keine Krankenhausauf-
enthalte während des Follow-Up-Zeitraums an. Ein RCT berichtete 
über eine Reihe von Krankenhausaufenthalten von PatientInnen, 
fand aber keinen statistisch signifikanten Unterschied zwischen dem 
CRP POCT und den Kontrollgruppen (RR 0,73, 95% CI: 0,25-2,09). 
Eine zweite Studie berichtete über deutlich mehr Krankenhausauf-
enthalte in der CRP POCT-Gruppe im Vergleich zur Kontrollgruppe; 
nach Adjustierung hinsichtlich möglicher Störfaktoren (Confounder) 
war der Unterschied jedoch nicht mehr statistisch signifikant (OR 
2,91, 95% CI: 0,96-8,85, p = 0,060). 
 
Genauigkeit der diagnostischen Tests 
Die Literatursuche identifizierte 15 Studien zur Genauigkeit der diagnosti-
schen Tests (DTA) (SR 2), die alle in Europa durchgeführt wurden. Die vor-
liegende Evidenz in Bezug auf Kinder war begrenzt, da nur eine einzige Stu-
die Kinder im Alter zwischen drei Monaten und 15 Jahren rekrutierte. Nur 
vier Studien verwendeten CRP POCT in der Primärversorgung; zwei Studien 
verwendeten ein CRP POCT-Gerät in einem Labor, während die restlichen 
Studien eine Standard-Laborausstattung benutzten. In den Studien wurde 
ein hohes Maß an Heterogenität festgestellt, was auf Unterschiede in den 
Kriterien zur Definition eines positiven Tests, in den diagnostischen Krite-
rien (einschließlich der Verwendung von CRP-Werten alleine oder als Teil 
eines klinischen Algorithmus), in den PatientInnenpopulationen und dem 
Fehlen eines universellen Referenzstandards für die Diagnose von RTIs, die 
Antibiotika erfordern, zurückzuführen ist. Für Analysezwecke wurden die 
Studien nach der Art der RTI gruppiert. 
Zwei Studien berichteten über den Nutzen von CRP-Tests bei der Diagnose 
von Sinusitis. Beide Studien untersuchten eine Reihe von Schwellenwerten, 
wobei Schwellenwerte von 10 bzw. 17 mg/L ausgewählt wurden, um eine 
Diagnose von Sinusitis auszuschließen. Eine Studie verwendete CRP als Teil 
einer klinischen Entscheidungsregel, was ermöglichte, dass die Hälfte der 
PatientInnen als risikoarm für Sinusitis eingestuft wurde. Die andere Studie 
untersuchte CRP in Kombination mit der Erythrozytensedimentationsrate 
(ESR) und stellte fest, dass der Zusatz von ESR die Sensitivität des Tests er-
höhte. 
Zwei Studien versuchten den optimalen Schwellenwert für die CRP-Tests bei 
PatientInnen mit Halsentzündungen zu bestimmen; es wurden unterschied-
liche Grenzwerte identifiziert (6 mg/L versus 35 mg/L). Diese Studien un-
terschieden sich jedoch in ihrem Ziel, wobei eine Studie CRP zur Unterschei-
dung zwischen bakterieller und nicht-bakterieller Pharyngitis und die ande-
re zur Unterscheidung zwischen A-Streptokokken (GAS)- und Nicht-GAS-
Pharyngitis einsetzte.  
 
keine der 
eingeschlossenen 
Studien berichtete 
 
über den Tod eines/einer 
PatientIn oder  
 
über erneute 
Konsultationen oder  
 
über 
Krankenhausaufenthalte 
aufgrund einer 
antibiotisch bedingten 
Nebenwirkung 
Genauigkeit der 
diagnostischen Tests:  
15 Studien eingeschlossen 
 
hohes Maß an 
Heterogenität der Studien: 
Verwendung in Labor oder 
on Primärversorgung 
Grenzwerte/ Schwellwerte 
CRP-Tests bei Diagnose 
von Sinusitis: 
Schwellenwerte von  
10 bzw. 17 mg/L 
CRP-Tests bei Diagnose 
von Pharyngitis: 
Schwellenwerte von  
6 mg/L bzw. 35 mg/L 
 
Zusammenfassung 
 
Bei einem Schwellenwert von 35 mg/L hatte CRP eine bessere Aussagekraft 
beim Nachweis als beim Ausschließen einer bakteriellen Pharyngitis und 
verbesserte sowohl die Sensitivität als auch die Spezifität (0,78 [0,61-0,91] 
bzw. 0,82 [0,73-0,88]) im Vergleich zur klinischen Diagnose allein. Die Auto-
rInnen verwendeten diesen Schwellenwert anschließend als Teil eines zwei-
stufigen klinischen Algorithmus, wobei bei etwa 30% der PatientInnen mit 
Halsschmerzen eine CRP-Messung nach der klinischen Beurteilung erforder-
lich war. Die Spezifität des Algorithmus war höher als die Sensitivität (0,95 
[0,88-1,00] gegenüber 0,74 [0,53-0,88]). Dieser zweistufige klinische Algo-
rithmus bedarf einer weiteren Validierung.  
 
Bei einem Schwellenwert von 6 mg/L kann CRP in Kombination mit dem 
Centor-Score nützlich sein, um GAS-Pharyngitis auszuschließen (Centor-
Score 1-4: Sensitivität: 0,90; Spezifität 0,45), aber nur, wenn RADT (rapid 
antigen detection test: Streptokokken-Schnelltest) nicht verfügbar ist (Cen-
tor-Score 1-4: Sensitivität: 0,90; Spezifität 0,97). Die geringe Spezifität dieses 
Grenzwertes bedeutet, dass es viele falsche positive Tests geben könnte, und 
daher PatientInnen unnötigerweise mit Antibiotika behandelt werden. 
 
Neun Studien berichteten über den Nutzen von CRP bei LRTI und/oder spe-
ziell bei einer Pneumonie.  
b Fünf Studien berichteten über die diagnostische Genauigkeit von 
CRP bei einem bestimmten Schwellenwert für die Diagnose einer 
Pneumonie.  
b Vier Studien berichteten über einen Grenzwert von 20 mg/L: Drei 
berichteten über eine Sensitivität zwischen 0,48 und 0,79, während 
die vierte Studie eine Sensitivität von 100% bei diesem Grenzwert 
angab. Eine Studie (n=69) berichtete über die diagnostische Genau-
igkeit bei einem unteren Schwellenwert von 11 mg/L (Sensitivität 
0,82), was darauf hindeutet, dass selbst bei diesem unteren Schwel-
lenwert einige Fälle von Pneumonie übersehen werden.  
b Bei einem Schwellenwert von 50 mg/L und 100 mg/L lag die Spezifi-
tät zwischen 0,84 - 0,96 und kann geeignet sein, um eine Diagnose 
für Pneumonie zu stellen.  
b Fünf Studien untersuchten die diagnostische Genauigkeit von CRP in 
Kombination mit Krankheits-Anzeichen und Symptomen zur Be-
stimmung der Pneumonie bei PatientInnen mit LRTIs.  
o Eine Studie ergab, dass der Zusatz von CRP bei einem 
Grenzwert von 20 mg/L zu einer erhöhten Spezifität, aber 
auch zu einer geringeren Sensitivität im Vergleich zur kli-
nischen Beurteilung allein führte, was darauf hindeutet, 
dass der Test in der Primärversorgung nur bedingt einge-
setzt werden kann, außer wenn der Hausarzt versucht eine 
Pneumonie nachzuweisen.  
o Vier weitere Studien verwendeten CRP-Tests in Kombina-
tion mit einem Anzeichen- und Symptommodell, um die 
PatientInnen nach ihrem Risiko für eine Pneumonie zu 
klassifizieren. In diesen Studien erhöhte der Zusatz von 
CRP-Tests zur klinischen Vorhersageregel („Clinical pre-
diction rule“) seine Unterscheidungskraft.  
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Leistungsfähigkeit der Analytik 
Die systematische Suche nach Studien zur Leistungsfähigkeit der Analytik 
ergab 18 Studien (SR 3). Diese lieferten Daten zu elf quantitativen - und zwei 
semi-quantitativen Geräten. In allen Studien wurde die analytische Leistung 
eines CRP POCT-Geräts mit der Standard-CRP-Messung durch geschultes La-
borpersonal mit Laboranalysegeräten verglichen. Daten über die Genauig-
keit, Präzision und Benutzerfreundlichkeit wurden für jedes Gerät aus den 
eingeschlossenen Studien extrahiert. Es gab eine beträchtliche Heterogenität 
zwischen den Studien in Bezug auf die Bedingungen, unter denen PatientIn-
nenblutproben entnommen wurden, den Betreiber des Geräts, die Patien-
tInnenmerkmale und die Art und Weise, wie die Studienendpunkte erfasst 
wurden. Die eingeschlossenen Studien zeigten im Allgemeinen ein hohes 
Bias-Risiko. 
Die analytische Leistung beschreibt die Fähigkeit des Assays, die CRP-Werte 
genau zu messen. Studien stellten fest, dass es nur wenige internationale 
Guidelines gibt, die analytische Qualitätsanforderungen für CRP POCT-
Geräte festlegen. Skandinavische Gesundheitsbehörden (Norwegen, Schwe-
den und Dänemark) schlagen als eine akzeptable Genauigkeit für CRP POCT 
ein „Bias“ (die Differenz zwischen dem Messwert und dem wahren Wert) 
von nicht mehr als 15% (10% für einige Gesundheitsbehörden) vor. Präzisi-
on ist ein Maß für den Zufallsfehler in einem Assay und kann als Variations-
koeffizient (CV) dargestellt werden; skandinavische Gesundheitsbehörden 
und andere Studien legen nahe, dass ein CV ≤10 % akzeptabel ist.  
b Nur zwei Studien bewerteten semi-quantitative Geräte. Die Überein-
stimmung zwischen dem Referenztest und dem POCT wurde für den 
Actim®-Test (Kappa 0,53 bis 0,93) als moderat bis gut und für den 
Cleartest® (Kappa 0,56 bis 0,61) als moderat bewertet. Es zeigte 
sich, dass die Genauigkeit des Tests nach der optimalen Lesezeit von 
fünf Minuten abnahm. Der Hauptvorteil dieser Geräte lag in den rela-
tiven Kosten. Die Nachteile waren die schwierige präanalytische 
Handhabung, die Genauigkeit und die zeitkritische Komponente des 
Tests. Darüber hinaus haben die hier enthaltenen semi-quantitativen 
Tests (Actim® und Cleartest®) eine Obergrenze von 80mg/L. 
b Die Mehrheit der Evidenz deutete auf eine akzeptable Leistung von 
allen elf quantitativen Geräten im Laborbereich hin. Die meisten Ge-
räte hatten eine mittlere Differenz von <10 mg/L oder <10% Bias 
außer bei Konzentrationen über 100 mg/L (Afinion™, NycoCard™, 
NycoCard™, NycoCard™ Reader II, QuikRead®101, Smart Eurolyser, 
iChroma™, Microsemi, AQT90 Flex).  
b Im Labor war die Präzision für die meisten Geräte (Afinion™, Nyco-
Card™, QuikRead go®, QuikRead® 101, Microsemi, AQT90 Flex und 
ABX Micros) akzeptabel, obwohl in mindestens einer Studie CV-
Werte von über 10% für den Smart Eurolyser, den NycoCard™ Rea-
der II und die iChroma™ Geräte in der Laborumgebung gemeldet 
wurden. Dies deutet darauf hin, dass unter Idealbedingungen im La-
bor, die meisten Geräte genau und präzise sind. 
Bei der Verwendung der CRP POCTs in der (patientennahen) Primärversor-
gung waren die Ergebnisse der Genauigkeit und Präzision der Geräte variab-
ler.  
b In Bezug auf die Genauigkeit berichtete die Afinion™ <5% Bias in 
zwei Studien, während das Bias für die NycoCard™, die QuikRead 
go® und die iChroma™ <15% waren.  
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b Die Genauigkeit war bei QuikRead® und dem Smart Eurolyser vari-
abler.  
b Für den QuikRead® 101 und die spinit®-Geräte betrug der CV in al-
len Studien <10%, während für den Smart Eurolyser und die iChro-
ma™ Geräte inkonsistente Ergebnisse gemeldet wurden.  
b Es gab nur sehr wenige Daten über die Genauigkeit bei der Verwen-
dung in der (patientennahen) Primärversorgung.  
Vier Studien verglichen mehrere Geräte und können einen direkten Ver-
gleich liefern. 
b Minnaard et al. kamen zu dem Schluss, dass im Laborbereich vier der 
Geräte eine akzeptable Leistung zeigten (Afinion™, NycoCard™ Rea-
der II, QuikRead go® und QuikRead 101), während der Smart Euro-
lyser eine hohe Ungenauigkeit aufwies. Der Afinion™ und der Smart 
Eurolyser wurden als die am einfachsten zu bedienenden Geräte ge-
nannt.  
b Brouwer et al. verglichen sechs quantitative Tests (Afinion™, Qui-
kRead go®, Smart Eurolyser, iChroma™, Microsemi und AQT90 Flex) 
und schlussfolgerten, dass Afinion™ und Smart Eurolyser aufgrund 
ihrer analytischen Leistung und einfachen Handhabung, die bevor-
zugten Messgeräte für CRP POCT waren.  
b Die Bukve et al. Studie verglich sechs Geräte, welche patientennahe 
in der Primärversorgung verwendet werden (Afinion™, QuikRead 
go®, QuikRead® 101, iChroma™, NycoCard™ und ABX Micros); die 
Afinion™ und QuikRead® Geräte hatten den geringsten systemati-
schen Bias und die Afinion™, QuikRead® und QuikRead go® Geräte 
waren mit einer guten TeilnehmerInnenleistung im Qualitätssiche-
rungsprogramm verbunden.  
b Die Studie von Monteny et al., die das Gerät NycoCard™ patientenna-
he in der Primärversorgung und das QuikRead®-Gerät im Labor 
verglich, ergab, dass das NycoCard™ Gerät eine bessere analytische 
Leistung aufweist. 
Vier Studien untersuchten die analytische Leistung der Geräte im Labor und 
in der Primärversorgung. Der Smart Eurolyser hatte eine akzeptable Genau-
igkeit und Präzision im Labor und in der (patientennahen) Primärversor-
gung; wobei eine bessere Leistung im Labor gezeigt wurde. Die anderen Ge-
räte (ABX Micros, iChroma™ und QuikRead®) hatten eine akzeptable analy-
tische Leistung im Labor, aber eine inakzeptable Präzision oder Genauigkeit 
in mindestens einem Primärversorgungszentrum oder bei höheren CRP-
Werten. Die Genauigkeit und Präzision scheinen daher negativ beeinflusst zu 
werden, wenn das Gerät in der (patientennahen) Primärversorgung ver-
wendet wird. 
In Bezug auf die Benutzerfreundlichkeit scheinen einfach zu bedienende Ge-
räte eine geringere präanalytische Handhabung zu erfordern und sind so 
konzipiert, dass sie für menschliche Fehler weniger anfällig sind. Die Ge-
samtzeit, die notwendig war um einen Test durchzuführen, war ein wichti-
ger Faktor. Die Zeiten variierten von etwas über drei Minuten (QuikRead® 
101) bis zu mehr als 13 Minuten (AQT90 Flex), wobei die Literatur keinen 
Aufschluss darüber gibt, welcher Zeitraum in der Primärversorgung als ak-
zeptabel angesehen werden kann. Die mehrfache Teilnahme an einem exter-
nen Qualitätssicherungssystem (EQAS), die Durchführung einer internen 
Qualitätskontrolle mindestens einmal pro Woche, die Art des verwendeten 
Instruments, die Durchführung der Tests durch qualifiziertes Personal im 
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Labor und die Durchführung von mehr als zehn CRP-Tests pro Woche, waren 
mit einer guten Testleistung verbunden. 
 
 
Laufende Studien 
Eine geplante Studie zur Bewertung der diagnostischen Testgenauigkeit ei-
nes semi-quantitativen CRP POCT-Geräts (FebriDx®) bei PatientInnen, die 
bezüglich einer akuten, ambulant erworbenen, fieberhaften Atemwegsinfek-
tion in der Primärversorgung, Notfallambulanz und Notaufnahme unter-
sucht werden, wurde identifiziert. Diese Studie soll im April 2019 beginnen 
PatientInnen zu rekrutieren.  
 
 
Diskussion 
Klinische Wirksamkeit und Sicherheit 
Die Ergebnisse deuten darauf hin, dass CRP POCT, wenn dieser zur Steue-
rung der Behandlung von PatientInnen mit Symptomen einer akuten RTI 
verwendet wird, zu einer Verringerung der Antibiotikaverschreibung so-
wohl bei der Erstkonsultation als auch bei der bis zu 28-tägigen Nachsorge 
führt. Es wird jedoch darauf hingewiesen, dass diese Ergebnisse auf Kurz-
zeit-Daten beruhen. Die PatientInnen in den Studien wurden üblicherweise 
14 bis 28 Tage lang beobachtet. Die vorliegende Evidenz gibt keinen Auf-
schluss darüber, ob die Auswirkungen auf das Verschreibungsverhalten von 
HausärztInnen über einen längeren Zeitraum anhalten.  
Die Subgruppenanalyse konnte zeigen, dass CRP POCT wirksam ist: die Anti-
biotikaverschreibungen bei der Erstkonsultation sowohl in den URTI als 
auch in den LRTI wurden reduziert; jedoch wurde in allen Studien eine er-
hebliche Heterogenität festgestellt, was zu einer verringerten Stärke der 
Evidenz führt. Es ist nicht möglich zu sagen, welche Auswirkung CRP POCT 
auf die Antibiotikaverschreibung bei Kindern mit RTIs hat, da die Daten be-
grenzt und die Ergebnisse nicht einheitlich sind. Keine der Studien bewerte-
te die Wirkung von CRP POCT ausschließlich bei älteren Erwachsenen (≥65 
Jahre). Weitere Studien sind notwendig, um die Wirksamkeit von CRP POCT 
in dieser Kohorte, die aufgrund einer hohen Prävalenz an Komorbiditäten 
ein hohes Risiko für RTI-Komplikationen hat, zu untersuchen.  
Neun von elf in die Meta-Analyse einbezogene Studien wurden in Europa 
durchgeführt. Auch wenn sich die Länder in Bezug auf die Standardversor-
gung und die Antibiotika-Verschreibungspraktiken möglicherweise unter-
scheiden, geht man davon aus, dass die Ergebnisse dieses Berichtes auf die 
Mehrheit der europäischen Primärversorgungs-Settings übertragbar sind. Es 
wird darauf hingewiesen, dass es eine Vielzahl an Interventionen in Bezug 
auf die Vermeidung von Antibiotikaresistenzen gibt und dass diese Interven-
tionen parallel oder isoliert eingesetzt werden können. Der Mix der angebo-
tenen Maßnahmen und die Reihenfolge ihrer Einführung können sich auf ih-
re Wirksamkeit auswirken. 
Die in diesem Bericht enthaltenen Studien bezogen sich nur auf drei von 15 
CE-gekennzeichneten Geräten - alle drei waren quantitative Geräte. Es ist 
nicht klar, ob diese Daten auch für semiquantitative Geräte zutreffend sind, 
da sich ihre Eigenschaften, Leistung und Akzeptanz möglicherweise unter-
scheiden.  
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Die Reduzierung der Antibiotika-Verschreibung scheint die PatientInnensi-
cherheit nicht zu beeinträchtigen. Es wird darauf hingewiesen, dass die in 
den Studien erwähnten Endpunkte eventuell nicht alle Sicherheitsbedenken 
berücksichtigen. Während schwerwiegende unerwünschte Ereignisse, die zu 
einer erheblichen Morbidität oder Mortalität führen, selten sind, sind Antibi-
otika-bezogene Nebenwirkungen häufig und können die kurzfristige ge-
sundheitsbezogene Lebensqualität beeinträchtigen. Veränderungen in der 
Häufigkeit seltener, schwerwiegender Komplikationen von RTIs (z.B. peri-
tonsillärer Abszess, Empyem und intrakranieller Abszess), die auf eine nicht 
rechtzeitige Antibiotikabehandlung zurückzuführen sind, können in klini-
schen Studien nicht präzise evaluiert werden. Diese Daten stammen aus 
großen Langzeit-Kohortenstudien, die darauf hindeuten, dass eine deutliche 
Reduzierung der Antibiotikaverschreibung gefahrlos erreicht werden kann, 
obwohl in Subgruppen mit erhöhtem Pneumoniesrisiko Vorsicht geboten ist. 
 
Genauigkeit der diagnostischen Tests 
Die Evidenz für die diagnostische Testgenauigkeit von CRP-Tests in der Pri-
märversorgung ist gekennzeichnet durch eine hohe Heterogenität 
b der PatientInnenpopulationen, 
b der diagnostischen Kriterien (einschließlich der Verwendung von 
CRP-Werten allein oder als Teil eines klinischen Algorithmus),  
b der CRP-Grenzwerte,  
b im Testbericht (wie die Durchführung des Tests protokolliert wird), 
sowie 
b das Fehlen eines universellen Referenzstandards für die Diagnose 
von RTIs, die eine Antibiotikabehandlung erfordern.  
Die Subgruppenanalysen (Kinder, ältere Erwachsene [≥65 Jahre], PatientIn-
nen, die Dienste außerhalb der Öffnungszeiten in Anspruch nehmen und sol-
che in Langzeitpflegeeinrichtungen [LTC]), waren aufgrund begrenzter Da-
ten nicht möglich. Nur eine Studie umfasste Kinder (im Alter von drei Mona-
ten bis 15 Jahren) und keine Studie berichtete speziell über CRP-Tests bei äl-
teren Erwachsenen. Daher können in diesen Subgruppen keine Rückschlüsse 
auf die diagnostische Testgenauigkeit der CRP-Tests gezogen werden; statt-
dessen sollten die Ergebnisse in Bezug auf die allgemeine Bevölkerung in-
terpretiert werden. Die Ergebnisse dieser systematischen Übersicht liefern 
wichtige Erkenntnisse über die Leistung von CRP als Test  
b zur Identifizierung von PatientInnen, die von einer Antibiotikabe-
handlung profitieren 
b für die Entscheidungshilfe bei einer Reihe von Erkrankungen. 
Die Evidenz für die diagnostische Testgenauigkeit von CRP bei URTI ist nicht 
eindeutig. Für den Einsatz von CRP-Tests bei PatientInnen mit Symptomen 
einer akuten Sinusitis wurde nur begrenzte Evidenz gefunden. Angesichts 
dessen und dem Umstand, dass die aktuellen klinischen Guidelines den Ein-
satz von Antibiotika bei akuter Sinusitis im Allgemeinen nicht empfehlen, ist 
unklar, was das Ziel der CRP-Tests (entweder alleine oder im Rahmen klini-
scher Vorhersageregeln [„Clinical prediction rules“] verwendet) wäre, wenn 
ein geeigneter Schwellenwert festgelegt werden könnte. Bei Pharyngi-
tis/Tonsillitis wird die Behandlung mit Antibiotika in der Regel nur bei einer 
Streptokokken-(GAS)-Infektion der Gruppe A empfohlen (5% bis 30% der 
PatientInnen mit Halsschmerzen).  
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Aktuelle klinische Guidelines empfehlen eine Antibiotikabehandlung bei 
Pneumonie unabhängig von der Ätiologie. Mit der Ausnahme von PatientIn-
nen, die ein erhöhtes Komplikationsrisiko aufweisen, werden Antibiotika in 
der Regel nicht für andere LRTIs empfohlen, da diese allgemein als selbstli-
mitierend mit begrenztem klinischen Nutzen einer Antibiotikabehandlung 
gelten. Die hohe Heterogenität in den Studien, welche die diagnostische 
Testgenauigkeit der CRP-Tests bei PatientInnen mit Pneumonie evaluieren, 
erschwerte den Vergleich zwischen den Studien: die Heterogenität bezog 
sich vor allem auf die Art der Intervention und auf die Berichterstattung der 
Testdurchführung. PatientInnen mit Pneumonie können einen niedrigen 
CRP-Wert aufweisen, daher kann die alleinige Verwendung von CRP-Werten 
dazu führen, dass Fälle von einer Pneumonie übersehen werden. Viele der 
DTA-Studien verwendeten CRP-Tests in Kombination mit einer klinischen 
Vorhersageregel („Clinical prediction rules“), was es schwierig machte, die 
Wirkung der CRP-Tests allein zu bestimmen. Während der Nutzen der CRP-
Tests zusätzlich zu den klinischen Zeichen und Symptomen für die Diagnose 
einer Pneumonie in der Primärversorgung unklar ist, erscheinen die Tests 
am zweckmäßigsten bei PatientInnen, bei denen Hausärzte unsicher bezüg-
lich der Diagnose sind. 
Ein wesentliches Ergebnis ist, dass die Sensitivität und Spezifität des Tests 
im Allgemeinen schlecht war. Man könnte einen Grenzwert so wählen, dass 
entweder die Sensitivität oder die Spezifität hoch ist, aber nicht beide. Wenn 
man einen Grenzwert wählt, der eine hohe Sensitivität aufweist, dann könn-
te der Test eher zum Ausschließen einer Krankheit verwendet werden, wäh-
rend die Einstellung auf eine hohe Spezifität besser zum Nachweis einer 
Krankheit geeignet ist. Die Ergebnisse deuten darauf hin, dass je nach Art der 
akuten RTI, unterschiedliche Grenzwerte geeignet sein können. Die Verwen-
dung unterschiedlicher Grenzwerte könnte jedoch zu Verwirrung führen, 
während die Verwendung eines universellen Grenzwertes zu unterschiedli-
chen Raten an Fehldiagnosen je nach RTI-Typ führen würde.  
CRP POCT - basierend auf der diagnostischen Testgenauigkeit - ist kein sehr 
guter Test um zwischen viralen und bakteriellen RTIs zu unterscheiden. Die-
ses Ergebnis widerspricht jedoch der signifikanten Auswirkung von CRP 
POCT auf die Antibiotikaverschreibung, die in den klinischen Wirksamkeits-
studien beobachtet wurde. Es kann daher sein, dass die Genauigkeit des 
Tests von geringerer Bedeutung ist; und es von größerer Relevanz ist, dass 
eine Diskussion zwischen dem/der Arzt/Ärztin und des/der PatientIn er-
möglicht wird, welche vielleicht zu einem konservativeren Behandlungsan-
satz für akute RTIs führt. 
 
Nur vier Studien bezogen sich auf CRP POCT in der Primärversorgung; alle 
anderen Studien verwendeten CRP-Tests, die vom Laborpersonal entweder 
mit einem CRP POCT-Gerät oder mittels einer Standardlaborausstattung 
durchgeführt wurden. Daher ist nicht klar, ob diese Ergebnisse für CRP POCT 
anwendbar sind, wenn sie patientennahe in der Primärversorgung durchge-
führt werden. Eine Studie berichtete, dass es Unterschiede in den von mit 
POCT-Geräten durchgeführten CRP-Messungen und den Standardlabormes-
sungen gibt, diese aber zu keine klinisch relevanten Unterschiede in der Di-
agnose von Pneumonie („radiographic pneumonia“) bei Erwachsenen, die in 
der Primärversorgung mit akutem Husten erscheinen, führen. 
Pneumonie: 
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Die systematische Übersichtsarbeit beschränkte sich auf PatientInnen, die 
mit Symptomen einer akuten RTI in der Primärversorgung erscheinen. Die-
ses Kriterium wurde strikt angewandt, sodass Studien, die PatientInnen um-
fassten, die sich an andere Behandlungseinrichtungen wie Notaufnahmen in 
Krankenhäusern, Notfallzentren und Ambulanzen wandten, ausgeschlossen 
wurden, es sei denn, spezifische Daten zur Primärversorgung konnten ex-
trahiert werden. Die Anwendbarkeit der Daten von diesen Settings auf die 
Primärversorgung wurde aufgrund der Unterschiede im Personal, im Zugang 
zu diagnostischen Dienstleistungen und im Spektrum der PatientInnen die 
dort erschienen, als eingeschränkt angesehen. Daten zu einer Reihe von CRP-
POC-Geräten wurden daher von diesem Bericht ausgeschlossen. Diese Ein-
schränkung ist eventuell für Länder, in denen bestimmte Ambulanzen und 
Notfallzentren als Teil des Primärversorgungssystems angesehen werden 
können, nicht relevant. 
 
Leistungsfähigkeit der Analytik 
Insgesamt 18 Studien bewerteten die analytische Leistung von zwei semi-
quantitativen und elf quantitativen POCT-Geräten. Die Literatur über die 
analytische Leistung quantitativer und semi-quantitativer POC-Tests variier-
te stark in Bezug auf das Studiendesign, die berichteten Ergebnisse und die 
Qualität der präsentierten Evidenz. Die analytische Leistung wurde als Maß 
für die Genauigkeit und/oder Präzision dargestellt. Zehn Studien beinhalten 
auch Informationen über die Benutzerfreundlichkeit des Gerätes. Es gab drei 
Methoden, die in den eingeschlossenen Studien verwendet wurden, wobei 
sich die Studien durch die Herkunft der Blutprobe, der/die BedienerIn, 
der/die den Test durchführte, oder das Setting für den Test (Labor oder 
Primärversorgung), unterschieden. Unterschiede in der Evaluierung der 
analytischen Leistung sowie in der Studienmethodik erschweren den direk-
ten Vergleich der Studiendaten. 
Die Relevanz der Genauigkeit und Präzision von CRP POCT-Geräten für die 
klinische Entscheidungsfindung, lässt sich am Beispiel der NICE-Guidelines 
für Pneumonien verdeutlichen. Diese enthalten die Empfehlung, dass CRP 
POCT bei PatientInnen mit LRTI-Symptomen, die in der Primärversorgung 
erscheinen, in Betracht gezogen werden sollen, wenn die Diagnose nach ei-
ner klinischen Beurteilung unklar ist. Weiters sollen Antibiotika auf der 
Grundlage des Testergebnisses verschrieben werden: CRP <20 mg/L (kein 
Antibiotikum erforderlich), ein CRP ≥100 mg/L (sofortige Antibiotikaver-
schreibung) und ein CRP von 20-99 mg/L (verzögerte Antibiotikatherapie). 
Obwohl einige der Geräte eine schlechtere Leistung in den unteren (<2 
mg/L) oder oberen (>100 mg/L) CRP-Konzentrationen aufwiesen, ist dies 
für den Einsatz dieser Geräte bei PatientInnen mit RTIs möglicherweise 
nicht klinisch relevant. 
Auf Grundlage der Ergebnisse, scheinen die meisten Geräte unter idealen 
Laborbedingungen ausreichend genau und präzise zu sein und können in der 
Primärversorgung eingesetzt werden. Es müsste aber sichergestellt werden, 
dass das Personal, das die Geräte in der Praxis verwenden wird, gründlich 
geschult wird. Darüber hinaus müsste ein externes Qualitätssicherungssys-
tem eingerichtet werden, um sicherzustellen, dass ein angemessenes Maß an 
Genauigkeit und Präzision über einen längeren Zeitraum gewährleistet ist. 
Der Kern eines Qualitätssicherungssystems ist die Verwendung von vordefi-
nierten Werten für die Genauigkeit und Präzision, sodass diejenigen, die CRP 
POCT in der Primärversorgung verwenden, sicher sein können, dass die 
Testergebnisse ein akzeptables Niveau an analytischer Leistung aufweisen.  
Obwohl es keine allgemein anerkannten Grenzwerte für die akzeptable Ge-
nauigkeit eines CRP POCT gibt, sind sich die skandinavischen Gesundheits-
behörden (Norwegen, Schweden und Dänemark) einig, dass ein Bias von 
Bericht enthält nur 
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mehr als +/- 15% eine schlechte Leistung anzeigt.  
 
 
Schlussfolgerung  
 
Studien deuten darauf hin, dass die Verwendung von CRP POCT zu einer sta-
tistisch signifikanten Verringerung der Anzahl an PatientInnen, die mit RTI 
in der Primärversorgung erscheinen und bei der Erstberatung ein Rezept für 
ein Antibiotikum erhalten, führt. Die Evidenz hierfür ist aber moderat. Diese 
Reduzierung scheint erreicht zu werden, ohne die PatientInnensicherheit zu 
beeinträchtigen, aber diese Ergebnisse basieren auf kurzfristigen Daten. Es 
ist nicht klar, ob die Verhaltensänderung mit der Zeit anhält oder ob die Be-
dingungen in den Studien (d.h. die kontinuierliche Verwendung von CRP 
POCT zur Entscheidungsunterstützung) beibehalten werden können. Ange-
sichts der hohen Antibiotika-Verschreibungsrate für akute RTIs, dürfte diese 
Verringerung klinisch bedeutend sein, da das zukünftige Risiko einer Antibi-
otikaresistenz reduziert und der unnötigen Einsatz von Antibiotika für 
selbstlimitierende RTIs vermindert wird - wenn antibiotikabedingte Schä-
den wahrscheinlicher sind als ein Nutzen.  
Im Hinblick auf die DTA, gibt es nur sehr wenig Evidenz für den Einsatz von 
CRP zur Entscheidungsunterstützung von Antibiotikaverschreibungen bei 
PatientInnen mit akuten RTIs in der Primärversorgung. Bei PatientInnen mit 
unklaren klinischen Befunden kann der CRP-Test nützlich sein, wenn er in 
Verbindung mit einer klinischen Untersuchung oder als Teil einer klinischen 
Entscheidungsregel verwendet wird. Das Ziel ist, jene PatientInnen zu identi-
fizieren, bei denen es unwahrscheinlich ist, dass sie von einem Antibiotikum 
profitieren könnten, insbesondere wenn nach der klinischen Untersuchung 
eine diagnostische Unsicherheit besteht. Allerdings ist eine weitere Validie-
rung der Vorhersageregeln, die CRP-Messungen beinhalten, erforderlich. 
Die analytische Leistung der in diesem Bericht bewerteten quantitativen 
CRP POCT-Geräte mit CE-Kennzeichnung ist weitgehend vergleichbar mit 
der von Labor-CRP-Tests, wenn diese unter Idealbedingungen verwendet 
werden. Die Leistung kann bei extremen Werten schlechter sein, was aber 
die Entscheidungsfindung in der Primärversorgung kaum beeinträchtigt, 
wenn die Entscheidung, ob ein Antibiotikum verschrieben wird, für alle Wer-
te über oder unter einem Schwellenwert gilt. Es gibt Evidenz für eine größe-
re Variabilität der Leistung, wenn CRP POCT von Personal, das keine Schu-
lung im Labor erhalten hat, in der Primärversorgung genutzt wird, wobei die 
Variabilität höchstwahrscheinlich auf einen Bedienungsfehler zurückzufüh-
ren ist. Einfach zu bedienende Geräte werden mit einer verbesserten Leis-
tung assoziiert. Um das Risiko von Bedienungsfehlern, die zu einer schlech-
ten analytischen Leistung beitragen, zu minimieren, ist eine angemessene 
Schulung erforderlich. Diese soll sicherstellen, dass die Geräte korrekt und 
angemessen verwendet werden. Ein Qualitätssicherungsprogramm soll da-
für sorgen, dass die Testleistung über einen längeren Zeitraum gewährleistet 
wird. 
Weitere Untersuchungen sind erforderlich, um die langfristige Wirksamkeit 
von CRP POCT zur Änderung des Verschreibungsverhaltens zu validieren 
und seine klinische Wirksamkeit und Sicherheit in bestimmten Subpopulati-
onen wie Kindern und älteren Erwachsenen (>65 Jahre) und in verschiede-
nen Settings der Primärversorgung (Dienste außerhalb der Öffnungszeiten 
und Langzeitpflegeeinrichtungen) zu validieren, in denen das Spektrum der 
PatientInnen unterschiedlich sein kann. 
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SUMMARY OF RELATIVE EFFECTIVENESS OF C-REACTIVE PROTEIN 
POINT-OF-CARE TESTING TO GUIDE ANTIBIOTIC PRESCRIBING FOR 
ACUTE RESPIRATORY TRACT INFECTIONS IN PRIMARY CARE  
Scope 
The scope of the assessment can be found here: Scope.  
The aim of this collaborative assessment was to evaluate the relative effectiveness and safety of 
using C-reactive protein (CRP) point-of-care testing (POCT) to guide antibiotic prescribing in pa-
tients with acute respiratory tract infections (RTIs) in primary care settings. The relative effective-
ness assessment (REA) sought to answer three questions by conducting three separate system-
atic reviews: 
 Does the use of CRP POCT in primary care lead to a significant reduction in antibiotic pre-
scribing without compromising patient safety? (SR1 – effectiveness and safety) 
 What is the diagnostic test accuracy (DTA) of CRP in patients presenting with acute RTIs in 
primary care? (SR2 – DTA) 
 How does the analytical performance of the commercially available CE marked CRP point-
of-care tests marketed for use in primary care compare with standard laboratory CRP 
measurement and with each other? That is, are they are they interchangeable in terms of 
accuracy, precision and ease of use? (SR3 – analytical performance) 
Introduction 
Description of technology and comparators  
Infection markers can be used to supplement the clinical diagnosis of an infectious disease. CRP 
is an acute-phase protein synthesised by the liver in response to infection or tissue inflammation. 
Normal serum or plasma CRP levels are below 5mg/L, but increase rapidly after an acute inflam-
matory response, peaking at 20 to 500mg/L after 48 hours. While raised levels of serum CRP 
often occur in bacterial infections (especially severe infections), typically only minor elevations are 
observed in viral infections. Traditionally CRP testing has been undertaken in the laboratory set-
ting; CRP point-of-care testing (POCT) refers to testing at or near the site of the patient encounter 
with the result being available within minutes to inform decision-making. (B0001)  
In the context of patients presenting to primary care with acute respiratory tract infections (RTIs), 
the aim of CRP POCT is to provide reliable test results which assist the clinician rule out a serious 
bacterial infection thereby supporting a decision not to prescribe an antibiotic to those who are 
unlikely to benefit from treatment. It may also help identify patients who could benefit from an 
antibiotic. (B0001) The test is indicated if, after clinical assessment, there is uncertainty as to 
whether an antibiotic should be prescribed. (B0002) 
Fifteen CE marked CRP POCT systems were identified for inclusion in this REA. These could be 
broadly classified into quantitative (using an analyser to provide a quantitative CRP measure-
ment) and semi-quantitative devices (using strips, dipsticks or single-use disposable tests) and 
are indicated for the measurement of CRP in human whole blood and in human serum and plas-
ma. All are subject to EU Regulation 2017/746 on In Vitro Diagnostic Devices (the IVDR) and are 
intended for use by healthcare professionals. (A0020) 
CRP POCT is suitable for use by non-laboratory-trained healthcare professionals in the primary 
care setting. (B0004) Basic training of healthcare professionals in the use of CRP POCT is re-
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quired. Differences in the size, format, handling requirements and test performance time of the 
devices potentially contribute to differences in their acceptability and performance when used at 
the point-of-care. (B0009) 
Health problem 
RTIs are the most frequent infections encountered in primary care; most are viral, but a small 
proportion are caused by bacteria and may respond to antibiotics. Depending on the site of infec-
tion, RTIs may be classified as upper (pharyngitis, tonsillitis, laryngitis, rhinosinusitis, otitis media 
and the common cold) or lower (pneumonia, bronchitis, tracheitis and acute infective exacerba-
tions of chronic obstructive pulmonary disease [COPD]). Influenza may affect both the upper and 
lower respiratory tract. (A0002)  
Most RTIs are self-limiting. The natural course of upper respiratory tract infections (URTIs) is typi-
cally shorter (ranging from four days for acute otitis media to 2.5 weeks for acute rhinosinusitis) 
than for lower respiratory tract infections (LRTIs) (ranging from three weeks for acute bronchi-
tis/cough to three to six months (to complete recovery) for community-acquired pneumonia 
[CAP]). (A0004) Worldwide, LRTIs, and in particular, pneumonia are associated with substantial 
morbidity and mortality. While the disease burden is lower in high-income countries, reflecting 
better access to vaccines and antibiotics, LRTIs still contribute to increased morbidity and mortali-
ty. (A0006)  
Patient groups generally considered to be at the highest risk of acute RTI and their sequelae in-
clude: paediatric (<5 years) and geriatric (>70 years) patients, those with a pre-existing lung con-
dition (such as COPD or asthma), immuno-compromised patients, and long-term care (LTC) resi-
dents of nursing homes. (A0003) For the purposes of this assessment, the population of interest 
is represented by patients of all ages who present with symptoms of acute RTI in primary care. 
(A0007) It is estimated that RTIs account for 15% of all consultations in primary care, with consul-
tations for UTRI-related illnesses more than twice as common as those for LRTIs. (A0023) 
Antimicrobial resistance (AMR) is a growing and significant threat to public health, and it is widely 
recognised that antibiotic resistance is driven by excessive and inappropriate antibiotic prescrib-
ing. Ecological studies have shown that increased antibiotic consumption correlates with in-
creased antibiotic resistance, with countries that have moderate to high consumption of antibiotics 
also having high levels of AMR. However, a causal link between antibiotic consumption and re-
sistance is difficult to establish. (A0002)  
At the patient level, there is a clear link between antibiotic dose and duration and the emergence 
of antibiotic resistance. There is also evidence that patients who have been treated frequently with 
antibiotics are at greater risk of antibiotic resistance. (A0003) AMR results in increased morbidity 
and mortality from bacterial infections. It contributed to an estimated 33,000 deaths in the EU in 
2015, with the highest burden in infants (aged < one year) and those aged 65 years or older [1]. 
AMR is estimated to cost the EU €1.5 billion each year due to extra healthcare costs for patients 
infected with multidrug resistant strains and productivity losses. Prudent use of antibiotics to pre-
vent development of AMR is an important component of the 2017 EU action plan against antimi-
crobial resistance [2]. (A0006) 
For URTIs, guidelines recommend clinical assessment should include a detailed clinical history 
and physical examination of the patient. Clinical prediction rules are used for some types of URTI 
to identify those patients most likely to benefit from antibiotic treatment. In uncomplicated cases of 
URTIs that do not exceed the expected durations of illness, a ‘no antibiotic’ prescribing strategy or 
a ‘delayed antibiotic’ prescribing strategy is generally recommended. For LRTI, the use of antibiot-
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ics is recommended in patients with pneumonia and in those at higher risk of complications, but 
antibiotics are not otherwise recommended to treat acute bronchitis. A number of clinical guide-
lines recommend CRP measurement if, after clinical assessment, a diagnosis of pneumonia has 
not been made and there is uncertainty as to whether an antibiotic should be prescribed. Antibi-
otic-related adverse events are common. Treatment exposes patients to an increased risk of an 
adverse event, so the need for treatment must be considered relative to the potential for harm. 
(A0024) (A0025) Overprescribing of antibiotics for RTIs in primary care is common, with high lev-
els of inappropriate prescribing documented in observational studies benchmarking antibiotic 
prescribing versus clinical guidelines. (A0025) 
Recommendations around the use of CRP POCT for patients with suspected LRTIs have been 
included in guidelines in Norway, Sweden, the Netherlands, Germany, Switzerland, Czech Re-
public, Estonia and the United Kingdom. The use of CRP POCT varies substantially across Eu-
rope. Although recommended and available for use in many European countries, there are no 
reliable data on the current and/or expected annual usage of CRP POC tests in European coun-
tries. (A0011) 
Methods 
The selection of assessment elements was based on the EUnetHTA Core Model® Application for 
Rapid Relative Effectiveness (REA) Assessments Version 4.2. Additional elements were added 
from the HTA Core Model® Application for Diagnostic Technologies Version 3.0.  
For the description and technical characteristics of technology (TEC) and health problem and 
current use of technology (CUR) domains, descriptive analyses of information from the various 
sources explored was carried out. Manufacturers of known commercially available CRP POC 
tests were contacted by the assessment team and requested to complete the Medical Devices 
Evidence Submission template. Manufacturers were asked to submit non-confidential evidence 
focusing on the technical characteristics and current use of the technology. The documentation 
provided was used along with material from company websites as a starting point to inform the 
TEC domain. The documentation provided was used in addition to the literature identified by the 
literature search to inform the TEC and CUR domains. 
Systematic literature searches of various databases were carried out to identify primary studies 
fulfilling the inclusion criteria outlined in the scope of the assessment for each of the three sys-
tematic reviews. Detailed tables of the search strategies are included in Appendix 1. No limitations 
were applied with regard to study design or language. The search for the third systematic review 
(analytical performance) was limited to publications from 1990 onwards, as performance data 
from studies previous to this were considered unlikely to be of relevance to current commercially 
available POC tests. Clinical trial registries were assessed for registered ongoing clinical trials or 
observational studies. Two authors from HIQA independently reviewed titles and abstracts for 
each systematic review search. The full text of potentially eligible articles was reviewed by the two 
authors independently and studies were included or excluded based on predefined criteria 
(Scope). Studies that did not provide data on the relevant outcomes were excluded. Studies that 
reported on duplicate data were identified and excluded if no additional data were available in the 
secondary publication. Abstracts from conferences were also excluded. Any disagreement in 
study selection was resolved through discussion. Studies excluded at full-text review are listed in 
Appendix 1. Relevant data for the clinical effectiveness and safety domains were extracted and 
recorded in evidence tables independently by the two authors. These steps were also checked by 
the co-authors. 
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For the systematic review of clinical effectiveness and safety, studies considered clinically ho-
mogenous in terms of participants, interventions and outcomes were pooled for meta-analysis 
using RevMan5.3 software. Risk ratios were calculated for dichotomous variables. Heterogeneity 
was investigated using the I
2 
statistic. Due to considerable heterogeneity across studies retrieved 
in both systematic review 2 and 3, meta-analysis of data was not appropriate. Results are de-
scribed qualitatively.  
Two reviewers independently assessed the quality or risk of bias of full-text articles included in the 
assessment using standardised critical appraisal instruments. The Cochrane risk of bias assess-
ment approach was used to assess randomised controlled trials (RCTs) and cluster RCTs. For 
non-randomised controlled trials and observational studies, the Newcastle Ottawa quality as-
sessment scale was used. The quality assessment of diagnostic accuracy studies (QUADAS-2) 
tool was applied to assess the risk of bias and applicability of diagnostic accuracy studies identi-
fied in systematic review 2 (diagnostic test accuracy). A modified QUADAS-2 tool was used to 
assess the risk of bias of studies in systematic review 3 (analytical performance). For the as-
sessment of the strength of evidence, the Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) approach was used. For the TEC and CUR domains, no quality 
assessment tool was used, but multiple sources (including national and European clinical guide-
lines, European surveillance data along with grey literature searches of HTA agency reports) were 
used in order to validate individual, possibly biased sources. 
Potentially relevant patient organisations were contacted during the scoping phase in order to 
understand the patient’s perspective, to identify possible additional outcomes of interest and to 
understand the relative importance of the outcomes identified. Input was provided by one patient 
advocacy organisation, Patient Focus (Ireland), with feedback provided based on the preliminary 
PICO and the draft project plan. The HTAi patient group submission template was used as the 
basis of a semi-structured telephone interview. The feedback provided was included in the dis-
cussions with the assessment team at the scoping e-meeting and was incorporated by the au-
thors in their rating of the outcomes of interest through GradePRO. 
Results 
Clinical effectiveness 
The systematic review of clinical effectiveness and safety (SR 1) included 12 studies, of which 
four studies were individual RCTs, three were cluster RCTs and five were non-randomised stud-
ies. Ten of the studies were carried out in Europe. All studies reported on at least one primary 
outcome. The studies identified as part of this systematic review related to only three of 15 CE 
marked CRP POC tests identified. Most studies only included adults; three included adults and 
children. 
Seven RCTs with 5,320 patients were included in the meta-analysis for the primary prescribing 
outcome (antibiotic prescription at index consult). The pooled estimate for the RCTs showed a 
statistically significant reduction in antibiotic prescribing at index consultation in the CRP POCT 
group compared with usual care (relative risk (RR) 0.76, 95% CI: 0.67–0.86, I
2
 = 70%). When 
grouped based on the method of randomisation (individual or cluster randomisation), the substan-
tial heterogeneity in the pooled estimate (I
2 
= 70%) reduced to 0% for cluster randomised trials 
(RR 0.68, 95% CI: 0.61, 0.75, I
2
 = 0%; n=3). However, substantial heterogeneity remained in the 
individually randomised group (n=4; I
2
 = 82%) which decreased to 5% with the removal of a Viet-
namese study (RR 0.90 95% CI: 0.80, 1.02, I2 = 5%, n=3). Overall, the certainty of the evidence 
assessed with the GRADE approach was moderate for this outcome. Non-randomised studies 
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(n=4, 4,839 patients) show a similar effect of CRP POCT on antibiotic prescribing with a pooled 
RR of 0.61 (95% CI: 0.54–0.69, I
2
 = 74%); GRADE certainty of evidence was very low. Five RCTs 
(2,744 patients) reported on the number of patients given antibiotic prescriptions within 28 days 
follow-up. All studies and the pooled estimate showed point estimates in favour of CRP POCT to 
reduce antibiotic prescribing within 28 days (RR 0.81, 95% CI: 0.74–0.88, I
2
 = 21%); however, in 
three of the studies the difference was not statistically significant. (D0021) 
Subgroup analysis was performed for upper versus lower RTIs for the outcome of antibiotic pre-
scribing at index consultation. The pooled data from RCTs suggest a significant reduction in pre-
scribing for patients presenting with URTI (RR 0.72, 95% CI: 0.58–0.90, I
2
 = 0%); however, these 
findings are based on only two studies. Four RCTs provided data on LRTI. The pooled RR sug-
gests that use of CRP POCT lowers antibiotic prescribing in patients with LRTI (RR 0.76, 95% CI: 
0.61–0.94); however, there is substantial heterogeneity (I
2
 = 59%), with only one study showing a 
statistically significant reduction compared with usual care. These results are supported by similar 
findings in non-randomised studies. (D0021) 
Two studies (one RCT and one non-randomised study) provided information on whether antibiot-
ics were prescribed for delayed or immediate use (n=378). No difference was reported in the 
number of patients provided with a delayed prescription between the CRP POCT and the usual 
care groups. However, one of the studies found significantly more prescriptions for antibiotics 
were redeemed in the usual care group (72% versus 23%). (D0021) 
Three RCTs (n=1,264 patients) reported on the number of patients that made a substantial or 
complete recovery by day seven. The pooled estimate for the RCTs showed no significant differ-
ence in the number of patients making a substantial improvement or complete recovery beyond 
seven days (RR 1.03, 95% CI: 0.93–1.14, I
2
 = 0%). In studies providing data regarding patient 
recovery beyond seven days, no significant difference was reported between the CRP POCT and 
usual care groups. In studies providing data in relation to time to resolution of acute RTI symp-
toms (n=4), all studies reported no significant difference between the CRP POCT and usual care 
groups. (D0005) (C0008) 
Studies showed point estimates in favour of usual care when considering the number of patients 
re-consulting; however, the difference in reconsultation rates was not statistically significant in any 
study or in the pooled meta-analysis (RCTs: n=4,524, RR 1.09, 95% CI: 0.93–1.27 I
2 
= 0%). 
(D0006) 
None of the included studies reported on physician satisfaction with CRP POCT. Four studies 
reported on patient satisfaction (n=1,885). Patients were generally satisfied with the care received 
as part of the clinician visit. The results of the pooled analysis showed no significant difference 
between the CRP POCT and control groups (RCTs: RR 0.82 [95% CI: 0.55–1.21], I
2
 = 48%). 
These findings were supported by the results of one non-randomised study. (D0017) 
Three studies included children (n=1 age >1 year; n=2 all ages) in addition to adults. In the two 
studies for which data could be extracted for meta-analysis, the effect of CRP POCT on prescrib-
ing of antibiotics was similar in both adults and children. However, one study found a significant 
effect in both groups while the other reported no effect in both groups. It was not possible to do a 
planned sub-group analysis for older adults (≥65 years) as none of the retrieved studies assessed 
the effect of CRP POCT exclusively in this cohort. Only one study included an upper age limit (65 
years). 
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Diagnostic test accuracy 
The search of the literature retrieved 15 diagnostic test accuracy (DTA) studies (SR 2), all of 
which were carried out in Europe. The evidence retrieved in relation to children was limited, with 
only one study recruiting children aged between three months and 15 years of age. Only four 
studies used CRP POCT in primary care; two used the CRP POCT device in a laboratory while 
the remaining studies used standard laboratory equipment. A high level of heterogeneity was 
noted across studies, reflecting differences in the criteria used to define test positivity, diagnostic 
criteria (including use of CRP levels in isolation or as part of a clinical algorithm), patient popula-
tions and the absence of a universal reference standard for the diagnosis of RTIs requiring antibi-
otics. For the purposes of analysis, studies were grouped according to the types of RTI identified 
in the systematic review. 
Two studies reported on the usefulness of CRP testing in diagnosing sinusitis. Both studies exam-
ined a range of thresholds and selected a threshold of 10 and 17 mg/L, respectively as suitable 
for ruling out a diagnosis of sinusitis [3, 4]. One study used CRP as part of a clinical decision rule, 
allowing half of the patients to be identified as low risk for sinusitis [3]. The other study examined 
CRP in combination with erythrocyte sedimentation rate (ESR) and found that the addition of ESR 
increased the sensitivity of the test [4]. (D1005, D1006) 
Two studies sought to determine the optimal threshold for CRP testing in patients presenting with 
sore throats, with differing cut-points identified (6 mg/L versus 35 mg/L). However, these studies 
differed in their aim, with one study using CRP to distinguish between bacterial and non-bacterial 
pharyngitis[5], and the other to distinguish between GAS and non-GAS pharyngitis [6]. At a 
threshold of 35 mg/L, CRP was found to better at ruling in than ruling out bacterial pharyngitis and 
improved both sensitivity and specificity (0.78 [0.61-0.91] and 0.82 [0.73-0.88], respectively) com-
pared with clinical diagnosis alone [5]. The authors subsequently used this threshold as part of a 
two-step clinical algorithm with approximately 30% of patients presenting with sore throat requir-
ing a CRP measurement after clinical assessment [7]. The specificity of the algorithm was higher 
than the sensitivity (0.95 [0.88-1.00] versus 0.74 [0.53-0.88]). This two-step clinical algorithm re-
quires further validation. At a threshold of 6 mg/L, CRP in combination with the Centor Score may 
be useful in ruling out GAS pharyngitis (Centor Score 1-4: sensitivity: 0.90; specificity 0.45), but 
only if RADT is not available (Centor Score 1-4: sensitivity: 0.90; specificity 0.97) [6]. The low 
specificity of this cut-point means that many false positives may be treated unnecessarily with 
antibiotics. (D1005, D1006) 
Nine studies reported on the usefulness of CRP in LRTI and, or specifically in pneumonia. Five 
studies reported on the diagnostic accuracy of CRP at a specified threshold for diagnosing pneu-
monia. Four studies reported on a cut-point of 20 mg/L: three reported a sensitivity between 0.48 
and 0.79 [8-11], while the fourth study reported a sensitivity of 100% at this cut-point [12]. One 
study (n=69) reported diagnostic accuracy at a lower threshold of 11 mg/L (sensitivity 0.82) [10], 
suggesting that some cases of pneumonia would be missed even at this lower threshold. At a 
threshold of 50 mg/L and 100 mg/L, specificity was between 0.84 and 0.96 and may be suitable 
for ruling in a diagnosis of pneumonia. Five studies investigated the diagnostic accuracy of CRP 
in combination with signs and symptoms for determining pneumonia in patients presenting with 
LRTIs. One study found the addition of CRP at a cut-point of 20 mg/L resulted in increased speci-
ficity, but reduced sensitivity compared with clinical judgement alone, suggesting it would have 
limited use in primary care unless the GP was trying to rule in a diagnosis of pneumonia [8]. Four 
other studies used CRP in combination with a signs and symptoms model to classify patients 
according to their risk of pneumonia. In these studies, addition of CRP testing to the prediction 
rule increased its discriminative power. Hopstaken et al. reported that, use of the rule could have 
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saved 41% of prescriptions for antibiotics with a 2.5% risk of missing a case of pneumonia [13]. In 
the study as part of the GRACE network, CRP was only useful in the intermediate risk category 
where there was clinical uncertainty, and allowed for the reclassification of around half of this 
group into high- or low-risk categories [14]. A further study by the GRACE consortium concluded 
that although CRP added diagnostic value to the signs and symptoms model, it had limited clinical 
utility in predicting a bacterial cause of LRTI [15]. (D1005, D1006) 
Analytical performance 
The systematic search for analytical performance studies returned 18 studies (SR 3) that provided 
data on 11 quantitative devices and two semi-quantitative devices. In all studies, the analytical 
performance of a CRP POCT device was compared with standard CRP measurement by trained 
laboratory staff using laboratory analyser equipment. Data on accuracy, precision and ease of use 
were extracted for each device from the included studies. There was considerable heterogeneity 
across studies in terms of the settings in which patient blood samples were obtained, the operator 
of the device, patient characteristics and how study outcomes were recorded. The included stud-
ies were generally found to be at high risk of bias in a number of domains. 
Analytical performance refers to the ability of the assay to accurately measure CRP levels. Stud-
ies noted that there are few international guidelines that specify analytical quality requirements for 
CRP POCT devices. Scandinavian health bodies (Norway, Sweden and Denmark) suggest ac-
ceptable levels of accuracy for CRP POCT are a bias (the difference between the measured value 
and the true value) that is no greater than 15% (10% for some health bodies). The most common 
methods of reporting accuracy were agreement from a Passing Bablok regression, correlation 
from a Pearson or Spearman correlation coefficient or a mean difference from Bland-Altman plots. 
Precision is a measure of the random error in an assay and can presented as a coefficient of vari-
ation (CV); Scandinavian health bodies and other studies suggest a CV ≤10 % is acceptable. 
(D1001) 
Only two studies evaluated semi-quantitative devices. The agreement between the reference test 
and the POCT was found to be moderate to good for the Actim
®
 test (Kappa 0.53 to 0.93) and 
moderate for the Cleartest
®
 (Kappa 0.56 to 0.61). The accuracy of the test was shown to de-
crease after the optimal read-time of five minutes. The main advantage of these devices was said 
to be their relative cost. The main disadvantages were the difficult pre-analytical handling, the 
accuracy, the time-critical nature of the tests, and that the results are not automatically entered 
into the patient record. In addition, the semi-quantitative tests included here (Actim
®
 and Cleart-
est
®
) have an upper limit of 80mg/L. (D1001, D1008) 
The majority of the evidence suggested acceptable performance for all eleven quantitative devic-
es in the laboratory setting. Most of devices had a mean difference of <10 mg/L or <10% bias 
except at concentrations above 100 mg/L (Afinion™, NycoCard™, NycoCard™ Reader II, 
QuikRead
®
 101, Smart Eurolyser, iChroma
™
, Microsemi, AQT90 Flex). Precision was also ac-
ceptable in the laboratory for most of the devices (Afinion™, NycoCard™,   QuikRead go
®
, 
QuikRead
®
 101, Microsemi, AQT90 Flex and ABX Micros), although CV values greater than 10% 
were reported in the laboratory setting in at least one study for the Smart Eurolyser, the Ny-
coCard™ Reader II and the iChroma™ devices. This suggests that under idealised circumstances 
in the laboratory most of the devices are accurate and precise. (D1007) 
When used at the point of care the results of accuracy and precision of the devices were more 
variable. In terms of accuracy, the Afinion™ reported <5% bias in two studies, while the bias for 
the NycoCard™,   the QuikRead go
®
, and the iChroma
™
 were <15%. The accuracy was more 
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variable for QuikRead
®
 and the Smart Eurolyser. Very little data were available on precision at the 
point of care. For the QuikRead
®
 101 and the spinit
®
 devices the CV was <10% in all studies, 
while inconsistent results were reported for the Smart Eurolyser and the iChroma
™
 devices. 
(D1007) 
Four studies compared multiple devices and provide a direct comparison of the devices [16-19]. 
Minnaard et al. concluded that four of the devices showed acceptable performance in the labora-
tory setting (Afinion™, NycoCard™ Reader II, QuikRead go
®
 and QuikRead 101), while the Smart 
Eurolyser had unacceptably high imprecision. The Afinion™ and Smart Eurolyser were reported 
to be the easiest to operate [18]. Brouwer et al. compared six quantitative tests (Afinion™, 
QuikRead go
®
, Smart Eurolyser, iChroma
™
, Microsemi and AQT90 Flex) and concluded that the 
Afinion™ and Smart Eurolyser were the preferred analysers for CRP POCT based on a combina-
tion of their analytical performance and ease of use [16]. The Bukve et al. study compared six 
devices at the point of care (Afinion™, QuikRead go
®
, QuikRead
®
 101, iChroma
™
, NycoCard™ 
and ABX Micros); the Afinion™ and QuikRead
®
 devices had the lowest systematic bias and the 
Afinion™, QuikRead
®
 and QuikRead go
®
 were associated with good participant performance in a 
quality assurance scheme [17]. The final study by Monteny et al., which compared the Ny-
coCard™ device at the POC and the QuikRead
®
 device in the laboratory setting, reported that the 
NycoCard™ device had better analytical performance [19] (D1007) 
Four studies examined analytical performance of the devices in the laboratory setting and the 
primary care setting [20-23]. The Smart Eurolyser had acceptable accuracy and precision in the 
laboratory and at the POC, but had better performance in the laboratory. The other devices (ABX 
Micros, iChroma
™
 and QuikRead
®
) had acceptable analytical performance in the laboratory but 
unacceptable precision or accuracy in at least one primary care centre or at higher CRP levels 
[21]. Accuracy and precision therefore appear to be negatively impacted when the device is used 
at the point of care. (D1007) 
In terms of ease of use, devices that are easier to use tend to have less pre-analytical handling 
and are designed in such a way that they are less susceptible to human error. The overall time 
taken for the test to be performed was an important factor, with times ranging from just over three 
minutes (QuikRead
®
 101) to over 13 mins (AQT90 Flex), but it is unclear from the literature what 
time period would be considered acceptable in the primary care setting. Participating in an exter-
nal quality assurance scheme (EQAS) more than once; performing internal quality control at least 
weekly; the type of instrument used; having laboratory-qualified personnel performing the tests; 
and performing more than ten CRP tests per week were associated with good test performance. 
(D1007) 
Safety 
For the assessment of safety, all 12 studies identified for inclusion in SR1 (effectiveness) were 
considered. 
None of the included RCTs or non-randomised studies reported the death of a patient. Five of the 
included RCTs specifically stated that there were no deaths during the study period. (D0011) 
(C0008) 
No study reported specifically on reconsultations or hospitalisations due to an antibiotic-related 
adverse drug reaction (ADR). Five RCTs reported no hospitalisations during the follow-up period. 
One RCT reported a number of patient hospitalisations, but found no significant difference be-
tween the CRP POCT and control groups (RR 0.73, 95% CI: 0.25–2.09). A second study reported 
significantly more hospitalisations in the CRP POCT group relative to the control group; however, 
C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care 
 EUnetHTA Joint Action 3 WP4 18 
after adjusting for all possible confounders the difference was no longer statistically significant 
(OR 2.91, 95% CI: 0.96–8.85, p = 0.060). (C0008) (D0011) 
Ethical, organisational, patient and social and legal aspects (if applicable) 
Potential ethical issues identified in relation to the implementation of CRP POCT included the 
potential for a small risk of harm to the patient or staff from blood-borne contamination. From an 
organisational perspective, it was noted that the introduction may lead to changes in the patient 
care pathway depending on who administers the test and communicates the results to the patient. 
Potential organisational issues may also arise relating to the development and implementation of 
a comprehensive quality assurance scheme to support testing in primary care. (Appendix 3) 
Upcoming evidence 
One planned trial evaluating the diagnostic test accuracy of a semi-quantitative CRP POCT de-
vice (FebriDx
®
) in patients being evaluated for acute community acquired febrile respiratory infec-
tion in primary care and urgent care outpatient offices and emergency departments was identified 
(Appendix 1 Table A11). This trial is scheduled to begin enrolling patients in April 2019. Feedback 
from an external expert identified that the 12-month follow-up to a large study included in SR1 
(effectiveness and safety) has been accepted for publication.  
Reimbursement 
The use of CRP POCT in patients with suspected LRTI has been included in guidelines in the UK, 
Norway, Sweden, the Netherlands, Germany, Switzerland, Czech Republic and Estonia to deter-
mine severity of infection and to guide antibiotic prescribing. CRP POCT to inform prescribing in 
primary care was noted to have been indicated in 16 out of 19 countries for which data were pro-
vided, and to be reimbursed for this indication in nine of these countries. (A0021) 
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Table 1: Summary of findings table of the use of CRP POCT to guide antibiotic prescribing for patients presenting with acute RTI in primary care 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study  
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other          
considerations 
CRP POCT 
standard 
care 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Number of patients given antibiotic prescriptions for acute RTI at index consultation 
7  randomised 
trials  
serious a,b not serious  not serious  not serious a,c none  1072/2702 
(39.7%)  
1432/2618 
(54.7%)  
RR 0.76 
(0.67 to 0.86)  
131 fewer per 
1,000 
(from 77 fewer 
to 181 fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Number of patients given antibiotic prescriptions for acute RTI at index consultation 
4  observational 
studies  
not serious  not serious  not serious  serious d none  1011/2326 
(43.5%)  
1784/2513 
(71.0%)  
RR 0.61 
(0.54 to 0.69)  
277 fewer per 
1,000 
(from 220 fewer 
to 327 fewer)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Number of patients given antibiotic prescriptions for acute RTI within 28 days* 
5  randomised 
trials  
not serious  not serious  not serious  serious c,d none  776/1368 
(56.7%)  
970/1376 
(70.5%)  
RR 0.81 
(0.74 to 0.88)  
134 fewer per 
1,000 
(from 85 fewer 
to 183 fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
CRP POCT to guide antibiotic prescribing in primary care settings for acute respiratory tract infections 
EUnetHTA Joint Action 3 WP4 20 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study  
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other          
considerations 
CRP POCT 
standard 
care 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Number of patients with substantial improvement or complete recovery at seven days follow-up 
3  randomised 
trials  
not serious  not serious  not serious  not serious  none  324/627 
(51.7%)  
336/637 
(52.7%)  
RR 1.03 
(0.93 to 1.14)  
16 more per 
1,000 
(from 37 fewer 
to 74 more)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Number of patients with substantial improvement or complete recovery at 28-days follow-up* 
3  randomised 
trials  
not serious  not serious  serious e not serious  none  207/264 
(78.4%)  
199/263 
(75.7%)  
RR 0.94 
(0.69 to 1.28)  
45 fewer per 
1,000 
(from 212 more 
to 235 fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Patient mortality at 28-days follow-up* 
5  randomised 
trials  
not serious  not serious  not serious  not serious  none  Out of 7,165 patients in 5 RCTs there were no reported deaths  ⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Number of patients given an antibiotic for delayed versus delayed + immediate 
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Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study  
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other          
considerations 
CRP POCT 
standard 
care 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1  randomised 
trials  
not serious   not serious   none  22/73 (30.1%)  29/81 (35.8%)  not pooled  see comment  -  IMPORTANT  
Number of patients given an antibiotic for delayed versus delayed + immediate 
1  observational 
studies  
not serious   not serious   none  10/27 (37.0%)  10/35 (28.6%)  not estimable   -  IMPORTANT  
Time to resolution of RTI symptoms 
4  randomised 
trials  
not serious  serious f not serious  serious f none  Studies were not pooled due to differences in the definition of the 
outcome. All four studies reported no significant difference in the 
time to resolution of symptoms between CRP POCT and usual 
care groups. Median time to resolution of symptoms in CRP 
POCT group ranged from 5 to 22 days. Median time in usual care 
group ranged from 4 to 22 days.  
⨁⨁◯◯ 
LOW  
CRITICAL  
Number of patients reconsulting 
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Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study  
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other          
considerations 
CRP POCT 
standard 
care 
Relative 
(95% CI) 
Absolute 
(95% CI) 
4  randomised 
trials  
not serious  not serious  not serious  not serious  none  272/2322 
(11.7%)  
230/2202 
(10.4%)  
RR 1.09 
(0.93 to 
1.27)  
9 more per 
1,000 
(from 7 fewer 
to 28 more)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Number of patients reconsulting 
1  observational 
studies  
not serious   not serious   none  14/60 
(23.3%)  
9/60 (15.0%)  not estima-
ble  
 -   
Number of patients in need of hospitalisation 
5  randomised 
trials  
not serious  serious 
g
 not serious  not serious  none  Three studies reported no hospitalisation of patients. One 
study reported no significant difference in hospitalisation 
between CRP POCT group and usual care group. One study 
reported significantly more hospitalisations in the CRP POCT 
group, but after controlling for all confounders this difference 
was no longer significant.  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Patient satisfaction 
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Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study  
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other          
considerations 
CRP POCT 
standard 
care 
Relative 
(95% CI) 
Absolute 
(95% CI) 
3  randomised 
trials  
not serious  not serious  not serious  serious 
a
 none  794/894 
(88.8%)  
756/871 
(86.8%)  
RR 0.82 
(0.55 to 
1.21)  
156 fewer per 
1,000 
(from 182 
more to 391 
fewer)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Patient satisfaction 
1  observational 
studies  
not serious   not serious   none  51/60 
(85.0%)  
51/60 
(85.0%)  
not estima-
ble  
 -  IMPORTANT  
* Not all studies had 28 days follow-up. Two studies had a follow-up period of 14 days and one had a 21-day follow-up period. 
Abbreviations: CI: Confidence interval; RR: Risk ratio 
Explanations 
a. Heterogeneity.  
b. Difference in effect estimate from cluster randomised RCTs and individually randomised RCTs.  
c. 95% CI cross the line of no effect in a number of studies.  
d. Moderate heterogeneity.  
e. Follow-up was 14 days, 21 days and 28 days for the three studies, therefore the evidence for recovery at 28 days directly applies to only one study.  
f. No attempt was made to pool data as different definitions were given for resolution of symptoms.  
g. Effect of CRP POCT on hospitalisation differs substantially.  
  
CRP POCT to guide antibiotic prescribing in primary care settings for acute respiratory tract infections 
EUnetHTA Joint Action 3 WP4 24 
Table 2: Summary of findings table of the diagnostic test accuracy of CRP in patients presenting with acute RTI in primary care  
Outcomes Impact № of participants  
(studies)  
Certainty of the evi-
dence 
(GRADE)  
CRP levels (mg/L) ** Pharyngitis/Tonsillitis: Reported mean CRP levels in patients were inconsistent (GAS [range 34.4-40 mg/L]; 
Non-GAS [range 15-29.9]). Studies differed in the spectrum of patients due to differences in inclusion criteria.  
 
LRTI/Pneumonia: Only one study reported mean CRP levels in children. In studies in adults, measured CRP 
concentrations were more consistent in patients without pneumonia (range 17-19 mg/L (n=2)) than in pneumonia 
patients (range 62-145mg/L (n=3)).  
Pharyngitis/Tonsillitis: 
(n=2) 
 
LRTI/Pneumonia: 
(n=4) 
Pharyngitis/Tonsillitis: 
⨁◯◯◯  
VERY LOW
 a,b,c
 
LRTI/Pneumonia: 
⨁⨁◯◯ 
LOW 
c, d
 
CRP optimal threshold** Sinusitis: The optimal cut-off point ranged from 10-17 mg/L.  
 
Pharyngitis/Tonsillitis: The optimal threshold was derived from the patient sample. A cut-off point of 35 mg/L was 
used to distinguish between bacterial and non-bacterial pharyngitis (n=1). A threshold of 6 mg/L was used to 
differentiate between GAS and non-GAS patients (n=1).  
 
Pneumonia/LRTI: Optimal cut-off points were chosen rather than derived and were 11, 20, 50 100 mg/L.  
Sinusitis: 
(n=2) 
 
Pharyngitis/Tonsillitis: 
(n=2) 
 
RTI/Pneumonia: 
(n=5) 
Sinusitis: 
⨁⨁⨁◯ 
MODERATE 
e
 
Pharyngitis/Tonsillitis: 
⨁⨁◯◯ 
LOW 
f,g
 
LRTI/Pneumonia: 
⨁⨁⨁◯ 
MODERATE 
h
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Table 2: Summary of findings table of the diagnostic test accuracy of CRP in patients presenting with acute RTI in primary care  
Outcomes Impact № of participants  
(studies)  
Certainty of the evi-
dence 
(GRADE)  
CRP alone at a specified 
threshold** 
Sinusitis: CRP was significantly associated with a diagnosis of sinusitis at a cut-off point of 15 mg/L. At a 
threshold of 10 mg/L, CRP testing may be useful as a rule-out test. However, neither study recommended the use 
of CRP alone as a diagnostic tool.  
 
Pharyngitis/Tonsillitis: CRP testing was found to perform better in differentiating between bacterial and non-
bacterial pharyngitis compared with clinical diagnosis only.  
 
LRTI/Pneumonia: At a cut-off point of 20 mg/L, in 3/4 studies the test demonstrated insufficient sensitivity to be 
used to reliably rule out pneumonia (sensitivity 0.48-0.79). At thresholds of 50 mg/L and 100 mg/L the test may be 
useful as a rule-in test (specificity 0.84-0.99).  
Sinusitis: 
(n=2) 
 
Pharyngitis/Tonsillitis: 
(n=1) 
 
LRTI/Pneumonia: 
(n=5)  
Sinusitis: 
⨁⨁⨁◯ 
MODERATE 
e
 
Pharyngitis/Tonsillitis: 
⨁⨁⨁◯ 
MODERATE 
g
 
 
LRTI/Pneumonia: 
⨁⨁⨁◯ 
MODERATE
 h,i
 
CRP + signs and symptoms at a 
specified threshold** 
Sinusitis: CRP testing in combination with other clinical tests (e.g. ESR measurement) or as part of a clinical 
decision rule may be useful in the diagnosis of acute sinusitis, particularly in identifying patients that are at low risk 
of acute bacterial sinusitis.  
 
Pharyngitis/Tonsillitis: CRP testing was found to be useful in identifying patients that would benefit from 
antibiotic treatment who were classified at intermediate risk of GAS pharyngitis based on a signs and symptoms 
model (n=1). However, a combination of the Centor Score and CRP was not found to be more accurate than other 
optional tests (i.e. RADT) (n=1).  
 
LRTI/Pneumonia: CRP testing + signs and symptoms model*** was found to be a better predictor of pneumonia 
than the signs and symptoms model alone and increased the discriminative power of the test.  
Sinusitis: 
(n=2) 
 
Pharyngitis/Tonsillitis: 
(n=2) 
 
 
LRTI/Pneumonia: 
(n=4) 
Sinusitis: 
⨁⨁⨁◯ 
MODERATE 
j
 
Pharyngitis/Tonsillitis: 
⨁⨁◯◯ 
LOW 
j,k 
Pharyngitis/Tonsillitis: 
⨁⨁◯◯ 
LOW 
j, k 
 
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
CI: Confidence interval  
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GRADE Working Group grades of evidence 
High certainty:   We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty:   Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty:  We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
Explanations 
a. Downgraded by one level for inconsistency: Studies were inconsistent with regard to the spectrum of patients included and CRP levels reported in non-GAS groups.  
b. Downgraded by one level for imprecision: Wide 95% confidence intervals  
c. Downgraded by one level for indirectness: Blood or serum CRP concentrations are not a direct measure of diagnostic test accuracy. 
d. Downgraded by one level for inconsistency: Studies were inconsistent with regard to mean or median CRP levels reported in pneumonia patients. 
e. Downgraded by one level for indirectness: CRP testing was used either in combination with other clinical criteria (i.e. erythrocyte sedimentation rate) or as part of a clinical prediction rule.  
f. Downgraded by one level for inconsistency: Studies were inconsistent with regard to thresholds used to define test positivity. 
g. Downgraded by one level for risk of bias: Current clinical guidelines recommend antibiotic treatment in patients with GAS pharyngitis only. The distinction between bacterial and non-bacterial pharyngi-
tis may not be as useful. 
h. Downgraded by one level for indirectness: 3/5 studies did not provide evidence or rationale for the cut-off points selected. 
i. Downgraded by one level for inconsistency: Studies report widely varying measures of sensitivity. 
j. Downgraded by one level for indirectness: Studies evaluated the diagnostic test accuracy of CRP POCT in addition to other diagnostic tools. The effect of CRP POCT alone for the diagnosis of RTI 
cannot be determined. 
k. Downgraded by one level for inconsistency: Studies were inconsistent regarding the usefulness of CRP POCT in addition to a clinical score for the diagnosis of RTI infection.  
 
**Measures of diagnostic test accuracy demonstrate clear threshold effects. That is, differences in accuracy are likely to be related to differences in the CRP cut-off point used in the study. It was there-
fore not appropriate to calculate summary estimates of accuracy for CRP POC tests as a group where a range of cut-off points have been used across studies. For this reason, the evidence is considered 
for each type of acute RTI identified in the systematic review. 
 
***The signs and symptoms model is defined as a clinical prediction rule in which investigators identified the best combination of medical signs, symptoms, and other findings in predicting the probability 
of pneumonia with the aim of reducing uncertainty surrounding medical decision-making by standardising the collection and interpretation of clinical data.  
CRP POCT to guide antibiotic prescribing in primary care settings for acute respiratory tract infections 
EUnetHTA Joint Action 3 WP4 27 
Table 3: Summary of findings table of the analytical performance of CRP POCT compared with laboratory CRP testing for RTIs in primary care 
Outcomes Impact № of participants  
(studies)  
Certainty of 
the evidence 
(GRADE)  
Accuracy  There was no systematic methodology for assessing accuracy and there was heterogeneity between studies in regard to the setting and 
operator of the device. Two studies assessed accuracy of semi-quantitative devices; 17 studies assessed quantitative devices. The agree-
ment with the reference standard for the semi-quantitative devices ranged from 0.53 to 0.93, this deteriorated if the test was read after the 
optimal 5 minutes. There was also evidence or inter-observer disagreement. The accuracy of most quantitative devices was acceptable 
under idealised laboratory conditions, but was poorer when used at the point of care. The accuracy of the devices tended to be poorer at high 
CRP concentrations (>100 mg/L), but this may not be clinically relevant.  
(18 observational 
studies)  
⨁◯◯◯ 
VERY LOW 
a,b,c
 
Precision  There was no systematic methodology for assessing precision. The acceptable level of imprecision was defined as a coefficient of variation 
less than 10%. The precision results were presented as within-day and between-day variation in the laboratory and primary care settings. 
Most devices reported acceptable precision in the laboratory setting (Smart Eurolyser, NycoCard™ Reader II & iChroma
™
 exhibited unac-
ceptable precision [>10%] in at least one study). Only five studies had precision data measured at the point of care. Generally precision was 
comparable or poorer at the point of care.  
(10 observational 
studies)  
⨁◯◯◯ 
VERY LOW 
a,b,c
 
Ease of Use  There was no systematic methodology for assessing ease of use. The results were reported from laboratory and healthcare personnel. A 
survey or Likert scale was used or general statements were provided by participants. The overall time taken for the test was a major factor, 
but it was unclear from the studies what was considered an acceptable time period in the primary care setting. The Afinion™ and Smart 
Eurolyser were noted for their user-friendliness.  
(8 observational 
studies)  
⨁◯◯◯ 
VERY LOW 
a,c,d
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
CI: Confidence interval  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.  
Explanations 
a. Using QUADAS 2, there was a risk of bias in a number of domains.  
b. The evidence for analytical performance was not consistent between studies; this may have been due to the operator or the setting in which the device was used.  
c. Some of the evidence is provided by studies in the laboratory setting with trained technicians as operators. These studies do not reflect the setting or operators that would use these devices in practice.  
d. For some devices there were inconsistent reports regarding their ease of use. 
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Discussion 
Clinical effectiveness and safety  
The results suggest that CRP POCT, when used to guide management of patients who present with 
symptoms of acute RTI, leads to reduced antibiotic prescribing both at index consultation and up to 28 
days follow-up. However, it is noted that these results are based on short-term data. Trials generally 
followed patients for 14 to 28 days. The average recruitment period across trials was 6.5 months, or 
7.5 months from the recruitment of the first patient to completion of follow-up for the last patient. 
Based on the available evidence it is not known if the impact on GP prescribing behaviour persists 
over a longer period of time. 
Subgroup analysis demonstrated that CRP POCT is effective at reducing antibiotic prescribing at 
index consultation in both URTI and LRTI; however, substantial heterogeneity was noted across stud-
ies, decreasing the strength of the evidence. It is not possible to state from this review what the im-
pact of CRP POCT is on antibiotic prescribing in children with RTIs given the limited data and the lack 
of consistency in results. None of the retrieved studies assessed the effect of CRP POCT exclusively 
in older adults (≥65 years). Further studies are necessary to examine the effectiveness of CRP POCT 
in this cohort as they are recognised to be at high risk of RTI complications due to a high prevalence 
of co-morbidities. Nine of the eleven studies included in the meta-analysis were carried out in Europe. 
Therefore, while recognising that countries may differ in what standard care comprises and their anti-
biotic prescribing practices, the findings of this systematic review are believed to be transferable to 
the majority of European primary care settings. It is noted that a diverse range of interventions might 
be considered as part of antimicrobial stewardship and that these interventions may be used in tan-
dem or in isolation. The mix of interventions offered and the sequence of their introduction may impact 
on their effectiveness.  
The identified studies included in this systematic review related to only three of the 15 CE marked 
devices, all of which were quantitative devices. It is not certain if these data will apply to semi-
quantitative devices given potential differences in their characteristics, performance and acceptability. 
There were very limited data on the number of antibiotics prescribed as a delayed prescription. Based 
on the findings of a single study, patients who receive a delayed prescription may be less likely to 
redeem it. If delayed prescriptions are common in cases where CRP levels are between 20 and 99 
mg/L, our effect estimate could be lower than would be seen in practice given that a higher proportion 
of these prescriptions may not be redeemed. 
The reduction in antibiotic prescribing does not appear to compromise patient safety. It is noted, that 
the outcomes reported in the trials may not capture all safety concerns. While serious adverse events 
that result in substantial morbidity or mortality are rare, antibiotic-related adverse events are common 
and may impact short-term health-related quality of life. However, it is also recognised that changes in 
the incidence of rare serious suppurative complications of RTIs (e.g., peritonsillar abscess, empyema, 
and intracranial abscess) arising from a failure to provide timely antibiotic treatment cannot be evalu-
ated precisely in clinical trials. These data are provided by large long term cohort studies which sug-
gest that substantial reductions in antibiotic prescribing can be safely achieved, although caution may 
be required in subgroups at higher risk of pneumonia. (A0006) 
Diagnostic test accuracy 
The evidence base for the diagnostic test accuracy of CRP testing in primary care is characterised by 
a high level of heterogeneity in patient populations, diagnostic criteria (including use of CRP levels in 
isolation or as part of a clinical algorithm), CRP cut-points, how the performance of the test is reported 
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and the absence of a universal reference standard for the diagnosis of RTIs requiring antibiotic treat-
ment. Meta-analysis of the data was therefore not appropriate and a narrative review was presented. 
Planned subgroup analysis (children, older adults [≥65 years of age] patients attending out-of-hours 
(OOH) services and those in long-term care (LTC) facilities) were not possible due to limited data. 
Only one study included children (aged 3 months to 15 years) and no study specifically reported on 
CRP testing in older adults. Therefore no conclusions can be drawn on the diagnostic test accuracy of 
CRP testing in these subgroups and instead, results should be interpreted in terms of the general 
population. The results of this systematic review do provide important insights into the performance of 
CRP as a test to help identify patients who will benefit from antibiotic treatment and to aid decision-
making for a number of conditions.  
The evidence in relation to the diagnostic test accuracy of CRP in URTI is inconclusive. Limited evi-
dence was found for the use of CRP testing in patients presenting with symptoms of acute sinusitis. 
Given this, and that current clinical guidelines do not generally recommend the use of antibiotics in 
acute sinusitis, it is unclear what the aim of CRP testing, on its own or as part of a clinical prediction 
rule, would be even if a suitable threshold could be established. 
In pharyngitis/tonsillitis, treatment with antibiotics is generally only recommended in those with group 
A streptococcal (GAS) infection (5% to 30% of those presenting with sore throat). A cut-point of 35 
mg/L CRP may be useful in discriminating bacterial from non-bacterial pharyngitis. One study sug-
gests that at this threshold CRP may be useful as part of a clinical prediction rule in patients present-
ing with sore throats, whose diagnosis remains inconclusive after clinical examination; however this 
score required further validation. In contrast, at a threshold of 6 mg/L the use of CRP in combination 
with a clinical prediction rule to rule out GAS could lead to unnecessary prescribing of antibiotic. This 
study also reported that CRP POCT may not perform better than other available tests (i.e. RADT) in 
the detection of GAS infection. (D1002)  
Current clinical guidelines recommend antibiotic treatment for pneumonia irrespective of the aetiology. 
With the exception of patients at higher risk of complications, antibiotics are generally not recom-
mended for other LRTIs as these are generally considered to be self-limiting with limited clinical bene-
fit from antibiotic treatment. 
The high level of heterogeneity across studies evaluating the diagnostic test accuracy of CRP testing 
in pneumonia patients, mainly concerning the type of intervention and how performance of the test 
was reported, made comparison across studies difficult. Patients with pneumonia may present with 
low levels of CRP, therefore use of CRP levels in isolation may lead to cases of pneumonia being 
missed. At a CRP cut-point of 20 mg/L, three out of four studies found the sensitivity to be <0.75, and 
considered it too low to use as a rule-out threshold for pneumonia, while most studies found a CRP 
cut-point of 50 or 100 mg/L as sufficiently specific to use as a rule-in threshold for the diagnosis of 
pneumonia. Many of the DTA studies used CRP testing in combination with a clinical prediction rule, 
making it difficult to determine the effect CRP testing had on its own. While the value of CRP testing 
in addition to clinical signs and symptoms for the diagnosis of pneumonia in primary care is unclear, it 
appears most useful in patients where primary care physicians have diagnostic uncertainty. (D1005) 
(D1006) 
A key finding of the review is that the sensitivity and specificity of the test was generally poor. It would 
be possible to pick a cut-point such that either the sensitivity or specificity was high, but not both. If a 
cut-point is chosen that ensures high sensitivity then the test may be better for ruling out, whereas 
setting it for high specificity is better for ruling in. The findings suggest that different cut-points might 
be suitable depending on the type of acute RTI with which the patient presents. However, the use of 
different cut-points could cause confusion, while the use of a universal cut-point would entail different 
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rates of misdiagnosis across RTI types. Taken at face value, based on the diagnostic test accuracy, 
CRP POCT is not a very good test for distinguishing between viral and bacterial RTIs. However, that 
finding is contradicted by the significant impact on antibiotic prescribing observed in the clinical effec-
tiveness trials. It may therefore be that the accuracy of the test is of lesser importance, and what is 
more critical is that it facilitates a discussion between the clinician and the patient and perhaps a more 
conservative treatment approach to managing acute RTIs. 
Only four studies related to CRP POCT in primary care; all other studies used CRP tests carried out 
by laboratory staff either using a CRP POCT device or standard laboratory equipment. Therefore, It is 
not certain if the findings are applicable to CRP POCT when performed at the point-of-care by the 
intended user. It is noted that one study reported that differences in CRP measurements obtained 
with POCT devices compared to standard laboratory measurement did not translate into clinically 
relevant differences in the diagnosis of radiographic pneumonia in adults presenting with acute cough 
in primary care.  
The review was limited to patients presenting to primary care with symptoms of acute RTI. This crite-
rion was strictly applied, so studies that included patients presenting to other treatment settings such 
as hospital emergency departments, urgent care centres and outpatient clinics were excluded unless 
the data specific to primary care could be extracted. The applicability of data from these settings to 
primary care was considered limited due to differences in staffing, access to diagnostic services and 
the spectrum of presenting patients. Data in relation to a number of CRP POC devices were therefore 
excluded from this systematic review. However, it is noted that the restriction may not be relevant to 
all countries, where certain outpatient clinics and urgent care centres may be considered part of the 
primary care system.  
Analytical performance  
A total of 18 studies evaluated the analytical performance of two semi-quantitative POCT devices and 
11 quantitative POCT devices. The literature regarding the analytical performance of quantitative and 
semi-quantitative POC tests varied widely in terms of the study design, reported results and the quali-
ty of evidence presented. Analytical performance was presented as a measure of accuracy and or 
precision. Ten studies also include information on the ease of use of the device. There were three 
methodologies used in the included studies, with studies differing in the origin of the blood sample, 
the operator performing the test or the setting for the test (laboratory or primary care). Differences in 
the assessment of analytical performance as well as differences in the study methodology make di-
rect comparison of the study data difficult. 
The relevance of the accuracy and precision of CRP POCT devices in clinical decision-making can be 
seen by using the NICE guidelines for pneumonia as an example. These provide a recommendation 
that CRP POCT should be considered for patients with symptoms of LRTI in primary care if a diagno-
sis is unclear after clinical assessment, and that antibiotics should be prescribed based on the test 
result, that is, CRP <20 mg/L (no antibiotic required), a CRP ≥100 mg/L (immediate antibiotic pre-
scription), and a CRP of 20–99 mg/L (consider a delayed antibiotic prescription). These are broad 
concentration categories and it could be argued that we are only interested to know if the analytical 
performance using CRP POCT is sufficient to ensure that the categorisation of patient samples is 
consistent with that which can be achieved with laboratory-grade testing. Therefore, while some of the 
devices have poorer performance in the lower (<2 mg/L) or upper (>100 mg/L) CRP concentrations, 
this may not be clinically relevant for the use of these devices for patients presenting with RTIs. 
On the basis of the findings, it would appear that most of the devices are sufficiently accurate and 
precise under ideal laboratory conditions and could be used in the primary care setting, but training 
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would need to be put in place to ensure healthcare personnel who are likely to use the devices in 
practice are thoroughly trained. In addition, an external quality assurance scheme would need to be 
established to ensure adequate levels of accuracy and precision are being maintained over time. 
Core to a quality assurance scheme is the use of predefined levels for accuracy and precision so that 
those using CRP POCT in primary care can be assured that test results have an acceptable level of 
analytical performance. Although there are no universally recognised cut-points to indicate acceptable 
accuracy of a CRP POCT, Scandinavian health bodies (Norway, Sweden and Denmark) agree that 
greater than +/- 15% bias indicated poor performance [17, 23]. Further work would be needed to es-
tablish what is an acceptable level of accuracy within each county.  
Conclusion 
We are moderately confident that the use of CRP POCT leads to a significant reduction in the number 
of patients presenting to primary care with an RTI being given an antibiotic prescription at their index 
consultation. We are confident that this reduction is achieved without compromising patient safety. 
These findings are based on short-term data. It is not clear if the behavioural change is sustained 
over time or if the conditions in the trials (that is, ongoing use of CRP POCT to inform decision mak-
ing) can be maintained. Given the high prescribing rate for acute RTIs, this reduction is likely to be 
clinically important as it reduces an individual’s future risk of antibiotic resistance as well as reducing 
unnecessary antibiotic use for self-limiting RTIs when antibiotic-related harm is more likely that 
benefit,. 
In terms of DTA, there is very limited evidence for the use of CRP to support antibiotic prescribing 
decisions in patients presenting with acute RTIs in primary care. In patients with ambiguous clinical 
findings, CRP testing may be useful when used in conjunction with clinical examination or as part of a 
clinical decision rule to identify those patients who are unlikely to benefit from an antibiotic, particularly 
where there is diagnostic uncertainty based on clinical examination alone. However, further validation 
of prediction rules incorporating CRP measurement is required. 
The analytical performance of the CE marked quantitative CRP POCT devices evaluated in this as-
sessment is broadly comparable to laboratory CRP testing when used in idealised circumstances. 
Performance may be poorer at extreme levels, but this is unlikely to impact decision-making in prima-
ry care where the decision to prescribe or not to prescribe an antibiotic applies to all values above or 
below a threshold. There is evidence of greater variability in performance when used by non-
laboratory trained healthcare staff in primary care, with the variation most likely due to operator error. 
Devices that are easier to use may be associated with improved performance. To minimise the risk of 
operator error contributing to poor analytical performance, adequate training is necessary to ensure 
devices are used correctly and appropriately, along with a quality assurance programme to ensure 
that test performance is maintained over time. 
Further research is required to validate the long-term effectiveness of CRP POCT to change prescrib-
ing behaviour and to validate its effectiveness and safety in specific sub-populations such as children 
and older adults (>65 years) and in different primary care settings (out-of-hours clinics and long-term 
care facilities) where the spectrum of patients may differ. 
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1 SCOPE  
PICO for systematic review 1: Effectiveness of using CRP POCT to guide antibiotic prescribing in 
patients with acute RTIs in primary care settings  
Description Project scope 
Population  The population of interest is represented by patients of all ages who present with symptoms 
of acute respiratory tract infection in primary care. 
Subgroups of particular interest include: children, older adults (≥65 years of age), patients 
attending out-of-hours (OOH) services and those in long-term care (LTC) facilities. 
ICD-10: J00 – J22 (upper and lower RTI), J40 (bronchitis not specified as chronic or acute), 
H65-H66 (otitis media).  
MeSH: C01.539.739, C08.730 (respiratory tract infection), C09.218.705.663 (otitis media), 
C07.550.781, C08.730.561, C09.775.649 (pharyngitis), C08.618.248, C23.888.852.293 
(cough) 
Intervention  CRP POC test for use in primary care setting (+/- communication training, +/- education 
component, +/- other biomarkers) in addition to standard care. 
Testing for CRP may assist the clinician in differentiating between bacterial and viral 
aetiology and therefore guide antibiotic prescribing. POC tests allow the test to be done at 
the time of consultation with results available within minutes. 
Twelve CE marked quantitative devices and three CE marked semi-quantitative methods 
will be considered in this assessment. The names of products and the corresponding 
manufacturers are: 
Quantitative devices: 
QuikRead
®
 CRP for use on QuikRead
®
 101 instrument; QuikRead go® CRP for use on 
QuikRead go
®
 instrument; QuikRead go
®
 CRP+Hb for use on QuikRead go
®
 instrument 
(Orion Diagnostica Oy) 
Alere Afinion™ CRP for use on Afinion™ AS100 analyser; NycoCard™ CRP test for use 
with NycoCard™ READER II (Abbott [Alere]) 
CRP assay for use with Cube S analyser (EuroLyser) 
CRP assay for iChroma
™
 instrument; AFIAS CRP for use with AFIAS 1 (Boditech Med) 
CRP assay run on AQT90 Flex (Radiometer Medical ApS ) 
CRP assay run on Microsemi instrument (Horiba) 
spinit
®
 CRP (Biosurfit) 
InnovaStar
®
 instrument (DiaSys Diagnostic Systems GmbH) 
Semi-Quantitative devices: 
Actim
®
 CRP (Medix Biochemica) 
Cleartest
®
 CRP (Servoprax) 
FebriDx
®
 (RPS Diagnostics) 
MeSH-terms: D12.776.034.145, D12.776.124.050.120, D12.776.124.486.157 (CRP), 
N04.590.874.500 (point of care tests) 
Comparison Standard care alone 
Outcomes Primary outcomes: 
Prescribing outcomes 
 Number of patients given antibiotic prescriptions (delayed +immediate) for acute RTI (at 
index consultation and at 28-days follow-up) 
Patient outcomes 
 Number of patients with substantial improvement or complete recovery at seven and 28-
days follow-up 
 Patient mortality at 28-days follow-up 
Secondary outcomes: 
Prescribing outcomes: 
 Number of patients given an antibiotic prescription for immediate use versus delayed use 
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Description Project scope 
 Number of patients who redeemed a prescription for an antibiotic 
Patient outcomes: 
 Time to resolution of acute RTI symptoms 
 ADR, including number of patients reconsulting or hospitalised due to ADR 
 Number of patients with RTI complications resulting in reconsultation 
 Number of patients with RTI complications in need of hospitalisation 
 HRQOL 
 Patient satisfaction 
 Physician satisfaction  
Rationale: the included outcomes have been identified from systematic reviews [24, 25] 
MESH terms: D27.505.954.122.085 (antibacterial agents) 
Study design RCTs, cluster RCTs, non-randomised studies, observational studies 
Abbreviations: ADR – adverse drug reactions; CRP – C-reactive protein; HRQOL – Health-related quality of life; LTC – long-
term care; MeSH – medical subject heading; OOH – out-of-hours; RCT – randomised controlled trial; RTI – respiratory tract 
infection. 
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PICOS for systematic review 2: Diagnostic test accuracy of CRP in patients presenting with 
acute RTIs in primary care 
Description Project scope 
Population  The population of interest is represented by patients of all ages who present with symptoms 
of acute RTI in primary care. Subgroups of particular interest include: children, older adults 
(≥65 years of age), patients attending out-of-hours (OOH) services and those in long-term 
care (LTC) facilities.  
ICD-10: J00 – J22 (upper and lower RTI), J40 (bronchitis not specified as chronic or acute), 
H65-H66 (otitis media),  
MeSH: C01.539.739, C08.730 (RTI), C09.218.705.663 (otitis media), C07.550.781, 
C08.730.561, C09.775.649 (pharyngitis), C08.618.248, C23.888.852.293 (cough) 
Intervention  CRP POC test for use in primary care setting (+/- other biomarkers). Testing for CRP may 
assist the clinician in differentiating between bacterial and viral aetiology and therefore 
guide the prescription of antibiotics. POC tests allow the test to be done at the time of 
consultation with results available within minutes. 
Any CE marked CRP POC quantitative or semi-quantitative method will be considered in 
this assessment: 
MeSH-terms: D12.776.034.145, D12.776.124.050.120, D12.776.124.486.157 (CRP) , 
N04.590.874.500 (POC tests) 
Comparison For the diagnostic test accuracy review, the diagnostic standard used for comparison will be 
dependent on the acute RTI of interest (microbiological/laboratory/radiological confirmation). 
Each disease group will be analysed separately. 
Outcomes Primary outcomes: 
 Sensitivity and specificity  
 PPV and NPV 
 Likelihood ratio 
 Area under the ROC curve (AUC) 
 DOR 
Study design Diagnostic test accuracy studies 
Abbreviations: AUC – area under curve; CRP – C-reactive protein; DOR – diagnostic odds ratio; DTA – diagnostic test 
accuracy; LTC – Long term care; MeSH – medical subject heading; OOH – out-of-hours; NPV – negative predictive value; PPV 
– positive predictive value; RTI – respiratory tract infection; ROC – receiver operating characteristic. 
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PICOS for systematic review 3: Analytic performance of commercially available CE marked 
CRP POCT  
Description Project scope 
Population  The population of interest is represented by patients of all ages who present to primary care. 
Intervention  CRP POC test for use in primary care setting (+/- other biomarkers) 
 
Twelve CE marked quantitative devices and three CE marked semi-quantitative methods 
will be considered in this assessment. The names of products and the corresponding 
manufacturers are: 
 
Quantitative devices: 
QuikRead
®
 CRP for use on QuikRead
®
 101 instrument; QuikRead go
®
 CRP for use on 
QuikRead go
®
 instrument; QuikRead go
®
 CRP+Hb for use on QuikRead go
®
 instrument 
(Orion Diagnostica Oy) 
Alere Afinion™ CRP for use on Afinion™ AS100 analyser; NycoCard™ CRP test for use 
with NycoCard™ READER II (Abbott [Alere]) 
CRP assay for use with Cube S analyser (EuroLyser) 
CRP assay for iChroma
™
 instrument; AFIAS CRP for use with AFIAS 1 (Boditech Med) 
CRP assay run on AQT90 Flex (Radiometer Medical ApS ) 
CRP assay run on Microsemi instrument (Horiba)) 
spinit
®
 CRP (Biosurfit) 
InnovaStar
®
 instrument (DiaSys Diagnostic Systems GmbH) 
 
Semi-Quantitative devices: 
Actim
®
 CRP (Medix Biochemica) 
Cleartest
®
 CRP (Servoprax) 
FebriDx
®
 (RPS Diagnostics) 
MeSH-terms: D12.776.034.145, D12.776.124.050.120, D12.776.124.486.157 (CRP), 
N04.590.874.500 (POC tests) 
Comparison Standard laboratory CRP measurement or another CRP POCT instrument 
Outcomes Primary outcomes: 
 Measures of accuracy (level of agreement between the result of one measurement and 
the true value) and precision (degree of reproducibility of the result) will be extracted for 
each CRP POCT device 
 
Secondary outcomes: 
 Where available, information on ease of use and suitability for primary care POCT will 
also be collected and summarised for each device 
Study design Any study reporting on analytical performance 
Abbreviations: CRP – C-reactive protein; MeSH – medical subject heading; POCT – point-of-care testing 
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2 METHODS AND EVIDENCE INCLUDED  
2.1 Assessment Team 
HIQA (lead authors):  
 Developed the first draft of the EUnetHTA project plan 
 Identified and contacted manufacturers  
 Performed the literature search and study selection  
 Conducted the assessment (extraction, analysis, synthesis and interpretation of findings)  
 Developed the first draft of the relative effectiveness assessment (REA) 
 Sent the first draft to dedicated reviewers, compiled feedback, answered comments and per-
formed changes according to reviewers’ comments 
HVB (co-authors): 
 Collaborated in the development of the EUnetHTA project plan 
 Checked, provided input and endorsed all steps (e.g. collaboration in literature selection, data 
extraction, assessment of risk of bias)  
 Checked, provided input and endorsed content of all domains. Collaborated on the writing of 
the discussion and conclusions, and endorsed same 
 Reviewed drafts of the assessment, proposed amendments where necessary and provided 
written feedback 
Dedicated reviewers: 
 Reviewed draft project plan, proposed amendments where necessary and provided written 
feedback 
 Rated the relevance of outcomes (GRADE method) 
 Reviewed assessments, proposed amendments where necessary and provided written feed-
back 
 
2.2 Scoping phase 
During the scoping phase, the assessment team, external experts, manufacturers and a patient rep-
resentative were consulted and asked to provide feedback regarding the population, intervention, 
comparator, patient-related outcomes, and study design (PICOS) for each of the three planned sys-
tematic reviews. A scoping meeting was organised before the start of the assessment to discuss the 
PICOS questions. This was attended by members of the assessment team, with external experts and 
the patient representative providing verbal feedback to the assessment team. The initial draft of the 
project plan agreed by the assessment team was circulated, developed and agreed upon by the au-
thors and co-authors. In order to provide further transparency to the process, GRADE and GRADEpro 
(an electronic tool that allows and facilitates participation of panel members) were used to rate the 
importance of the outcomes identified. 
 
2.3 Source of assessment elements 
The selection of the assessment elements for each of the four domains – the description and tech-
nical characteristics of the technology, the health problem and current use of the technology, clinical 
effectiveness, and safety – was based on the assessment elements contained in the EUnetHTA Core 
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Model® Application for rapid relative effectiveness assessment (REA) Version 4.2 
https://www.eunethta.eu/wp-content/uploads/2018/06/HTACoreModel_ForRapidREAs4.2-3.pdf [26]. 
Additionally, assessment elements from other HTA Core Model Applications (diagnostic technologies) 
were screened and included or merged with the existing questions if deemed relevant. General ques-
tions referring to selected issues were translated into specific answerable questions, which were ei-
ther grouped together or answered individually, as appropriate. 
 
2.4 Search  
To identify relevant studies, systematic searches were carried out on the following databases: 
 MEDLINE (OVID, Pubmed) 
 Embase 
 CINAHL (via EBSCOHost) 
 The Cochrane Library 
In addition, for systematic review 3 on analytical performance, OpenGrey and Scopus were searched 
as this type of study is more likely to be found in the grey literature. Hand searching of the literature 
was also undertaken including a cross-check of the reference list of included studies and relevant 
systematic reviews as well as citation tracking. Ad hoc internet searches were undertaken to identify 
other relevant grey literature. Finally, lists of relevant studies provided by manufacturers in their sub-
mission files were searched for additional studies. Submission files were submitted by three compa-
nies: Abbott (Alere), Orion Diagnostica Oy, and RPS Diagnostics. These files were used along with 
material from other company websites to inform the technology description domain. The following 
clinical trial registries were searched for registered ongoing clinical trials and observational studies: 
ClinicalTrials.gov and International Clinical Trials Registry Platform (ICTRP). Detailed tables can be 
found in the ‘documentation of the search strategies’ in Appendix 1. A separate search for clinical 
guidelines (G-I-N, National Guidelines Clearinghouse, hand searches) was also undertaken. 
This REA comprises three systematic reviews that covered assessment elements for the clinical ef-
fectiveness and safety domains. The purpose of these reviews is to answer three research questions 
in relation to the use of CRP POCT to guide antibiotic prescribing in patients presenting with symp-
toms of acute RTI in primary care settings (Table 4).  
Table 4: Research questions answered and the related systematic reviews 
No. Question Systematic Review 
1 Does the use of CRP POCT in primary care lead to 
a significant reduction in antibiotic prescribing with-
out compromising patient safety? 
Effectiveness and safety 
2 What is the diagnostic test accuracy of CRP in pa-
tients presenting with acute RTIs in primary care? 
Diagnostic test accuracy studies  
3 Do the commercially available CE marked CRP 
POC tests marketed for use in primary care com-
pare with standard laboratory CRP measurement 
and do they have comparable analytical perfor-
mance? That is, are they interchangeable in terms 
of accuracy, precision and ease of use?  
Analytical performance  
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Search strategies were designed for the various databases identified above for each of the three sys-
tematic reviews. Details of the search strategies are provided in Appendix 1. 
At the time of the systematic literature searches, no limitations were applied with regard to study de-
sign or language. No limits were applied for the year of publication for the first two systematic reviews 
(clinical effectiveness and diagnostic test accuracy). The search for the third systematic review (ana-
lytical performance) was limited to publications from 1990 onwards as performance data from older 
studies were considered unlikely to be relevant to the current commercially available POC tests.  
Two authors from HIQA independently reviewed titles and abstracts for each systematic review 
search. The full text of potentially eligible articles was reviewed by the two authors independently and 
the study included or excluded based on predefined criteria (see Section 1: Scope). Studies that did 
not provide data on the relevant outcomes were excluded. Studies that reported on duplicate data 
were identified and excluded if no additional data were available in the secondary publication. Ab-
stracts from conferences were also excluded. Any disagreement in study selection was resolved 
through discussion. Studies excluded at full-text review are listed in Appendix 1. The study selection 
process for each of the three systematic reviews is described in Section 2.5 and Section 5.  
Information to inform the description and technical characteristics of the technology (TEC) and current 
use (CUR) domains was obtained from relevant literature identified in the systematic reviews, the 
EUnetHTA submission files, clinical guideline sites, and hand searches including searches of manu-
facturer websites. 
2.5 Study selection 
As this REA comprises three systematic reviews on three related but separate research questions, to 
facilitate ease of reading, details of the studies selected for each of the three separate systematic 
reviews are included in Section 5. 
2.6 Data extraction and analyses 
Four review authors (KOB, KJ, LM, PM) independently extracted data using prepared data extraction 
forms developed for these three systematic reviews (SR 1: KOB and KJ; SR 2: PM and KJ; SR 3: 
KOB and LM). The authors resolved any discrepancy through discussion or with a fifth author (PH).  
Measures of treatment effect are reported as a risk ratio with 95% confidence intervals for each di-
chotomised outcome. When results could not be pooled, they were presented qualitatively. Where it 
was appropriate to pool data, Review Manager 5 software was used to perform meta-analysis. Heter-
ogeneity was investigated using the I
2 
statistic. The choice between fixed and random effects meta-
analysis was based on an assessment of the statistical and clinical heterogeneity across studies. 
Where substantial statistical heterogeneity was observed and sufficient studies were available, a me-
ta-regression was considered to explore study characteristics that may be potential sources of heter-
ogeneity. The following subgroup analyses were planned by: 
 Study type: RCT versus cluster RCT versus observational studies 
 Age group: children versus adults, younger adults (<65 years) versus older adults (≥65 years) 
 Presenting symptoms: upper versus lower RTIs 
 Setting: out of hours and those in long-term care  
The sample size of cluster randomised controlled trials were modified as recommended in the 
Cochrane Handbook [27]. Design effect = 1 + (M-1) ICC, where M is the mean cluster size (that is, the 
average number of people in each cluster) and the ICC is the inter cluster correlation. For studies 
where the ICC was reported, the ICC was taken from the study. When it was not reported, the ICC 
was taken from the literature as recommended in the Cochrane handbook. 
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2.7 Quality rating  
2.7.1 Quality appraisal for systematic review 1 (effectiveness and safety) 
Two reviewers from HIQA independently assessed the quality or risk of bias of full-text articles includ-
ed in the review using standardised critical appraisal instruments, with any disagreements resolved 
through discussion. As both randomised controlled trials and non-randomised studies were included, 
two separate methods were used to assess the risk of bias of included studies. The Cochrane risk of 
bias tool was used to assess RCTs and cluster RCTs https://methods.cochrane.org/bias/assessing-
risk-bias-included-studies#The%20Cochrane%20Risk%20of%20Bias%20Tool [28]. This tool is used 
to assess the included studies for selection bias (random sequence generation and allocation con-
cealment), performance bias, detection bias, attrition bias, reporting bias and any other sources of 
bias [28]. For non-randomised controlled trials and observational studies, the Newcastle Ottawa quali-
ty assessment scale was used. With this tool, the studies are assessed for selection bias, comparabil-
ity and outcomes (https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0078156/). 
The quality of the body of evidence was assessed for each outcome using GRADE (Grading of Rec-
ommendations, Assessment, Development and Evaluation) [29]. External experts and members of 
the authoring, co-authoring and reviewing teams were involved in grading the importance of each of 
the outcomes identified. Feedback from the patient representative was included as part of the authors’ 
review. The main findings of the review were presented in the ‘Summary of findings’ (SoF) table, cre-
ated using the GRADE PRO tool (https://gradepro.org/). Primary review outcomes were listed with 
estimates of relative effects along with the number of participants and studies contributing data for 
each outcome. For each individual outcome, the quality of the evidence was assessed using the 
GRADE approach, which involves considering the risk of bias within studies (limitations in design, 
inconsistency, indirectness, imprecision and publication bias). Magnitude of the effect, dose-response 
effect and other plausible confounders were considered in relation to observational studies. Results 
are expressed as one of four levels of quality (high, moderate, low or very low), the definitions of 
which are outlined in Table 5.  
Table 5: Definition of quality of evidence (GRADE) 
Quality rating Definition 
High “We are very confident that the true effect lies close to the estimate of the 
effect.” 
Moderate “We are moderately confident in the effect estimate. The true effect is likely 
to be close to the estimate of the effect, but there is a possibility that it is 
substantially different.” 
Low “Our confidence in the effect estimate is limited. The true effect may be 
substantially different from the estimate of the effect.” 
Very low “We have very little confidence in the effect estimate. The true effect is likely 
to be substantially different from the estimate of the effect.” 
Source: GRADEpro handbook https://gdt.gradepro.org/app/handbook/handbook.html, Table 5.1 
Relevant subgroup analyses were assessed for the most important outcomes. Evidence from obser-
vational studies was by default rated as low; however, the quality could be upgraded based on: 1) a 
strong or very strong association; 2) a dose-effect relationship; 3) if all plausible confounding may be 
working to reduce the demonstrated effect or increase the effect if no effect was observed. 
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2.7.2 Quality appraisal for systematic review 2 (diagnostic test accuracy)  
The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was applied to assess the 
risk of bias in all studies identified in systematic review 2. This tool is designed for use in systematic 
reviews to evaluate the risk of bias across four domains (patient selection, index test, reference 
standard and flow of participants) and applicability across three domains (patient selection, index test 
and reference standard) and is guided by prompt questions. Two authors from HIQA independently 
assessed the risk of bias of included studies. Disagreements with regard to judgements were resolved 
through discussion. 
2.7.3 Quality appraisal for systematic review 3 (analytical performance) 
Standardised critical appraisal instruments to rate the quality of analytical performance studies are 
limited. As a result, a modified QUADAS-2 tool was used to assess the risk of bias of studies in sys-
tematic review 3. All questions from QUADAS-2 were retained. These related to patient selection, 
index test, reference test, and flow of participants. An additional question was added relating to the 
operator of the index test. Two authors from HIQA independently assessed the quality of the included 
studies. Disagreements in judgements were resolved through discussion. 
Risk of bias and QoE 
Details of the risk of bias of the studies included in systematic reviews (SRs) 1 (effectiveness and 
safety), 2 (diagnostic test accuracy) and 3 (analytical performance) are included in Sections 5.3, 5.8 
and 5.9, respectively, and in Appendix 1. 
2.8 Description of the evidence used 
Details of the main characteristics of the studies included in systematic reviews (SRs) 1 (effectiveness 
and safety), 2 (diagnostic test accuracy) and 3 (analytical performance) are included in Sections 5.4, 
5.5 and 5.9, respectively and in Appendix 1. 
2.9 Patient involvement 
Potentially relevant patient organisations were identified through an ad hoc search of the internet, 
national contacts and via European umbrella organisations. A standardised email was sent to these 
organisations and followed with further email and phone contact where appropriate. One patient ad-
vocacy organisation, Patient Focus (Ireland), identified through this process agreed to participate in 
the REA and signed the necessary DOICU form. This organisation was involved as part of the scop-
ing phase in order to understand the patient’s perspective, to identify possible additional outcomes of 
interest and to understand the relative importance of the outcomes identified. The preliminary PICO 
was provided to the organisation along with the draft project plan which provided additional back-
ground information. The HTAi patient group submission template was used as a basis of a semi-
structured telephone interview. The feedback provided was included in the discussions with the as-
sessment team at the scoping e-meeting and was incorporated by the authors in their rating of the 
outcomes of interest through GradePRO.  
2.10 Deviations from project plan 
While the scope of the assessment was not changed (that is, no change to the PICOS), additional 
assessment elements (AEs) were added from the diagnostic accuracy core model as they were more 
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relevant to the outcomes being described than the AEs in the REA model. Additional AEs added 
were: D0021 change in management, “How does use of the test change physicians' management 
decisions”; D1001 “What is the accuracy of the test against the reference standard”; D1003 “What is 
the reference standard and how likely does it classify the target condition correctly”; D1005 “What is 
the optimal threshold in this context”; D1006 “Does the test reliably rule in or out the target condition”; 
D1008 “What is known about the intra- and inter-observer variation in test interpretation”. 
For SR2, a number of identified studies reported mean CRP levels in the sample population. Although 
this is not a measure of diagnostic test accuracy, it was included in the analysis to provide context in 
relation to the clinical usefulness of CRP cut-points. 
Evidence from SR 3 (analytical performance) suggested the accuracy and precision of CRP POCT is 
sufficiently comparable to that of standard laboratory-based testing. For this reason, studies that 
measured CRP levels using CRP POCT devices (at the point of care or in the laboratory) or used 
standard laboratory CRP measumement were considered eligible for inclusion in SR 2 (diagnostic test 
accuracy). Clarity as to how CRP levels were measured is provided when reporting study results. 
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF TECHNOLOGY 
(TEC) 
3.1 Research questions  
Element ID Research question 
B0001 What is C-reactive protein (CRP) point-of-care testing (POCT)? 
A0020 For which indications have each of the CRP POCT devices/methods received CE 
marking?  
B0002 What is the claimed benefit of CRP POCT technology in relation to standard care for 
guiding antibiotic treatment in patients presenting to primary care settings with 
symptoms suggestive of an acute RTI?  
What might be the potential harms or risks of this technology in relation to standard 
care? 
B0004 Who administers CRP POCT? In what context is it provided? In what primary care 
settings is it used (e.g. GP practices, out-of-hours clinics, long-term care facilities)? 
B0009 What equipment, supplies and training are needed to implement CRP POCT in 
primary care? 
B0003  
 
A0021 
What is the phase of implementation of CRP POCT in the various European 
countries participating in EUnetHTA? 
What is the reimbursement status of CRP POCT in primary care in the European 
countries participating in EUnetHTA? 
 
3.2 Results 
Features of the technology and comparators 
[B0001] – What is C-reactive protein (CRP) point-of-care testing (POCT)? 
Pathology test results inform diagnostic and treatment decisions that affect health outcomes. These 
tests have traditionally been performed in laboratories which have systems in place to ensure that the 
results obtained are comparable between different laboratories and of a consistent quality. Techno-
logical development has allowed some pathology testing to be performed near or at the site of the 
patient at the time of the consultation or encounter. This testing is usually performed outside a labora-
tory environment by health professionals including nursing and medical staff. Referred to as ‘near 
patient testing’ under Regulation (EU) 2017/746 on in vitro diagnostic medical devices (the IVDR) or 
more commonly as ‘point-of-care testing (POCT)’, it is intended to provide more rapid and accessible 
test results to inform patient care than can be achieved from laboratory settings [30]. For consistency, 
the term POCT will be used in this REA. 
This REA is limited to the use of CRP POCT in patients who present with symptoms of acute RTI in 
the primary care setting. In the case of CRP POCT, the purpose of the test is to assist the clinician 
assess the likelihood of a serious bacterial infection as opposed to a less serious bacterial infection or 
viral infection, thereby supporting a decision whether or not to provide an antibiotic. CRP is one of the 
cytokine-induced acute-phase proteins produced by the liver, the levels of which rise during a general, 
non-specific response to various infectious and inflammatory triggers [31-35]. CRP combines with 
bacterial polysaccharides or phospholipids released from damaged tissue to become an activator of 
the complement pathway. In healthy people, the serum or plasma CRP levels are below 5 mg/L [36-
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38]. A rapid increase in CRP can occur about six hours after an acute inflammatory stimulus, with 
CRP values peaking at approximately 20 to 500 mg/L after 48 hours [39, 40]. As elevated CRP levels 
may be associated with pathological changes, the CRP assay provides information for the diagnosis, 
therapy, and monitoring of infectious and inflammatory diseases [31, 35, 39, 40]. Raised concentra-
tions of serum CRP often occur in bacterial infections; however, typically only minor elevations are 
observed in viral infections [41]. Therefore, when used in combination with clinical judgement, CRP 
POCT may aid the medical practitioner to rule out serious bacterial infections thereby supporting a 
decision not to provide an antibiotic to those who are unlikely to benefit from treatment.  
Fifteen CRP POCT devices were identified for inclusion in this REA during the scoping phase. These 
can be broadly divided into two categories:  
 Quantitative devices (devices comprising a test kit and analyser) 
 Semi-quantitative devices (devices comprising strips, dipsticks or single-use disposable tests) 
Table 6 provides an overview of the two different categories of CRP POCT devices, including their 
mechanism of action, similarities and differences. 
Table 6: Overview of commercially available quantitative and semi-quantitative CRP POCT 
devices 
Device 
type 
Mechanism of action Similarities Differences 
Quantitative 
assay kit 
and 
analyser 
instrument 
Analysis using: 
Immunoturbidimetric 
measurement using 
fingerstick blood 
samples, whole blood, 
serum or plasma (n=6). 
Solid-phase immuno-
chemical (or immuno-
metric) assays (n=2). 
Fluorescence 
immunoassays (n=2) 
Solid-phase sandwich 
immunoassay (n=1). 
Multi-method 
immunoassay with 
haematology and clinical 
chemistry targets (n=1). 
All tests: 
 Are CE marked 
 can detect whether 
CRP levels are low 
or high in a blood 
sample. 
 use relatively small 
volumes (2.5 to 20 
μL of capillary 
blood.  
 time to result does 
not exceed 15 
mins for any 
technology.  
 . 
All 12 tests require an analyser. 
Quantitative CRP result. 
Time to result ranges from 4 to 
13.5 mins across 12 analysers. 
Analytical range: 0.5 mg/L to 400 
mg/L with all technologies 
covering 8 to 160 mg/L. 
Additional POCT assays are 
possible with all analysers. 
Semi-
quantitative 
test strips, 
dipsticks or 
single-use 
disposable 
test (SUDT) 
Immunochromatographic 
assay test strip for CRP 
(n=2). 
Lateral flow 
immunoassay using 
direct sampling micro-
filtration technology 
(n=1). 
Tests do not require an analyser. 
Semi-quantitative result – 
categorised as low, medium or 
high for strips and low or high for 
SUDT. 
Time to result ranges from 7.5 to 
15 mins across 3 tests. 
Analytical range for CRP in bands 
for semi-quantitative tests: 0 – 
>80 mg/L for strips and ≥ 20 mg/L 
for the single-use disposable 
device. 
One device co-tests for the viral 
biomarker MxA.  
Abbreviations: n = number of tests with the specified mechanism of action 
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Quantitative tests require a small amount of whole blood, plasma or serum. The results are expressed 
in mg/litre (mg/L) with clinical guidelines typically recommending treatment with antibiotics when the 
CRP result is above a certain level. Certain analysers are suitable for use with other assays in addi-
tion to CRP; for example immunochemical faecal occult blood tests, urine albumin, glycated haemo-
globin, urine albumin/creatinine ratio, D-dimer levels, lipoprotein A, total leucocytes, white blood cells, 
haematocrit and haemoglobin. 
Semi-quantitative tests do not require an analyser. A small amount of capillary blood is applied direct-
ly to the test strip, or mixed with dilution buffer for a dipstick test, which then provides an indication of 
whether the patient has a low, medium or high CRP level. For one particular device, the CRP test is 
used in combination with a viral biomarker (that is, Myxovirus resistance protein A (MxA) in the 
FebriDx
®
 test) to provide additional information regarding the likely aetiology (bacterial or viral) of the 
infection [34]. 
Table 7 provides the features of the 15 marketed CRP POCT devices in Europe relevant to this as-
sessment. Data to inform this table were collected from the manufacturers and the literature review in 
the assessment process. Additional data were obtained from medtech innovation briefings on three of 
the CRP POCT devices: Alere Afinion™ CRP, QuikRead go
®
 and FebriDx
®
 undertaken by NICE in 
the UK [32-34].  
Local, national and international clinical guidelines describe how CRP POCT may be used to inform 
prescribing decisions in primary care. For example, in the UK, NICE guidelines for the diagnosis and 
management of pneumonia in adults [42] recommend: 
 the use of CRP POCT when it is not clear if antibiotics should be prescribed based on clinical 
assessment  
 not routinely offering antibiotic therapy if the CRP concentration is less than 20mg/L 
 considering a delayed antibiotic prescription (a prescription for use at a later date if the symp-
toms worsen) if the CRP concentration is between 20mg/L and 100mg/L  
 offering antibiotic therapy if the CRP concentration is greater than 100mg/L. 
It should be noted that semi-quantitative devices will narrow the CRP threshold choices available for 
clinical guidance on higher CRP cut-points. 
The CRP POCT can be used in combination with communication training, an education component 
and/or tests for other biomarkers in addition to standard care to assist the treating clinician in differen-
tiating between bacterial and viral aetiology, and thereby guide antibiotic prescribing. In order for the 
administration of CRP POCT to be most beneficial in the primary care setting, it must provide timely 
results to the medical practitioner, ideally within a number of minutes so, that they are available within 
the usual allotted consultation time. 
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Table 7: Features of the intervention 
Technology 
 Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument Proprietary 
name 
QuikRead go
®
 CRP assay 
and QuikRead go
®
 
instrument 
QuikRead go
®
 CRP+Hb 
assay and QuikRead go
®
 
instrument 
QuikRead
®
 CRP assay and 
QuikRead
®
 101 instrument 
Alere Afinion™ CRP assay 
and Alere Afinion™ AS100
*
 
or Alere Afinion™ 2
**
 
Analyser 
NycoCard™ CRP assay 
and NycoCard™ Reader II 
Manufacturer Orion Diagnostica Oy Orion Diagnostica Oy Orion Diagnostica Oy bbott Diagnostic 
Technologies AS 
Abbott Diagnostic 
Technologies AS 
Reference 
codes 
QuikRead go
® 
CRP assay: 
135171 (50 tests), 151461 
(25 tests), 135174 (500 
tests). Localised test 
versions: 133891, 
145215,135172,135173,13
5283, 135174,125175 and  
QuikRead go
®
 instrument: 
133893. Localised 
versions: 
135867,149915,145218,13
6196 
QuikRead
® 
CRP control: 
68296 QuikRead
 
go
®
 CRP 
control High: 137071 
QuikRead go
®
 CRP+Hb 
assay: 140068 (50 tests) 
and  
QuikRead go Instrument: 
133893. Localised 
versions: 
135867,149915,145218,13
6196 
QuikRead
® 
CRP control: 
68296 QuikRead
 
go
®
 CRP 
control High: 137071 
QuikRead
®
 CRP assay:  
134191, 134193 (50 tests).     
Additional test versions: 
67961, 128574,128577, 
68798, 06160, 
134194,134197,134195, 
134198,128575,106161 
and  
QuikRead
®
 101 instrument: 
06040, 06078 
QuikRead
®
 CRP control: 
68296 
Alere Afinion™ CRP:  
1116526, 1116522, 
1116524, 1116023 (15 
tests) and  
Afinion™ AS100 Analyser:  
1116049 or 
Alere ™ 2 Analyser: 
1116679, 1116680, 
1116681   
Alere Afinion™ CRP 
control: 1116057  
NycoCard™ CRP:        
1116078, 1116080 and 
NycoCard™ Reader II: 
1116149 
Alere Afinion™ CRP 
control: 1116057 
 
Class/GMDN 
code 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC; 
GMDN code 53705. 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC; 
GMDN code 53705 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC; 
GMDN code 53705 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC; 
GMDN code 53707 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC; 
GMDN code 53707 
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Technology 
 Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument Additional tests Strep A, iFOB Strep A, iFOB iFOB, U-ALB HbA1c, lipid panel, ACR HbA1c, D-dimer, U-
Albumin 
Method Immunoturbidimetric assay Immunoturbidimetric assay Immunoturbidimetric assay Solid phase immuno-
chemical assay 
Solid phase immuno-
metric assay 
Sample size & 
type 
(+alternative 
materials) 
20 μL capillary blood  
(venous whole blood, 
plasma or serum) 
20 μL capillary blood  
(venous whole blood, 
plasma or serum) 
20 μL capillary blood  
(venous whole blood, 
plasma or serum) 
 
2.5 μL capillary blood  
(venous whole blood, 
serum or plasma) 
5 μL capillary blood  
(venous whole blood, 
serum or plasma) 
Analytical range 
(whole blood) 
5 – 200 mg/L CRP  5 – 200 mg/L CRP 
o 50 – 245 g/L Hb 
 
8 – 160 mg/L CRP 5 – 200 mg/L CRP 
 
8 – 200 mg/L CRP 
 
Calibration No – automatic No – automatic Yes – 15 sec  No – automatic Yes – 15 sec 
Haematocrit 
auto-correction 
 
 
 
 
Yes
a
 Yes
a
 No Yes
a
 No – calibrated to read 
40% Ht 
Special storage 
requirements  
for test (e.g. 
refrigeration)  
CRP Reagent caps (in 
opened and unopened 
aluminium tube): 2-8°C (until 
expiry); 15-25°C; 24 hrs per 
day (1 month) & 7.5 hrs per 
day (3 months). 
Prefilled cuvettes in 
unopened foil pouches: 2-
25°C (until expiry). 
It will take 15 minutes for an 
individual refrigerated 
prefilled cuvette to reach 
room temp. 
CRP Reagent caps (in 
opened and unopened 
aluminium tube): 2-8°C (until 
expiry); 15-25°C; 24 hrs per 
day (1 month) & 7.5 hrs per 
day (3 months). 
Prefilled cuvettes in 
unopened foil pouches: 2-
25°C (until expiry). 
It will take 15 minutes for an 
individual refrigerated 
prefilled cuvette to reach 
room temp. 
CRP Reagent caps (in 
opened and unopened 
aluminium tube): 2-8°C (until 
expiry); 15-25°C; 24 hrs per 
day (1 month) & 7.5 hrs per 
day (3 months). 
Prefilled cuvettes in 
unopened foil pouches: 2-
25°C (until expiry). 
It will take 15 minutes for an 
individual refrigerated 
prefilled cuvette to reach 
room temp. 
Test Cartridge must 
reach an operating 
temperature of 15-30°C 
before use. Upon 
removal from refrigerated 
storage, leave the test 
cartridge in unopened foil 
pouch for at least 15 
mins. 
NycoCard™ test tube with 
dilution liquid is stored in 
refrigerator. It must be 
brought to room 
temperature before 
analysis. 
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Technology 
 Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument Analyser size 
and weight 
14.5 x 15.5 x 27 cm                    
1.7 kg 
14.5 x 15.5 x 27 cm                    
1.7 kg 
8 x 14 x 22 cm                         
1.0 kg 
17 x 19 x 34 cm and 5.0 
kg*         20 x 19 x 33 cm 
and 3.4 kg** 
20 x 17 x 7 cm instrument 
box 2.95 x 14.4 cm  
(reader pen) 0.54 kg 
Analyser warm-
up time  
50 sec 50 sec 30 sec Afinion™ AS100: 3 min 
Alere™ 2 Analyser: 1 
min 30sec sec 
25 sec 
Performance 
time for pre- and 
actual analysis   
4.5 min                                          
(= 2.5 min + 2 min) 
4.5 min                                         
(= 2.5 min + 2 min) 
5.5 min                                     
(= 2.5 min + 3 min) 
Afinion™ AS100: 4.25 
min (=30sec + 3.75min) 
Alere™ 2 Analyser: 
3.30min (=30sec 
+3.0min) 
8 min 35 sec                                
(= 3 min 35 sec + 5 min) 
Practical 
aspects of test  
Pre-analytical handling: 
capillary with plunger, inner 
reagent cap pushed through 
while putting cap on cuvette. 
Same as for QuikRead go
®
 
CRP assay.  2 results from 
a single sample in a single 
run. 
Pre-analytical handling 
involves manual sample & 
reagent mixing performed 
prior to analysis on device. 
Auto-self check with 
integrated error 
detection. Error codes 
possible due to small 
sample volume that may 
dry out after the 1min 
limit instructed in the 
package insert. Analyser 
cannot be moved if on.  
Manual sample dilution, 
conjugate application and 
washing prior to analysis. 
Also need to manually 
adjust and white calibrate 
the reader pen of the 
battery-operated 
instrument. 
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Technology 
 Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument Connectivity Yes to data transfer to 
electronic patient files. 
Measurement results can be 
sent to LIS. 
 
Yes to data transfer to 
electronic patient files. 
Measurement results can be 
sent to LIS. 
 
Yes to data transfer to 
electronic patient file and 
LIS/HIS using QuikRead
®
 
Quiklink. 
Yes to data transfer to 
electronic patient files. 
Alere Afinion™ Data 
Connectivity Converter 
(ADCC) is also included 
for simple transfer of 
patient and controls 
results to LIS/HIS. 
No to data ransfer to 
electronic patient files. 
Print function Yes Yes No Yes No 
Data storage on 
device 
Yes Yes No Yes No 
Device lifespan  Approx. 5 years or ≥ 50,000 
measurements per device 
Approx. 5 years or ≥ 50,000 
measurements per device 
Approx. 5 years or ≥ 50,000 
measurements per device 
Not reported Not reported 
Maintenance  Designed to be free of 
regular maintenance with 
built-in  self-check 
operations. 
Designed to be free of 
regular maintenance built-in  
self-check operations. 
Designed to be free of 
regular maintenance built-in  
self-check operations. 
Cleaning of cartridge 
chamber with a swab 
once a month. 
The white calibration 
device, the pen tip and the 
pen ring of the 
instrument/pen should be 
inspected regularly and 
replaced if dirty or 
damaged. 
Software 
updates  
New software can be 
updated to the instrument 
with a USB stick.  
New software can be 
updated to the instrument 
with a USB stick. 
Software version 7.0 or 
newer shortens the assay 
reaction time. No detail on 
how software is updated. 
USB stick upgrade 
process provides 
analyser with software 
updates. 
Not possible. 
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Technology 
 Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument Quality checks QuikRead
® 
CRP control 
(68296) and QuikRead
® 
go 
CRP control High (137071) 
are intended for routine 
quality control of CRP 
assays by the QuikRead
® 
go 
instrument. Low and high                                
conc. approx. 30 and 85 
mg/L. Self-diagnosis 
operational checks 
. 
QuikRead
® 
CRP control 
(68296) and QuikRead
® 
go 
CRP control High (137071) 
are intended for routine 
quality  control of CRP 
assays by the QuikRead
® 
go 
instrument . Low and high                             
conc. approx. 30 and 85 
mg/L. Self-diagnosis 
operational checks 
 
QuikRead
®
 CRP control 
(68296) is intended for 
routine quality control of 
CRP assays by the 
QuikRead
®
 101 instrument. 
Target control                               
conc. approx. 50 mg/L 
Alere Afinion™ CRP 
Control from Alere is 
recommended for routine 
quality control testing 
with each new lot or 
delivery of new CRP test 
kits. 
Alere Afinion™ CRP 
Control is recommended 
for routine quality control 
testing with each new lot 
or delivery of new CRP 
test kits. 
Training & 
support 
Additional costs associated 
with training. No details 
provided. 
Additional costs associated 
with training. No details 
provided. 
Additional costs associated 
with training. No details 
provided. 
Manufacturer provides 
online learning videos 
and on-site training at no 
extra cost. 
Manufacturer provides 
online learning videos and 
on-site training at no extra 
cost. 
Warranty 2 years 2 years 2 years 12 months 12 months 
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 Technology 
Semi-
/quantitative 
Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Proprietary 
name 
Eurolyser CRP assay and   
Cube S Analyser 
iChroma™ CRP test cartridge 
and iChroma™ Reader 
AFIAS™ CRP test 
cartridge and  AFIAS 1™ 
Analyser 
AQT90 Flex CRP assay 
and AQT90 Flex analyser 
Microsemi CRP reagent 
unit and Microsemi 
analyser Manufacturer Eurolyser  Diagnostica 
GmbH 
Boditech Med Boditech Med Radiometer Medical ApS Horiba Ltd 
Reference 
codes 
Eurolyser CRP assay:             
ST 0100 CRP test kit (32 
tests) 
ST 0102 CRP test kit with 
integrated capillary ( 32 
tests) 
ST 1000 CRP control kit (2 
x 2ml)(low/high) 
Cube S analyser: CA 0110 
iChroma
™
 CRP test cartridge 
for use with 
iChroma
™
 Reader 
 
Reference codes not 
reported.  
AFIAS™ CRP  
for use with  
AFIAS 1™ Analyser 
AQT90 Flex CRP Reagent 
pack (capacity for 200 
separate tests and waste 
disposals)  
AQT90 Flex immunoassay 
analyser 393-838 
Reference code from 2008 
CE declaration (March 
2015) 
Microsemi CRP Reagent 
Unit  (50 tests per 
cartridge, 2 cartridges per 
box) 
 
Microsemi analyser 
Class/GMDN 
code 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC 
General Category IVD, CE 
marked in accordance with 
the IVD directive 
98/79/EC; GMDN code 
53705 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC 
Additional tests Microalbumin, D-Dimer, 
Ferritin, iFOB, K
+
 , 
Lipoprotein A, Troponin I, 
ASO, CRP, hsCRP, 
Cystatin C (GFR), Hb, 
HbA1c, PT (INR) 
Troponin I, CK-MB, 
myoglobin, hsCRP, PSA, 
AFP, HbA1C, cortisol, 
malaria, reumafactor IgM, D-
dimera, CEA
b
, TSH
b
, T4
b
, 
FSH
b
, hCG
b
, LH
b
, prolactin
b
, 
testosterone
b
, ferritin
b
, iFOB
c
, 
microalbumin
c
 
Quantitative testing 
possible using c-tip for 
TSH, PCT, and HbA1c 
D-dimer, beta-hCG, 
troponin I, troponin T, CK-
MB, myoglobin, NT-
proBNP 
WBC, RBC, Hb, Ht, 
platelets, lymphocytes, 
monocytes, granulocytes  
(calculated: MCV, MCH, 
MCHC, RDW, PDW, MPV) 
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 Technology 
Semi-
/quantitative 
Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Method Immunoturbidimetric assay Fluorescence sandwich 
immunoassay 
Fluorescence 
immunoassay  
Solid phase sandwich 
immunoassay 
Immunoturbidimetric assay 
Sample size & 
type 
(+alternative 
materials) 
5 μL capillary blood 
sample (venous blood/ 
serum) 
10 μL capillary blood sample    
(venous blood/ 
plasma/serum) 
10uL or 50uL capillary 
blood sample from finger 
or heel (whole blood/ 
plasma/serum) 
2 mL venous blood sample          
(plasma) 
 
18 μL capillary blood 
sample + dead volume in 
the tube to 100 μL. 
(venous blood) 
Analytical range 
(whole blood) 
2.0 – 240 mg/L CRP  2.5 – 300 mg/L CRP 
 
0.5~200 mg/L CRP 5 – 500 mg/L CRP 
 
2.0 – 230 mg/L CRP 
Calibration No – automatic No Yes. ID Chip recorded 
once for each specific lot. 
Yes. Adjustment needed 
when using a new lot no. 
reagent pack (time 
needed: 48 mins). 
No 
Haematocrit 
auto-correction 
Yes
a
  No No Yes
a 
 Yes
a
 
Special storage 
requirements for 
test (e.g. 
refrigeration) 
Storage in refrigerator (2-
8°C). Allow single test at 
least 10 mins to warm up 
to room temperature. 
 
Storage in refrigerator (2-8 
°C). Allow detection buffer 
(DB) tube to attain room 
temperature for 30 mins 
before performing test.                   
2-8ºC for DB / 4-30ºC for 
cartridge. 
Storage in refrigerator (2-
8°C). 
No special storage 
requirements. Closed 
analysis system.  
No special storage 
requirements stated on 
company brochure. 
Analyser size 
and weight 
Instrument: 16 x 13 x 14.5 
cm   2.4 kg  
(Tablet 14.2 x 7.2 x 0.8 
cm) 
18.5 × 8 × 25 cm                           
1.3 kg 
32  x 20 x 18 cm                     
3.9 kg 
45 × 46 × 48 cm                      
35 kg 
43 × 26 × 45 cm                      
19 kg 
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 Technology 
Semi-
/quantitative 
Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Analyser warm-
up time  
Not reported Not reported Not reported Not reported Not reported 
Performance 
time for  pre- 
and actual 
analysis  
5 min  
(= 1 min + 4 min) 
5 min  
(= 2 min + 3 min) 
5 min  
(= 2 min + 3 min) 
13.5 min  
(= 30 sec + 13 min)       
Add 4 mins to install 
reagent pack if necessary 
4.5 min  
(= 30 sec + 4 min) 
Practical 
aspects of test  
Automated, maintenance-
free analysis with pre-set 
calibration curves & auto-
self-test routine. Integrated 
capillary not always easily 
filled with blood. 
Allow detection buffer tube to 
attain room temperature for 
30 mins before performing 
test. Relatively complicated 
preanalytical handling using 
sample with detection buffer. 
Requirement to shake 10 
times and discard first 2 drops 
before adding 2 drops to test 
cartridge. Portable analyser. 
Semi-automatic 
immunodiagnostic device 
which uses all-in-one 
cartridges; it automatically 
mixes and dispenses 
samples when user loads 
sample only. Desktop 
analyser (but easy to 
carry). Empty the C-tip 
waste box daily. 
The system minimises pre-
analytical sample handling 
and utilises a closed 
sample system for reagent 
mixing and measurement. 
No contact with blood or 
waste. Needs venous 
blood samples and 
involves considerable time 
for analysis. Up to 15 
cartridges placed in inlet 
with up to 16 tests each. 
CRP measurement only 
possible in combination 
with haematology 
parameters. All-in-one: 3 
reagents in the same 
cartridge and no need for 
cartridge removal after 
use. 
Connectivity Yes. Eurolyser CUBE is 
suited for connecting to 
eHealth services due to its 
internet and network 
capable android 
application on the tablet 
PC. 
Yes. Online connection 
indirectly possible with LIS. 
Yes. LIS / HIS 
communication. 
Yes. Online connection 
possible with HIS and LIS. 
Yes. Online connection 
possible with  LIS. 
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 Technology 
Semi-
/quantitative 
Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Print function Seiko DPU-414 thermal 
printer & Seiko Label 
Printer 650 SE are 
optional accessories 
Printer (optional) Data output via Internal 
Printer  
Hardware includes 4” 
thermal-sensitive printer 
Integrated thermal printer 
Data storage on 
device 
Yes. Data transfer is 
possible to external 
devices 
No details reported Yes. 5,000 patient results Yes. 2,000 patient results Yes. 180 patient results 
Device lifespan  Not reported Not reported Not reported Not reported Not reported 
Maintenance  Designed as maintenance-
free. Instrument is 
calibrated at the factory 
and has an internal self-
check procedure during 
every measurement. 
No details reported No details reported No details reported Refer to “zero-
maintenance” concept 
applicable to the 
technology. 
Software 
updates  
Embedded software and 
new versions are released 
for free when new features 
or functionality 
improvements are added. 
Updated via the CUBE 
app. 
No details reported No details reported No details reported No details reported 
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 Technology 
Semi-
/quantitative 
Quantitative CRP analysers 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
Quality checks The CUBE system uses 
single-use reagents, and 
internal measurements are 
to be performed once a 
week. Integrated QC 
system. 
No details reported No details reported Built in quality control for 
continuous analyser 
performance evaluation. 
Liquid quality control 
(LQC) materials for 
the AQT90 FLEX 
analyser help estimate the 
precision of test results 
and detect systematic 
analytical deviations that 
may arise from reagent or 
analyser variation. 
Quality control target 
values uploaded by flash 
card. 
Training & 
support 
Online video tutorials for 
analyser set up and 
training. 
No details reported No details reported No details reported No details reported 
Warranty No details reported No details reported No details reported No details reported No details reported 
 
  
CRP POCT to guide antibiotic prescribing in primary care settings for acute respiratory tract infections 
EUnetHTA Joint Action 3 WP4 55 
 
 Technology 
Semi-
/quantitative 
Quantitative CRP analysers Semi-quantitative CRP tests 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
CRP test strips Single-use disposable test 
Proprietary 
name 
spinit
®
 CRP disposable 
disc and spinit
®
 instrument 
CRP IS™ test kits and 
Innovastar™analyser 
Actim
®
 CRP dip sticks Cleartest
® 
CRP strips FebriDx
®
 
Manufacturer Biosurfit DiaSys Diagnostic 
Systems  
Medix Biochemica Servoprax RPS Diagnostics 
Reference 
codes 
spinit
®
 CRP disposable 
disc (20 test kit size) 
Reference codes not 
reported 
CRP IS™ test kits 
270699910761 (50 
determinations per test kit) 
270699910760 (100 
determinations per test kit)    
and  
Innovastar™analyser 
Actim
®
 CRP kit 
31031ETAC      (20 CRP 
test packs) 
Cleartest
® 
CRP strips C3 
4050 (10 and 20 CRP test 
packs) 
FebriDx
® 
BP0036 (25 CRP 
test kit) 
Class/GMDN 
code 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC 
General Category IVD, CE 
marked in accordance with 
the IVD directive 98/79/EC; 
GMDN: 64042. 
Additional tests Hb1Ac and other blood 
components (total 
leucocytes, white blood 
cells and haematocrit) 
Glucose, haemoglobin, 
HbA1c 
No No MxA 
Method Multi-method combination 
of  immunoassay, 
haematology and clinical 
chemistry targets in a 
disposable test panel 
Immunoturbidimetric test Immunochromatographic Immunochromatographic Lateral flow immunoassay  
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 Technology 
Semi-
/quantitative 
Quantitative CRP analysers Semi-quantitative CRP tests 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
CRP test strips Single-use disposable test 
Sample size & 
type (+ 
alternatives) 
5 μL capillary blood 
sample       (whole blood 
(venous and capillary), 
serum and plasma) 
10 μL capillary blood 
sample (whole blood and 
plasma) 
 
10 μL capillary blood 
sample       (can also 
sample from anti-
coagulated whole blood ) 
10 μL capillary blood 
sample       (can also 
sample from anti-
coagulated whole blood ) 
5 μL capillary blood sample         
Analytical range 
(blood) 
2 – 180 mg/L CRP 5 - 400 mg/L CRP 0 – >80 mg/L CRP 0 – >80 mg/L CRP Qualitative thresholds: CRP ≥ 
~ 20 mg/L MxA ≥ ~40 ng/mL 
Calibration No  
 
No – precalibrated tests. 
But original calibration 
stability for 9 months only. 
To ensure measuring 
accuracy of the parameter 
reagent lot in use, 
recalibration is 
recommended. 
N/A N/A N/A 
Haematocrit 
auto-correction 
No Yes
a
 No No No 
Special storage 
requirements for 
test (e.g. 
refrigeration) 
Storage in refrigerator (2 - 
8 °C) 
Ready-to-use unit dose 
test.  Shelf life 18 months 
from production.  
Storage at 2 to 25 °C. 
Stored unopened, Each 
component can be used 
until the expiry date 
marked on the component. 
Storage at 2 - 30 °C. No refrigeration or special 
storage conditions required. 
The shelf-life for the test kits 
is 2 years at room 
temperature. 
Analyser size 
and weight 
24 x 22 x 31 cm                         
4 kg 
20 x 15  x 17 cm                       
4 kg 
N/A N/A N/A 
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 Technology 
Semi-
/quantitative 
Quantitative CRP analysers Semi-quantitative CRP tests 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
CRP test strips Single-use disposable test 
Analyser warm-
up time  
No details reported No details reported N/A N/A N/A 
Performance 
time for  pre- 
and actual 
analysis   
5 min  
(= 1 min* + 4 min)          
(*however wait-time of at 
least 3 mins after fridge 
removal before opening 
pouch)  
8 min  
(= 1 min + 7 min)           
7.5 min  
(= 2.5 min + 5 min) 
7.5 min  
(= 2.5 min + 5 min*) 
(*analysis time should  not 
be later than 10 min ) 
10 min  
(= performance + time to 
result). Analysis time should 
not exceed 3 hours of the 
results being displayed. 
Practical 
aspects of test  
Must remove disc from 
refrigerator and wait at 
least 3 minutes before 
opening pouch. 
Fully automated system – 
no manual steps required 
during measurement. 
Single cartridge containing 
all reagents needed for 
testing. Precalibrated tests 
– no time-consuming 
calibration. 
Relatively complicated 
pre-analytical handling, 
semi-quantitative, inter-
observer variation, cut-off 
at 80 instead  of 100 mg/L. 
Relatively complicated 
pre-analytical handling, 
semi-quantitative, inter-
observer variation, cut-off 
at 80 instead of 100 mg/L. 
FebriDx
® 
does not require any 
additional ancillary 
equipment. FebriDx
®
 “high 
CRP” reading suggests ≥ 
20mg/L. 
Connectivity Yes. LIS / HIS 
communication 
No details reported N/A N/A N/A 
Print function Print-out of test results in 
standard labels with printer 
(optional accessory) 
No details reported N/A N/A N/A 
Data storage on 
device 
Yes 50 results   Results display for 3 hours. 
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 Technology 
Semi-
/quantitative 
Quantitative CRP analysers Semi-quantitative CRP tests 
Device type  Assay kit & analyser 
instrument 
Assay kit & analyser 
instrument 
CRP test strips Single-use disposable test 
Device lifespan  Not reported Not reported Single-use strip Single-use strip Single-use disposable test. 
Shelf life of 2 years at room 
temperature. 
Maintenance  No maintenance as per 
manufacturer website 
 
No details reported N/A N/A N/A 
Software 
updates  
No details reported Link to IS Software for 
software download and 
update instructions 
N/A N/A N/A 
Quality checks A self-check is performed 
automatically when 
running a test 
No details reported N/A N/A External controls are 
available. 
Training & 
support 
No details reported No details reported Not reported Not reported Training provided through UK 
distributor as well as RPS 
Detectors.com or FebrDx.com 
(NICE MIB July 2017) 
Warranty No details reported No details reported N/A N/A N/A 
Abbreviations: ACR (Albumin/creatinine ratio); AFP (Alpha-fetoprotein); ASO (Anti-Streptolysin-O); CEA (oncofetal glycoprotein); CK-MB (Creatine Kinase either muscle or brain type); FSH 
(follicle-stimulating hormone); GMDN (Global Medical Device Nomenclature); Hb (haemoglobin); HbA1c (glycated haemoglobin); hCG (human chorionic gonadotropin);  HIS (Hospital Information 
System); hsCRP (high-sensitivity CRP); Ht (haematocrit); iFOB (faecal immunochemical test for haemoglobin); IVD (in vitro diagnostic); K+ (Potassium); LH (Luteinising hormone);  LIS (Laboratory 
Information System); MCH (mean corpuscular haemoglobin); MCHC (mean corpuscular haemoglobin concentration); MCV (mean corpuscular volume); MPV (mean platelet volume); MxA Myxovirus 
resistance protein A); N/A (not applicable); NT-proBNP (N-terminal pro b-type natriuretic peptide); PCT (Procalcitonin); PDW (platelets distribution width); PSA (prostate specific antigen); PT(INR) 
Prothrombin Time (international normalized ratio) ; RBC (red blood cell); RDW (red blood cells distribution width); Strep A (Streptococcus pyogenes); T4 (Thyroxine); TSH (thyroid stimulating 
hormone); U-ALB (quantitative test for albumin in urine samples); WBC (white blood cell). 
Footnotes: a. If the Hct value is outside the range 20-60 %, no CRP test result will be reported and an information code will be displayed). In these cases serum or plasma samples are 
recommended for CRP analysis; b. Only in serum/plasma, centrifuge step necessary; c. Urine/faeces. 
Sources included: Brouwer (2015)[16] ; Minnaard (2013) [18]; NICE Medtech Innovation Briefing reports for QuikRead
®
 [33], Alere Afinion™ [32] and FebriDx
®
 [34]; dossier submissions from 
Orion, Abbott, Medix Biochemica and RPS Diagnostics, and available information from manufacturers’ websites. 
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[A0020] – For which indications have each of the CRP POCT instruments/methods received CE 
marking? 
A summary of the regulatory status of the identified CRP POCT devices is provided in Table A16 in 
Appendix 2. Orion Diagnostica was the first to launch a fully quantitative CRP POCT system 
(QuikRead
®
) in 1993. This original device has been followed by newer-generation quantitative devices 
from Orion Diagnostica and competing manufacturers in the in vitro diagnostic medical device market. 
The tests are indicated for the quantitative determination of CRP in human whole blood and in human 
serum and plasma. The measurement of CRP provides information for the detection and evaluation of 
infection, tissue injury, inflammatory disorders and associated diseases. These tests are CE marked 
in accordance with the IVD Directive (98/79/EC) and are classified as general category IVDs. The CE 
marking process for this class of IVDs involves the manufacturer self-declaring that the device is in 
conformity with the IVD Directive. Semi-quantitative CRP test strips, Actim
®
 and Cleartest
®
, are also 
CE marked in accordance with the IVD directive.  
The first semi-quantitative CRP and viral biomarker co-test was CE marked in September 2014: 
FebriDx
®
 is a CE marked rapid in vitro immunoassay for the semi-quantitative measurement of CRP 
and qualitative measurement of Myxovirus resistance protein A (MxA) in peripheral whole blood. An 
updated version of the device that included an all-in-one built-in safety lancet, calibrated blood collec-
tion and transfer system, and integrated push-button buffer delivery mechanism to help prevent user-
related errors and improve test performance has since been developed. 
All these IVD medical devices are intended for use by a healthcare professional. The CRP system is 
indicated for use in patients when it is not clear if antibiotics should be prescribed based on clinical 
assessment alone. 
CRP POCT devices are subject to EU Regulation 2017/746 on In Vitro Diagnostic Devices (IVDR) 
which came into force at the end of May 2017 [30]. The regulations will have a staggered transitional 
period, with full application after five years. These regulations replaced a number of existing directives 
and are intended to strengthen the current regulatory system by providing: 
 clearer requirements for clinical data on IVD medical devices, and their assessment 
 more specific product requirements, such as a unique identifier for IVD medical devices 
 improved pre-market assessment and post-market surveillance of all high-risk devices 
 increased control and monitoring of Notified Bodies by the National Competent Authorities 
and the Commission 
 more stringent requirements for POCT (near-patient tests) 
 enhanced traceability for IVDs. 
One of the key changes under the IVDR relates to the conformity assessment procedures required of 
manufacturers prior to an IVD being placed on the market. Requirements vary based on the risk clas-
sification of the device, that is, for low-risk (Class A) up to high-risk (Class D). Assessment and certifi-
cation by a notified body for medical devices will be required for those IVD devices in Classes B, C 
and D. Class A devices placed on the market in a sterile condition shall also require notified body 
involvement, limited to the sterile aspects of the product. Devices for POCT (near patient testing) are 
classified in their own right under Rule 4(b) Annex VIII of the 2017 IVDR regulations. Depending on 
the intended purpose specified by the manufacturer, CRP tests will likely be in Class C (under Rule 3) 
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or Class B (under Rule 6). This represents a significant change to the existing regulatory system, 
where the majority of IVDs are self-declared by the manufacturer rather than being assessed by a 
notified body. Detailed requirements for the performance evaluation of IVDs are outlined in the IVDR. 
Under the IVDR, IVDs for POCT must perform appropriately for their intended purpose taking into 
account the skills of the intended user and the potential variation in the user’s technique and environ-
ment, with sufficient information provided in order for the user to be able to correctly interpret the re-
sult provided. It is recognised that the enhanced regulatory burden arising from implementation of the 
IVDR may impact the number and range of IVDs on the market. 
Within each country, the organisation designated as the Competent Authority for medical devices 
has a role is to ensure that all medical devices sold into the market comply with the relevant legisla-
tion. This means that a medical device must achieve the performance criteria specified by the manu-
facturer and in doing so must not compromise the health and safety of patients, service providers 
and any other persons. In their role as a Competent Authority, these organisation must operate a 
vigilance system for medical devices. Vigilance issues include adverse incidents and field safety 
corrective actions (FSCAs). Reporting includes voluntary reporting systems for users of medical 
devices, healthcare professionals or any other person who identifies a medical device safety issue. 
There is a mandatory requirement for manufacturers to report vigilance issues to the appropriate 
national Competent Authority. The European guidelines for a medical devices vigilance system are 
outlined in MEDDEV 2.12/1 [16, 43]. 
A field safety corrective action (FSCA) is an action taken by a manufacturer to reduce a risk of death 
or serious deterioration in the state of health associated with the use of a medical device that is al-
ready placed on the market. Such actions, whether associated with direct or indirect harm, should be 
reported and should be notified via a field safety notice (FSN). The FSCA may include, for example: 
the return of a medical device to the supplier; device modification; advice given by manufacturer 
regarding the use of the device and/or the follow up of patients, users or others. It is very important 
that providers of CRP POCT have adequate traceability systems in place in the event of a field safe-
ty corrective action necessitating, for example, a review of results or the recall of patients for repeat 
testing. 
[B0002] – What is the claimed benefit of CRP POCT technology in relation to standard care for 
guiding antibiotic treatment in patients presenting to primary care settings with symptoms 
suggestive of an acute RTI? What might be the potential harms or risks of this technology in 
relation to standard care? 
The aim of the CRP POCT technology is to provide reliable CRP test results, which allow physicians 
to differentiate between mild and severe RTIs, and to rule out potentially serious bacterial infections, 
when it is not clear if antibiotics should be prescribed based on clinical assessment alone. The phy-
sician follows diagnostic and treatment guidelines, basing antibiotic treatment decision(s) for the 
patient (of no antibiotic therapy, delayed antibiotic prescription or offering antibiotic therapy) on 
whether CRP results fall below or above explicit thresholds as outlined earlier. 
The technology should therefore have a moderating influence on the need for the physician to issue 
an immediate prescription for antibiotics. The test result should be available in minutes during patient 
consultation to support an immediate treatment decision in primary healthcare settings, eliminating 
the delay in receiving laboratory results (which can often take hours or even days to arrive) and 
speeding up patient referral to secondary care if required. By assisting physicians to make immedi-
ate treatment decisions, the technology is intended to enhance patient safety and compliance with 
clinical guidelines for the management of RTI, as well as physician and patient satisfaction. CRP 
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POCT conducted during the patient visit has been found to increase patient satisfaction and under-
standing of when antibiotics are and are not needed [44].  
Debate over the accuracy of POC tests and their effect on antibiotic prescribing is ongoing. Some 
studies have found the analytical performance of POCT comparable to laboratory testing, while oth-
ers have reported that certain pieces of equipment are more accurate and precise than others [18, 
45]. The ability of CRP POCT to aid in the diagnosis of serious bacterial RTIs is unclear, with some 
studies finding it useful in primary care [46], while others have reported it to have limited utility [47]. 
The subsequent effect of CRP POCT on the prescription of antibiotics has shown conflicting results, 
with some studies finding it significantly reduces antibiotic prescribing [24, 48], while others have 
found it has little effect [46, 49] or may even lead to an increase in antibiotic use [50] and hospitalisa-
tion rates [24]. CRP POCT can produce false positive as well as false negative results, leading to the 
possibility of over- or under-treatment of RTIs [24].Some commonly prescribed medications (such 
as, lipid-lowering agents, ACE inhibitors, ARBs, anti-diabetic agents, anti-inflammatory and anti-
platelet agents, and beta- adrenoreceptor antagonists) are known to lower CRP levels, and this 
should be taken into account during the patient consultation, as a low CRP test result may carry a 
risk of inappropriate treatment choices by the clinician [51]. Over-treatment can lead to avoidable 
adverse reactions to antibiotics and contribute to antimicrobial resistance; while under-treatment due 
to a failure to prescribe timely antibiotic therapy could potentially lead to increased morbidity or mor-
tality.  
The safety and effectiveness and diagnostic test accuracy of CRP POCT in patients presenting with 
acute RTI as well as the analytical performance of the commercially available CE marked tests is 
assessed in detail in the safety and effectiveness domains of this report. 
[B0003] – What is the phase of development and implementation  
of the technology and the comparator(s)? Overlaps with: 
[A0021] – What is the reimbursement status of CRP POCT in primary care in the European 
countries participating in EUnetHTA? 
The use of CRP POCT in patients with suspected LRTI has been included in guidelines in the UK, 
Norway, Sweden, the Netherlands, Germany, Switzerland, Czech Republic and Estonia to determine 
severity of infection and to guide antibiotic prescribing [42, 52]. Leading adopters of the technology 
include the Netherlands and the Scandinavian countries [18]. The UK NICE guidelines for the diag-
nosis and management of pneumonia in adults (2014) have issued a non-mandatory recommenda-
tion that CRP POCT should be considered for people with symptoms of LRTI in primary care if a 
diagnosis is unclear after clinical assessment, and that antibiotics should be prescribed based on the 
result. 
In many European countries, healthcare is budget-driven rather than reimbursement-driven. These 
countries appear not to provide direct reimbursement for the use of CRP POCT in primary care. The 
reimbursement estimate per test was estimated from data provided by one of the five manufacturers 
who engaged in the REA, and from data shared by the WP4 partner from the relevant country. A 
summary of the reimbursement recommendations and implementation phase for CRP POCT in Eu-
rope is provided in Table A17 in Appendix 2. 
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[B0004] – Who administers CRP POCT? In what context is it provided? In what primary care 
settings is it used (e.g. GP practices, out-of-hours clinics, long-term care facilities)? 
As indicated in A0020, the identified CRP POCT devices are intended for use by healthcare profes-
sionals and are suitable for use in primary care. The suggested use of CRP POCT is in patients 
presenting with symptoms of acute RTI where the clinical assessment of the infection type (bacterial 
or viral) is inconclusive, and it is unclear if antibiotics should be prescribed. Depending on the clinical 
guideline or care pathway developed, the test may be administered by the GP, practice nurse, 
healthcare assistant or pharmacist [53]. Primary care settings may include GP practices, out-of-
hours clinics, long-term care facilities and community pharmacies. Commercially available CRP 
POCT analysers intended for use in primary care range in size and weight (from 1kg to 35kg) with 
some considered to be portable instruments that can be easily moved to the point-of-need, for ex-
ample if a GP is providing care in a number of settings including out-of-hours clinics or long-term 
care facilities. However it is noted that moving instruments could impact their analytical performance.  
 
[B0009] – What equipment, supplies and training are needed to implement CRP POCT in 
primary care? 
The type of equipment required for implementing CRP POCT in primary care depends on whether 
the technology adopted is a quantitative test (that is, assay with analyser) or semi-quantitative test 
(that is, strip or single-use disposable device). The features of the commercially available CE 
marked technologies identified in this REA are listed in Table 7. [B0001] 
For certain brands of CRP POCT analyser and assay vial system, scanners and barcode label printers 
may be required to facilitate information transfer of the batch and lot number of the assay vial to the 
electronic health record of the patient. The facility to either scan or directly upload results into the clini-
cal record and laboratory information management system could be considered beneficial when con-
sidering potential wide-scale implementation of the technology within a healthcare system. 
Lancets and capillary sticks are needed for the capillary blood sample for all tests, with the exception 
of the FebriDx
®
, which has an integrated lancet and capillary in the single-use disposable device. 
When providing POCT, suitable facilities are required for sample collection, execution of the point-of-
care tests, storage of instrumentation (if any), safe disposal of sharps and clinical waste, and to en-
sure that consumables such as test kits and reagents are stored under the appropriate conditions as 
defined by the manufacturer. Relevant regulations include the European Union (Prevention of 
Sharps Injuries in the Healthcare Sector) Regulations 2014 [54].  
Refrigeration of test kits at 2-8°C is required for a number of the assay tests identified, with a specifi-
cation that the kits be brought to room temperature prior to use. The unique storage details specific 
to each device are listed in Table 7.  
Given the requirement for a blood, serum or plasma sample, usual local and national infection preven-
tion and control guidelines will apply to minimise the risk of the patient acquiring a preventable 
healthcare-associated infection and also to protect staff from acquiring an infection in the workplace. 
Disposable gloves should be worn for all activities that carry a risk of exposure to blood or body fluids. 
The disposal of all samples and other test materials should follow usual official regulations. Con-
sumables such as lancets, disposable strips, cartridges, patient samples, and any used cuvettes, 
capillaries and plungers if required for the analyser type, should be handled and disposed of as ap-
propriate for potentially infectious (bio-hazardous) waste. Waste receptacles must be of sufficient 
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size and volume to accommodate the waste generated, including sharps bins where relevant. When 
used in accordance with good laboratory practice, good occupational hygiene and the instructions 
for use, the reagents supplied with these tests should not present a hazard to health. Some of the 
assays minimise the exposure to test reagents as they use all-in-one test cartridges (with the rea-
gent included), while one analyser (AQT90) uses a closed-sample system for reagent mixing. 
Basic training of healthcare professionals is required to use CRP POCT in primary care. The level of 
training involved will depend on whether the technology adopted is a quantitative test (that is, assay 
with analyser) or semi-quantitative test (that is, test strip, dipstick or single-use disposable device). 
Training in preanalytic handling including machine calibration is required for quantitative tests; train-
ing in the interpretation of the tests is required for both quantitative and semi-quantitative tests. The 
practical aspects of using the available tests and the level of training support available from manu-
facturers (where provided) are detailed in Table 7. In addition, support may be needed from labora-
tories to provide advice on quality assurance, external quality control and training in tandem with that 
provided by the manufacturers.  
In some countries, national guidelines for the implementation of POCT in primary care are available 
that detail the requirements for staff training in the use of POCT. For example, the “Guidelines for 
Safe and Effective Management and Use of Point of Care Testing in Primary and Community Care 
in Ireland (2009)” [55], state that: 
“It is imperative that all staff performing POCT are trained and competent in the use of the test. This 
training may be conducted by the manufacturer or authorised representative. Relevant professional 
organisations may also provide training on certain tests. It is important to agree the detail and level of 
training to be provided by the manufacturer or his representative at the time of purchase of the POC 
test and to ensure that this training is completed and recorded prior to implementation of the POCT 
service. Training records should be kept in each testing location. Where appropriate, trainers should 
be designated and such individuals should receive extra training. A training record template is 
included in Appendix 7.5. The competency of the individual performing POCT should be assessed on 
an ongoing basis and supplementary training provided if required.  
A training programme should be put in place and should include the following elements: 
 Instructions on safe working practices 
 Principles of operation of the device 
 Review of the manufacturer’s instructions for use (IFU), limitations of the device, interfer-
ences 
 Review and understanding of error messages, interpretation, and appropriate responses  
 Calibration and quality control requirements, including acceptable limits, appropriate rec-
ord keeping and required actions for failed results 
 Patient preparation, sample collection and handling according to the manufacturer’s stated 
requirements and health and safety regulations 
 Interpretation and recording of patient results and appropriate patient referral and follow-
up 
 Training of new recruits and periodic refresher training for service providers”  
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There may also be a healthcare policy requirement to include communication training and/or an 
education piece for physicians and patients around the link between antibiotic prescribing and anti-
microbial resistance. 
The workflow at the testing site may need to be reconsidered if POCT has not previously been used 
in the primary care setting (that is, who will perform the test and report the result to the patient). For 
quantitative tests, the number of analysers required will depend on the number of practitioners 
performing the test and the layout of the practice setting.  
Independent accreditation is an important and often mandatory requirement for pathology laboratories 
as part of their quality assurance processes. International standards for POCT have been developed 
by the International Standards Organization (ISO) in the form of ISO 22870: 2016 [56]. This document 
gives specific requirements applicable to POCT and is intended to be used as a companion to ISO 
15189: 2012 Medical Laboratories – Requirements for Quality and Competence Standard. The ISO 
22870 standard specifies requirements for competence and quality in POCT performed in hospitals, 
clinics and healthcare organisations providing ambulatory care; it excludes patient self-testing in a 
home or community setting. National guidelines in some countries recommend that any POCT service 
in primary care be ISO accreditable [55, 57]. These guidelines may recommend any site providing a 
POCT service to undergo a relevant accreditation procedure in order to provide assurance of the 
validity of the point-of-care results taking into account clinical context and patient safety [57]. 
Examples of organisations that provide external quality assurance include SKUP (www.skup.org), a 
Scandinavian cooperation between agencies in Denmark, Norway and Sweden for evaluation of near-
patient laboratory equipment, which publishes independent evaluations of the analytical performance 
of CRP POCT equipment; and Weqas in Wales (www.weqas.com), which is supporting roll-out of 
CRP POCT to inform antibiotic prescribing in Wales. 
3.3 Discussion  
CRP POCT devices are indicated for the quantitative determination of CRP in human whole blood 
and in human serum and plasma. The measurement of CRP provides information for the detection 
and evaluation of infection, tissue injury, inflammatory disorders and associated diseases.  
The aim of the CRP POCT technology is to provide reliable test results, which allow physicians to 
differentiate between mild and severe RTIs, and to rule out potentially serious bacterial infections, 
when it is not clear if antibiotics should be prescribed based on clinical assessment alone. The test is 
therefore expected to be used as a rule-out tool and have a moderating effect on the prescribing of 
antibiotics. 
CRP POCT can be used in combination with communication training, an education component and/or 
tests for other biomarkers in addition to standard care to assist the treating clinician in differentiating 
between bacterial and viral aetiology, and thereby guide antibiotic prescribing. It is proposed that use 
of CRP POCT enhances patient safety and compliance with clinical guidelines, as well as physician 
and patient satisfaction. There is a risk, however, that CRP POCT can produce false positive as well 
as false negative results, leading to the possibility of over- or under-treatment of RTIs. Over-treatment 
can lead to avoidable adverse reactions to antibiotics; while in those who are under-treated, there is 
the potential risk of increased rates of morbidity or mortality. 
Fifteen CE marked CRP POCT devices (that is, devices that are declared to be in conformity with the 
IVD directive) were identified for inclusion in this REA. These could be broadly classified into one of 
two categories: quantitative methods (that is, analysers using either capillary or venous blood) and 
semi-quantitative methods (that is, strips, dipsticks or single-use disposable tests using capillary 
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blood). These technologies differ in a number of respects, including the size and portability of the 
analyser devices; the requirement for calibration and the extent to which pre-analytical handling is 
required; analyser warm-up and performance times; and the degree to which test data can be stored 
on the device, printed and/or transferred to electronic patient files. These differences may impact the 
acceptability and performance of the various devices for the intended user (that is, healthcare staff 
who are not laboratory specialists working in the primary care setting) and their use could have impli-
cations for practice management and workflow. 
There must be confidence in the CRP results delivered from CRP POCT in primary care. Doctors 
require accurate and reliable technology that will deliver CRP results that their patients can trust. ISO 
accreditation of the CRP POCT sites addresses issues relating to clinical governance, risk manage-
ment, user competence training, internal quality control and external quality assurance of testing, with 
national guidelines in some countries recommending that any POCT service should be ISO accred-
itable. 
Use of CRP POCT in the management of patients with suspected LRTI has been included in guide-
lines in the UK, Norway, Sweden, the Netherlands, Germany, Switzerland, Czech Republic and Esto-
nia, with the Netherlands and Scandinavian countries being leading adopters of the technology in 
primary care. At least 18 European countries have CRP POCT technology available to medical practi-
tioners for use in patients in primary, outpatient and/or ambulatory care settings, although reimburse-
ment status and policy differs between countries. 
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4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR) 
4.1 Research questions 
Element ID Research question 
A0002 What conditions do acute RTIs comprise and how are these defined?  
What is antimicrobial resistance and how is it related to antibiotic prescribing 
patterns? 
A0003 What are the known risk factors for acute RTIs?  
What factors increase the prevalence of antimicrobial resistance in the population? 
A0004 
Overlaps 
with 
 
A0005 
What is the natural course of acute RTIs?  
(As RTIs are a collection of specific diagnoses, each diagnosis will be discussed 
briefly, e.g. pneumonia, pharyngitis.) 
What are the symptoms and burden of disease of an acute RTI for the patient?  
(Again, as RTIs are a collection of specific diagnoses, each diagnosis will be 
discussed briefly, e.g. pneumonia, pharyngitis.) 
A0006 What are the consequences of acute RTIs for society?  
What are the consequences of antimicrobial resistance for society? 
A0007 What is the target population of this assessment? 
A0024 
Overlaps 
with 
A0025 
How are acute RTIs currently diagnosed according to published guidelines from 
European countries?  
How are acute RTIs currently managed according to guidelines from European 
countries? How are they managed in practice? 
A0023 What is the epidemiology of RTIs across the European Union in primary care 
settings? 
A0011 To what extent is CRP POCT currently used in Europe to guide antibiotic 
prescribing?  
 
 
4.2 Results 
Overview of the disease or health condition 
[A0002] – What conditions do acute RTIs comprise and how are these defined?  
Respiratory tract infections (RTIs) are the most frequent infections encountered in primary care; most 
are viral, but a small number are caused by bacteria and may respond to antibiotics. Symptoms of 
RTI include cough, discoloured and/or increased sputum production, pain, fever, blocked and/or runny 
nose, respiratory distress, loss of voice, feeling unwell, or combinations of focal and systemic 
symptoms. RTIs may be classified as upper or lower respiratory tract infections, the boundary of 
which is typically the larynx. Upper respiratory tract infections (URTIs) include pharyngitis, tonsillitis, 
laryngitis, rhinosinusitis, otitis media and the common cold [24]. Lower RTIs (LRTIs) include 
pneumonia, bronchitis, tracheitis and acute infective exacerbations of COPD. Influenza may affect 
both the upper and lower respiratory tract. The pragmatic definition of a LRTI adopted in the 2011 
guidelines produced by the European Respiratory Society (ERS) in collaboration with the European 
Society for Clinical Microbiology and Infectious Disease (ESCMID) is as follows: ‘an acute illness 
(present for 21 days or less), usually with cough as the main symptom, with at least one other lower 
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respiratory tract symptom (sputum production, dyspnoea, wheeze or chest discomfort/pain) and no 
alternative explanation (for example, asthma)’ [58]. 
The distinction between the upper and lower respiratory tract is illustrated in Figure 1. The definition of 
the different types of acute RTIs, their associated symptoms, and burden of disease, along with the 
natural course of the illnesses at an individual patient level, are detailed in Table A4 (Appendix 1). 
Figure 1: Anatomy of the respiratory tract 
 
 
 
 
 
 
 
 
 
 
In the majority of cases of RTI, no pathogen is identified, primarily because the organism is missed, or 
as in the case of patients presenting in primary care, testing is not performed because of challenges 
obtaining samples, limited access to diagnostics, and the limited clinical utility in obtaining results 
subsequent to the requirement for an empirical treatment decision to be made. A potential pathogen 
was identified in 59% of adults presenting to primary care with LRTI in a large EU-funded prospective 
case-control diagnostic study (n=3,104) undertaken in eleven European countries by the GRACE 
(Genomics to combat Resistance against Antibiotics for Community-acquired lower respiratory tract 
infection (LRTI) in Europe) consortium. Overall, a bacterial pathogen was identified in 21% of patients 
and a viral pathogen was identified in 48% of patients; both bacterial and viral pathogens were 
identified in 10% of cases [59]. The most common bacterial pathogens isolated were Streptococcus 
pneumoniae (5.5%) and Haemophilus influenzae (5.4%), while the most common viral pathogens 
isolated were human rhinovirus (20.1%), influenza virus (9.9%) and human coronavirus (7.4%). This 
evidence is consistent with the literature reported in the 2011 European Respiratory Society (ERS)/ 
European Society for Clinical Microbiology and Infectious Diseases (ESCMID) guidelines which noted 
that viruses are isolated in up to 60% of community-acquired LRTIs. The most common bacterial 
pathogens isolated are Streptococcus pneumoniae and Haemophilus influenza, although published 
estimates vary, ranging from 3% to 30% and from 3% to 14%, respectively, of community-acquired 
LRTI cases [58]. 
The aetiology of a subset of LRTI, specifically community-acquired pneumonia (CAP) in adults 
presenting to primary care, was also reported in the prospective study by the GRACE consortium. 
CAP was diagnosed in 4.5% of adults (6.4% of those >65 years) presenting with LRTI in primary care. 
Potential bacterial pathogens were significantly more likely to be identified in those with CAP, with a 
bacterial pathogen identified in 30% of cases. Viral pathogens were identified in 37% of cases, while 
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both bacterial and viral pathogens were identified in 7% of cases. No pathogen was identified in 40% 
of CAP cases. Again, the most common bacterial pathogens isolated were Streptococcus 
pneumoniae (9.2%) and Haemophilus influenzae (14.2%) [59]. This evidence is also consistent with 
other literature including that reported in the 2011 ERS/ESCMID guidelines which noted that viruses 
are involved in up to 30% of CAP, again with Streptococcus pneumoniae and Haemophilus influenzae 
being the most common bacterial pathogens [58, 60, 61].  
What is antimicrobial resistance and how is it related to antibiotic prescribing patterns? 
Antimicrobial-resistant organisms are found in people, food, animals, plants, and the environment (in 
water, soil, and air) and they can move between ecosystems [62]. Antimicrobial resistance (AMR) 
occurs naturally and over time when microorganisms (such as bacteria, fungi, viruses, and parasites) 
are exposed to antimicrobial substances [62]. As a result, treatments become ineffective and 
infections persist in the body, increasing the risk of spread to others [62]. However, new AMR 
mechanisms are emerging and spreading globally, threatening our ability to treat infectious diseases, 
resulting in prolonged illness, disability, and death, and increasing the cost of healthcare. Although the 
emergence of AMR is a natural phenomenon, the misuse and overuse of antimicrobials is 
accelerating this process [63]. 
The European Antimicrobial Resistance Surveillance Network (EARS-Net) has documented the 
changing epidemiology of bacteraemias in Europe, highlighting the emergence and spread of totally or 
almost totally resistant bacteria in European hospitals [64]. Of note, however, is the fact that the primary 
care setting accounts for 80% to 90% of all antibiotic prescriptions [65]. In 2017, the European Centre 
for Disease Control (ECDC) Surveillance Atlas of Infectious Disease reported high levels of 
Streptococcus pneumoniae with combined non-susceptibly to penicillins and macrolides in Bulgaria, 
Cyprus, Croatia, France, Iceland, Lithuania, Poland, Romania, Slovakia and Spain (Figure 2).  
Figure 2: Antimicrobial resistance (combined non-susceptibility for penicillins and 
macrolides) versus Streptococcus pneumoniae in EU/EEA countries, 2017 
Source: The European Centre for Disease Control (ECDC). 
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During the same period, high levels of carbapenem-resistant Klebsiella pneumoniae were reported in 
Cyprus, Greece, Italy, and Romania. This trend indicates higher rates of antimicrobial resistance in 
southern and eastern European countries.  
The European Surveillance of Antimicrobial Consumption Network (ESAC-Net) collates data for the 
EU and EEA countries on community-level antibiotic consumption for systemic use. Data for 2016 
indicate an EU/EEA population-weighted mean consumption of 21.9 DDD per 1,000 inhabitants per 
day. Although consumption was noted to be lower than in previous years, overall antibiotic 
consumption in the community showed no significant decreasing trend for the period 2012‒2016 [66]. 
There is substantial inter-country variation with consumption ranging from 10.4 (the Netherlands) to 
36.3 (Greece) DDD per 1,000 inhabitants per day (Figure 3). A number of countries, specifically 
Finland, Luxembourg, Norway and Sweden (Northern Europe), showed a decreasing trend in 
consumption during the 2012–2016 period, whereas increases were noted in Greece and Spain 
(Southern Europe) [66].  
Figure 3: Consumption of antibiotics for systemic use in the community, EU/EEA countries, 
2016 (expressed as DDD per 1 000 inhabitants per day) 
 
Source: The European Centre for Disease Control (ECDC) Summary of the latest data on antibiotic consumption in the EU 
(November 2017) [66]. 
 
This correlation between increased antibiotic consumption (which can be interpreted as a proxy for 
antibiotic prescribing patterns) and increased antibiotic resistance has been observed in a number of 
ecological studies. These studies have identified countries in the south and east of Europe that have 
moderate to high consumption of antibiotics as also having high rates of antimicrobial resistance [67]. 
Quality appraisal of antibiotic use is also undertaken by ESAC using twelve different quality indicators 
based on the type of antibiotic consumed (n=5), the relative proportions of these types (n=4), the use 
of broad versus narrow spectrum antibiotics (n=1), and seasonal variation in consumption (n=2). The 
2012 ESAC quality appraisal of antibiotic use in an outpatient setting between 2004 and 2009 also 
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showed an important north-south divide when the quality of antibiotic use is considered, with northern 
countries more likely to be rated as having high-quality use [68]. 
While antibiotic use is widely associated with antibiotic resistance, demonstrating causality is difficult 
because of population-based confounders and because there is wide variation in the effects of 
antibiotics that are within the same class on the selection of resistant organisms [69]. However, 
several case reports of fluoroquinolone-associated Clostridium difficile diarrhoea have been published 
[70]. A systematic review and meta-analysis of a large set of studies (n=243) found that antibiotic 
consumption is associated with the development of antibiotic resistance at both the individual and 
community level. This link was reported to be particularly strong for countries in Southern Europe [71]. 
At the patient level, there is a clear link between antibiotic dose and duration and the emergence of 
antibiotic resistance; there is also evidence that patients who have been treated frequently with 
antibiotics are at greater risk of antibiotic resistance [67, 71]. As mentioned previously, the EARS-Net 
has noted the emergence and spread of totally or almost totally resistant bacteria in European 
hospitals [64]. Of note, however, is that the primary care setting accounts for 80% to 90% of all 
antibiotic prescriptions [65]. However, it is noted that due to difference in molecular mechanisms of 
resistance and associated fitness costs (transmissibility), the persistence of resistance differs 
between antibiotics. For example, compared with the newer macrolides azithromycin and 
clarithromycin, persistence of resistance selection following amoxicillin therapy in patients with 
community-acquired LRTI is significantly shorter [69]. 
[A0003] – What are the known risk factors for acute RTIs? 
The respiratory tract is vulnerable to infection from bacteria or viruses. RTIs are seasonal and tend to 
be more common during the winter. Children tend to acquire more URTIs than adults. This is due to 
the lack of immunity to the multiple viruses that can cause colds. Most RTIs are self-limiting. However, 
extra care and additional treatment may be required for people who are more vulnerable to the effects 
of opportunistic infections. The following factors, which include individual characteristics and 
behaviours, patient disease states and medications, and environmental exposures, are associated 
with a higher risk of RTI [72]: 
 Aged < five years or >70 years  
 Smokers 
 Pre-existing lung condition (such as COPD or asthma) 
 Immuno-compromised (such as HIV positive patients)  
 Immuno-suppressive medication regimen (such as tacrolimus) 
 Long-term care residents of nursing homes 
 Under-nutrition in children  
 Indoor and ambient air pollution. 
The risk factors for complicated influenza should also be noted for select populations [73]:  
 Aged < six months or >65 years  
 Morbid obesity (BMI ≥40) 
 Pregnancy (including up to two weeks post-partum)  
 Neurological, hepatic, renal, pulmonary and chronic cardiac disease  
 Diabetes mellitus  
 Severe immunosuppression.  
The 2015 Global Burden of Disease Study of LRTIs detected a relationship between incidence and 
mortality from LRTIs and the Social Demographic Index (SDI) [74]. Mortality from LRTIs decreased 
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rapidly when transitioning from low to middle SDI countries. This association with socio-demographic 
issues is particularly evident for children aged less than five years where the burden of LRTI remains 
high. This may have implications for subsets of socially-deprived populations within European 
countries. 
The risk of complications in a primary care patient with LRTI was also assessed by the Joint Task 
Force of the European Respiratory Society (ERS) and European Society for Clinical Microbiology and 
Infectious Diseases (ESCMID) [58]. They recommend that patients with an elevated risk of 
complications should be monitored carefully and referral to hospital should be considered. In patients 
aged 65 years of age and older, the following characteristics are associated with a complicated 
course [58]:  
 presence of chronic obstructive pulmonary disease (COPD), diabetes or heart failure  
 previous hospitalisation in the past year  
 taking oral corticosteroids 
 antibiotic use in the previous month 
 general malaise  
 absence of upper respiratory symptoms  
 confusion/diminished consciousness 
 abnormal vital signs, including tachycardia (heart rate >100), fever ( >38°C), tachypnoea 
 (respiratory rate >30) or hypotension(blood pressure <90/60) 
 when the primary care physician diagnoses pneumonia.  
In patients aged less than 65 years, the task force reported that diabetes, a diagnosis of pneumonia 
and possibly also asthma are risk factors for complications. For all age groups, serious conditions 
such as active malignant disease, liver and renal disease and other disorders that are relatively rare 
in primary care, but which affect immunocompetence, also increase the risk of complications. 
What factors increase the prevalence of antimicrobial resistance in the population? 
The major drivers behind the occurrence and spread of antimicrobial resistance (AMR) are the use of 
antimicrobial agents and the transmission of antimicrobial-resistant microorganisms between humans, 
between animals, and between humans, animals and the environment. While antimicrobial use exerts 
ecological pressure on bacteria and contributes to the emergence and selection of AMR, poor 
infection prevention and control practices and inadequate sanitary conditions favour the further 
spread of these bacteria [75]. Globalisation, the rapid and frequent traveling and the increasing 
international market exchange of foods and feeds, and modern healthcare will increase the spread 
and selection of resistant bacteria favouring the persistence of multi-resistant bacteria [76].  
As discussed in section A0002, other factors that may affect the development of AMR in patients 
include the dose, duration of treatment and class of antibiotic (selective pressure), disease 
transmission and exposure rates, host susceptibility (such as vaccination status), and transmissibility 
(fitness cost) of the pathogen [77]. Currently, approximately 40% of Streptococcus pneumoniae 
isolates are penicillin-resistant in several countries that lack significant conjugate vaccine coverage 
[78].  
Recent antibiotic use has been identified as the foremost risk factor for the development of resistance 
among invasive pneumococcal disease cases, but other risk factors include age (particularly children 
aged less than five years), female gender, hospitalisation, living in an urban area, attending day care, 
paediatric serotypes (that is, serotypes found commonly in children), HIV infection, and 
immunosuppression. Studies have found that previous use of beta-lactam antibiotics, extremes of age 
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(for example, children aged less than five years and the elderly), and child care attendance were 
associated with penicillin-non-susceptible pneumococcal infections [78]. Antimicrobial resistance may 
also result from indiscriminate or poor use of antibiotics; for example, the early termination of 
antibiotic treatment by the patient when the initial symptoms of the infection have improved [54]. 
The English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report of 
2018 also provides data linking trends in antibiotic use with the proportion of common isolates 
resistant to key antibiotics. The robustness of some resistance reporting has been questioned due to 
the use of specific automated antibiotic susceptibility testing devices by some laboratories which may 
over-estimate particularly intermediate resistance levels [79]. An electronic database study in 
Oxfordshire (1999–2011) demonstrated a link between increased use of co-amoxiclav with an 
increased incidence of Escherichia coli bacteraemia attributable to co-amoxiclav-resistant isolates. 
The increasing proportion of co-amoxiclav resistant isolates was preceded by change in antibiotic 
policy from second- and third-generation cephalosporins towards co-amoxiclav with gentamicin as the 
empirical treatment for sepsis in response to rising Clostridium difficile infection rates [80]. 
The rapid seasonal decrease in resistance associated with markedly reduced antibiotic use suggests 
that drug-resistant Pneumococci may pay a fitness cost [81]. The observed fitness cost of resistance 
genes/mutations is a prerequisite for reversibility of antibiotic resistance by reduced antibiotic use 
[76]. However, so far the clinical evidence for reversibility is limited [82, 83]. The potential of reversing 
antibiotic resistance through the reduction of antibiotic use will depend on the fitness cost of the 
resistance mechanism, the epidemic potential of the bacteria/strain, and the transmission route of the 
species [76]. 
Effects of the disease or health condition 
[A0004] – What is the natural course of acute RTIs? Overlaps with: 
[A0005] – What are the symptoms and the burden of disease of an acute RTI for the patient?  
As detailed in A0002, RTIs comprise a collection of specific diagnoses which can be broadly classified 
as upper and lower RTIs, the boundary of which is typically the larynx. The definition and symptoms 
of each of these conditions, along with the burden of the disease and the natural course of the illness 
in the individual patient, are detailed in Table A4 (Appendix 1). The natural course of URTIs is 
typically shorter (ranging from four days for acute otitis media to 2.5 weeks for acute rhinosinusitis) 
than for LRTI (ranging from three weeks for acute bronchitis/cough to three to six months (to complete 
recovery) for community-acquired pneumonia [CAP]). 
LRTIs with a bacterial aetiology are often assumed to result in a different illness course than non-
bacterial causes, but evidence of actual difference is lacking. The illness course of a bacterial LRTI in 
a large study population (n=1,021) of adult patients presenting to primary care with symptoms of 
acute cough for whom pneumonia was not clinically suspected was evaluated as part of a secondary 
analysis of a multicenter European trial by the GRACE consortium. While a slightly worse course of 
disease was observed in those for whom a bacterial origin was identified, the relevance of this 
difference was not found to be clinically meaningful. The authors concluded that, similar to non-
bacterial LRTI, the illness course of bacterial LRTIs (where clinical pneumonia is not suspected) is 
generally mild and self-limiting [84].  
The Global Burden of Disease study of LRTIs focused on the burden associated with pneumonia and 
bronchitis in 195 countries during 2015 [72]. It estimated that LRTIs were the fifth leading cause of 
death (of 249 causes) and the leading infectious cause of death worldwide. LRTIs were the second-
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leading cause of disability-adjusted life years (DALYs) globally in 2015 after ischaemic heart disease. 
Globally, pneumonia remains the most common cause of death in children younger than five years of 
age, causing 1.6 million deaths annually. A proportion of RTIs are vaccine-preventable, with variation 
in access to and uptake of vaccines contributing to differences in disease burden. For example, while 
the pneumoccocal vaccine is recommended for children by the World Health Organization (WHO), 
global coverage was estimated at only 25% in 2013, with estimates that pneumococcal disease is 
responsible for over 30% of deaths from vaccine-preventable diseases in children [85]. The Global 
Burden of Disease study also highlights the burden of LRTIs in the elderly population, with nearly 
700,000 deaths in patients aged older than 70 years due to pneumococcal pneumonia worldwide [72]. 
Among high-income countries (21 of the 34 of which are European), LRTIs were responsible for 
486,408 deaths (that is, 45.5 per 100,000) and 5.1 million DALYs in 2015; a 21.6% increase in deaths 
and 9% increase in DALYs was noted between 2005 and 2015 [72].  
The number of deaths due to LRTI in children aged younger than five years in the high income 
countries was estimated at 3.4 per 100,000 in 2015; this represented a decrease of 34.9% between 
2005 and 2015 [72]. Data from 14 hospital-based studies estimate the incidence of admissions for 
severe acute LRTI in Europe in 2010 was approximately 14 episodes per 1,000 children per year in 
children aged 0-11 months, and approximately seven episodes per 1,000 children per year in those 
aged 0-59 months. This translates to approximately 553,000 episodes per annum in children aged 
younger than five years in Europe [86]. 
As noted in A0005, patients with COPD are at increased risk of acute RTIs and their sequelae. UK 
estimates of inpatient mortality attributable to exacerbations of COPD range from 4% to 30% [87]. The 
wide variation in these estimates results from the fact that studies investigated different subgroups of 
patients. The factors contributing to frequent exacerbations remain unclear, but viral infections appear 
to be a major cause of exacerbations. The Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints (ECLIPSE) cohort study identified a distinct “frequent exacerbator” group, who 
were more susceptible to exacerbations of COPD irrespective of their disease severity [88]. These 
patients could be identified by a previous history of two or more exacerbations per year. Patient 
mortality has been shown to be significantly related to the frequency of these severe exacerbations 
requiring hospital care [89]. There are also data on mortality following discharge from hospital after 
treatment for an acute exacerbation of COPD. In the UK it has been reported that death occurred in 
14% of cases (184/1,342) within three months of admission [90]. COPD exacerbations were 
responsible for more than 0.9% of all 11.7 million hospital admissions and 2.4% of the 4.2 million 
acute medical admissions in England for 2003/2004. Most of these admissions are on an emergency 
basis, with the mean length of stay remaining almost unchanged at about ten days [87].  
 [A0006] – What are the consequences of acute RTIs for society? 
The societal consequences of acute RTIs focuses on the substantial burden of these infections on 
healthcare utilisation in primary care.  
As documented in A0004, data from the Global Burden of Disease study, LRTI are associated with 
substantial morbidity and mortality. These data are limited to LRTIs and are primarily based on data 
from hospital in-patient databases. No European-equivalent database was identified relevant to the 
burden of RTIs in primary care. The General Practice Research Database (now part of the Clinical 
Practice Research Datalink, a publicly funded research data service) in the UK has been widely used 
for pharmacoepidemiological research. It comprises anonymised electronic data submitted by general 
practitioners covering approximately 5% of the total UK population. Using these data, a 2007 study 
looking at the health burden of influenza in England and Wales estimated that 779,000 to 1,164,000 
general practice consultations, 19,000 to 31,200 hospital admissions and 18,500 to 24,800 deaths 
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annually are attributable to influenza infections [91]. These data on GP consultations tally with the 
seasonal mean estimate of 789,219 influenza-attributable GP episodes between 1995 and 2009 in 
the UK [92]. In an average season during this time period, 2.4% of children aged less than five years 
and 1.3% of elderly patients aged over 74 years had a GP episode for respiratory illness attributed to 
influenza A. The corresponding figures for influenza B were 0.5% and 0.1%, respectively. The study 
noted that while the bulk of the burden in primary care falls on those aged less than 45 years, elderly 
patients are more likely to be hospitalised and to die [92]. Annual influenza epidemics are estimated 
to cause between 12,000 and 13,800 deaths in the UK [73]. 
In total, it is estimated that there are 5.5 million consultations each year for acute respiratory illness in 
England and Wales [91]. However, the majority of such consults often relate to other RTIs, including 
specifically acute cough or bronchitis and URTIs, such as acute otitis media (AOM), sore throat/ 
pharyngitis/tonsillitis, rhinosinusitis and the common cold, which are largely self-limiting and 
complications are likely to be rare if antibiotics are withheld [93]. The safety of reducing antibiotic 
prescribing for self-limiting RTIs in primary care was examined in a cohort study of registered patients 
with 45.5 million person years of follow-up data between 2005 and 2014 from 610 UK general 
practices [94]. It was reported that slightly higher rates of pneumonia and peritonsillar abscess were 
reported in general practices with lower antibiotic prescribing rates for RTIs. This translated into 
potentially one additional case of pneumonia each year and one additional case of peritonsillar 
abscess each decade in a general practice with an average list size of 7,000 patients that reduced the 
proportion of RTI consultations with antibiotics prescribed by 10%. It was noted that that 
complications could be fewer if GPs stratify antibiotic prescribing according to the level of risk. There 
was no evidence found that mastoiditis, empyema, meningitis, intracranial abscess, or Lemierre’s 
syndrome were more frequent in the low prescribing practices. Achieving such reductions in antibiotic 
prescribing would be expected to reduce the risks of antibiotic resistance, the side effects of 
antibiotics, and the medicalisation of largely self-limiting illnesses [94]. 
Antibiotic treatment of RTIs can expose patients to an increased risk of an adverse event or an 
episode of drug-associated toxicity. Common side-effects of antibiotics are gastrointestinal symptoms, 
skin rashes, and thrush; specific effects with particular antibiotic classes include nephrotoxicity 
associated with aminoglycosides, teeth staining attributable to tetracyclines, and tendonitis and 
tendon rupture with fluoroquinolones. New restrictions on the use of fluoroquinolone antibiotics have 
been recommended by the EMA Committee for Human Medicinal Products (CHMP) due to their 
association with certain prolonged, serious, disabling, and potentially irreversible drug reactions [95]. 
The relative merit of the benefits and harms of antibiotic treatment can be considered in the context of 
the numbers needed to treat and to harm. For example, in the case of acute bronchitis the numbers 
needed to treat (NNT) to benefit is six based on the outcome of abnormal lung exam, and eleven 
based on the outcome of a clinician’s global assessment [96]. For the same indication, the number 
needed to harm (NNH) is 24. That is, 24 patients need to be treated for one to experience a harm. By 
contrast, for acute otitis media the NNT is 24 and the NNH is 13 [97]. For acute sinusitis, the NNT 
ranges from seven to 20 depending on the outcome measure, and the NNH is 10 [98]. It is clear that 
harm may be a more likely outcome than benefit, depending on the choice of outcome. It should be 
borne in mind that the benefits and harms may not be considered of equal importance. The key point 
is that harms from antibiotic consumption are common in patients with acute RTIs. 
Consequences of antimicrobial resistance for society 
The consequence of antimicrobial resistance is increased mortality and morbidity from bacterial 
infections, as well as an increased economic burden on the healthcare sector in the treatment and 
care of patients infected with multidrug resistant strains, and a loss of productivity in society [99, 100]. 
CRP POCT to guide antibiotic prescribing in primary care settings for acute respiratory tract infections 
EUnetHTA Joint Action 3 WP4 75 
If resistance to currently available antibiotics becomes widespread, this will adversely impact on the 
delivery of effective medical care in a wide range of clinical settings. A risk assessment study of 
antibiotic pan-drug-resistance in the UK indicated that there is an approximately 20% chance of such 
a situation arising in the UK over a five-year timeframe. The impact of such an event, were it to occur, 
would be very significant in clinical and public health terms, with marked increases in morbidity and 
mortality [100]. 
The societal costs in Europe of selected antibiotic-resistant bacteria were estimated to be about €1.5 
billion a year in 2007 [101]. Antimicrobial resistance kills around 50,000 people a year in the US and 
Europe, and is estimated to kill more than 700,000 people globally [63]. Predictive macroeconomic 
models, which found that if resistance is not addressed, the world will produce around $8 trillion USD 
less per year by 2050, and a cumulative $100 trillion USD would be wiped off the world’s production 
over the next 35 years [63]. However, this review on antimicrobial resistance only estimates lost 
economic output, and does not take into account any increased associated healthcare costs. 
Antimicrobial resistance increases the cost of healthcare with lengthier stays in hospitals and more 
intensive care required [62]. It complicates treatment and can result in additional antibiotic courses 
and outpatient visits, excess hospitalisations and work loss [78]. Specific to antibiotic-resistant 
pneumococcal pneumonia, a 2014 study by Reynolds et al. found that resistance led to 32,398 
additional outpatient visits and 19,336 additional hospitalisations, accounting for $91 million USD (4%) 
in direct medical costs and $233 million USD (5%) in total costs, including work and productivity 
losses [102]. In adults, increased costs due to penicillin non-susceptible pneumonia and bacteremia 
were due to prolonged hospitalisations and the use of more expensive antibiotics [78]. Data from the 
US estimated that 55% of all antibiotics prescribed for acute RTIs in outpatients are probably not 
needed, leading to a waste of $732 million (1999 dollar values) of $1.32 billion spent [77]. 
 
Current clinical management of the disease or health condition 
[A0024] [A0025] – How is the disease or health condition currently diagnosed and managed 
according to published guidelines and in practice?  
RTIs are commonly encountered in primary care, with data suggesting that they account for around 
60% of antibiotic prescriptions issued within primary care [93]. However, as previously noted, acute 
RTIs are often viral, self-limiting and do not require an antibiotic [93, 96, 103]. A number of European 
and national guidelines for the diagnosis and management of acute RTIs are summarised in Table A5 
(Appendix 1).  
There are commonalities in the care pathways for the diagnosis and management of acute RTIs 
across Europe. URTIs (common cold, acute sore throat/acute pharyngitis/acute tonsillitis, acute otitis 
media (AOM) and acute rhinosinusitis) are characterised as self-limiting, and often viral in aetiology. 
For these URTIs, the guidelines recommend that a clinical assessment should include a history 
(presenting symptoms, use of over-the-counter or self-medication, previous medical history, relevant 
risk factors, relevant co-morbidities) and a physical examination to identify relevant clinical signs [93]. 
For acute sore throat, pharyngitis and tonsillitis, there is a preference for using clinical prediction rules 
(such as the Fever PAIN, McIsaac or Centor scores) to identify those patients likely to benefit from 
antibiotics, rather than routinely conducting a pharyngeal swab for group A Streptococci (GAS) [93, 
104-107]. A diagnosis of AOM is generally made on the basis of conventional otoscopy, and there is 
little evidence that antibiotics reduce complications from AOM. For acute sinusitis, patients present 
with symptomatic inflammation of the mucosal lining of the nasal cavity and paranasal sinuses (<four 
weeks’ duration). Unilateral symptoms and purulence make bacterial aetiology more likely. In 
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uncomplicated cases of URTIs that do not exceed the expected durations of illness, a no-antibiotic 
prescribing strategy or a delayed antibiotic prescribing strategy is generally recommended for patients 
[93, 98]. The guidelines suggest advice should be given to patients about the typical duration of 
illness and how to manage symptoms, including using analgesics for pain and antipyretics for fever. 
Antibiotics are generally only recommended for patients who are systemically very unwell, for patients 
with signs or symptoms of a more serious illness and/or complications, and for patients who are at 
high risk of complications due to a pre-existing co-morbidity. Select patient groups (such as those 
immunocompromised or with severe co-morbidities) may require immediate antibiotic treatment.  
Seasonal influenza is a vaccine-preventable disease and annual Influenza vaccination remains the 
most effective preventive strategy for severe influenza. While the ECDC recommend the vaccine for 
all Europeans, it is noted to be especially important for those at higher risk of serious influenza 
complications: individuals with specific chronic medical conditions, pregnant women, and children 
aged 6-59 months, the elderly and healthcare workers [108]. 
Guidelines for the management of LRTI and specifically community-acquired pneumonia (CAP) in 
adults have been published by a number of European countries in addition to consensus guidelines 
published by a joint taskforce of the European Respiratory Society (ERS) and the European Society 
for Clinical Microbiology and Infectious Disease (ESCMID) [58]. The guidelines distinguish between 
cough (or acute bronchitis) and pneumonia. The use of CRP measurement is recommended if after 
clinical assessment a diagnosis of pneumonia has not been made and it is unclear if antibiotics 
should be prescribed. Use of antibiotics is recommended in patients with a diagnosis of pneumonia 
and in those with LRTI with risk factors for complications (such as co-morbidities), but not in other 
patients who are less unwell including those with acute bronchitis. 
Acute LRTI is a broad description of a group of disease entities, encompassing acute bronchitis, 
pneumonia and exacerbations of chronic lung disease. In primary care, it can be difficult to 
differentiate between those different conditions without doing extensive additional diagnostic tests due 
to the substantial overlap in presenting symptoms. As noted, patients can present with cough, sputum 
production, dyspnoea, tachypnoea, fever, chest discomfort /pain, wheezing and auscultatory 
abnormalities [58]. Reports indicate that around 5–12% of patients presenting in primary care with 
symptoms of a LRTI are diagnosed with CAP [109, 110] and 22–42% of these patients are admitted 
to hospital [42]. The Dutch College of General Practitioners (NHG) guidelines provide 
recommendations regarding the use of CRP levels to help inform antibiotic prescribing in patients who 
present with signs and symptoms of pneumonia and in those patients with acute cough who have 
other risk factors for complications due to their age (<3 months or >75 years) or relevant 
comorbidities. A prospective observational study evaluated the use of CRP POCT with these 
guidelines, and found that differences in antibiotic prescription rates among GPs were most obvious in 
patients who presented with CRP values between 20 and 100 mg/L. Most GPs followed the NHG 
guidelines and did not prescribe antibiotics to patients with low (that is, less than 20mg/L) CRP values 
[111].  
Interestingly, in cases of acute cough studied in 13 countries in Europe, the variation in clinical 
presentation of patients did not explain the considerable variation in antibiotic prescribing, with such 
variation not being associated with clinically important differences in recovery [112]. Without access to 
CRP POCT, there may be “defensive over-prescribing of antibiotics” by doctors for patients 
presenting with symptoms of LRTI, especially where the clinical assessment is inconclusive and the 
need for antibiotics is unclear. A 2015 observational study from the Netherlands of the (antibiotic) 
management of patients with RTIs, whose care was benchmarked to the prescribing guidelines for 
acute otitis media (AOM), acute sore throat, rhinosinusitis or acute cough, reported an overall 
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antibiotic prescription rate of 38%. Of these prescriptions, 46% were not indicated by the guidelines. 
Relative overprescribing was highest for throat (including tonsillitis) and lowest for ear consultations 
(including AOM). Absolute overprescribing was highest for LRTIs (including bronchitis). 
Overprescribing was highest for patients between 18 and 65 years of age, when GPs felt patients’ 
pressure for an antibiotic treatment, for patients presenting with fever and with complaints longer than 
one week [113]. 
A 2018 US retrospective study examining the adherence to guidelines from the Infectious Disease 
Society of America (IDSA) for the testing and treatment of children with pharyngitis found that 28% of 
the antibiotics prescribed for pharyngitis in the cohort were not indicated for the specified condition 
[114].  
The efficacy of antibiotics in the treatment of adults presenting with acute LRTI, in whom pneumonia 
was not suspected clinically, was assessed in an international (12 European countries) randomised 
placebo-controlled trial by the GRACE consortium (n=2,061). There was no clear evidence of benefit 
seen with amoxicillin therapy. Compared with placebo, the use of amoxicillin was not associated with 
a difference in symptom severity or the duration of symptoms rated “moderately bad” or worse in the 
first few days of infection (HR 1.06 [95% CI: 0.96–1.18]), neither overall nor when limited to patients 
aged 60 years or older. While new or worsening symptoms were significantly less common in the 
amoxicillin group (15.9% versus 19.3%, p=0.043), the number needed to treat (NNT) was high 
(NNT=30) and was matched by a similarly sized number needed to harm for side effects (NNH=21) 
[103]. Similar estimates were reported by a 2017 updated Cochrane review examining the efficacy of 
antibiotics in the treatment of acute bronchitis [96]. In many cases, the use of antibiotics will not be 
beneficial to the patient’s recovery and will expose them to potential side effects. 
Given concern around persistent high rates of inappropriate prescribing, quality indicators have been 
developed to identify ideal or acceptable antibiotic prescribing rates for a range of RTIs in primary 
care. A study by the ESAC elicited expert opinion from 40 experts from 25 countries across seven 
dimensions on three quality indicators (percentage prescribed an antibiotic, recommended antibiotics 
and use of quinolones) [115]. The recommended ideal antibiotic prescribing proportions was between 
0 and 20% for a range of URTIs, while it was 90 to 100% for CAP. A similar study in the UK that elic-
ited the expert opinion of 14 academic experts from the UK, and validated the estimates through an 
online survey of 43 practising prescribers in primary care reported broadly consistent ideal or 
acceptable antibiotic prescribing rates [74]. 
Target population 
[A0007] – What is the target population of this assessment? 
This is defined in the project Scope. However, the size of the target population for this intervention is 
difficult to estimate.  
[A0023] – What is the epidemiology of RTIs across the European Union in primary care 
settings? 
No international studies were identified that reported European-level data for patients presenting with 
RTI in primary care. As noted in section A0006, the Global Burden of Disease study reports 
international data for RTIs, but these data do not include incidence data from primary care.  
In the absence of similar epidemiological data limited to patients presenting to primary care, the data 
reported in this section relies heavily on published studies and surveillance data from a limited 
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number of European countries, in particular the Netherlands and the United Kingdom for which large-
scale studies based on primary care data were identified.  
Estimates from the Second Dutch National Survey of General Practice (2000-2002) [116] report that 
15% of all episodes in general practice related to RTI illness. In total, 4.2% of those presenting to 
primary care were diagnosed with a RTI with an incidence rate of 144 per 1,000 person-years. On 
average, URTI and LRTI accounted for 100 and 44 GP consultations per 1,000 person-years, 
respectively. If signs and symptoms were added to the total incidence figures, the incidence of GP 
consultations for RTI was 215 per 1,000 person-years. The median age of patients presenting to a GP 
with at least one episode of RTI was 31 years (range 0 to 105) and 44% were male. A subset of 
patients had at least three episodes of GP-diagnosed RTI in one year (42 per 1,000 total patient 
population). The incidence of URTI was significantly higher in children aged less than five years than 
in other year-cohorts (392 per 1,000 child-years; relative risk (RR) 4.9 (95% CI: 4.8–5.0)), and with 
the exception of acute otitis media (15 versus 16/1,000; RR 0.9, 95% CI: 0.85–0.95), incidences were 
higher for females than for males (103 versus 74 per 1,000; RR 1.4 (95%CI: 1.35–1.45). Among 
patients presenting to primary care, the four most common URTIs diagnosed were rhinitis, acute 
sinusitis, acute otitis media and acute tonsillitis with incidence rates of 51.0, 22.7, 15.6 and 10.2 per 
1,000 person-years, respectively. A U-shape association was observed between age and LRTI with a 
higher incidence observed in children aged 0 to 4 years (78 per 1000) and adults aged 75 years and 
older (70 per 1,000) compared with the other age categories (23 per 1,000). This U-shape association 
was also evident when restricted to diagnoses of pneumonia with incidence rates of 16.6 and 
21.6/1,000 person years in those aged 0-4 years and adults aged 74 years and older, respectively. 
The incidence of both upper and lower RTI was significantly higher in patients with chronic lung 
disease (209/1,000 [RR: 1.5] and 156/1000 person years [RR 5.2], respectively) compared with the 
total patient population. LRTIs were also noted to be significantly more common in patients with 
diabetes mellitus (RR: 2.2) and cardiovascular disease (RR: 2.2) [116].  
Using data from the UK General Practice Research Database which, as noted in A0006, has been 
widely used for pharmacoepidemiological research, Millett et al. estimated the incidence of 
community-acquired LRTI and pneumonia among older adults (age ≥65 years) over a 14-year study 
period (1997-2011). The crude overall LRTI incidence in primary care was 122.93 episodes/1,000 
person years. Incidence increased with increasing age from 92.21 episodes/1,000 person-years (65-
69 years) to 187.91 episodes/1,000 person-years (85-89 years), and was noted to be higher in males 
than females. Incidence was also noted to be higher in patients with a history of COPD. The overall 
incidence of CAP was 7.99/1,000 person years, was higher in males than females, and was noted to 
increase significantly with increasing age (from 2.81 to 21.81 episodes/1,000 person-years in those 
aged 65-69 years and 85-89 years, respectively) [117]. 
The substantial burden associated with RTIs was also confirmed in a more recent study of respiratory 
and communicable disease incidence from a primary care sentinel network in England. The 2014-
2015 mean weekly incidences of the common cold, acute otitis media (AOM), pneumonia and 
influenza-like illness were 105.09, 25.95, 2.48, and 9.77 cases per 100,000 population, respectively; 
there was evidence of seasonal variation for all four conditions. A U-shape association was again 
observed for pneumonia: after controlling for other factors, multivariate logistic regression analysis 
showed that compared with those aged 0-4 years, the odds of a pneumonia were significantly lower 
for those aged 5 to 24 years (OR 0.33) and those aged 25 to 49 years (OR 0.57) and highest for 
those aged 75 years and older (OR 6.37) [118].  
A proportion of RTIs are vaccine-preventable, with variation in vaccination policy, and access to and 
uptake of vaccine, contributing to differences in disease burden. As noted in (A0025) seasonal 
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influenza is a vaccine-preventable disease and annual influenza vaccination remains the most 
effective preventive strategy for severe influenza. However, the substantial burden associated with 
influenza in primary care is also evident in a study using data from the UK Clinical Practice Research 
Datalink (CPDR) and surveillance data that tracked GP episodes for respiratory illness, otitis media 
and antibiotic prescriptions attributable to influenza during 14 seasons (1995-2009). Seasonal mean 
estimates of influenza-attributable GP episodes were 857,996 corresponding to 1.5% of the total 
population, with a wide inter-seasonal variability. In an average season, 2.4% of children aged less 
than five years and 1.3% of those aged 75 years and older had a GP episode for respiratory illness 
attributed to influenza A; while 0.5% and 0.1% respectively had episodes related to influenza B. Of 
note, two-thirds of influenza-attributable GP episodes were estimated to result in a prescription of 
antibiotics [92]. 
As noted, no large-scale international studies were identified that reported European level data for 
patients presenting with RTI in primary care. However, one retrospective observational study of 
primary care databases from Belgium, the Netherlands and Sweden reported on the incidence of 
consultations for seven acute infections (URTI, sinusitis, tonsillitis, otitis media, bronchitis, pneumonia 
and cystitis) in 2012 and the antibiotic prescriptions corresponding with these diagnoses. For the six 
RTI diagnoses under study, consultation incidences were 162, 173 and 296 per 1,000 registered 
patients per year for Sweden, the Netherlands and Belgium, respectively. Consultation incidence for 
the diagnoses of URTI and bronchitis in Belgium were twice as high as those observed in the 
Netherlands and Sweden. In the Netherlands, the consultation incidence for sinusitis was higher than 
in the other countries, while the consultation incidence for tonsillitis in Sweden was twice that of the 
Netherlands. High consultation incidences were associated with high antibiotic prescription rates, with 
GPs in the Netherlands and Sweden noted as prescribing fewer antibiotics for RTIs than those in 
Belgium [119]. 
While data have been collected on GP visits for influenza-like illness in different countries, given the 
wide rates of national case definitions, differences in consultation behaviour, vaccination coverage 
and obligatory doctor visits for absence from school or work, the estimated consultation rates differ 
between countries. A large community study on influenza in the UK, the Flu Watch cohort study, 
which has been used by the European Influenza Surveillance Network (EISN) to estimate the burden 
of influence in Europe, reported age-group specific and overall estimates of the rates of symptomatic 
influenza disease. Seasonal and pandemic influenza over five successive cohorts (England 2006-
2011) were tracked. The proportion of illnesses resulting in at least one GP consultation was 11.6%, 
15.3% and 21% for those with any respiratory illness, influenza-like illness with, and without, 
confirmed fever, respectively [120].  
[A0011] – To what extent it is CRP POCT currently used in Europe to guide antibiotic 
prescribing?  
As outlined in A0021, CRP POCT testing for patients with suspected LRTI has been included in 
guidelines in Norway, Sweden, the Netherlands, Germany, Switzerland, Czech Republic and Estonia 
and the United Kingdom [42, 52]. The Scandinavian countries in particular have been leading 
adopters of the technology [18]. Although recommended and available for use in many European 
countries, there are no reliable data on the current and/or expected annual usage of CRP POC tests 
in the respective European countries, or the extent to which practitioners adhere to the clinical 
guidelines regarding their use. An international cross-sectional survey reported on the use of POC 
tests by primary care clinicians in Australia, the USA and Europe (Belgium, the Netherlands and the 
UK) [121]. CRP POCT was carried out by 48% of the Dutch primary care clinicians, which contrasted 
with a usage of 3% reported for Belgium and 15% for the UK. In the survey, clinicians from Belgium 
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and the UK expressed a desire to use CRP POCT (75% and 61%, respectively) that was higher than 
their current use of the tests. This latent demand for access to CRP POCT is suggestive of an unmet 
clinical need in primary care to assist prescribing decisions for patients presenting with RTIs. As 
outlined in A0021, the CRP POCT technology is being used in a wide range of European countries. 
Many European countries also appear not to provide direct reimbursement of the technology in the 
primary care setting.  
4.3 Discussion 
RTIs are the most frequent infections encountered in primary care. No international studies were 
identified that reported European-level data on the burden of RTIs in this setting therefore estimates 
used in this report rely heavily of published studies and surveillance data from a limited number of 
European countries for which large-scale studies based on primary care data were identified. These 
confirmed the substantial burden of RTIs, with estimates that 15% of all episodes in primary care 
relate to RTIs, with consultations for URTI-related illness more than twice as common as those for 
LRTI. Given differences in consultation behaviour, vaccination coverage and obligatory doctor visits 
for absences from school or work, consultation rates for RTIs are likely to differ between countries. 
While consultation rates may vary, there is broad consistency in clinical guidelines in the care 
pathways for diagnosis and management of acute RTIs. URTIs are characterised as self-limiting and 
often viral in aetiology with a no-antibiotic or delayed antibiotic prescribing strategy generally 
recommended in uncomplicated URTIs that do not exceed the expected durations of illness. 
Immediate antibiotic therapy is typically only recommended for URTIs in patients who are systemically 
very unwell and for those patients who are at high risk of complications due to a pre-existing co-
morbidity. In respect of LRTI, there is also broad consistency in guidelines for the diagnosis and 
management of LRTI and specifically CAP. Studies suggest that around 5–12% of patients presenting 
in primary care with symptoms of a LRTI are diagnosed with CAP. Given the substantial morbidity and 
mortality associated with CAP and the higher probability of a bacterial aetiology, antibiotics are 
recommended in all patients with a clinical diagnosis of pneumonia and in those with LRTIs with risk 
factors for complications (such as co-morbidities). Antibiotics are not recommended in those patients 
who are less unwell including those with acute bronchitis, with European guidelines recommending 
use of CRP measurement if after clinical assessment a diagnosis of pneumonia has not been made 
and it is unclear if antibiotics should be prescribed. 
European surveillance data indicate a greater than threefold variation between countries in the 
consumption of antibiotics for systemic use in the community, with a trend towards higher antibiotic 
consumption in southern and eastern European countries. Given the substantial burden of acute RTIs 
in primary care and despite the broad consistency between national guidelines for RTIs, much of this 
variation may relate to variation in actual antibiotic prescribing practices for these conditions in 
primary care. Over-prescribing of antibiotics is common in this setting, with high levels of 
inappropriate prescribing documented in observational studies benchmarking antibiotic prescribing 
versus guidelines. Prescribing an unnecessary antibiotic will potentially expose the patient to 
needless adverse effects without aiding recovery. Furthermore, there is the major societal concern 
about the increasing emergence of antimicrobial resistance (AMR), a major driver for which is the 
misuse and overuse of antibiotics. European surveillance data has documented substantial inter-
country variation in the prevalence of antimicrobial resistant strains including penicillin-resistant 
Streptococcus pneumoniae, with a trend towards higher rates of antimicrobial resistance in southern 
and eastern European countries.  
While antibiotic use is widely associate with antibiotic resistance, demonstrating causality is difficult 
because of population-based confounders and wide variation in the effects of antibiotics that are 
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within the same class on the selection of resistant organisms. There is very limited evidence that a 
reduction in the overall rates of antibiotic prescribing leads to reversal or an overall reduction in AMR. 
At a patient level, however, there is a clear link between antibiotic dose and duration and the 
emergence of antibiotic resistance with evidence also that patients who have been frequently treated 
with antibiotics are at greater risk of AMR. 
The use of CRP POCT to inform prescribing for patients with suspected LRTI in primary care has 
been included in national guidelines in several European countries. A survey of EUnetHTA partners 
suggests that CRP POCT is available for use in at least 17 European countries with confirmation that 
the technology is reimbursed when used in primary care for this indication in Denmark, Hungary, the 
Netherlands, Norway, Poland, Slovenia and Switzerland. 
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5 CLINICAL EFFECTIVENESS (EFF) 
5.1 Research questions – Systematic review 1 
Element ID Research question 
Change in Management (AE from Diagnostic core model) 
D0021 How does use of CRP POCT change physicians' management decisions?  
 
Effectiveness (REA AEs) 
D0001 
 
What is the expected beneficial effect of the intervention on mortality? Overlaps with 
C0008 – patient safety. 
D0005 
 
How does the technology affect symptoms and findings (severity, frequency) of the 
disease or health condition? Overlaps with C0008 – patient safety. 
D0006 
 
How does the technology affect progression (or recurrence) of the disease or health 
condition? Overlaps with C0008 – patient safety. 
D0011 
 
Does the use of CRP POCT to guide antibiotic prescribing lead to reduced adverse 
events as a result of lower antibiotic prescribing rates compared with standard care? 
D0012 
 
What is the effect of CRP POCT on health-related quality of life? 
D0013 
 
What is the effect of CRP POCT on disease-specific quality of life? 
D0017 
 
Were patients satisfied with the use of CRP POCT to guide antibiotic prescribing for 
their RTI? 
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5.2 Study selection 
Literature search and study selection process for systematic review 1 (effectiveness and safety) 
Figure 4: Flow chart systematic review 1 (effectiveness and safety) 
 
 
* Some studies were excluded for more than one reason and therefore 64 reasons were given for full-text 
exclusion for 59 studies. 
A total of 5,007 articles were identified through database searching and manufacturers’ submissions. 
After title and abstract screening, 71 articles were identified as being potentially relevant. Of these, 59 
articles were subsequently excluded due to the reasons listed in Figure 4. The most common reason 
for exclusion was the lack of a relevant comparator group. The majority of these studies were obser-
vational studies that reported on CRP POCT versus no CRP POCT, but upon reading the full text of 
Records identified through 
database searching  
Medline (OVID) n =1,841 
EMBASE n = 2,974 
CINAHL (EBSCOHost) n=2,019 
Cochrane Library n=286 
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Additional records identified 
through other sources  
(n=6) 
Records after duplicates removed  
(n=5,007) 
Records screened 
(n=5,007) 
Records excluded 
(n=4,936) 
Full-text articles 
assessed for eligibility  
(n=71) 
Full-text articles excluded, 
with reasons  
(n=59*) 
Exclusion criteria: 
-  Inappropriate population (n =8) 
-  Not Primary care (n=5) 
-  Not Point-of-Care CRP test (n=6) 
-  No relevant comparator (n=19) 
-  No outcomes of interest (n=2) 
-  Inappropriate study design (n=3) 
-  Protocol (n=1) 
-  Conference abstract (n=6) 
-  Not original article (n=3) 
-  Can’t extract outcome data (n=6) 
-  Studies with duplicate data (n=5) 
Studies included in qualitative synthesis  
(n=12) 
RCTs (n=7) 
Non randomized studies (n= 5) 
Studies included in quantitative synthesis 
(meta-analysis) 
(n=11) 
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the article it was clear that all physicians had access to CRP POCT, but that some chose not to use it. 
These studies were excluded as it was unclear if the non-use of CRP POCT was because these phy-
sicians never used it in their practice to inform a decision or because following clinical examination of 
the individual patients they felt it was unnecessary. Five studies were identified that presented dupli-
cate data of studies that were already included [122-126]. This left 12 studies for inclusion in system-
atic review 1 [127-138], of which 11 studies were included in the meta-analysis [127, 129-138]. The 
twelfth study met our inclusion criteria, but did not present enough information in the paper to allow 
data to be extracted for meta-analysis; attempts to contact the author were unsuccessful [128]. This 
study (Bjerrum et al. 2004) only reported on the primary outcome (the number of patients given an 
antibiotic prescription at the index consultation) and the results from this study have been included in 
the narrative for this outcome.  
The search also identified seven relevant systematic reviews [24, 48, 49, 139-142]. These studies 
were checked for additional references. One systematic review [48] included four additional studies, 
two of which had been excluded in this study as they were duplicate studies [124], and two studies 
were excluded as the testing was undertaken in an emergency department and therefore did not meet 
the inclusion criteria [143, 144]. In the scoping phase of this assessment, we identified a relevant 
Cochrane review by Aabenhaus et al. from 2014 [24]. A decision was made at that time not to directly 
update this review as our review included additional outcomes of interest and it included more study 
types (observational studies in addition to RCTs); however, we did base our review on the Aabenhaus 
review. The references of included studies were also searched for additional relevant articles, but 
none were identified. Manufacturers’ submissions were also checked for additional studies; six were 
identified that appeared to be relevant, but on full-text review all were excluded. 
 
5.3 Quality rating 
Details of the quality of the evidence included in this systematic review are included in Appendix 1. 
 
5.4 Results 
5.2.1  Effectiveness and safety of using CRP POCT to guide antibiotic prescribing in patients with 
acute respiratory tract infections (RTIs) in primary care settings (Systematic Review 1) 
Included studies 
The systematic review retrieved 12 studies that assessed the effectiveness and safety of using CRP 
POCT to guide antibiotic prescribing in patients presenting to primary care with acute RTIs (Table 8). 
Four studies were individually randomised RCTs (n=3,345) [130-132, 138], three were cluster RCTs 
(n=4,874, modified sample size n=1,975) [127, 129, 135] and five were non-randomised studies 
(n=8,998 for four studies included in meta-analysis) [128, 133, 134, 136, 137]. A detailed description 
of the twelve studies is found in Appendix 1 (Table A6). The sample size of cluster RCTs was modi-
fied as described in section 2.6. 
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Table 8: Main characteristics of studies included  
Author and 
year or 
study name 
Study  
type 
Number 
of 
patients 
Intervention(s) Main  
endpoints 
Included in 
clinical 
effectiveness 
and/or safety 
domain 
SR 1: Effectiveness and safety 
RCTs  
Andreeva 
2014 
Cluster 
RCT 
179 CRP POCT 
(Afinion™ test 
system) 
Antibiotic Rx at index 
consultation, Antibiotic Rx 
at 28 days F/U, Substantial 
improvement/complete 
recovery at 7 and 28 days, 
Mortality, Reconsultations 
Effectiveness 
Safety 
Cals 2009  Cluster 
RCT 
431 CRP POCT 
NycoCard™ II 
reader 
Antibiotic Rx at index 
consultation, Antibiotic Rx 
at 28 days F/U, Substantial 
improvement/complete 
recovery at 7 and 28 days, 
Mortality, Time to 
resolution of RTI 
symptoms, 
Reconsultations, Patient 
satisfaction 
Effectiveness 
Safety 
Cals 2010 RCT 258 CRP POCT 
QuikRead
®
 
CRP 
Antibiotic Rx at index 
consultation, Antibiotic Rx 
at 28 days F/U, Substantial 
improvement/complete 
recovery at 7 and 28 days, 
Mortality, Antibiotic Rx for 
delayed used, Time to 
resolution of RTI 
symptoms, 
Reconsultations, Patient 
satisfaction 
Effectiveness 
Safety 
Diederichse
n 2000 
RCT 812 CRP POCT 
NycoCard™ 
reader 
Antibiotic Rx at index 
consultation, Substantial 
improvement/complete 
recovery at 7 and 28 days 
Effectiveness 
Safety 
Do 2016 RCT 2,037 CRP POCT 
NycoCard™ 
analyser with 
NycoCard™ II 
reader 
Antibiotic Rx at index 
consultation, Antibiotic Rx 
at 28 days F/U, Mortality, 
Time to resolution of RTI 
symptoms, 
Reconsultations, 
Hospitalisations, Patient 
satisfaction 
Effectiveness 
Safety 
Little 2013 Cluster 
RCT 
4,264 CRP POCT 
QuikRead
®
 
CRP 
Antibiotic Rx at index 
consultation, Mortality, 
Time to resolution of RTI 
symptoms, 
Reconsultations, 
Hospitalisation 
Effectiveness 
Safety 
Melbye 
1995 
RCT 239 CRP POCT 
NycoCard™ 
Reader 
 
Antibiotic Rx at index 
consultation, Antibiotic Rx 
at 28 days F/U, Substantial 
improvement/complete 
recovery at 7 and 28 days 
 
Effectiveness 
Safety 
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Author and 
year or 
study name 
Study  
type 
Number 
of 
patients 
Intervention(s) Main  
endpoints 
Included in 
clinical 
effectiveness 
and/or safety 
domain 
Non-randomised studies 
Bjerrum 
2004 
Observatio
nal study 
367 
GPs 
CRP POCT Antibiotic Rx at index 
consultation 
Effectiveness 
 
Jakobsen 
2010 
Observatio
nal 
803 CRP POCT 
NycoCard™ 
CRP 
QuikRead
®
 
CRP 
Antibiotic Rx at index 
consultation 
 
Effectiveness 
 
Kavanagh 
2011 
Pilot 
cross-
sectional 
study 
120 CRP POCT 
QuikRead
®
 
CRP 
Antibiotic Rx at index 
consultation, Antibiotic Rx 
for delayed used, 
Reconsultations, Patient 
satisfaction 
Effectiveness 
Safety 
Llor (a) 
2012 
Non-
randomise
d before-
after study 
3,356* CRP POCT 
NycoCard™ 
CRP 
 
Antibiotic Rx at index 
consultation 
 
Effectiveness 
 
Llor (b) 
2012 
Non-
randomise
d before-
after study 
560* CRP POCT 
NycoCard™ 
CRP 
 
Antibiotic Rx at index 
consultation 
 
Effectiveness 
 
*Only those patients who received the full intervention were included. 
Abbreviations: CAP – community acquired pneumonia; CRP – C-reactive protein; DTA – diagnostic test accuracy; F/U – 
follow-up; LRTI – lower respiratory tract infection; POCT – point-of-care testing; RCT – randomised controlled trial; Rx – 
prescription  
 
Ten of the studies were carried out in Europe, one in Russia [127], and one in Vietnam [132]. The 
length of follow-up varied from no follow-up to 28 days. All included studies reported on at least the 
primary outcome, that is, antibiotic prescribing at the index consultation. Presenting symptoms and 
inclusion criteria differed between studies, with some studies including only patients with LRTIs [127, 
137, 138], others patients with URTI only (in particular sinusitis) [128, 134, 136], while others included 
both URTI and LRTI [129-133, 135]. Some studies included patients with exacerbations of chronic 
obstructive pulmonary disease (COPD), while others excluded patients with chronic disease. Most 
studies only included adults, while three included adults and children [128, 131, 132]. The studies 
tended to include more woman than men (RCT range 57-72% female) (Appendix 1, Table A6). Three 
studies received funding from the manufacturers of the CRP POCT devices [130, 134, 138]. The iden-
tified studies included in this relative effectiveness assessment (REA) related to only three of the 15 
CE marked devices (QuikRead
®
 CRP kit/QuikRead
®
 101, Alere Afinion™ CRP, and NycoCard™ CRP 
for use with NycoCard™ II Readers). All three of these devices are quantitative devices. 
The non-randomised studies differed substantially from the RCTs in a number of ways and as a result 
have been analysed separately. Not only did they differ in terms of study design, but they also differed 
in terms of access to the intervention. In the RCTs, all patients in the intervention group received the 
intervention, while no patients in the control group received it. In the non-randomised studies, the 
intervention group had access to CRP POCT, but the clinicians may or may not have used it, while 
the control group had no access to CRP POCT. 
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As there was clinical heterogeneity due to the spectrum of RTIs included in each study (Table A6), a 
random effects model was used for meta-analysis unless otherwise stated.  
 
Change in management 
[D0021] – How does use of the test change physicians' management decisions?  
Number of patients given an antibiotic prescription at the index consultation 
All 12 studies (randomised n=7; observational n=5) reported on this outcome [127, 129-138]. In the 
meta-analysis, the seven RCTs (individually randomised studies n=3,345; cluster randomised trials 
with modified sample size n=1,975) and four non-randomised studies (n=4,839) all showed point es-
timates in favour of CRP POCT to reduce antibiotic prescribing; however, in four studies the differ-
ence was not statistically significant (Figure 5) [127, 131, 134, 138].  
The pooled estimate for the RCTs showed a statistically significant reduction in antibiotic prescribing 
in the CRP test group, compared with usual care (RR 0.76, 95% CI: 0.67–0.86, I
2
 = 70%) (Figure 5). 
There was substantial heterogeneity in this pooled estimate (70%). This could not be attributed to 
differences in trial type, as even in our planned subgroup analysis, grouping the trials based on type 
of randomisation used (individual or cluster), there was substantial heterogeneity in the individually 
randomised group (I
2
 = 82%, n=4), but not in the cluster randomised group (I
2
 = 0%, n=3). When per-
forming a sensitivity analysis, much of the heterogeneity observed in the individually randomised sub-
group was due to the 2016 study by Do et al. (I
2
 decreases from 82% to 5% when this study is re-
moved) [132]. The study by Do et al. differs from the other studies as it was carried out in Vietnam, 
while the other studies were carried out in Europe or Russia. It also reported a high level of antibiotic 
prescribing in the usual care arm, even though they excluded patients with severe RTIs. Inclusion of 
the study by Do et al. in the meta-analysis of individually randomised trials produced a pooled effect 
of CRP POCT on antibiotic prescribing of RR 0.82 (95% CI: 0.67, 1.00, I
2 
=
 
82%, n=4) while removing 
this trial produces an RR of 0.90 (95% CI: 0.80, 1.02, I
2
 = 5%, n=3). Removal of this study from the 
pooled analysis makes only a small difference to the overall pooled effect estimate (RR 0.78 95% CI: 
0.66, 0.92, I
2 
= 68%, n=6). In the cluster randomised trials, there was a statistically significant reduc-
tion in antibiotic prescribing in the CRP POCT group compared with usual care (RR 0.68 95% CI: 
0.61, 0.75, I
2
 = 0%). However, it should be noted that two of these three studies (Cals 2009 [129] and 
Little 2013 [135]) used a factorial design and included a communications component that was shown 
by the authors to have a significant effect on lowering antibiotic prescriptions at the index consultation 
both on its own and when used in combination with CRP POCT. Removal of these studies from the 
meta-analysis had only a small effect on the pooled estimate (RR 0.80, 95% CI: 0.67, 0.96, I
2
 =77%).  
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Figure 5: Forest plot: Antibiotic prescribing at index consultation (RCTs and Cluster RCTs) 
 
 
The observational studies show a similar effect of CRP POCT on antibiotic prescribing with a pooled 
RR of 0.61 (95% CI: 0.54–0.69) (Figure 6). There was substantial heterogeneity in the pooled esti-
mate with an I
2
 = 74%. In a sensitivity analysis, it was identified that the 2010 study by Jakobsen et al. 
was the source of the heterogeneity. When this trial was removed from the meta-analysis, the effect 
of CRP POCT on antibiotic prescribing remained, but the heterogeneity decreased (RR 0.64, 95% CI: 
0.61–0.68, I
2
 = 0%, n=3). The study by Jakobsen et al. compared antibiotic prescribing in Norway and 
Sweden, where CRP POCT is often used in routine consultation, to Wales in the UK where it is not 
available to GPs. As Sweden and Norway and the UK have different health systems and patients may 
have different expectations about receiving an antibiotic, this control group may not have been a suit-
able comparator [133]. The 2004 study by Bjerrum et al. also reported a significant difference in pre-
scribing between their CRP POCT group and the usual care group, but the data were not available in 
a format where it could be extracted for meta-analysis (OR 0.43, 95% CI: 0.33–0.58) [128]. 
The number needed to test (NNT) using CRP POCT to save one antibiotic prescription was calculated 
and ranged between 3 and 20 people, depending on the study type. That is:  
 RCTs (all), NNT 10.0 (95% CI: 4.8–151.5) 
 RCTs (without Do 2016), NNT 19.8 (95% CI: 9.0–102.0) 
 Cluster RCTs, NNT 6.3 (95% CI: 5.0–8.6) 
 RCTs + Cluster RCTs, NNT 7.6 (95% CI: 5.2–14.4) 
 RCTs + Cluster RCTs (without Do 2016), NNT 9.0 (95% CI: 5.6–22.4) 
 Observational studies, NNT 3.5 (95% CI: 2.9–4.6) 
Study or Subgroup
1.1.1 Individually randomised trials
Cals 2010
Diederichsen 2000
Do 2016
Melbye 1995
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.03; Chi² = 16.62, df = 3 (P = 0.0008); I² = 82%
Test for overall effect: Z = 1.97 (P = 0.05)
1.1.2 Cluster randomised trials
Andreeva 2014
Cals 2009
Little 2013
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.54, df = 2 (P = 0.76); I² = 0%
Test for overall effect: Z = 7.08 (P < 0.00001)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 19.82, df = 6 (P = 0.003); I² = 70%
Test for overall effect: Z = 4.23 (P < 0.0001)
Test for subgroup differences: Chi² = 2.83, df = 1 (P = 0.09), I² = 64.7%
Events
56
179
441
54
730
18
20
304
342
1072
Total
129
414
1017
108
1668
49
65
920
1034
2702
Events
73
184
647
68
972
22
31
407
460
1432
Total
129
398
1019
131
1677
38
59
844
941
2618
Weight
12.9%
18.5%
22.5%
12.8%
66.8%
6.0%
6.4%
20.8%
33.2%
100.0%
M-H, Random, 95% CI
0.77 [0.60, 0.98]
0.94 [0.80, 1.09]
0.68 [0.63, 0.74]
0.96 [0.75, 1.24]
0.82 [0.67, 1.00]
0.63 [0.40, 1.00]
0.59 [0.38, 0.91]
0.69 [0.61, 0.77]
0.68 [0.61, 0.75]
0.76 [0.67, 0.86]
CRP testing Usual care Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours CRP testing Favours usual care
CRP POCT to guide antibiotic prescribing in primary care settings for acute respiratory tract infections 
EUnetHTA Joint Action 3 WP4 89 
 
Figure 6: Forest plot: Antibiotic prescribing at index consultation (Non-randomised studies) 
 
 
Number of patients given an antibiotic prescription within 28 days follow-up. 
Five RCT studies reported on this outcome (Figure 7) [127, 129, 130, 132, 138], of which three were 
individually randomised studies (n=2,533) and two were cluster randomised studies (modified sample 
size n=211). No observational studies reported on prescribing beyond the index consultation. All in-
cluded studies showed point estimates in favour of CRP POCT to reduce antibiotic prescribing within 
28 days (RR 0.81, 95% CI: 0.74–0.88, I
2
 = 21%); however, in three of the studies the difference was 
not significant. Not all of the studies had a follow-up period of 28 days: the study by Melbye et al. had 
a 21-day follow-up period [138], while the studies by Do et al. and Andreeva et al. had a 14-day fol-
low-up period [127, 132]. There was no indication that more patients subsequently received an antibi-
otic during the follow-up period in the CRP POCT group compared with usual care. 
Figure 7: Forest plot: Antibiotic prescribing within 28 days (RCTs and Cluster RCTs) 
 
 
Planned subgroup analysis 
Study or Subgroup
Jakobsen 2010
Kavanagh 2011
Llor 2012
Llor 2012b
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 11.51, df = 3 (P = 0.009); I² = 74%
Test for overall effect: Z = 7.63 (P < 0.00001)
Events
175
27
653
156
1011
Total
503
60
1488
275
2326
Events
209
35
1288
252
1784
Total
300
60
1868
285
2513
Weight
26.0%
9.7%
34.8%
29.5%
100.0%
M-H, Random, 95% CI
0.50 [0.43, 0.58]
0.77 [0.54, 1.10]
0.64 [0.60, 0.68]
0.64 [0.57, 0.72]
0.61 [0.54, 0.69]
CRP testing Usual care Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours CRP testing Favours usual care
Study or Subgroup
1.2.1 Individually randomised trials
Cals 2010
Do 2016
Melbye 1995
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 2.11, df = 2 (P = 0.35); I² = 5%
Test for overall effect: Z = 6.04 (P < 0.00001)
1.2.2 Cluster randomised trials
Andreeva 2014
Cals 2009
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 1.24, df = 1 (P = 0.27); I² = 19%
Test for overall effect: Z = 2.63 (P = 0.009)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 5.07, df = 4 (P = 0.28); I² = 21%
Test for overall effect: Z = 4.58 (P < 0.00001)
Test for subgroup differences: Chi² = 1.49, df = 1 (P = 0.22), I² = 32.9%
Events
68
598
61
727
20
29
49
776
Total
129
1017
108
1254
49
65
114
1368
Events
84
747
78
909
27
34
61
970
Total
129
1019
131
1279
38
59
97
1376
Weight
15.8%
58.2%
14.5%
88.6%
5.1%
6.4%
11.4%
100.0%
M-H, Random, 95% CI
0.81 [0.66, 1.00]
0.80 [0.75, 0.85]
0.95 [0.76, 1.18]
0.82 [0.76, 0.87]
0.57 [0.39, 0.85]
0.77 [0.55, 1.10]
0.68 [0.51, 0.91]
0.81 [0.74, 0.88]
CRP testing Usual care Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours CRP testing Favours sual care
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Subgroup analysis was performed for upper (sinusitis, sore throat, etc.) versus lower RTIs (bronchitis, 
acute exacerbations of COPD, pneumonia, cough, etc.) for the outcome of antibiotic prescribing at the 
index consultation. Eight studies (three RCTs [130, 135, 138], one cluster RCT [127] and four non-
randomised studies [133, 134, 136, 137]) provided data on either LRTI or URTI or both (Figure 8 and 
Figure 9). 
Figure 8: Forest plot: Antibiotic prescribing at index consultation in LRTI and URTI (RCTs and 
Cluster RCTs) 
 
Figure 9: Forest plot: Antibiotic prescribing at index consultation in LRTI and URTI (Non-
randomised studies) 
 
Two RCTs provided data on URTI [130, 135]. Overall, the pooled estimate shows a significant reduc-
tion in antibiotic prescribing between the CRP POCT group and the usual care group for URTI in both 
RCTs (RR 0.72, 95% CI: 0.58–0.90, I
2
 = 0%). The non-randomised studies show a similar finding, 
both studies have a point estimate favouring CRP POCT, but the difference is not statistically signifi-
cant in the Kavanagh et al. study but is significant in the Llor 2012 study. Overall, the pooled estimate 
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shows a significant reduction in antibiotic prescribing between the CRP POCT group and the usual 
care group (RR 0.65, 95% CI: 0.59–0.73, I
2
 = 0%).  
Four RCTs provided data on LRTI [127, 130, 135, 138]. Three of the studies had a non-significant 
reduction in antibiotic prescribing in the CRP POCT group compared with the usual care group [127, 
130, 138], while one study showed significant difference [135]. The pooled RR suggests CRP POCT 
does lower antibiotic prescribing in patients with LRTI (RR 0.76, 95% CI: 0.61–0.94), however there is 
substantial heterogeneity (I
2
 = 59%). This finding is backed up by two non-randomised studies (Llor 
2012 and Jakobsen) with a pooled estimate of RR 0.57 (95% CI: 0.45–0.72, I
2
 = 89%). 
Two RCTs [131, 132] included adults and children. The study by Do et al. found a similar and signifi-
cant effect of using CRP POCT on antibiotic prescribing with children and adults (children n=1,028, 
RR 0.69, 95% CI: 0.62–0.78; adults n=1,008, RR 0.67, 95% CI: 0.60–0.76; combined cohort n=2,036, 
RR 0.68, RR: 0.63-0.74). The study by Dierderichsen et al. also included adults and children in their 
study. While they did not report the antibiotic prescribing separately for adults and children, the 
Cochrane review by Aabenhaus et al. used unpublished data to calculate the effect of CRP POCT in 
children and adults separately for this study and reported that CRP POCT did not have a significant 
effect on the prescribing of antibiotics in either group (children n=139, RR 1.09, 95% CI: 0.70–1.71; 
adults n=673, RR 0.91, 95% CI: 0.78–1.07)[24]. As noted previously, the effect of CRP POCT on an-
tibiotic prescribing in the combined cohort in this study was not significant (children and adults n=812, 
RR 0.94, 95% CI: 0.80 to 1.09).  
Although it was not possible to do a subgroup analysis based on CRP cut-points, there was an option 
to undertake subgroup analysis of studies where there was a clear recommendation to the GP on the 
basis of specified CRP levels, specifically if CRP is < 20 mg/L not to prescribe antibiotics, to prescribe 
antibiotics when CRP is > 100 mg/L and to use clinical judgement when CRP is between 20 and 99 
mg/L as per NICE guidelines for pneumonia. Four studies fit this criteria (see Table 9 for a description 
of algorithms used in each study), two individually randomised RCTs [130, 132], one cluster RCT 
[135] and one non randomised study [137]. Combining the RCTs (using modified sample size for clus-
ter RCT) produces a pooled estimate of RR 0.69 ([95% CI: 0.65, 0.74], I
2
 = 0%). The non-randomised 
study by Llor et al. agreed with the pooled estimate (0.64 [0.60, 0.68]), suggesting that providing GPs 
with clear cut-points based on clinical guidelines may enhance the effect of CRP POCT on antibiotic 
prescribing.  
Table 9: Algorithms used in studies 
Author Year Algorithm, if used 
Studies with clear recommendation to the GP 
Cals 2010 Advice was given based on CRP test values. No antibiotics if CRP <20mg/L, immedi-
ate antibiotics of CRP >100 mg/L and consider a delayed prescription for CRP levels 
between 20 and 99 mg/L. Physicians could deviate from the advice at any time 
Do 2016 Recommend that antibiotics should not be prescribed if CRP ≤20 mg/L for patients 
aged 6–65 years and if CRP ≤10 mg/L for patients aged 1–5 years. Adults with CRP 
≥100 mg/L and children with CRP ≥50 mg/L should generally receive antibiotics and 
hospital referral should be considered. Between these thresholds no specific recom-
mendation was given and clinicians were advised to use their clinical discretion. 
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Llor 2012 Advice based on CRP cut-points. GPs were advised to use CRP test only in cases of 
doubt, and not as a standalone test, withholding antibiotic therapy for CRP values <20 
mg/L and prescribing an antibiotic for values >100 mg/L. 
Little 2013 Recommended cut-points for CRP. CRP ≤ 20 mg/l – self-limiting LRTI, withhold antibi-
otics. CRP 21-50 mg/L – majority of patients have self-limiting LRTI, assessment of 
signs, symptoms, risk factors and CRP is important, withhold antibiotics, in most cas-
es. CRP 51-99 mg/L – assessment of signs, symptoms, risk factors and CRP is cru-
cial, withhold antibiotics in the majority of cases and consider delayed antibiotics in the 
minority of cases. CRP ≥ 100 mg/L – severe infection, prescribe antibiotics 
Other Algorithms used in studies 
Andreeva 2014 GPs were told that antibiotics were usually not needed when the CRP value was below 
20 mg/L and that a prescription could be indicated for CRP values above 50 mg/L, 
taking into account the duration of illness, but that giving antibiotics should be decided 
on a case-by-case basis. 
Bjerrum 2004 None reported. 
Cals 2009 CRP <20 – pneumonia extremely unlikely. CRP 20 to 50 – pneumonia very unlikely. 
CRP 50 to 100 – clear infection, most likely bronchitis possibly pneumonia, combining 
clinical findings and CRP very important. CRP >100 – severe infection, pneumonia 
more likely. 
Diederichsen 2000 Advice was given to the GPs that a normal CRP value (<10mg/L) and a CRP value 
<50 mg/L was seldom the result of bacterial infection. 
Jakobsen 2010 None reported. 
Kavanagh 2011 Based on CRP cut-points. CRP value of <20 was considered indicative of a viral or 
self-limiting infection. A value of 20 to 50 was taken to indicate a ‘borderline’ level (at 
which advice would usually be given to observe symptoms over 48 hours with explana-
tion in relation to red flag symptoms and signs, and the possible issue of a delayed 
antibiotic prescription). A level of >50 was considered to be indicative of a bacterial 
infection. 
Llor 2012 The GPs were informed about the evidence regarding CRP use in RTIs and it was 
emphasised that the test result should always be interpreted in combination with pa-
tient history recording and clinical examination. A CRP test result >40 mg/L was inter-
preted as a support for the decision to prescribe antibiotics, while a CRP test result 
<10 mg/L supported the decision on no antibiotic prescribing. 
Melbye 1995 Disease duration 0-24 hours: CRP <50 mg/L – no change in clinical decision. Give 
antibiotics at CRP ≥50 mg/L. Disease duration 1-6 days: Do not give antibiotics at CRP 
<11 mg/L, CRP 11-49 mg/L no change in clinical decision, give antibiotics at CRP ≥50 
mg/L. Disease duration seven days or more: Do not give antibiotics at CRP <11 mg/L, 
CRP 11-24 mg/L no change in clinical decision, give antibiotics at CRP ≥25 mg/L. 
Number of patients given an antibiotic prescription for immediate use versus delayed use and re-
demption of prescriptions 
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One RCT [130] and one non-randomised study [134] included information on whether the prescribed 
antibiotic was delayed or for immediate use. Delayed antibiotic prescribing is a strategy of providing a 
patient with a prescription for an antibiotic, but advising them not to fill the prescription unless their 
symptoms persist or worsen, or if laboratory results (if requested) subsequently indicate a bacterial 
infection. These studies (by Cals et al. 2010 and Kavanagh et al. 2011), showed no difference in the 
number of patients provided a delayed prescription between the CRP group and the usual care 
groups (RR 0.84, 95% CI: 0.53–1.33 and RR 1.30, 95% CI: 0.63–2.66, respectively). However, the 
study by Cals et al. 2010 also looked at how many patients redeemed their delayed prescription, and 
found significantly more redeemed prescriptions in the usual care group compared with the CRP 
POCT group (72% versus 23%). As the study by Cals et al. 2010 showed no significant difference in 
recovery at seven days between the CRP POCT group and the usual care group ([D0005], [C0008]), 
this might suggest that patients were more reassured that they did not need an antibiotic when the 
findings from the clinical examination were supported by their CRP test result. Further qualitative 
studies would need to be done to explore the reasons for redemption of delayed prescriptions. Other 
than the study by Cals et al. 2010, no study provided information on the number of patients who re-
deemed a prescription for antibiotics. 
 
Mortality 
[D0001] – What is the expected beneficial effect of the technology on mortality? 
As this AE overlaps with C0008, results will be presented in Section 6.2 (Safety). In brief, out of 7,165 
patients (CRP test group n=3,696, usual care group n= 2,469), there were no reported deaths. It is 
therefore unlikely that the use of CRP POCT will have any beneficial or detrimental effect on mortality. 
 
Morbidity 
[D0005] – How does the use of CRP POCT to guide antibiotic prescribing affect symptoms and 
findings (severity, frequency) of RTI?  
This AE overlaps with C0008. 
Number of patients with substantial improvement or complete recovery at seven days and 28 days 
Three RCTs (n=1,264 patients) reported on the number of patients that made a substantial or com-
plete recovery by day seven (Figure 10) [130, 131, 138]. The study by Diederichsen et al. did not in-
clude this information in their paper, but the author had provided this information for the Cochrane 
review by Aabenhaus et al. and this data was extracted directly from the Aabenhaus review [24]. 
There was no difference in the number of patients making a substantial or compete recovery between 
the CRP POCT group and the usual care group at seven days (RR 1.03, 95% CI: 0.93–1.14, I
2
 = 0%). 
Of note, the study by Cals et al. 2009 (n= 388 patients) also reported that there was no significant 
difference in clinical recovery between the groups at seven days, but the data were not extractable for 
meta-analysis [24, 129]. 
Three studies (one individually randomised RCT [138] and two cluster RCTs [127, 129]) reported on 
recovery beyond seven days: Andreeva et al., Melbye et al. and Cals et al. reported on clinical recov-
ery at 14 days, 21 days and 28 days, respectively. Cals 2009 data was extracted directly from the 
Aabenhaus et al. review [24] as this data was not available in the study paper. In all three studies, 
there was no difference in recovery beyond seven days between the CRP POCT group and the usual 
care group (n=527, with modified sample sizes for cluster RCTs. RR 0.94 [95% CI: 0.68–1.28], I
2
 = 
0%). 
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Figure 10: Forest plot: Recovery by day seven (RCTs and Cluster RCTs) 
 
 
Time to resolution of acute respiratory infection symptoms 
Four studies (two individually randomised RCTs [130, 132] and two cluster randomised RCTs [105, 
129]) reported on the time to resolution of symptoms (Table 10) [129, 130, 132, 135]. All four studies 
reported the median time to resolution of symptoms; however, no attempt was made to pool these 
data as the definition of resolution of symptoms differed between studies. All of the studies reported 
no significant difference in the time to resolution of symptoms between the CRP POCT and usual care 
groups, even when one group had received more antibiotics than the other group. 
Table 10: Median time to resolution of symptoms 
Author 
(year) 
Patients Median time to 
symptom resolu-
tion in CRP 
group (days) 
IQR 
(days) 
Median time to 
symptom resolution 
in usual care group 
(days) 
IQR 
(days) 
Do 
(2016) 
All patients 5 4 to 7 5 4 to 7 
  Children 5 3 to 7 5 4 to 7 
  Adults 6 4 to 10 5 4 to 8 
Cals 
(2010) 
Rhinosinusitis 14 10 to 28 14 7 to >28 
 LRTI 15.5 9.5 to 28 20 13.3 to >28 
Cals 
(2009) 
All patients 22 14 to 28 22 14 to 28 
Little 
(2013) 
All patients 5 3 to 9 5 3 to 9 
  URTI 5 3 to 7 4 3 to 8 
  LRTI 6 3 to 9 5 3 to 9 
 
[D0006] – How does CRP POCT affect progression (or recurrence) of the RTIs?  
This AE overlaps with C0008 and is also discussed in the Safety domain. 
  
Study or Subgroup
1.3.1 Individually randomised trials
Cals 2010
Diederichsen 2000
Melbye 1995
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.43, df = 2 (P = 0.49); I² = 0%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.43, df = 2 (P = 0.49); I² = 0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
Events
27
251
46
324
324
Total
118
407
102
627
627
Events
31
252
53
336
336
Total
125
384
128
637
637
Weight
51.1%
29.5%
19.4%
100.0%
100.0%
M-H, Random, 95% CI
1.03 [0.89, 1.18]
1.12 [0.93, 1.34]
0.94 [0.75, 1.18]
1.03 [0.93, 1.14]
1.03 [0.93, 1.14]
CRP testing Usual care Risk Ratio (Non-event) Risk Ratio (Non-event)
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours usual care Favours CRP testing
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Number of patients reconsulting 
Six studies reported on reconsultations – five RCTs (of which two were individually randomised and 
three were cluster randomised trials) and one non-randomised study (Figure 11) [127, 129, 130, 132, 
134, 135]. While the point estimates for reconsultation exceeded that of the usual care group in all but 
one study, this difference was not statistically significant in any study. The difference in reconsultation 
rates between the CRP POCT group and the usual care group was not statistically significant in the 
pooled meta-analysis (RCTs n=4,524, RR 1.09, 95% CI: 0.93–1.27 I
2
= 0% and non-randomised study 
n=120, RR 1.56, 95% CI: 0.73–3.32).  
Figure 11: Forest plot: Reconsultations (RCTs and Cluster RCTs) 
 
 
[D0011] – Does the use of CRP POCT to guide antibiotic prescribing lead to reduced adverse 
events as a result of lower antibiotic prescribing rates compared with standard care? 
This AE overlaps with C0008 and is reported in the Safety domain. 
 
Health-related quality of life 
[D0012] – What is the effect of the technology on generic health-related quality of life? 
There were no studies that reported on health-related quality of life (HRQoL). 
 
[D0013] – What is the effect of the technology on disease-specific quality of life? 
There were no studies that reported on disease-specific quality of life. 
 
Satisfaction 
[D0017] – Were patients satisfied with the technology? 
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Patient and physician satisfaction 
None of the included studies reported on physician satisfaction with CRP POCT. Four studies in total 
reported on patient satisfaction (n=1,885). In three of these studies satisfaction with their clinician visit 
was measured using a Likert scale: one individually randomised study [130], one cluster randomised 
study [129] and one non randomised study [134]. The fourth study was an RCT and the authors used 
a scale of 1 to 10 to measure patient satisfaction regarding participation in the trial [132]. The patients 
were generally satisfied with the care received and there was no significant difference between the 
CRP POCT group and the control group (RCTs RR 0.82 [95% CI: 0.55, 1.21], I
2
 = 48%; non-
randomised study Kavanagh et al. RR 1.00, 95% CI: 0.86–1.16). Although in one study, Cals et al. 
2010, patients were more often satisfied in the CRP POCT group than in the usual care group (Figure 
12). 
Figure 12: Forest plot: Patient satisfaction, satisfied (RCTs and Cluster RCTs) 
 
 
5.5 Discussion 
Overall, our results suggest that CRP POCT, when used to guide management of patients who pre-
sent with symptoms of acute RTI, leads to reduced antibiotic prescribing both at index consultation 
and up to 28 days follow-up. All studies showed a point estimate that favours the use of CRP testing 
in reducing antibiotic prescribing, but in some studies this difference was not significantly different to 
usual care. There was substantial heterogeneity in the pooled results for the individually randomised 
RCTs and the non-randomised studies. A sensitivity analysis showed that most of the heterogeneity 
in the individually randomised RCTs was due to one study by Do et al., which was carried out in Vi-
etnam [132]. The study had a high level of prescribing in the usual care arm (63.5%), even though 
they excluded anyone presenting with severe acute RTIs and therefore may have been different to 
the other studies. Removal of this study from the RCT analysis results in a non-significant reduction in 
antibiotic prescribing in the CRP POCT group with much lower heterogeneity (I
2
 = 5%). In the non-
randomised studies, the effect of CRP POCT on reducing antibiotic prescribing remains, but the het-
erogeneity is reduced (I
2
 = 0%) with the removal of one study that used a control group from a differ-
ent country to the intervention group [133]. This reduction in antibiotic prescribing in the CRP POCT 
group does not appear to lead to a significant difference in clinical recovery or reconsultation rates.  
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Delayed prescribing is a method whereby a prescription is issued to the patient for use at a later date 
if their symptoms do not improve. Only two studies reported on the use of delayed prescriptions [130, 
134] and there appears to be no significant difference in the use of delayed prescriptions between the 
CRP POCT group and the usual care group. The use of delayed prescriptions has been shown to be 
a very effective method of reducing antibiotic prescription redemption [145]. In both of these studies, 
the algorithm given to the GPs in the CRP POCT group suggested the use of a delayed prescription if 
the CRP levels were intermediate. As a result, one might expect more delayed prescribing in the 
group receiving the CRP POCT; however, in both of these studies it appeared that GPs were already 
using delayed prescribing in their usual care. Of note, Cals et al. also looked at redemption rates for 
the delayed prescriptions and found it to be significantly lower in the CRP POCT group. While it is not 
possible to draw a conclusion based on a single paper, this could suggest that knowing their CRP 
POCT result provides patients with greater assurance that an antibiotic is not warranted.  
In the studies that reported on patient satisfaction [129, 130, 132, 134], the patients were mostly satis-
fied and there was no difference in satisfaction between the CRP POCT group and the usual care 
group, suggesting that the provision of CRPPOCT neither improves nor disimproves their consultation 
experience. 
In addition to the outcomes we had identified as important, one study [127] reported on referral to 
radiography and found there was a significantly lower rate of referral in the CRP POCT test group 
compared with the usual care group (55.5% versus 96% p=0.004). Although no conclusions can be 
drawn from this, if CRP POCT leads to a reduction in referrals for further testing it could lead to sub-
stantial savings for the healthcare system without negatively impacting on patient safety. 
A number of the studies [129, 135-137] included an educational or communications component in 
their intervention with CRPPOCT. This may have enhanced the effect of CRP POCT on antibiotic 
prescribing, but the removal of Little 2013 and Cals 2009 from the RCT meta-analysis only changes 
the pooled risk ratio a small amount and still leads to the conclusion that CRP POCT leads to a signif-
icant reduction in antibiotic prescribing (RR 0.80, 95% CI: 0.67–0.96). 
Due to a lack of studies, we were unable to carry out all of our pre-planned subgroup analysis. From 
the 2014 Cochrane review by Aabenhaus et al. [24] we expected heterogeneity by study type. There-
fore we planned subgroup analysis for individually randomised and cluster randomised trials; non-
randomised (observational) studies were analysed separately due to the difference in quality of this 
study type. There were sufficient studies to analyse URTI separately to LRTI and in all study types 
antibiotic prescribing was significantly lower in the CRP POCT group (Figure 5, Figure 6) suggesting 
that CRP POCT is useful for both upper and lower RTIs. However, there was substantial heterogenei-
ty, particularly in the non-randomised studies. Only three studies included children, and in the two 
studies for which data could be extracted for meta-analysis, the effect of CRP POCT on prescribing of 
antibiotics was similar in both adults and children [24, 125, 132]. However, one study found a signifi-
cant effect in both adults and children while the other reported no effect in both groups. In light of the 
limited data including children and the lack of consistency in results, it is not possible to state from this 
review what the impact of CRP POCT is on antibiotic prescribing in children with RTIs.  
Although most studies included adults of all ages, there was no separation of results for younger 
adults (<65 years) versus older adults. More studies involving CRP POCT would be useful in older 
adults as older adults often have co-morbidities and may be on multiple medications, and it is current-
ly unclear what effect this may have on CRP POCT and on GP prescribing. There were no studies 
that met our inclusion criteria that included patients from long-term care facilities or out-of-hours clin-
ics, so it was not possible to look at these populations separately.  
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Our study shows similar results to other published systematic reviews in the area [24, 48, 139, 142], 
with the conclusion that although some studies show no significant difference between CRP POCT 
and usual care in terms of antibiotic prescribing, when combined, the pooled estimates suggest CRP 
POCT does have a significant effect on prescribing. We included both RCTs and observational stud-
ies in our review to ensure the review reflected the findings from a range of study types and not just 
clinical trials where GPs might be more motivated to follow the suggested algorithms and limit their 
antibiotic prescribing. 
The studies included in the systematic review were all characterised by patient follow-up periods of no 
more than four weeks. The average recruitment period across trials was 6.5 months, or 7.5 months 
from the recruitment of the first patient to completion of follow-up for the last patient. One study has 
subsequently published data with 3.5 years follow-up that gives some evidence in relation to the 
sustained impact of CRP POCT for RTIs. These limited data suggests that the initial introduction of 
CRP POCT might be associated with behavioural change that leads to reduced consultation by 
patients for subsequent episodes of RTI. A key question is whether the availability of CRP POCT 
within a general practice continues to impact on antibiotic prescribing over the longer term. That 
impact could be initiated through raised awareness among both patients and clinicians, and that the 
associated behavioural change might be sustained. Whether those behavioural changes require 
ongoing access to CRP POCT is not known, and it is possible that behaviours could revert to those in 
place prior to its introduction. 
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5.6 Research questions – Systematic review 2 (Diagnostic test accuracy) 
Element ID Research question 
Diagnostic core model 
D1002 How does the test compare to other optional tests in terms of accuracy measures? 
D1003 What is the reference standard for acute RTI and how likely does it classify the 
target condition correctly? 
D1005 
Overlaps with 
What is the optimal threshold value in this context? 
D1006 Do CRP levels reliably rule in or rule out the target condition? 
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5.7 Study selection 
Literature search and study selection process for systematic review 2 (diagnostic test 
accuracy) 
Figure 13: Flow chart systematic review 2 (diagnostic test accuracy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A total of 4,846 studies were identified through searches of the selected databases and the grey liter-
ature. Following screening, 49 articles were identified as being potentially relevant. Of these, 35 stud-
ies were later excluded. Reasons for exclusion are documented in Figure 13. The most common rea-
son for exclusion was inappropriate setting, that is, the study was not limited to patients presenting to 
a primary care setting. Following an eligibility assessment, 15 studies were included in the analysis. 
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The search also identified three relevant systematic reviews [47, 146, 147] and one meta-analysis 
[25]. A cross-check of the references included in these papers resulted in one potentially relevant 
paper being identified [148]. The paper was excluded following contact with the author as data relat-
ing to primary care patients excluding those presenting to outpatient clinics were not available. 
 
5.8  Quality rating 
Details of the quality of the evidence included in this systematic review are included in Appendix 1, 
Figures A2 and A3. 
 
5.9 Results 
Included studies 
The search of the literature retrieved 15 diagnostic test studies that evaluated the diagnostic test ac-
curacy of CRP in patients presenting with acute RTIs in primary care (Table 11).  
Table 11: Main characteristics of studies included in systematic review of DTA 
Author and 
year or 
study name 
Study  
type 
Number 
of 
patients 
Intervention(s) Main  
endpoints 
Included in 
diagnostic 
test accuracy 
domain 
Sinusitis 
Ebell 2017 DTA (Acute 
rhinosinusitis) 
175 Standard CRP 
laboratory 
measurement 
DOR Effectiveness 
Hansen 
1995 
DTA (Acute 
rhinosinusitis) 
168 NycoCard™ 
CRP 
DOR, sensitivity, 
specificity, PPV, NPV 
Effectiveness 
Pharyngitis/Tonsilitis 
Calvino 
2014 
DTA (Acute 
pharyngitis) 
149 CRP POCT 
QuikRead go
®
 
Mean CRP level Effectiveness 
Christensen
2014 
DTA (Acute 
tonsillitis) 
100 Standard CRP 
laboratory 
measurement 
Mean CRP level, 
Sensitivity, 
Specificity, AUC 
Effectiveness 
Gulich 2002 DTA (Acute 
pharyngitis) 
265 NycoCard™ 
CRP 
Sensitivity, 
Specificity, PPV, 
NPV, AUC 
Effectiveness 
Gulich 1999 DTA (Acute 
pharyngitis) 
161 NycoCard™ 
CRP 
Sensitivity, 
Specificity, PPV, NPV 
Effectiveness 
Pneumonia 
Heiskansen-
Kosma 
2000 
DTA (Acute 
pneumonia) 
193 Standard CRP 
laboratory 
measurement 
Mean CRP level,  Effectiveness 
Holm 2007 DTA (LRTI) 364 Standard CRP 
laboratory 
measurement 
Sensitivity, specificity, 
PPV, NPV, DOR 
Effectiveness 
Hopstaken 
2003 
DTA (LRTI) 243 Standard CRP 
laboratory 
measurement 
AUC, DOR Effectiveness 
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Hopstaken 
2009 
DTA (LRTI) 95 Standard CRP 
laboratory 
measurement 
Sensitivity, specificity, 
PPV, NPV, AUC 
Effectiveness 
Lagerström 
2006 
DTA (CAP) 82 CRP POCT 
device 
(NycoCard™ 
reader) in 
laboratory 
Median CRP levels Effectiveness 
Melbye 
1988 
DTA (CAP) 69 Standard CRP 
laboratory 
measurement 
Sensitivity, specificity, 
NPV, LR 
Effectiveness 
Minnaard 
2015 
DTA (acute 
pneumonia) 
200 CRP POCT 
device 
(Afinion™, 
NycoCard™ 
reader II, 
Eurolyser Smart 
700/340, 
QuikRead go
®
, 
QuikRead
®
 101) 
in laboratory 
Sensitivity, specificity, 
PPV, NPV 
Effectiveness 
Teepe 2016 DTA (acute 
cough) 
3,104 Standard CRP 
laboratory 
measurement 
AUC, PPV, NPV Effectiveness 
Van Vugt 
2013 
DTA (acute 
cough) 
2,820 Standard CRP 
laboratory 
measurement 
Sensitivity, specificity, 
PPV, NPV, LR, AUC, 
DOR 
Effectiveness 
Abbreviations: CAP – community acquired pneumonia; CRP – C-reactive protein; DTA – diagnostic test accuracy; F/U – 
follow-up; LRTI – lower respiratory tract infection; POCT – point-of-care testing; RCT – randomised controlled trial; Rx – 
prescription; PPV – positive predictive value; NPV – negative predictive value; LR – likelihood ratio; AUC – area under the 
curve; DOR – diagnostic odds ratio 
 
All fifteen studies were carried out in Europe [3-7, 9-12, 14, 15, 149-153]. The studies evaluated the 
utility of CRP testing across a range of RTIs including pharyngitis, acute tonsillitis, sinusitis and LRTI 
including pneumonia. The majority of included studies enrolled patients aged 15 years and older [3-7, 
9-12, 14, 151-153]. One study recruited children aged between three months and 15 years of age 
only [150]. The utility of CRP levels in the evaluation of patients presenting with signs and symptoms 
of RTI was assessed using cut-points ranging from 6 to 100 mg/L. CRP levels were measured using 
commercially available POCT devices suitable for use in primary care in four of the 15 studies [4, 5, 7, 
153]. Two studies used a CRP POC test; however, the analyses were carried out by a laboratory 
technician [9, 11]. The remaining studies used standardised laboratory testing for CRP [3, 6, 10, 12, 
14, 15, 150-152]. Two studies received research funding from manufacturers of CRP POCT devices 
[11, 14]. A detailed description of the 15 studies is provided in Appendix 1 (Table A7). 
Diagnostic test accuracy may vary between patient subgroups. For the purposes of analysis, studies 
have been grouped according to the type of RTI identified in the systematic review. There was a high 
level of heterogeneity across studies, reflecting differences between studies in the criterion used to 
define test positivity, diagnostic criteria, patient populations, and due to the absence of a universal 
reference standard for the diagnosis of RTIs requiring antibiotics. For this reason, meta-analysis of 
the data was not appropriate. Due to the inconsistency of effect measures and positivity thresholds 
reported by individual studies, a narrative summary of the reported diagnostic test accuracy outcome 
measures is provided. As noted, details of study, population, intervention and comparator characteris-
tics are provided in Appendix 1 (Table A7). A number of identified studies reported mean CRP levels 
in the sample population. Although this is not a measure of diagnostic test accuracy, it is included in 
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the analysis to provide context in relation to the clinical usefulness of CRP cut-points. Measurement of 
patient CRP levels is not intended to reflect the diagnostic test accuracy of CRP POC tests. In the 
majority of the included studies sensitivity and specificity data were reported and presented. To aid 
with the interpretation of these data, additional tables have been included in the appendix that report 
the likelihood ratios (LR) for studies for which it was possible to extract or calculate these values 
(Appendix 1, Table A9, Table A10 and Figure A1). 
Evidence in relation to two assessment elements ([D1005] and [D1006]) was identified for three RTI 
types: sinusitis, pharyngitis or tonsillitis and LRTIs or pneumonia. As there is substantial overlap be-
tween the AEs, the evidence is presented sequentially for the three conditions to facilitate ease of 
reading. 
Sinusitis 
[D1005] – What is the optimal threshold value in this context? Overlaps with: 
[D1006] – Do CRP levels reliably rule in or rule out acute sinusitis requiring antibiotic therapy?  
Two studies were identified for inclusion, an overview of which can be found in table Appendix 1 
(Table A7). 
A 2017 paper by Ebell et al. reported the results of a univariate logistic regression analysis of the as-
sociation between CRP levels and acute maxillary rhinosinusitis across a range of cut-points (10 
mg/L, 15 mg/L and 20 mg/L). The authors reported that at a CRP threshold of >15 mg/L, the diagnos-
tic odds ratio (DOR) of acute sinusitis was 4.75 (95% CI: 2.50–9.02), when using the presence of 
purulent or mucopurulent fluid from antral puncture as the reference standard (Table 12). A clinical 
decision rule incorporating signs, symptoms and CRP testing at a cut-point of ≥17 mg/L classified 
almost half of patients as low risk, allowing clinicians to rule out acute bacterial rhinosinusitis in these 
patients and to treat them symptomatically without prescribing antibiotics [3].  
A 1995 paper by Hansen et al. assessed the usefulness of CRP testing using the NycoCard™ CRP 
POCT device for the prediction of acute maxillary sinusitis across a range of CRP thresholds (<11 
mg/L, 11-24 mg/L, 25-49 mg/L, >49 mg/L), using the presence of purulent or mucopurulent fluid from 
antral puncture as the reference standard [4]. A cut-point of 10 mg/L was found to be the most appro-
priate threshold above which most patients were likely to have acute maxillary sinusitis. Sensitivity 
and specificity were reported to be 0.73 and 0.6, respectively, at this threshold, suggesting that at this 
cut-point CRP POCT may be most useful as a rule-out test to identify patients who do not require 
antibiotic therapy for resolution of symptoms (Table 12; Appendix 1, Table A9). The addition of eryth-
rocyte sedimentation rate (ESR) increased the sensitivity of the test, but not its specificity (0.82 and 
0.57, respectively).  
Table 12: Diagnostic test accuracy of CRP for acute maxillary sinusitis 
Author  
year 
Sensitivity 
 
Specificity  PPV 
 
NPV 
 
DOR (95% CI) 
Ebell 2017 
(n=175, 
sinusitis* 
52%, bacte-
rial sinusi-
tis** 35%) 
    >10mg/L*: 4.29 (2.27-
8.11) 
>15mg/L*: 4.75 (2.50-
9.02) 
>20mg/L*: 3.92 (2.02-
7.61) 
>10mg/L**: 2.56 (1.32 – 
4.97) 
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>15mg/L**: 2.75 (1.42-
5.33) 
>17 mg/L**: 2.75 (1.42-
5.33) 
>20mg/L**: 2.43 (1.28-
4.6) 
Hansen 
1995 
(n=174, 
sinusitis 
53%) 
10 mg/L: 0.73 
25 mg/L: 0.52 
50 mg/L: 0.33 
CRP 10 mg/L + 
ESR: 0.82 
10 mg/L: 0.6 
25 mg/L: 0.78 
50 mg/L: 0.9 
CRP 10 mg/L + 
ESR: 0.57 
CRP 10 mg/L 
+ ESR: 
0.68  
 
CRP 10 
mg/L + ESR: 
0.74 
 
11-24 mg/L: 2.7 (1.2-
6.1) 
25-49 mg/L: 3.5 (1.4-
8.6)  
>49 mg/L: 7.4 (3.1-18) 
*Reference standard: Antral puncture revealing purulent or mucopurulent fluid. 
**Reference standard: Positive bacterial culture of antral puncture fluid.  
 
Pharyngitis and tonsillitis 
[D1005] – What is the optimal CRP threshold value in this context? Overlaps with: 
[D1006] –Do CRP levels reliably rule in or rule out pharyngitis and tonsillitis requiring 
antibiotic therapy? 
Four studies published between 1999 and 2014 were identified. A summary of the studies is included 
in Appendix 1 (Table A7). 
CRP levels in patients with pharyngitis or tonsillitis  
Calvino et al. investigated the use of CRP POCT to identify patients with GAS infection among those 
presenting to primary care with acute pharyngitis who met all four Centor criteria (clinical signs and 
symptoms that indicate a higher likelihood of isolating Streptococcus: absence of cough, tonsillar exu-
dates, history of fever, tender anterior cervical adenopathy) [153]. Using throat culture as the refer-
ence standard, the prevalence of bacterial pharyngitis and GAS were high (80.4% and 55.7%, respec-
tively). There was no statistically significant difference in mean CRP concentrations between GAS 
infection (34.4 mg/L [95% CI: 25.6–43.3]) and non-GAS infection (29.9 mg/L [95% CI: 19.7–40.2]). 
Mean CRP levels were noted to be higher in patients with group C Streptococcus (n=13, mean 56.3 
mg/L) compared with GAS infection. Mean CRP levels were comparable for patients with GAS infec-
tion and patients for which no bacterial cause of pharyngitis could be identified (n=29, 27.9 mg/L) 
(Table 13). On this basis, the authors concluded that CRP levels are not useful for distinguishing 
those patients who require antibiotic therapy. 
Christensen et al. reported the mean CRP value in a group of patients (aged 15 to 40 years) present-
ing with signs of acute tonsillitis and meeting at least one of the four Centor criteria [6]. In contrast to 
the finding of Calvino et al., mean CRP levels were found to be significantly higher in patients with 
GAS isolated compared to those without GAS (44 mg/L [95% CI: 38–60], 15 mg/L [95% CI: 10–19], 
respectively) (Table 13).  
Determining an optimal CRP threshold and the diagnostic accuracy at a specified threshold 
A 1999 prospective observational study by Gulich et al. reported that CRP POCT can improve diag-
nostic accuracy in differentiating bacterial from non-bacterial pharyngitis in primary care [5]. The study 
population comprised patients presenting with symptoms of sore throat; the prevalence of bacterial 
pharyngitis was 23.6% [5]. An optimal threshold value of 35 mg/L was determined by ROC analysis to 
differentiate between bacterial and non-bacterial pharyngitis (AUC 0.85). At this cut-point, sensitivity 
and specificity were reported to be 0.78 (95% CI: 0.61–0.90) and 0.82 (95% CI: 0.73–0.88), respec-
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tively (Table 14, Appendix 1 Table A9). This was an improvement from clinical diagnosis only (sensi-
tivity 0.61 [95% CI: 0.45–0.75], specificity 0.73, [95% CI: 0.65–0.81]) (Appendix 1 Figure A1. Using 
clinical assessment and CRP measurement, 81% of patients presenting with symptoms of sore throat 
(n=161) were correctly diagnosed compared with 70% of patients diagnosed without information on 
CRP measurement (n=179). The distinction between bacterial and non-bacterial pharyngitis may not 
be as useful in terms of current antibiotic prescribing guidelines where antibiotic treatment is only 
recommended in those with GAS pharyngitis. 
Determining an optimal CRP threshold and the diagnostic accuracy at a specified threshold in 
combination with a clinical prediction rule 
In a subsequent 2002 study, Gulich et al. derived and validated a two-step clinical prediction rule 
combining clinical examination in patients presenting with a sore throat, with selective CRP POCT in 
patients at intermediate risk to aid in the diagnosis of GAS pharyngitis [7]. The study reported a preva-
lence of throat swabs positive for GAS of 28.7% (95% CI: 20.4–37.0) and 27.5% (95% CI: 22.2–37) 
for the derivation (n=116) and validation phases (n=265), respectively (Table 14). A ‘strepto-score’ 
was calculated based on clinical presentation and an algorithm used to triage patients as low, inter-
mediate or high probability of GAS streptococcal infection. CRP POCT was only considered neces-
sary in patients with an intermediate strepto-score (four or five points out of a possible eight). The 
NycoCard™ CRP device was used to measure CRP and a threshold of ≥35mg/L was used as per the 
1999 study. The sensitivity and specificity of the algorithm in the derivation phase were 0.88 (95% CI: 
0.58–0.99) and 0.95 (0.81-1.0) and in the validation phase were 0.74 (95% CI 0.53–0.89) and 0.95 
(95% CI: 0.88–1.0), respectively, for the diagnosis of GAS infection compared with the diagnostic 
reference standard (Table 14, Appendix 1 Table A9). In the validation part of the study, 80 patients 
(30%) required a CRP POCT (148 (56%) had a low score and 37 (14%) had a high score and did not 
require a CRP POCT). The results suggest that use of CRP POCT (at a threshold of 35 mg/L) as part 
of a two-step clinical prediction rule may be useful in identifying patients with ambiguous clinical find-
ings who would benefit from antibiotic treatment.  
Christensen et al. aimed to determine if the addition of CRP levels to a diagnostic regime incorporat-
ing the Centor score and/or rapid antigen detection test (RADT) could increase diagnostic accuracy in 
the detection of GAS. The study was limited to patients aged 15 to 40 years presenting with a sore 
throat and who met one or more of the Centor criteria [6]. Microbiological analysis of throat swabs 
was used as the reference standard. CRP levels were measured using standard laboratory testing. 
The prevalence of GAS was 26%. The Youden index (sensitivity + specificity -1) was used to deter-
mine the best cut-off value (6 mg/L) to distinguish between GAS and non-GAS acute tonsillitis. At the 
threshold of 6 mg/L, sensitivity was high (90%), but specificity was found to be only 45% (Table 14). 
The discriminative power of the test was good with an AUC of 0.77 (0.66–0.87). The specificity of the 
test improved substantially (from 45% to 70%) when CRP measurement was used only in patients 
with a Centor score of 2 to 4; however, this was at the expense of decreased sensitivity (from 90% to 
83%) (Table 14, Appendix 1 Table A9). Use of CRP testing only in patients with a Centor score of 2 to 
4 resulted in a minimal change in the AUC (0.76 (95% CI: 0.65–0.88)). The sensitivity, specificity and 
AUC were higher for the RADT than CRP in the differentiation between GAS and non-GAS acute 
tonsillitis. The authors concluded that CRP testing at a cut-off of 6 mg/L was not useful in the diagno-
sis of GAS infection either alone or in combination with the RADT and should only be used when 
RADT is not available.  
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Table 13: CRP levels in patients with pharyngitis or tonsillitis  
Author  
(year) 
Prevalence Mean CRP values (mg/L)  
Calvino 2014 
(n=149) 
Bacterial pharyngitis: 
80.4% 
GAS: 55.7% 
GAS (56.1%): 34.4 (95% CI: 25.6–43.3) 
Non-GAS (43.9%): 29.9 (95% CI: 19.7–40.2) 
GBS (5.4%): 19.1 (95% CI: 0–41.0) 
GCS (8.8%): 56.3 (95% CI: 25.7–86.9)  
GGS (3.4%): 31.6 (95% CI:0–65.3) 
Other Streptococcus (6.7%): 9.2 (95% CI:4.4–14.0) 
No bacteria (19.5%): 27.9 (95% CI: 11.0–44.9) 
Christensen 
2014 
(n=100) 
BacterialTonsillitis: 
52% 
GAS: 26% 
GAS (26%): 44 (95% CI: 38–60)  
non-GAS (74%): 15 (95% CI:10–19) 
Abbreviations: CRP – C-reactive protein; PPV – Positive predictive value; NPV – Negative predictive value; AUC – Area 
under the curve; CI – confidence interval; GAS – group A Streptococcus; GBS – group B Streptococcus; GCS – group C 
Streptococcus; GGS – group G Streptococcus. 
 
Table 14: Diagnostic test accuracy of CRP in identifying patients with acute pharyngitis or 
tonsillitis in primary care settings who require antibiotic therapy  
Author 
(number of 
patients, 
prevalence) 
CRP Cut-
point 
(mg/L) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
AUC (95% 
CI) 
Gulich 1999 
(N=161, 
bacterial 
pharyngitis: 
23.6%) 
≥ 35ml/L* 0.78 (0.61–0.90) 0.82 (0.73–0.88) 0.57 (0.42–
0.70) 
0.92 (0.85–
0.96) 
0.85 
Gulich 2002 
(Phase1: 
n=116, 
GAS:28.7% 
phase 2: 
n=265, GAS: 
27.5%) 
≥ 35ml/L* Derivation 
Streptoscore**: 
0.88 (0.58–0.99) 
Validation 
Strepto score: 
0.74 (0.53–0.89) 
Derivation 
Streptoscore**: 
0.95(0.81–1.0) 
Validation 
Strepto score: 
0.95 (0.88–1.00) 
Validation 
Strepto 
score**: 
0.86 (0.65– 
0.95 
 
Validation 
Strepto 
score**: 
0.91 (0.81–
0.96) 
 
 
Christensen 
2014 
(n=100, 
bacterial 
tonsillitis 
52%, GAS 
26%) 
6mg/L Centor score 1–
4:* 
0.90 
 
Centor score 2–
4* 
0.83 
 
Centor score 
1–4:* 
0.45 
 
Centor score 
2–4* 
0.70 
  Centor 
score 1–4:* 
0.77 (0.66–
0.87) 
Centor 
score 2–4:* 
0.76 (0.65–
0.88) 
Abbreviations: CRP – C-reactive protein; PPV – Positive predictive value; NPV – Negative predictive value; AUC – Area 
under the curve; CI – confidence interval; GAS – group A Streptococcus; GBS – group B Streptococcus; GCS – group C 
Streptococcus; GGS – group G Streptococcus. 
*The Centor criteria (tonsillar exudate, tender anterior cervical lymphadenopathy or lymphadenitis history of fever (over 38°C), 
and/or absence of cough) are an algorithm to estimate the probability of group A β haemolytic Streptococcus (GABHS) as the 
origin of sore throat. Each of the Centor criteria score 1 point (maximum score of 4). 
**The clinical strepto-score (throat mucosa, uvula, tonsils, soft palate) was based on clinical examination. Each criterion was 
scored 0 to 2 points (total score 0 to 8 points). 
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LRTI and Pneumonia 
Nine studies included in the analysis investigated the diagnostic value of CRP measurement in pa-
tients presenting with signs and symptoms of LRTI including pneumonia in primary care (Appendix 1) 
(Table A7). 
[D1005] – What is the optimal CRP threshold value in this context? Overlaps with:  
[D1006] – Do CRP levels reliably rule in or rule out pneumonia? 
CRP levels in pneumonia patients 
Two studies presented the mean CRP level in patients with radiologically confirmed pneumonia, one 
in a paediatric population and the other in an adult population. Heiskanen-Kosma et al. studied the 
ability of CRP to distinguish bacterial from viral pneumonia in paediatric patients with radiologically 
confirmed pneumonia (n=193). Patients were divided into four groups according to the aetiology of 
infection (pneumococcal, mycoplasmal or chlamydial, viral or unknown aetiological groups) as deter-
mined by laboratory analysis of sera. CRP values as measured using standard laboratory testing 
were similar between the groups and there was no significant association with the aetiology of pneu-
monia (range 24.9 to 31.8 mg/L), (Table 15). Lagerstrom et al. analysed serum CRP concentrations 
using a laboratory-based NycoCard™ reader in adult patients with radiologically confirmed CAP [9]. 
The median CRP was reported to be 65 (5-150) mg/L. CRP levels exceeded 5 mg/L, 20mg/L, 50mg/L 
and 100mg/L in 93%, 79%, 59% and 31% of patients, respectively, suggesting that at a cut-point of 
100 mg/L only a third of pneumonia cases would be identified (Table 15). It was noted that patients 
with CRP <20 mg/L had been ill for longer prior to CRP measurement (median 8.5 days [range 1-14] 
versus 6 days [range 1-28] for all patients). 
Three studies presented the difference in the mean CRP value in patients with pneumonia and those 
without pneumonia. Hopstaken et al. assessed the diagnostic test accuracy of CRP in patients pre-
senting with signs and symptoms of LRTI. Median CRP levels as measured using standard laboratory 
testing were higher in the pneumonia (145 mg/L (36-213)) than the non-pneumonia group (17 mg/L 
(2-216)). Substantial overlap was evident in measured CRP levels in patients with and without pneu-
monia. Three studies from the GRACE consortium reported average CRP levels within a sample of 
patients presenting to primary care physicians with acute cough [11, 14, 15]. Standard laboratory 
measurement was used in two studies while the third used a number of CRP POCT in the laboratory. 
The results may have been drawn from the same study data and are very similar for the studies by 
Van Vugt 2013 and Minnaard 2015. Teepe 2016 differed from the other two studies as it identified a 
subset of patients with bacterial pneumonia (Table 15). Overall, in adults, there was greater con-
sistency in the mean CRP levels reported in patients without pneumonia than in those with pneumo-
nia (Table 15).  
Table 15: CRP levels in patients presenting with symptoms of LRTI in primary care 
Author  
Year 
Mean CRP values (mg/L) 
Mean CRP levels in patients with radiologically confirmed CAP 
Heiskanen-Kosma 
2000 
Pneumococcal aetiology: 26.8 mg/L (20.1–33.5 mg/L) 
Mycoplasmal or chlamydial aetiology: 31.8 mg/L (20.5–33.1 mg/L)  
Viral aetiology: 26.1 mg/L (19.1–33.1 mg/L)  
Unknown aetiology: 24.9 mg/L (18.8–31.0 mg/L) 
Lagerström 2006 65 (5–150)* 
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CRP: 
> 100mg/L: 31% 
< 50mg/L: 41% 
< 20mg/L: 21% 
>5mg/L: 93% 
Mean CRP levels in pneumonia and non-pneumonia patients 
Hopstaken 2009 Pneumonia : 145 mg/L (36–213)*  
No pneumonia: 17 mg/L(2–216)* 
Minnaard 2015** 
 
Van Vugt 2013** 
 
Teepe 2016** 
Pneumonia: 62 mg/L (SD 81)  
No pneumonia: 19 mg/L ( SD 28) 
Pneumonia: 69 mg/L (SD 83) 
No pneumonia: 19 mg/L (SD 35) 
LRTI bacterial infection: 34 mg/L (SD 53) 
Bacterial pneumonia: 97 mg/L (SD 98) 
All patients: (19 mg/L (SD 35) 
Abbreviations: CRP – C-reactive protein; CAP – community acquired pneumonia; SD – standard deviation. 
*Data presented as median (range). 
**These studies are presented together as they were both part of the GRACE consortium study and it would appear that the 
study population used in the Minnaard study was a subset of the cohort used by Van Vugt and Teepe. 
 
Determining the optimal threshold and diagnostic accuracy of CRP measurement at specified 
cut-points 
Five studies evaluated the use of CRP testing alone in the diagnosis of pneumonia at a cut-point of 
>20 mg/L (Table 16, Table 17, Table 18, Appendix 1 Table A9, Table A10). Holm et al. studied CRP 
levels (as measured using standard laboratory testing) as a predictor of pneumonia in adults diag-
nosed with community-acquired pneumonia (CAP) by their GP [151]. A cut-point of 20 mg/L was cho-
sen by the authors from the literature, on the basis that a relatively low value is required to achieve 
acceptable sensitivity in predicting pneumonia in primary care. They reported that at a cut-off of 20 
mg/L, CRP was found to have better sensitivity than a GP’s clinical diagnosis alone in the identifica-
tion of pneumonia patients (0.73 versus 0.60) while other measures of diagnostic test accuracy (spec-
ificity, PPV, NPV) were comparable. However, the authors concluded that the sensitivity and specifici-
ty of CRP in predicting pneumonia was too low (Table 16). 
Lagerstrom et al. measured CRP levels in a laboratory using a POCT device in patients with respira-
tory symptoms and clinically suspected CAP (n=177) recruited into a previous study [9]. They report-
ed CRP results at a threshold of 20 mg/L and 50 mg/L, but it was unclear why these thresholds were 
selected. At a cut-point of 20 mg/L, sensitivity and specificity were 0.79 and 0.65, respectively (Table 
16). The improved specificity of the test at a cut-point of 50 mg/L (0.84) compromised test sensitivity 
(0.59). As 41% of pneumonia patients had CRP levels <50 mg/L and 21% had CRP levels <20 mg/L, 
the authors concluded that CRP testing is not sufficiently sensitive to rule out pneumonia in primary 
care.  
Minnaard et al. aimed to compare the diagnostic test accuracy of CRP POCT devices versus labora-
tory standard CRP tests, and to determine if differences in test accuracy affect the ability of tests to 
predict pneumonia in adults [154]. Cut-points of 20 mg/L and 100 mg/L were selected from the litera-
ture and guidelines as they were the most commonly used thresholds for distinguishing pneumonia 
from non-pneumonia. At a cut-off of 20 mg/L, sensitivity was low for a rule-out test and was compara-
ble across all CRP tests, ranging from 48.0% to 61.4% (Table 17). At a cut-point of 100 mg/L speci-
ficity was high and ranged from 97.7 to 99.0%, indicating that at this threshold the test was sufficiently 
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specific to rule in pneumonia (Table 18). The authors concluded that all five POCT devices used in 
the study performed as well as the laboratory analyser in detecting pneumonia.  
Hopstaken et al. aimed to assess the diagnostic value of CRP for pneumonia in primary care patients 
with LRTI. CRP measurement was undertaken using standard laboratory testing. ROC curves were 
constructing summarising the diagnostic test accuracy of CRP in differentiating pneumonia from acute 
bronchitis across a range of CRP thresholds (10 mg/L, 20 mg/L and 100 mg/L) [12]. In contrast to the 
studies by Holm et al, Lagerstrom et al. and Minnaard et al., at a cut-point of 20 mg/L the test demon-
strated 100% sensitivity in identifying pneumonia patients which was therefore determined by the 
authors to be the optimal cut-off value to rule out pneumonia in a primary care setting (Table 16). 
Unlike the other studies (which were published between 2006 and 2015), an earlier study by Melbye 
et al. published in 1988 did not investigate CRP at a threshold of 20 mg/L. Instead, they investigated 
the diagnostic value of CRP measuring using standard laboratory testing at cut-points of >11 mg/L 
and >50 mg/L in differentiating pneumonia from non-pneumonia in patients aged 15 years and older 
treated with antibiotics by a GP for clinically suspected pneumonia [10]. The authors did not state their 
reasons for selecting these thresholds, but found at a threshold of 11 mg/L, sensitivity and specificity 
were 0.82 and 0.60, respectively (Table 16). Increasing the CRP threshold to 50 mg/L resulted in 
improved specificity (0.96), but at the expense of lower sensitivity (0.74). The authors concluded that 
further studies must be done to establish the most practical cut-off level in the diagnosis of pneumo-
nia.  
Table 16: Diagnostic test accuracy of CRP at pre-specified cut-points in patients presenting 
with symptoms of LRTI in primary care  
Author  
Year 
Sensitivity  Specificity  PPV  NPV  Likelihood 
ratios 
AUC  DOR (95% 
CI) 
Holm 2007 CRP ≥20 
mg/L: 
0.73 
 
CRP ≥20 
mg/L: 
0.65 
 
CRP ≥20 
mg/L: 
0.24 
 
CRP ≥20 
mg/L: 
0.94 
  CRP ≥20 
mg/L: 
5.02 
(2.59–
9.88) 
Hopstaken 
2009 
CRP 10 
mg/L: 100,  
CRP 20 
mg/L: 100,  
CRP 100 
mg/L: 81.8 
CRP 10 
mg/L: 36.1,  
CRP 20 
mg/L: 50.6,  
CRP 100 
mg/L: 84.3 
CRP 10 
mg/L: 
17.2,  
CRP 20 
mg/L: 
21.2,  
CRP 100 
mg/L: 40.9 
CRP 10 
mg/L: 100,  
CRP 20 
mg/L: 100,  
CRP 100 
mg/L: 97.2  
 AUC 0.90  
Lagerstrom 
2006 
CRP 20 
mg/L: 0.79 
 
CRP 
50mg/L: 
0.59 
CRP 20 
mg/L: 0.65 
 
CRP 50 
mg/L: 0.84 
CRP 20 
mg/L: 
66.33% 
 
CRP 50 
mg/L: 
76.19 
CRP 20 
mg/L: 
78.48% 
 
CRP 50 
mg/L: 
70.18 
CRP 20 
mg/L: 
LR+ = 2.28 
LR- = 0.32 
 
CRP 50 
mg/L: 
LR+ = 3.71 
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LR- = 0.49 
Melbye 1988 CRP > 11 
mg/L: 82%,  
CRP > 50 
mg/L: 74%  
CRP > 11 
mg/L 60%,  
CRP > 50 
mg/L: 96% 
 CRP > 11 
mg/L: 
0.28,  
CRP > 50 
mg/L: 0.8 
CRP > 11 
mg/L: 2.1,  
CRP > 50 
mg/L: 37 
  
Minnaard 
2015 
Tables 
17/18 
Tables 
17/18 
Tables 
17/18 
Tables 
17/18 
   
Abbreviations: CRP – C-reactive protein; PPV - Positive predictive value; NPV – Negative predictive value; AUC – Area under 
the curve; CI – confidence interval; LR+ – Positive likelihood ratio; LR- – Negative likelihood ratio; AUC – Area under the curve; 
DOR – Diagnostic odds ratio; SD – Standard deviation. 
Table 17: Single test accuracy measures at CRP cut-point of 20 mg/L in patients presenting 
with acute cough in primary care [11] 
CRP test Sensitivity (95% CI) Specificity (95% CI) PPV % (95% CI) NPV % (95% CI) 
Laboratory analyser 61.4 (53.2 – 69.1) 76.0 (74.3 – 77.5) 11.8 (9.6 – 14.3) 97.4 (96.6 – 98.0) 
Afinion 55.0 (45.2 – 64.4) 73.0 (63.6 – 80.7) 9.6 (7.8 – 11.9) 96.9 (96.0 – 97.6) 
NycoCard™ Reader 
II 
54.0 (44.3 – 63.4) 75.0 (65.7 – 82.5) 10.1 (8.2 – 12.5) 96.9 (96.1 – 97.6) 
Eurolyser Smart 48.0 (38.5 – 57.7) 79.0 (70.0 – 85.8) 10.7 (8.5 – 13.3) 96.7 (95.8 – 97.3) 
QuikRead go
®
 52.0 (42.3 – 61.5) 72.0 (62.5 – 79.9) 8.8 (7.1 – 11.0) 96.6 (95.7 – 97.3) 
QuikRead
®
 101 49.0 (39.4 – 58.7) 74.0 (64.6 – 81.6) 9.0 (7.1 – 11.2) 96.5 (95.6 – 97.2) 
Abbreviations: CI – confidence interval; PPV – Positive predictive value; NPV – Negative predictive value. 
Table 18: Single test accuracy measures at CRP cut-point of 100 mg/L in patients presenting 
with acute cough in primary care [11] 
CRP test Sensitivity (95% CI) Specificity (95% CI) PPV % (95% CI) NPV % (95% CI) 
Laboratory analyser 24.3 (17.9 – 27.8) 97.7 (97.0 – 98.2) 35.4 (26.6 – 45.4) 96.1 (95.3 – 96.8) 
Afinion 20.0 (13.3 – 28.9) 99.0 (94.6 – 99.9) 51.1 (38.2 – 63.8) 95.9 (95.1 – 96.6) 
NycoCard™ Reader 
II 
20.0 (13.3 – 28.9) 98.0 (93.0 – 99.4) 34.3 (24.9 – 45.1) 95.9 (95.1 – 96.6) 
Eurolyser Smart 19.0 (12.5 – 27.8) 99.0 (94.6 – 99.9) 49.8 (36.9 – 62.8) 95.9 (95.1 – 96.6) 
QuikRead go
®
 20.0 (13.3 – 28.9) 99.0 (94.6 – 99.9) 51.1 (38.2 – 63.8) 95.9 (95.1 – 96.6) 
QuikRead
®
 101 19.0 (12.5 – 27.8) 99.0 (94.6 – 99.9) 49.8 (36.9 – 62.8) (95.1 – 96.6) 
Abbreviations: CI – confidence interval; PPV – Positive predictive value; NPV – Negative predictive value. 
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Determining the optimal threshold in combination with signs and symptoms 
In daily practice, the interpretation of a CRP value is made in addition to clinical judgement based on 
presenting signs and symptoms. 
Holm et al. investigated the diagnostic test accuracy of CRP measurement in combination with a GP’s 
diagnosis of pneumonia. Holm et al. found the combination of a GP’s clinical diagnosis and CRP 
measurement at a threshold of ≥20 mg/L was less sensitive (0.49 versus 0.60), but more specific 
(0.84 versus 0.68) than a GP diagnosis alone (Table 19). 
Four studies investigated the use of CRP testing in combination with a clinical prediction rule to differ-
entiate between pneumonia and other LRTI in general practice (Table 19). Three used standard la-
boratory testing while one reported CRP levels as measured using different CRP POCT devices in a 
laboratory. Hopstaken et al. described the diagnostic value of performing and recording extensive 
standardised medical history and clinical examination in combination with CRP measurement. ROC 
curves were constructed and the respective AUC were calculated to determine the overall diagnostic 
power of CRP at different cut-off values (10 mg/L, 20 mg/L, and 50 mg/L). In combination with signs 
and symptoms, CRP of 20 mg/L was selected as the optimal CRP threshold. The ‘symptoms and 
signs + CRP cut-off value of 20’ prediction model was significantly better at predicting the probability 
of pneumonia than the ‘symptoms and signs’ only model (P<0.001) [155]. Use of the clinical decision 
rule allowed a group of patients at low risk of pneumonia to be identified. The combined predictive 
value of patients not having pneumonia was 97% (95% CI: 92–99%). If the prediction rule was applied 
to patients who received antibiotic treatment, 41% of prescriptions could have been avoided, with a 
2.5% risk of patients with pneumonia being missed. The authors noted further validation of the predic-
tion rule to identify low-risk patients was required.  
Van Vugt et al. aimed to quantify the diagnostic accuracy of CRP in addition to signs and symptoms 
for the prediction of pneumonia [14].Adults presenting with acute cough (n=2,820) were grouped into 
pneumonia (n=140) or no pneumonia based on chest radiographs (prevalence CAP = 5%). The diag-
nostic accuracy of CRP at clinically relevant thresholds (>20 mg/L, >30mg/L, >50mg/L, >100 mg/L) 
was investigated for the prediction of pneumonia in adults presenting with acute cough in addition to 
14 preselected diagnostic criteria based on history taking and physical examination [14].The optimal 
cut-off level was assessed using the AUC. A simplified diagnostic risk classification system using six 
different signs and symptoms was subsequently developed by rounding all regression coefficients in 
the model. Addition of CRP at the optimal cut-off of >30 mg/L significantly increased the AUC (from 
0.70 (0.65-0.75) to 0.77 (0.73-0.81); p<0.05), and improved the diagnostic classification (net reclassi-
fication improvement 28% (95% CI: 17–30%) (Table 19). The signs and symptoms model was useful 
in correctly identifying patients with low (score of 0, probability <2.5%) or high (score ≥3, probability 
>20%) risk of pneumonia in 26% of the patients. In 74% of patients where doubt remained (estimated 
risk 2.5%-20%), measurement of CRP helped to correctly exclude pneumonia. Of the 1,987 patients 
without pneumonia who were classified as intermediate risk, the addition of CRP >30 mg/L meant 957 
were reclassified correctly to low risk and 64 were incorrectly classified as high risk. Of the 105 pa-
tients with pneumonia classified as intermediate risk, the addition of CRP reclassified 27 incorrectly to 
low risk and 22 to high risk. Thirty nine percent (54/140) of all patients with radiographic pneumonia 
had a CRP <20 mg/L. These patients tended to be older (p=0.01), more often had positive signs and 
symptoms of the diagnostic model and more often used steroids (inhaled or oral). However, despite 
increased diagnostic accuracy with the addition of CRP measurement to clinical signs and symptoms, 
a substantial group of patients were classified as intermediate risk, for which clinical decision-making 
remains challenging. 
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Minnaard et al. applied the same symptoms and signs model as Van Vugt with and without CRP to 
their nested case control population. Minnaard’s study population was also drawn from the GRACE 
study and may be a subset of the cohort used in the Van Vugt study (Table 19). As with the Van Vugt 
study, use of the signs and symptoms model without CRP testing had an AUC of 0.70 (95% CI: 0.65–
0.75) and this increased to 0.79 following the addition of CRP testing. Each of the five POC tests (Af-
inion™, NycoCard™ Reader II, Smart Eurolyser, QuikRead go
®
 and QuikRead
®
 101) had a similar 
diagnostic accuracy to the laboratory CRP analyser (AUC 0.79 to 0.80 compared with 0.79 with la-
boratory CRP analyser).  
A third study from the GRACE consortium used the same cohort of patients as Van Vugt and Min-
naard (n = 3,104), but they used the presence of prespecified bacteria in respiratory samples (either 
sputum sample or nasopharyngeal swabs) to identify patients with a bacterial LRTI (n = 539, 17%) 
and a combination of chest radiograph and the presence of prespecified bacteria in respiratory sam-
ples to determine if patients had bacterial pneumonia (n=38, 1%) [15]. CRP was added dichotomously 
at a threshold of 30 mg/L to other diagnostic criteria that had been shown to be independent predic-
tors of bacterial LRTI (discoloured sputum) or bacterial pneumonia (comorbidity, temperature ≥ 38
o
C, 
crackles on lung auscultation). The addition of CRP to the other diagnostic criteria increased the AUC 
for bacterial LRTI from 0.56 (95% CI: 0.54 -0.59) to 0.62 (95% CI:0.59 – 0.65) and for bacterial pneu-
monia from 0.68 (95% CI: 0.58 – 0.77) to 0.79 (95% CI: 0.71 – 0.87). The authors concluded that 
although CRP added diagnostic value to their signs and symptoms models it had limited clinical utility 
in predicting a bacterial cause of LRTI. 
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Table 19: Diagnostic test accuracy of CRP in combination with signs and symptoms in patients presenting with symptoms of LRTI in primary care 
Author  
Year 
Sensitivity  Specificity  PPV  NPV  Likelihood ratios AUC (95% CI) DOR (95% CI) 
Holm 2007 Clinical pneumonia 
+ CRP ≥20 mg/L: 
0.49 
Clinical pneumonia 
+ CRP ≥20 mg/L: 
0.84 
Clinical pneumonia 
+ CRP ≥20 mg/L: 
0.32 
Clinical pneumonia 
+ CRP ≥20 mg/L: 
0.91 
  Clinical pneumonia 
+ CRP ≥20 mg/L: 
4.97 (2.60–9.52) 
Hopstaken 
2003 
     CRP 10 mg/L: 0.77 
CRP 20 mg/L: 0.8 
CRP 50 mg/L: 0.87 
CRP 10 mg/L: 11.7 
(1.55–88.61)  
CRP 20 mg/L: 8.48 
(2.45–29.39)  
CRP 50 mg/L: 17.62 
(5.77–53.85) 
Teepe 
2016* 
  For LRTI bacterial 
infection: Signs and 
Symptoms (discol-
oured sputum) + 
CRP >30 mg/L:  
0.371 (95% CI: 
0.312 – 0.433) 
 
For bacterial pneu-
monia: Signs and 
Symptoms (Comor-
bidity, temperature ≥ 
38oC, crackles on 
lung auscultation) + 
CRP >30 mg/L:  
0.25 (95% CI: 0.006 
– 0.806) 
For LRTI bacterial 
infection: Signs and 
Symptoms (discol-
oured sputum) + 
CRP >30 mg/L:  
0.875 (95% CI: 
0.854 – 0.893) 
 
For bacterial pneu-
monia: Signs and 
Symptoms (Comor-
bidity, temperature ≥ 
38oC, crackles on 
lung auscultation) + 
CRP >30 mg/L:  
0.997 (95% CI: 
0.993 – 0.999) 
 For LRTI bacterial 
infection: Signs and 
Symptoms (discol-
oured sputum) + 
CRP >30 mg/L:  
0.62(95% CI: 0.59 – 
0.65 
 
For bacterial pneu-
monia: Signs and 
Symptoms (Comor-
bidity, temperature ≥ 
38oC, crackles on 
lung auscultation) + 
CRP >30 mg/L:  
0.79 (95% CI: 0.71 
– 0.87 
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Author  
Year 
Sensitivity  Specificity  PPV  NPV  Likelihood ratios AUC (95% CI) DOR (95% CI) 
VanVugt 
2013* 
Low risk:** 22%  
High risk:** 29% 
Low risk:** 43% 
High risk:** 97% 
High risk:** 31% Low risk:** 98% 
 
Low risk:**  
Positive likelihood 
ratio 0.4, Negative 
likelihood ratio: 1.8 
Intermediate risk:**  
Positive likelihood 
ratio 1.2 Negative 
likelihood ratio 0.9 
High risk:**  
Positive likelihood 
ratio 8.6 Negative 
likelihood ratio 0.7 
CRP >30 mg/L: 0.77 
(0.73–0.81) 
CRP >20 mg/L: 3.5 
(2.4–5) 
CRP >30 mg/L: 3.8 
(3.7–5.5) 
CRP >50 mg/L: 4.8 
(3.2–7.1) 
CRP >100 mg/L: 6.0 
(3.6–10) 
 
Minnaard 
2015* 
     Signs and symp-
toms model: 0.70 
(95% CI: 0.65–0.75) 
Signs and symp-
toms model + CRP: 
0.79 
 
* These studies are presented together as they were part of the GRACE study and it would appear that the study population used in the Minnaard study was a subset of the cohort used by Van 
Vugt and Teepe. 
** Probability of pneumonia based on signs and symptoms (breathlessness, absence of runny nose, diminished vesicular breathing, crackles, tachycardia, temperature (>37.8°C)) in addition to 
CRP measurement. 
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[D1002] – How does the test compare to other optional tests in terms of accuracy measures? 
This systematic review of diagnostic accuracy is limited to CRP testing for the specified indications, 
and as such a comprehensive analysis of the performance of alternative tests was beyond the scope 
of this study. This section is therefore restricted to descriptions of test accuracy of alternate tests iden-
tified in clinical guidelines (A0024) (A0025) and in the studies included in this systematic review 
(Table 11). 
Sinusitis 
Hansen et al. evaluated the diagnostic value of erythrocyte sedimentation rate (ESR) for acute maxil-
lary sinusitis. ESR and CRP concentration were found to be better diagnostic criteria than other symp-
toms and signs related to this condition, and both analyses can be performed in general practice. The 
combination of these two variables had a sensitivity of 0.82 and specificity of 0.57, and were said to 
be better than clinical examination only as a basis for deciding to give antibiotics. However, the study 
did not seek to determine which of the two infection markers had greater diagnostic value. Ebell et al. 
found that CRP and ESR were the strongest individual predictors of acute bacterial rhinosinusitis 
compared to other signs and symptoms associated with the condition as determined by univariate 
logistic regression analysis. The odds ratio for CRP was higher than for ESR, suggesting that CRP 
may have greater predictive value at determining which patients have acute sinusitis. However, this 
study did not set out to ascertain which of the infection markers was a better predictor; the aim was to 
develop a clinical decision rule. 
A 2016 systematic review of imaging and laboratory tests used in the diagnosis of acute rhinosinusitis 
identified a single study that evaluated the accuracy of a test strip comparable to those ordinarily used 
in the diagnosis of urinary tract infection [147]. It is suggested that such test strips offer an inexpen-
sive, simple alternative to other diagnostic tests such as CT scans and antral puncture which are con-
sidered to be undesirable for use in primary care due to the associated expense and impracticality, 
respectively [156]. The researchers found that leucocyte esterase and nitrite were highly specific, 
while pH and protein were highly sensitive. A score that assigned points (0 to 3) to each of these tests 
successfully identified patients at low (0%), moderate (33%) and high (100%) risk of acute rhinosi-
nusitis. However, the study was considered to be at high risk of bias as it used imaging rather than 
antral puncture as the reference standard and the thresholds for classifying patients into risk groups 
were established post-hoc [147]. Three studies identified in the systematic review evaluated the pres-
ence of leucocytes in nasal washings, with LR+ ranging from 3.06 to 4.92, and LR- from 0.08 to 0.74. 
Rhinoscopy for pus in the nasal cavity or throat and white blood cell count both lacked sufficient accu-
racy for the diagnosis of acute rhinosinusitis [147].  
 
Pharyngitis or Tonsilitis  
To enhance the appropriate prescribing of antibiotics, clinical prediction rules have been developed to 
distinguish streptococcal pharyngitis from pharyngitis by other causes. Rapid antigen detection tests 
(RADT), which use a pharyngeal swab and yield results in five to seven minutes, have also been de-
veloped to detect GAS. 
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Identified clinical practice guidelines for pharyngitis advocate the use of the four-point Centor score 
(oral temperature ≥38.3°C, tonsillar exudate, absence of cough, and swollen cervical lymph nodes), 
the McIsaac score or FeverPAIN score to stratify patients based on their probability of GAS. The 
guidelines recommend limiting antibiotic treatment (deferred or immediate) or antibiotic treatment 
conditional on further testing (that is, a positive rapid antigen detection test [RADT]) to those with 
higher scores (Centor score 3-4; McIsaac score ≥2; FeverPAIN ≥2) (A0025). A combination of CRP 
measurement and clinical examination based on the Centor score was used in three out of four stud-
ies retrieved evaluating CRP testing in pharyngitis patients [6, 7, 153, 157]. As a decision rule for con-
sidering antibiotic prescribing (score ≥3) in adults presenting to primary care with pharyngitis, the Cen-
tor score is reported to have a reasonable specificity (0.82, 95% CI: 0.72–0.88) and a post-test prob-
ability of 12% to 40% based on a prior prevalence of GAS of 5% to 20% [158]. In a systematic review 
of RADTs, the heterogeneity between studies was moderate but immunochromatographic RADTs 
were noted to be very sensitive (range 86% to 91%) and highly specific (range 93% to 97%) for the 
detection of GAS pharyngitis in adults, but the evidence was inconsistent in children. For enzyme-
linked immunoassay RADTs, only a few studies were identified in the review; in adults the results 
were inconsistent, while they were shown to have high sensitivity and specificity in children (0.86 and 
0.92). Specificity is decreased because of the poor capability of the test to differentiate between acute 
tonsillitis secondary to GAS and tonsillar infection of other origin in GAS carriers [159]. The clinical 
sensitivity of the RADT is noted to be influenced by the quality of the tonsillar swab, physician experi-
ence and the GAS inoculum [6]. 
Use of other infection markers, such as procalcitonin, white blood cell count and absolute neutrophil 
count to detect GAS acute tonsillitis, have also been investigated. In addition to CRP POCT, the study 
by Christensen et al. aimed to determine if the addition of infection markers such as procalcitonin, 
white blood cell count, and the absolute neutrophil count could increase diagnostic accuracy when 
used alongside the Centor score and RADT. CRP testing was more sensitive (90%), but less specific 
(45%), than procalcitonin (sensitivity 72%; specificity 58%), white blood cell count (sensitivity 69%; 
specificity 73%), or absolute neutrophil count (sensitivity 66%; specificity 87%). However, the sensitiv-
ities and specificities were higher using the RADT than any of the infection markers. The authors con-
cluded that CRP, procalcitonin, white blood cell count and absolute neutrophil count should not be 
performed in patients with acute tonsillitis, as they do not contribute significantly to an increase in the 
sensitivity or specificity of the RADT.  
 
LRTI including pneumonia 
Diagnosis of pneumonia in primary care is usually based on clinical findings, but may sometimes be 
supported by microbiological analysis of sputum samples. However, sputum culture may grow bacte-
ria without any clinical relevance and therefore findings from microbiological analysis cannot be used 
as definitive evidence of the causative agent of infection [151]. As it is not feasible to obtain chest 
radiographs in all patients with LRTI in primary care, clinicians typically rely on signs and symptoms 
and simple additional tests, when available. The diagnostic value of history and findings on clinical 
examination for pneumonia in primary care were evaluated in the study by Van Vugt et al. included in 
this systematic review. The AUC for previously published models of signs and symptoms for pneumo-
nia varied between 0.55 (95% CI: 0.50–0.61) and 0.68 (95% CI: 0.66–0.76). All models showed poor 
calibration for pneumonia, with a Hosmer-Lemeshow of p<0.001, indicating poor fit. The authors de-
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veloped a simplified diagnostic model based on symptoms and signs (absence of runny nose; pres-
ence of breathlessness, crackles and diminished breath sounds on auscultation; tachycardia 
[>100/min]; and fever [≥37.8°C]) which had an AUC of 0.70 (95% CI: 0.65–0.75) and good calibration 
for pneumonia (Hosmer-Lemeshow of p=0.50). The diagnostic value of procalcitonin in addition to 
signs and symptoms was also evaluated but was found to provide limited additional value (increased 
AUC to 0.71 [0.67 to 0.76] in this cohort of primary care patients presenting with LRTI) [14] Teepe et 
al. investigated the diagnostic utility of adding CRP or procalcitonin to a signs and symptoms 
diagnostic model for bacterial LRTI and separately for bacterial pneumonia. Although they found that 
CRP added diagnostic value to their model, procalcitonin did not [15].  
 
[D1003] – What is the reference standard for acute RTIs and how likely is it to classify the 
target condition correctly? 
The reference standard varies depending on the clinical indication for which CRP testing is being 
used. As outlined in (A0002), RTIs comprise a collection of specific diagnoses which can be broadly 
classified as URTIs and LRTIs. The reference standards for these conditions differ (A0024) and 
(A0025). This section is limited to those RTIs for which studies were identified in this systematic re-
view of diagnostic test accuracy. 
Sinusitis 
The identified reference standard for the diagnosis of acute maxillary sinusitis is computed tomogra-
phy (CT) and/or sinus aspiration [4]. Practice guidelines generally do not recommend the use of imag-
ing because: the accuracy of radiography is thought to be poor; ultrasound and radiography are not 
widely available in the primary care setting; and CT is expensive and results in potentially harmful 
radiation exposure. Although a CT scan is highly sensitive for the detection of fluid in the sinuses, this 
fluid may also be caused by a viral infection, so the test lacks specificity, and is therefore suboptimal 
as a reference standard [3, 147]. For example, in one study mucosal swelling or increased fluid in the 
maxillary sinuses was reported in 70% of patients on CT; however only 53% had purulence or muco-
purulence on puncture, indicating that CT alone is not sufficient for the diagnosis of acute maxillary 
sinusitis [4]. Antral puncture can detect purulent secretions which are associated with bacterial infec-
tion. Bacterial culture of these secretions is the most specific test for the diagnosis of acute maxillary 
sinusitis. However, as bacteria may not grow in vitro, even if present in the sinus, the test cannot be 
considered 100% sensitive as a reference standard [3]. While antral puncture plus/minus bacterial 
culture is suggested as the preferred reference standard test, it is not widely used due to the discom-
fort associated with the test and the lack of expertise in performing antral puncture in the primary care 
setting [147]. ROC curves constructed for the three different reference standards for acute sinusitis, 
abnormal finding on a CT scan, the presence of purulent or mucopurulent fluid from an antral punc-
ture of the maxillary sinus, and positive bacterial culture of antral fluid yielded AUC of 0.75, 0.77 and 
0.72, respectively [3]. 
Pharyngitis or tonsillitis  
Microbiological culture of throat swabs remains the gold standard to diagnose tonsillar bacterial infec-
tion. The accuracy of throat swab cultures was noted to be 90% by Gulich et al., as reported in a pre-
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vious study [5]. Microbiological culture has several limitations which limit its routine use in primary 
care, most notably its relative expense and that it cannot inform therapeutic decisions during the first 
consultation given a turnaround time of 48 to 72 hours [6]. The majority of clinical guidelines recom-
mend limiting the use of antibiotics to pharyngitis/tonsillitis caused by streptococcal infections and/or 
GAS in particular. Microbiological culture of throat swabs may determine GAS carrier status; however, 
the cause of infection may be attributable to other pathogens. Furthermore, in vitro culture conditions 
may not facilitate growth of the bacterial sample, even if present in the respiratory tract. 
LRTI including pneumonia 
No gold standard for LRTI requiring antibiotics exists. Community acquired pneumonia is an anatomi-
cal diagnosis based on radiographic and clinical criteria. It includes infections due to bacterial, fungal 
and viral aetiologies with the severity of the condition varying depending on host and virulence fac-
tors. It is not considered necessary to distinguish between bacterial and viral pneumonia given that all 
relevant guidelines advocate identification of patients with pneumonia and treatment with antibiotics 
regardless of bacterial or viral aetiology [14]. Conventional radiography is the reference standard for 
defining pneumonia in international guidelines and medical literature. However, interpretation of chest 
radiographs is subject to inter-observer variation [10, 151]. It is noted that interpretation of minor 
pathological changes may not be reliable [9, 10], with studies acknowledging that use of chest radiog-
raphy as a reference standard has the potential to lead to misclassification [11]. A 2015 meta-analysis 
of the diagnostic test accuracy of different imaging options for community-acquired pneumonia re-
ported a pooled sensitivity of 0.77 (0.73 to 0.80) and specificity of 0.91 (0.87 to 0.94) for chest X-ray 
using hospital discharge diagnosis as the reference standard [160, 161]. One study, used a combina-
tion of chest radiograph and the presence of pre-specified bacteria from a respiratory sample (sputum 
or nasopharyngeal swab) to identify patients with bacterial pneumonia [15]. 
Chest radiography is not recommended for routine use in primary care for economic and logistical 
reasons [12, 151]. Good practice also recommends that patient exposure to potentially harmful ionis-
ing radiation should be avoided where possible. In general practice, the decision to initiate antibiotic 
treatment therefore relies on clinical assessment, although its predictive value is noted to be poor. For 
example, the study by Holm et al. noted that the PPV of a GP’s clinical diagnosis of radiographic 
pneumonia was only 0.23 [151]. Accurate diagnostic markers are therefore needed to inform clinical 
decision-making during the first consultation. 
5.10 Discussion  
CRP POCT was carried out in primary care by the intended user in only four studies. As noted in 
B0001, POCT refers to testing at or near the site of the patient encounter with the result being availa-
ble within minutes to inform decision-making. In the context of this DTA review, the question ad-
dressed is whether the availability of a CRP level could improve DTA compared with the reference 
diagnostic standard being used for that condition. How CRP is measured is therefore not an issue, so 
studies that measured CRP levels using CRP POCT devices in the laboratory (that is, operated by 
laboratory-trained personnel) or standard laboratory CRP measurement were considered as eligible 
for inclusion. The relative accuracy and precision of CRP POCT compared with these techniques is 
considered in SR3 (analytical performance) The evidence base for the diagnostic test accuracy of 
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CRP testing in primary care is characterised by a high level of heterogeneity in patient populations, 
diagnostic criteria, CRP cut-points, how the performance of the test was reported and the absence of 
a universal reference standard for the diagnosis of RTIs requiring antibiotic treatment. Meta-analysis 
of the data was therefore not appropriate and a narrative review is presented. Planned subgroup 
analysis (children, older adults (≥65 years of age), patients attending out-of-hours (OOH) services and 
those in long-term care (LTC) facilities) were not possible due to limited data. However, the results of 
this systematic review do provide important insights into the performance of CRP as a test to help 
identify patients who will benefit from antibiotic treatment and to aid decision-making for a number of 
conditions. 
As outlined in the study PICOS, the study was limited to patients presenting to primary care with 
symptoms of acute RTI. This criterion was strictly applied, so studies that included patients presenting 
to other treatment settings such as hospital emergency departments, urgent care centres and outpa-
tient clinics were excluded unless the data specific to primary care could be extracted. The applicabil-
ity of data from these settings to primary care was considered limited due to differences in staffing, 
access to diagnostic services and the spectrum of presenting patients. This restriction may not be 
relevant to all countries, where certain outpatient clinics and urgent care centres may be considered 
part of the primary care system. While some studies highlighted the similarity between patients pre-
senting to primary care clinics and those who self-refer to urgent care clinics and emergency depart-
ments, these studies were still excluded as concerns remained around potential differences in staffing 
and access and diagnostics services. However, this meant that certain CRP POC devices such as 
FebriDx
®
 were not included in this systematic review as the available studies did not meet our inclu-
sion criteria for setting [162, 163]. FebriDx
®
 combines CRP at a cut-point of 20 mg/L with a viral bi-
omarker.  
The diagnostic test accuracy of CRP in sinusitis 
Two studies reporting the usefulness of CRP testing in diagnosing acute sinusitis provided limited 
evidence of benefit. Both studies examined a range of thresholds and chose a relatively low CRP 
threshold (10 mg/L and 17 mg/L) that was suitable for ruling out a diagnosis of acute bacterial sinusi-
tis. A clinical decision rule incorporating signs, symptoms and CRP at a cut-point of ≥17 mg/L allowed 
half of patients to be identified as low risk for acute bacterial sinusitis, allowing clinicians treat them 
symptomatically without prescribing antibiotics, with the authors noting that prospective validation of 
the tool through further research was required. However, considering many current clinical guidelines 
do not generally recommend the use of antibiotics in acute sinusitis, the utility of CRP testing on its 
own or as part of a clinical prediction rule is unclear [98]. A 2016 systematic review of test accuracy in 
the diagnosis of acute rhinosinusitis in primary care identified four studies that assessed the perfor-
mance of CRP testing [147]. While this review was not limited to a GP setting, it did include one of the 
studies reported here [4]. Pooled analysis of all four studies reported sensitivities of 73%, 39% and 
22% at thresholds of 10mg/L, 20-25mg/L and 40-49mg/L. The corresponding specificity estimates 
were 60%, 87% and 91%, respectively. The review concluded that there was “no clearly preferred 
single threshold for defining an abnormal (CRP) test”, and suggested the use of two thresholds to 
define low (<10mg/L), medium (10-30mg/L) and high (>30mg/L) risk groups. In the context of current 
antibiotic prescribing guidelines, CRP testing has limited additional benefit to clinical decision-making 
for the diagnosis of sinusitis. 
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The diagnostic test accuracy of CRP in pharyngitis or tonsillitis 
Among patients with acute pharyngitis, many clinical guidelines recommend that only those infections 
caused by streptococcal infections and particularly group A beta-haemolytic Streptococcus (GAS) 
should be treated with antibiotics [164]. Patients with other viral or bacterial infections generally do not 
benefit from antibiotics. GAS pharyngitis is usually self-limiting, but may rarely be associated with 
serious complications which can be prevented with antibiotic treatment. For this reason, the majority 
of the evidence retrieved on the diagnostic test accuracy of CRP in identifying patients with acute 
pharyngitis/tonsillitis who require antibiotic therapy specifically relates to the identification of those 
patients with GAS pharyngitis. Two studies presented the mean levels of CRP in patients with acute 
pharyngitis or tonsillitis, with contrasting results [6, 153]. The inclusion criteria differs substantially 
between these studies with patients in the Calvino study presenting with all four Centor criteria, while 
in the Christensen study none of the included patients had a Centor score of four. The studies also 
differed in the proportion of patients in the non-GAS group with no bacteria or other non-GAS bacte-
ria. It is unclear if other types of bacterial infection would be expected to cause a similar rise in CRP 
levels; in the Calvino study group C streptococcal infection caused the highest rise in CRP values 
(mean CRP 56.3mg/L group C versus 34.4 mg/L group A). In addition, as the reference standard was 
a throat swab, some of the patients who were positive for GAS may have been carriers who also had 
viral/other bacterial pharyngitis and this proportion may have differed between studies.  
Two studies sought to determine the optimal threshold for CRP testing in patients presenting with 
sore throats [5, 6, 157]. The cut-point chosen differed substantially (6 mg/L versus 35 mg/L). The 
studies differed in their aim in that the Guilich study sought to use CRP to distinguish between bacte-
rial and non-bacterial pharyngitis, while the study by Christensen et al. wanted to distinguish between 
GAS and non-GAS pharyngitis.  
Guilich et al. reported that at a threshold of 35 mg/L, CRP is better at ruling in than ruling out bacterial 
pharyngitis and improves both the sensitivity and specificity of GP clinical diagnosis alone. They sub-
sequently went on to use this threshold as part of a two-step clinical algorithm whereby about 30% of 
patients presenting with sore throat required a CRP measurement after clinical assessment. The 
specificity of the algorithm was higher than the sensitivity (Table 14). As not treating patients with 
GAS pharyngitis is generally not a major safety concern in most countries, the lower sensitivity but 
higher specificity may be an acceptable trade-off. However, the score developed in this study needs 
validation. Christensen et al., at a threshold of 6 mg/L, reported that CRP in combination with the 
Centor score may be useful in ruling out GAS pharyngitis, but only if RADT is not available. Given the 
mean value and 95% CI for those with non-GAS infection was 15 mg/L (95% CI: 10–19) in this study, 
the cut-point of 6 mg/L may have been too low to adequately distinguish between patients with acute 
pharyngitis caused by GAS and non-GAS infection. The low specificity of this cut-point means that 
many false positives may be treated unnecessarily with antibiotics. 
Overall, CRP at a cut-point of 6 mg/L CRP is unlikely to be useful in guiding antibiotic prescribing 
either on its own or in combination with the Centor score as it is better at ruling out GAS pharyngitis, 
but would lead to unnecessary antibiotic prescribing.  
A cut-point of 35 mg/L may be useful for determining bacterial pharyngitis and one study suggests it 
could be useful for determining GAS pharyngitis as part of a clinical prediction rule, but further valida-
tion studies would be required. Notably, patients with evidence of GAS infection according to microbi-
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ological analysis of pharyngotonsillar swabs had a mean CRP concentration of 34.4 mg/L (95% CI: 
25.6–43.3) in the study by Calvino et al. suggesting that at a threshold of 35 mg/L as proposed by 
Gulich et al. some patients presenting with GAS infection may not be identified.  
In conclusion, the identification of GAS infection, CRP testing appears to be most useful when used in 
combination with a clinical signs and symptoms. However, it should be noted that other alternatives 
exist, such as RADT, while may have better diagnostic test accuracy for GAS pharyngitis.  
The diagnostic test accuracy of CRP in LRTI / pneumonia 
Current clinical guidelines recommend antibiotic treatment for pneumonia, but not for other lower res-
piratory tract infections as these are generally considered to be self-limiting with limited clinical benefit 
from antibiotic treatment [42].  
There was limited data on the levels of CRP in paediatric patients. One study included in this review 
included paediatric patients with pneumonia and reported mean levels between 24 and 32 mg/L, they 
reported infants <12 months had very low CRP levels (mean 14 mg/L, unmeasurable in 65% of in-
fants <12 months) and therefore more studies are needed to establish the diagnostic accuracy of 
CRP in children presenting with LRTIs. In adults, there was greater consistency in CRP levels in 
those patients without pneumonia (mean CRP 17 to 19 mg/L), than those with those with pneumonia 
(mean CRP 62 to 145 mg/L). CRP concentration was shown to be low (<20 mg/L) in a proportion of 
adults with pneumonia (Van Vugt 39%, Lagerstrom 21%) [9, 14]. 
Five studies reported on the diagnostic accuracy of CRP at a specified threshold for diagnosing 
pneumonia. Four studies reported on a cut-point of 20 mg/L, three of which reported a sensitivity be-
tween 0.48 and 0.79, which was considered by the authors to be too low to reliably rule out pneumo-
nia [9, 11, 151]. In contrast, the fourth study by Hopstaken reported a sensitivity of 100% at a cut-
point of 20 mg/L. Melbye reported a sensitivity of 0.82 at a cut-point of 11 mg/L, suggesting that 18% 
of pneumonia patients could be missed at this lower CRP level. At a threshold of 50 mg/L (n=2) and 
100 mg/L (n=2) specificity was between 0.84 and 0.99, and may be suitable for ruling in a diagnosis of 
pneumonia [9-12].  
Five studies investigated the diagnostic accuracy of CRP in combination with signs and symptoms for 
determining pneumonia in patients presenting with LRTIs. One study, Holm et al., found the addition 
of CRP at a cut-point of 20 mg/L increased the specificity of clinical judgement, but reduced the sensi-
tivity, suggesting it would have limited use in primary care unless the GP was trying to rule in a diag-
nosis of pneumonia. Three other studies [13-15] used CRP in combination with a clinical prediction 
rule to classify patients as being at low, intermediate or high risk of pneumonia. In these studies, addi-
tion of CRP testing to the prediction rule increased its discriminative power. In Teepe the addition of 
CRP increased the diagnostic value of their prediction rule, but the authors concluded that it was in-
sufficient to exclude a bacterial pneumonia. In the Hopstaken paper, use of the rule would have saved 
41% of prescriptions for antibiotics with a 2.5% risk of missing a case of pneumonia. In the Van Vugt 
study, CRP was only useful in the intermediate risk category where there was clinical uncertainty, and 
allowed for the reclassification of around half of this group into high- or low-risk categories. 
A number of identified studies reported mean CRP levels in pneumonia patients. While not a measure 
of DTA, it provides useful context for decision-making. Low CRP values do not preclude a diagnosis 
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of pneumonia as evident from studies of adults [9] and children [150] with radiologically confirmed 
pneumonia. This was also evident in the substantial overlap in measured CRP levels between pneu-
monia and non-pneumonia patients in one large prospective study by the GRACE consortium.[14] 
Overall, the results suggest that low values of CRP cannot exclude a diagnosis of pneumonia, and 
should only be used to supplement clinical decision-making. Based on the findings of the assessment, 
integrating signs and symptoms with CRP testing is likely to be the most useful application of CRP 
POCT. However, given the potential for CRP levels to remain below those expected to be indicative of 
pneumonia, particularly in relation to paediatric patients, the results should be interpreted with cau-
tion. The addition of CRP to clinical decision rules may improve antibiotic prescribing decisions in 
general practice. However, despite increased diagnostic accuracy with the addition of CRP measure-
ment to clinical signs and symptoms, using the clinical decision rules in the available literature, a sub-
stantial group of patients remain classified as intermediate risk, for which clinical decision-making 
remains challenging. 
A key finding of the review is therefore that the sensitivity and specificity of CRP was generally poor. It 
would be possible to pick a cut-point such that either the sensitivity or specificity was high, but not 
both. If a cut-point is chosen that ensures high sensitivity then the test may be better for ruling out, 
whereas setting it for high specificity is better for ruling in. The findings suggest that different cut-
points might be suitable depending on the type of acute RTI with which the patient presents. Howev-
er, the use of different cut-points could cause confusion, while the use of a universal cut-point would 
entail different rates of misdiagnosis across RTI types. Taken at face value, based on the diagnostic 
test accuracy, CRP POCT is not a very good test for distinguishing between viral and bacterial RTIs. 
However, that finding is contradicted by the significant impact on antibiotic prescribing observed in the 
clinical effectiveness trials. It may therefore be that the accuracy of the test is of lesser importance, 
and what is more critical is that it facilitates a discussion between the clinician and the patient and 
perhaps a more conservative treatment approach to managing acute RTIs. 
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5.11 Research questions – Systematic review 3 (analytical performance) 
Element ID Research question 
Diagnostic core model 
D1001 How does the analytical performance of CRP POCT compare with standard 
laboratory CRP testing? 
 
D1007 How does analytical performance vary in different settings? 
 
D1008 What is known about the intra- and inter-observer variation in test interpretation? 
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5.12 Study selection  
 
Figure 14: Flow chart systematic review 3 (analytical performance) 
*Seven studies meeting inclusion criteria were subsequently excluded for reasons outlined in section 5.4 “Included studies”.  
A total of 746 studies were identified from database searching. Submission files received from manu-
facturers were also consulted to identify relevant studies for this review; six articles were identified as 
being potentially relevant, however, all six had already been identified through the systematic search. 
After consultation with laboratory experts, six additional studies were identified from the Scandinavian 
evaluation of laboratory equipment for point of care testing (SKUP) [20-23, 165, 166] resulting in 752 
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through other sources  
EUnetHTA manufacturers 
submissions (n = 6) 
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Records after duplicates removed  
(n = 752) 
Records screened  
(n = 752) 
Records excluded  
(n = 701) 
Full-text articles 
assessed for eligibility  
(n =51) 
Full-text articles excluded, 
with reasons  
(n = 26) 
Exclusion criteria: 
-  Inappropriate population (n=5) 
-  No outcomes of interest (n = 7) 
-  Conference abstract (n = 7) 
-  Inappropriate study design (n=2) 
-  Inappropriate setting (n=4) 
-  Translation unavailable (n=1) 
 
 
Studies meeting inclusion 
criteria   
(n = 25) 
Studies included in 
qualitative synthesis  
(n = 18)* 
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studies to be screened. After title and abstract screening, 51 potentially relevant articles were identi-
fied for full-text review. Following the exclusion of 26 studies for reasons listed in Figure 14, 25 stud-
ies remained that were relevant for inclusion in this review. At the full-text stage the most common 
reasons for exclusion were inappropriate population and no relevant outcomes. These studies often 
included a specific irrelevant disease group as the population of interest or did not report on accuracy, 
precision or ease of use of the device. Four studies were excluded as they were performed in the 
emergency department. One study was in Korean and no appropriate translation could be identified 
[167]. No relevant systematic review was retrieved from any database during the search.  
 
5.13 Results 
Included studies – study characteristics  
The systematic review of analytical performance of CRP POCT devices retrieved a total of 25 studies 
[16-23, 168-177]. While five of these studies relating to the NycoCard™ device were identified as 
meeting the inclusion and exclusion criteria, on review it was evident that there had been substantive 
updates to the device (from a semi-quantitative to a quantitative device) since their publication, so that 
the results could not be considered relevant to the currently marketed version of the device. These 
studies were therefore excluded from this review [178-182]. In addition, of the six studies undertaken 
as part of an external validation assessment by the Scandinavian evaluation of laboratory equipment 
for point of care testing (SKUP), two studies were identified as being updates due to substantive 
changes in the POCT device, so the decision was taken not to include the two original studies in the 
review. This review is therefore limited to 18 studies [16-23, 168-177]. The literature was identified 
from eight countries with all but one study (n=1 Japan) conducted in Europe. Study details are sum-
marised in Table 20 below. A detailed summary of the included studies is provided in Appendix 1 
(Table A8). 
In all studies the analytical performance of CRP POCT was compared with standard CRP measure-
ment by trained laboratory staff using laboratory-grade analyser equipment. Three approaches to how 
the comparison was undertaken were identified: 
Approach A: fresh whole capillary or whole blood samples were obtained as appropriate and tested at 
the point of care by those who would ordinarily use the device at the point of care with a second ve-
nous sample from the patient sent to the laboratory for standard testing. In most studies a healthcare 
professional performed the test at the point of care, but in some Scandinavian studies, biomedical 
scientists in the primary care centres performed the test at the point of care. 
Approach B: venous samples submitted from patients in primary care or hospital inpatients were test-
ed in the hospital laboratory by a trained laboratory technician using both a POCT device and a labor-
atory analyser. The venous samples included fresh whole blood (with anticoagulant) or serum sam-
ples and frozen samples from laboratory library stores. 
Approach C was taken by an external quality assurance (EQA) study in Norway. Blood samples of 
known CRP concentration were distributed to primary care centres. POCT was then undertaken by 
healthcare professionals and staff to assess the performance of the device when operated by the 
intended user.  
CRP POCT to guide antibiotic prescribing in primary care settings for acute respiratory tract infections 
126 
 
 
 
 
Approach A only was adopted in two studies [176, 177], approach B only in ten studies [16, 18, 168-
175] and approach C only in one study [17]. Both approaches A and B were adopted in four studies, 
thereby allowing different aspects of analytical performance to be assessed within the same study 
[20-23]. Finally, in one study Approach A was used for one device and approach B was used to as-
sess another device [19]. 
Blood samples used for CRP testing were obtained from patients attending primary care (n=5) [16, 
19, 174, 176, 177] and samples submitted to the hospital laboratory (n=3) [168, 169, 175]. In five 
studies [18, 170-173] CRP testing was undertaken on frozen samples from laboratory library stores. 
There were four external quality assessment studies by SKUP that used both hospital and primary 
care blood samples. Finally, the external quality assessment study by Bukve et al. used prepared 
laboratory and hospital samples [17]. 
One study limited the inclusion criteria to patients presenting to primary care with symptoms of sus-
pected RTI [174]. The remaining studies did not have specific inclusion criteria, but instead included 
patients with a range of medical conditions for which a CRP blood test was clinically indicated. Details 
of the patient population (presenting symptoms, age, gender) were not generally reported for those 
studies using laboratory library samples.  
Length of time between testing samples at the point-of-care and transportation of a patient blood 
sample to the laboratory for standardised laboratory measurement was unclear across the literature. 
Longer time delays may have led to sample degradation, but it is unclear the effect this would have on 
the CRP levels. Furthermore, in most studies it was unclear for what length of time laboratory library 
samples had been stored before CRP levels were tested.  
There were five studies that compared the performance of more than one CRP POCT device (range 
2-8) [16-19, 170]. These studies were mostly conducted in a laboratory to eliminate or reduce the risk 
of operator bias. One study tested one device at the point of care and then transferred a venous sam-
ple to the laboratory to be tested on a different POCT device by laboratory technicians [19]. A total of 
two semi-quantitative (Actim
®
, Cleartest
®
) [16, 172] and eleven quantitative POCT devices were as-
sessed. Results for the NycoCard™ and NycoCard™ Reader II device have been presented sepa-
rately, as have results for the QuikRead
®
 101 and QuikRead go
®
 devices. 
In two of the included studies (Brouwer et al. and Bukve et al.), graphs were provided with relevant 
bias data, the data points were extracted from these graphs using two software packages 
(https://automeris.io/WebPlotDigitizer/ and https://datathief.org/). 
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Table 20: Main characteristics of studies included (all studies included in the effectiveness 
domain) 
Author and 
year or study 
name 
Study  
type 
Number 
of 
samples 
(setting 
tested) 
Intervention (s) Main  
endpoints 
Bains (2017) Analytical 
Performance 
44 (Lab) iChroma
™
 Accuracy (bias, correlation)  
Brouwer (2015) Analytical 
Performance 
100 (Lab)  Actim
®
*; 
Cleartest
®
*, 
Afinion™, QuikRead 
go
®
, Eurolyser 
Smart, iChroma
™
, 
Microsemi, AQT90 
Flex 
Accuracy (agreement, bias, 
correlation)  
Precision (CV)  
Ease of use 
Bukve (2016) Analytical 
Performance 
3 (Lab) 
22 (POC) 
ABX Micros 200, 
Afinion™, 
iChroma
™
, 
NycoCard™,   
QuikRead go
®
 
Accuracy (bias) 
Ciftci (2014) Analytical 
Performance 
96 (Lab) iChroma
™
 Accuracy (bias 
Clouth (2009) Analytical 
Performance 
200 (Lab) NycoCard™,   ABX 
Micros CRP 
Accuracy (agreement, bias)  
Precision (CV)  
Ease of use 
De Graff (2016) Analytical 
Performance 
43 (Lab)) Spinit
®
 Accuracy (correlation)  
Precision (CV) 
Evrard (2005) Analytical 
Performance 
100 (Lab) Actim
®
* Accuracy (agreement) 
Ease of use 
Ivaska (2015) Analytical 
Performance 
48 (Lab) Afinion Accuracy (bias, correlation) 
Matheeussen 
(2018) 
Analytical 
Performance 
2,922 
(POC)  
QuikRead
®
 101 Accuracy (agreement, bias, 
correlation)  
Precision (CV) 
Minnaard 
(2013) 
Analytical 
Performance 
8 (Lab)  Afinion™, 
NycoCard™   
Reader II, Eurolyser 
Smart,QuikRead 
go
®
, 
QuikRead
®
 101 
Accuracy (bias)  
Precision (CV) 
Ease of use 
Monteny 
(2006) 
Analytical 
Performance 
59 (Lab 
and POC) 
NycoCard™,   
QuikRead
®
 
Accuracy (agreement, bias, 
correlation)  
Nomura (2014) Analytical 
Performance 
244 (Lab)  Microsemi Accuracy (correlation) 
Seamark 
(2003) 
Analytical 
Performance 
234 (POC) QuikRead
®
 Accuracy (bias, correlation)  
Precision (CV) 
Ease of use 
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Author and 
year or study 
name 
Study  
type 
Number 
of 
samples 
(setting 
tested) 
Intervention (s) Main  
endpoints 
SKUP (2001) Analytical 
Performance 
40 (Lab) 
40 (POC) 
QuikRead
®
 101 Accuracy (agreement, bias, 
correlation)  
Precision (CV)  
Ease of use 
SKUP (2002) Analytical 
Performance 
160 (Lab 
and POC)  
ABX Micros CRP Accuracy (agreement, bias, 
correlation)  
Precision (CV)  
Ease of use 
SKUP (2011) Analytical 
performance 
114 (Lab) 
80 (POC) 
iChroma
™
 Accuracy (agreement, bias, 
correlation) 
Precision (CV)  
Ease of use 
SKUP (2013) Analytical 
Performance 
100 (Lab) 
86 (POC)  
Smart Eurolyser Accuracy (agreement, bias, 
correlation)  
Precision (CV) 
Ease of use 
Verbakel 
(2013) 
Analytical 
Performance 
135 (POC) Afinion Accuracy (agreement, bias) 
Ease of use  
Notes: * Semi-quantitative tests. All other quantitative. 
Abbreviations: CV – co-efficient of variation; POC – point of care; Lab – laboratory. 
 
5.14 Quality rating 
Details of the quality of the evidence included in this systematic review are included in Appendix 1, 
Figures A5 and A6. 
An important potential source of bias is the source of funding of the studies. One study was spon-
sored by the manufacturer [176] and in a further two studies, the equipment and training was funded 
by the manufacturer [171, 177]. Research in one of the studies was undertaken by company employ-
ees [175]. Four studies were recipients of educational grants [19, 173, 174, 177]. 
[D1001] – How does the analytical performance of CRP POCT compare with standard 
laboratory CRP testing?  
 How does the accuracy of CRP POCT devices compare with standard laboratory-based CRP 
testing?  
 How precise are the CRP POCT devices? 
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Accuracy 
Data in relation to three main indicators of accuracy were presented in the literature for quantitative 
CRP POCT devices: correlation, agreement and bias. These terms were used interchangeably in the 
literature. The following is a brief explanation of how these terms are used in this assessment. 
Correlation: This was presented as a linear regression which quantifies the strength of the relationship 
[183]. Correlation was reported as a Spearman’s, Pearson’s or intra-class correlation coefficient with 
the r value indicating the strength of relationship (range: -1 to +1) and the r
2
 value (range: 0-1) ex-
plaining the proportion of variance that the two variables have in common [183]. 
Agreement: Regression analysis was used to indicate the level of agreement between the laboratory 
standard method and the POCT method. For quantitative devices, this was reported using a Passing 
Bablok regression analysis (n=4 studies) [16, 19, 174, 177] or a Deming regression (n=1). The Pass-
ing Bablok regression analysis overcomes some of the limits of correlation analysis related to data 
distribution and presents a constant or proportional difference between two methods. If the slope of 
the regression line includes 1.00, there is no proportional difference between the device and the la-
boratory reference method. For semi-quantitative devices, the agreement between the CRP POCT 
device and the reference test was reported as a Cohen’s Kappa value (range 0-1), with values closer 
to 1 indicated high levels of agreement between the methods.  
Bias: This was reported in five studies as a mean difference or percentage difference in CRP values 
calculated from a Bland-Altman plot [16, 18, 19, 174]. The Bland-Altman method describes the 
agreement between two quantitative measurements and establishes limits of agreement using the 
mean and standard deviation. Bland-Altman recommends that 95% of the data points for the mean 
difference between the two methods should lie within two standard deviations. It gives an indication of 
how much the POCT measurements deviate from the reference measurements and the direction of 
this bias. In other studies, a mean difference or percentage mean difference was presented but it was 
not clear if Bland-Altman methodology had been used [17, 20-23, 168, 169, 173, 176, 177]. 
Accuracy of semi-quantitative devices 
The accuracy of two semi-quantitative devices compared with standard CRP laboratory measurement 
was reported in two studies, both of which were undertaken by trained laboratory staff in the laborato-
ry (Table 21). In the study by Brouwer et al., two independent observers read the test-strip results and 
these values were compared with the CRP level as measured by standard laboratory testing using 
four CRP concentration categories (CRP <10 mg/L, 10-40 mg/L, 40-80 mg/L and >80 mg/L); results 
were reported as Cohen’s Kappa values reflecting the level of agreement between the measure-
ments. Both semi-quantitative devices performed poorly when read after five minutes (the optimal 
time as indicated by the manufacturer) with Kappa values ≤0.63 and ≤0.61 for Actim
®
 and Cleartest
®
, 
respectively. The percentage discrepancy between CRP POCT and standard testing measurement 
ranged between 27% and 35% for the Actim
®
 strips and 29% and 33% for Cleartest
®
. The tests were 
re-read at 15 minutes to evaluate if test accuracy varied according to the time at which they were 
read. The accuracy of both tests was found to decline, with Kappa values of ≤0.46 and ≤0.25 reported 
for the Actim
®
 and Cleartest
®
 devices, respectively. Separately, the accuracy of the Actim
®
 device was 
also reported by Evrard et al. who reported an overall Kappa value of 0.93 when tested using samples 
from four CRP concentration categories (<10, 10-40, 40-80, >80mg/L). 
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Table 21: Agreement of the semi-quantitative POCT tests with the reference standard 
Device Agreement 
(κ) 
Discrepancy 
(%) 
Agreement 
(κ) 
Discrepancy 
(%) 
 After 5 minutes After 15 minutes 
Actim
®[172]
 0.93
 
   
Actim
®[16]
     
Observer 1 0.53 35 0.46 39 
Observer 2 
Inter-observer agreement 
  
Intra-observer agreement 
Observer 1 
Observer 2 
0.63 
0.81 
27 
14 
0.39 
0.83 
44 
12 
5 minutes vs. 15 minutes 
0.64 
0.60  
Cleartest
®[16]
     
Observer 1 0.61 29 0.17 60 
Observer 2 0.56 33 0.25 56 
Inter-observer agreement 0.55 33 0.74 16 
Intra-observer agreement 
Observer 1 
Observer 2 
5 minutes vs. 15 minutes 
0.40 
0.20 
Abbreviations: K - Cohen’s Kappa 
 
Accuracy of quantitative devices 
A summary of the accuracy results for the quantitative CRP POCT are presented in Table 22. Results 
obtained under idealised laboratory conditions and at the point of care (primary care setting) are pre-
sented separately. Seventeen studies evaluated quantitative devices, twelve of which evaluated the 
accuracy of 10 different POCT devices in the laboratory; eight studies evaluated the accuracy of sev-
en POCT devices in the primary care setting. As noted in Section 5.3, all studies compared the CRP 
result obtained on the POCT device with that obtained using standard CRP measurement by trained 
laboratory staff using laboratory-grade analyser equipment. The comparator equipment differed be-
tween studies. (Appendix 1 (Table A8).) Three main indicators of accuracy were reported: correlation, 
agreement and bias; studies varied in the number of accuracy indicators they reported (range: 1 to 3). 
In Table 22 the correlation coefficients (r or R) and the coefficient of determination (r
2
 or R
2
) all ex-
ceed 0.9, indicating excellent correlation between the devices and the reference laboratory measure-
ment irrespective of whether the device was tested in the laboratory or at the point of care. No corre-
lation data were available for the NycoCard™   Reader II.  
Agreement with a laboratory reference standard was reported in four studies as the result of Passing-
Bablok regression analysis for seven devices tested in the laboratory setting [16, 19, 170, 174]. In a 
comparative study of six quantitative devices, Brouwer et al. noted that the AQT90 Flex and Smart 
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Eurolyser exhibited the best agreement (1.03 [95% CI: 1.00–1.06]; 1.00 [95% CI: 0.96–1.04], respec-
tively). Values close to the reference standard were reported for the Afinion™, Microsemi and 
QuikRead go
®
 devices, but their 95% CI did not include the value 1.00 (0.87, 95% CI: 0.84–0.91, 
1.16, 95% CI: 1.14–1.18 and 0.85, 95% CI: 0.83–0.87 respectively), indicating that the devices sys-
tematically under- or overestimated the CRP level (Table 22). A lower level of agreement was noted 
for the iChroma
™
 device (0.79 [95% CI: 0.76–0.82]) [16]. Results from studies by Matheeussen et al. 
and Monteny et al. reported a systematic underestimation of CRP levels by the QuikRead
®
 101 device 
(0.94 [95% CI: 0.93–0.95])[174], (0.83 [95% CI: 0.81–0.85]) [19], respectively). 
Three studies assessed agreement with the reference standard when tested at the point of care using 
Passing Bablok regression analysis (Table 22) [19, 171, 177]. Good agreement was noted for the 
Afinion™ (1.02, 95% CI: 1.01–1.08) [177] and NycoCard™ (0.95, 95% CI: 0.9–1.0) devices [19, 177]. 
Using Deming regression, the spinit
® 
device was noted to overestimate CRP values by 12% [171]. 
Thirteen studies reported the accuracy of CRP POCT devices compared with the laboratory standard 
on the basis of their bias calculated as a mean difference or percentage difference in CRP level. Six 
of these studies were set in the laboratory [16, 18, 19, 23, 168, 170, 173, 174], seven were set in the 
POC [17, 19-21, 23, 176, 177], with two studies reporting bias from the laboratory and the POC 
(Table 22) [19, 23]. 
Two studies provided the majority of the data for the laboratory setting as they compared multiple 
devices [16, 18]. Minnaard et al. compared five quantitative CRP devices (Afinion™, NycoCard™ 
Reader II, Smart Eurolyser, QuikRead go
®
 and QuikRead
®
 101) [18]. The study took place under ide-
alised laboratory conditions and compared the accuracy of the devices using low concentration 
(<20mg/L), intermediary (20-100mg/L) and high concentration (100mg/L) CRP samples, the results of 
which are summarised in Table 22. For all devices, the mean difference was less than 2mg/L at low 
concentrations (<20 mg/L), with QuikRead go
®
 (0.2mg/L, 95% CI: -1.2–1.5) and the NycoCard™ 
Reader II (0.3 mg/L, 95% CI: -4.4–5.0) being the most accurate. At the intermediary concentration 
(20-100 mg/L) the Afinion™ was the most accurate device (-0.3mg/L, 95% CI: -6.4–5.8) with all the 
other devices reporting a mean difference between 2.3 mg/L (QuikRead go
®
) and 7.8 mg/L (Smart 
Eurolyser). The largest mean difference values were reported with the high concentration (>100 mg/L) 
CRP sample, ranging between 0.9mg/L (95% CI: -53.2–55.0) (Smart Eurolyser) and 14.7mg/L (95% 
CI: -21.1–50.5) (Afinion). The authors concluded that the Afinion™, NycoCard™ Reader II, QuikRead 
go
®
 and QuikRead
®
 101 showed better agreement than the Smart Eurolyser device and that for all of 
the POC devices tested the agreement between the POC test and the laboratory standard decreased 
at higher CRP concentrations resulting in wider confidence intervals around the mean differences at 
CRP concentrations greater than100 mg/L.  
Brouwer et al. reported on six quantitative devices (QuikRead go
®
, Smart Eurolyser, Afinion™, 
iChroma
™
, Microsemi and AQT90 Flex), with all bar the iChroma
™
 (-12.3 mg/L) reporting a mean dif-
ference between ±3.7mg/L (Afinion) and ±9.2 mg/L (QuikRead go
®
) (Table 22) [16]. Additional studies 
for the Afinion™, NycoCard™ and QuikRead
®
 101 devices in the laboratory reported mean differ-
ences <±2.5 mg/L [170, 173, 174]. Additional studies for the iChroma
™
 device reported mean differ-
ences of -8.1mg/L [168] and -7 mg/L [169]. A SKUP analysis reported on the % bias for the iChroma
™
 
device in the laboratory setting as 0.4%, however, the device over predicted at low concentrations by 
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6.6% and under predicted at high concentrations by 6.2%, clearly showing that presenting the bias at 
different concentrations of CRP provides a more useful overview of the devices performance [22]. 
One external quality assurance scheme (EQAS) for CRP POCT reported the accuracy of multiple 
devices (Afinion™, NycoCard™,   QuikRead go
®
, QuikRead
®
 101, iChroma
™
 and ABX Micros) in the 
primary care setting in Norway [17]. The EQAS scheme evaluated instrument performance at two 
different CRP concentration levels using certified reference material. Each participant received two 
EQA samples which comprised whole blood with human recombinant CRP added to a known concen-
tration (25.0mg/L and 63.9mg/L). The Afinion™ and the QuikRead
®
 101 were found to have low bias 
(<±2%) at both concentrations (Table 22). Comparable results were found for the QuikRead go
®
, Ny-
coCard™ and iChroma
™
 devices with estimates of bias at 25 mg/L between ±7% and ±10% and esti-
mates of bias at 63.9 mg/L between ±9% and ±15%. The QuikRead go
®
 (12.0%, 95% CI: 11.0; 13.0) 
and NycoCard™ (14.9%, 95% CI: 10.1; 20.0) performed particularly poorly when the higher concen-
tration sample was tested. The ABX Micros had bias of -6.2% at the lower concentration and lower 
bias at the higher concentration level (25.0 mg/L -6.2%, at 63.9 mg/L 0.0%). Consistent with the 
Bukve study, Verbakel et al. reported low levels of bias (≤ 2%) for the Afinion™ device when tested in 
the primary care setting [17, 177]. Inconsistent data were found for a number of these devices in other 
studies. In contrast to the Bukve study, the NycoCard™ device was found to have low levels of bias 
(<2%), even at high concentrations (>70 mg/L) [19]. A SKUP study from 2002, in contrast to the 
Bukve study, reported poor levels of accuracy for the ABX Micros device in four primary care centres 
[17, 21]. The SKUP study reported the POC results to be around 40% lower (n= 4 primary care prac-
tices) than the hospital reference method. Testing was repeated in two of these practices after six 
months of use with improvements in accuracy seen (from approx. 28% lower to 14% lower than the 
reference method) in these centres, suggesting that with practice operators made fewer mistakes. 
In two of the SKUP reports and a study by Monteny et al., accuracy data is reported in the laboratory 
and at the point of care [19, 20, 23]. A 2001 SKUP study reported data on the QuikRead
®
 device 
when tested at the point of care in three general practices using whole blood and in the laboratory 
setting using plasma. In the laboratory, the study found good consistency between the laboratory 
reference method and the QuikRead device (Regression equation y=0.98x +0.32, Table 22). Howev-
er, in the POC setting the device consistently underestimated the CRP levels compared with the hos-
pital reference method; this underestimation was greater at higher CRP concentrations (<75 mg/L 
approx.-10%, >75 mg/L up to -20%). The authors suggested the discrepancy was due to the use of 
whole blood at the point of care with no correction for haematocrit. Subsequent to this feedback, the 
company responded that the device would be recalibrated (3% at the lower end of the concentration 
range and 13% at the higher end) to correct these systematic differences. The data from this 2001 
SKUP report are therefore less likely to be relevant.  
In the SKUP analysis for the Smart Eurolyser, data were reported as a percentage bias at different 
concentrations (Table 22) [23]. The bias in the laboratory ranged from -4.4% (-7.4; -1.4) to 9.6% (5.6; 
13.5). When tested at two POC centres the bias was a maximum of -17.0% (-24.0;-9.6) at low CRP 
concentrations. The overall bias across the range of CRP concentrations at the two POC centres was 
-9.8% and -10.3%, respectively. This indicates a clear difference when using CRP POCT devices in 
the laboratory and at the point of care. SKUP pre-defines an acceptable level of bias as of +/- 1 mg/L 
or <26% from the comparison method. In total, 98% of the results for the Smart Eurolyser fulfilled this 
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goal for accuracy with venous EDTA samples in the hospital evaluation and with capillary samples at 
both primary health care centres.  
Monteny et al. also reported the Bland Altman mean difference based on CRP concentration in the 
laboratory and POC setting [19]. However in this study different devices were used, with NycoCard™ 
being used at the POC and QuikRead
®
 being used in the laboratory setting. The overall mean differ-
ence for the QuikRead
®
 101 was -6.1mg/L; at concentrations below 70mg/L the mean difference was 
-0.4mg/L, but this increased to -26.4mg/L at higher concentrations (>70mg/L). This is in contrast with 
the Minnaard study that reported a bias of 3.2 mg/L at concentrations over 100 mg/L. Monteny also 
reported on the NycoCard™ device at the POC and overall the NycoCard™ device was more accu-
rate than the QuikRead
®
 101 device (overall mean difference of 0.6 mg/L; 1.4 mg/L at lower CRP 
concentrations and -1.9 mg/L at higher concentrations). The authors concluded that the NycoCard™ 
device was more suitable for use in primary care. 
In addition to accuracy results reported in Table 22, Bukve et al. reported on an external quality as-
surance scheme (EQAS) for CRP POCT in Norway which comprised 19 rounds of EQAS (twice a 
year for nine years), with a mean of 2,134 participating GP offices or nursing homes in each round 
[17]. Participants’ performance was considered good if the reported CRP measurement from their 
POCT equipment was within +/- 8% of the target interval, poor if the result exceeded the target value 
by +/- 15% and acceptable for results between these limits. The percentage of participants exhibiting 
good performance in each survey varied from 78% to 81%; good performance increased over time 
with participation in further rounds of EQA. The authors also examined what factors were associated 
with good performance compared with acceptable/poor performance and found that participants were 
more likely to achieve a good performance if they had taken part in more than one EQAS round, had 
a trained laboratory scientist performing the test, performing the test more than ten times per week, 
performing internal quality control at least once per week and the type of instrument used. In the lo-
gistic regression analysis, the authors reported QuikRead
®
 101 as the reference values and found 
QuikRead go
®
 had an OR of 0.87 (95% CI: 0.76–0.98), Afinion™ OR 0.70 (95% CI: 0.65–0.77), 
iChroma
™
 OR 0.36 (95% CI: 0.31–0.42), ABX Micros CRP OR 0.34 (95% CI: 0.29–0.42) and Ny-
coCard™ CRP/NycoCard™ CRP with Reader II OR 0.32 (95% CI: 0.31–0.42). This suggests that 
those who had good participant performance were more likely to be using QuikRead
®
 101, QuikRead 
go
®
 or Afinion™. However, the authors also noted that changing the instrument did not seem to have 
a significant effect on results. Overall, GP offices tended to perform better than nursing homes, emer-
gency primary healthcare centres and occupational healthcare centres, but the authors noted this 
may be related to how often the test is performed in these settings. 
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Table 22: Accuracy of the quantitative POCT tests compared with a reference standard when tested in the laboratory or at the point of care 
 Laboratory Point of Care 
Device Number 
of 
studies 
(n) 
Agreement 
(Slope of 
Passing-
Bablok 
Regression 
[95% CI]) 
Bias: Mean difference 
from Bland Altman Plot 
(CI 95%) or % Bias 
 
Correlation* 
(95% CI) 
 
Number 
of 
studies 
(n) 
Agreement: 
Slope of 
Passing-
Bablok 
Regression 
(95% CI) 
Bias: Mean difference from 
Bland Altman Plot (CI 95%) 
or % Bias 
Correlation* 
(95% CI)  
Afinion™  n=3 [16, 
18, 173] 
0.8 
(0.84-0.91) 
[16] 
<20mg/L: -1.1 mg/L (-3.2; 
1.0) 
 20-100mg/L: -0.3mg/L (-
6.4;5.8) 
>100mg/L: 14.7mg/L (-
21.1;50.5) [18] 
-3.7mg/L [16] to 2.3mg/L (-
5.5;10.1) [173]  
SCC r
2
: 0.982 
(0.973-0.988) 
[16] 
ICC: 0.994 
(0.990-0.997) 
[173] 
 
n=2 [17, 
177] 
1.02 (1.01-
1.08) [177] 
 
1.3% (-15.4;12.8) [177]  
25mg/L: 1.7% (1.0;2.5) 
63.9mg/L: 2.0% (1.0;3.0) [17] 
NR 
NycoCard n=1 [170] Equivalency of 
both tests 
shown by 
Passing- Ba-
blok [170] 
No systematic differences 
between tests shown with 
Bland Altman [170] 
SCC R: 
0.9838 [170]  
n=2 [17, 
19] 
0.95 (0.9 – 
1.0) [19] 
0-70mg/L:1.4mg/L (2SD:11) 
>70mg/L:-1.9mg/L (2SD:35.4) 
Overall: 0.6mg/L (2SD: 
19.7)[19] 
25.0mg/L: 7.8% (3.0;13.0) 
63.9mg/L: 14.9% (10.1;20.0) 
[17] 
PCC r: 0.99 
[19]  
NycoCard™ 
Reader II 
n=1 [18] NR <20mg/L:  0.3mg/L (-4.4;5.0)                     
20-100mg/L: 3.0mg/L (-
6.2;12.2) 
 >100mg/L: -10.7mg/L (-
30.4;9.1) [18] 
NR n=0 NR NR NR 
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QuikRead 
go
®
            
n=2 [16, 
18] 
0.85 (0.83-
0.87) [16] 
<20mg/L: 0.2mg/L (-1.2;1.5)                                   
20-100mg/L: 2.3mg/L (-
3.6;8.3) 
>100mg/L: -8.9mg/L(-
21.4;3.5)[18] 
-9.2 mg/L [16] 
SCC r
2
: 0.996
(0.994-0.997) 
[16]  
n=1 [17] NR  25.0mg/L: 8.0% (7.1;8.9) 
63.9mg/L: 12.0% (11.0;13.0) 
[17] 
NR 
QuikRead
®
 
101 
n=4 [18-
20, 174] 
0.83 (0.81-
0.85)[19] to 
0.94 (0.93-
0.95) [174] 
 
Regression 
slope: 0.98 
[20] 
<20mg/L: -1.4mg/L (-3.2;0.4)                            
20-100mg/L: -6.5mg/L (-
15.6;2.7) 
>100mg: 3.2mg/L(-8.4;14.8) 
[18] 
0-70mg/L:-0.4mg/L 
(2SD:11.8) 
>70mg/L:-26.4mg/L (2SD: 
44) 
Overall: -6.1mg/L (2SD 
31.3)[19] 
0.4mg/L (18.8;19.5) [174]  
PCC r: 
0.99[19]  
SCC r:0.976 
(0.973-0.979) 
[174] 
R
2
: 0.977 [20] 
n=3 [17, 
20, 176] 
NR 25.0mg/L: 1.7% (0.8;2.6) 
63.9mg/L: -0.6% (-1.6;0.5) [17] 
-1mg (+/-10mg/L) [176] 
<75mg/L: -10% 
>75 mg/L: -20% 
Stated as approximate results 
[20] 
PCC r: 0.996 
[176] 
Smart Euro-
lyser 
n=3 [16, 
18, 23] 
1.00 
(0.96;1.04) 
[16] 
<20mg/L: 1.9mg/L(-
10.2;14.1) 
20-80mg/L: 7.8 mg/L               
(-27.7;43.3) 
 >100mg/L: 0.9mg/L               
(-53.2;55.0) [18] 
Low (1.8-27,4 mg/L):             
-4.4% (-7.4;-1.4)                      
Medium (27.5-41.1 mg/L) 
5.5% (2.9;8.2)                          
High (41,7-280 mg/L): 9.6% 
(5.6;13.5) [23] 
-3.9 mg/L [16] 
SCC r
2
: 0.970 
(0.954-0.980) 
[16]  
n=1 [23] NR Primary Health Centre 1:                                      
Low (0.3-13.5mg/L):                         
-11.2% (-14.7;-7.8)                       
High (14.3-148mg/L):                      
-8.6%(-12.9;-4.3)              
Overall: -9.8% (-12.5;-6.9) 
Primary Health Centre 2: 
Low (0.3-9.0mg/L): -17.0%  (-
24.0;-9.6) 
High (9.7-109mg/L): -4.8%  (-
9.9;0.3) 
Overall: -10.3%(-15.1;-5.6) 
[23] 
 
NR 
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iChroma
™
  n=4 [16, 
22, 168, 
169] 
0.79  
(0.76;0.82) 
[16] Linear 
Regression = 
0.74 [168]  
Low (0.0-13.5mg/L): 6.6% 
(2.8;10.4)                         
Medium (13.5-56.4mg/L): 
3.3% (1.0;7.6)                        
High (56.6-264.6mg/L):        -
6.2%  (-10.2;2.2)                    
Overall: 0.4%(-2.2;2.9)[22]                                 
-8.1mg/L [168]                               
-7mg/L (-139.1;125.1) [169] 
-12.3 mg/L [16] 
r
2
 = 0.905[168] 
SCC r
2
: 0.967 
(0.953-0.976) 
[16]
 
n=1 [17] NR 25.0mg/L:-9.7%(-11.6;-7.7) 
63.9mg/L:-9.1%(-8.18;-0.2) 
[17] 
NR 
Microsemi n=2 [16, 
175] 
1.116 
(1.14;1.18) 
[16] 
 
5.1 mg/L [16] r=0.989[175] 
SCC r
2
: 0.997 
(0.9969-0.998) 
[16]  
n=0 NR NR NR 
spinit
®
 n=0  NR NR n=1 [171] Deming re-
gression value 
=1.12 [171] 
NR R=0.98 [171] 
AQT90 Flex n=1 [16] 1.03 
(1.00;1.06) 
[16] 
5.8 mg/L [16] SCC r
2
: 0.992 
(0.995-0.998) 
[16] 
n=0 NR NR NR 
ABX Micros 
200  
n=2 [21, 
170] 
 
Regression 
slope 0.84 to 
1.15 [21] 
NR SCC R:0.9934 
R: 0.98 – 0.99 
[21] 
n=2 [17, 
21] 
NR 25.0mg/L: -6.2%(-10.0;-2.1) 
63.9mg/L: 0.0%(-1.0;1.0) [17] 
Primary care centres (n=4): 
Overall: 40%  
Primary care centres in-
volved initially and at 6 
months (n=2): 
10-135mg/L: -27.6% 
After 6 months use this de-
creased to -14.7%. [21] 
R
2
: 0.81 to 
0.98 for 4 
practices [21] 
Note: Correlation values reported included: Spearman (SCC) Pearson (PCC)* & Intra-class correlation coefficient (ICC) 
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Precision 
The precision of eleven CRP POCT devices was evaluated in ten studies (Table 23). Precision 
was most often expressed as the level of imprecision and reported as a coefficient of variation 
(CV). Imprecision was reported as “within-day variation”, whereby the same samples are tested 
multiple times on the same device on the same day and a “between-day variation” where the 
same sample was tested on the same device on multiple days. Studies also compared the preci-
sion of the devices at different CRP concentrations (low, medium, high). The number of samples 
used; the range of CRP concentrations defined as low, medium and high; and the number of 
measurements taken varied greatly between studies. A number of studies noted that there is no 
agreed international standard in relation to the maximum acceptable level of imprecision. The 
studies by SKUP and Brouwer stated a priori that the maximum acceptable imprecision they con-
sidered was a CV of ≤10%. Minnaard et al. considered a value of ≤15% sufficient.  
Of the ten studies reporting precision data for devices when tested under idealised laboratory 
conditions, two studies by Brouwer et al. [16] and Minnaard et al. [18] which compared the analyt-
ical performance of eight and five CRP POCT devices, respectively, provided the majority of the 
data. Brouwer et al. [16] tested within-day variation using two samples with CRP concentrations 
ranging from 57mg/L to 120mg/L. Minnaard et al. [18] used a low concentration sample (18-
25mg/L) and high concentration sample (95-136mg/L) and tested both within-day and between-
day precision. 
Overall acceptable levels of precision (CV <10%) were reported for the Afinion™, QuikRead go
®
, 
QuikRead
®
 101, Microsemi, AQT90 Flex and ABX Micros devices when tested in in the laboratory 
setting. In studies that compared the precision of the devices at a number of CRP concentration 
ranges, precision was noted to be concentration dependent with greater levels of imprecision 
reported at the extremes of the concentration range (Table 23).  
High levels of imprecision (CV >10%) were reported in studies for the iChroma
™
, NycoCard™ II 
Reader devices. Inconsistent data were obtained for the Smart Eurolyser device with acceptable 
(within-day CV <10%) precision reported by Brouwer et al. and poor levels of precision (maximum 
CV = 19.4% [within-day] and 30.5% [between-day]) reported by Minnaard et al. (Table 23). 
Fewer studies reported data in relation to the precision of the devices when tested at the point of 
care with data available for only five quantitative devices (ABX Micros 200, iChroma
™
, QuikRead
®
 
101, Smart Eurolyser & spinit
®
). Six studies reported within-day precision of devices when tested 
at the point of care [22, 23, 176], four of which were SKUP reports. Acceptable levels of precision 
(CV <10%) were reported for two (QuikRead
®
 system and spinit
®
) of the five CRP POCT devices 
assessed. Inconsistent levels of precision were reported for the iChroma
™
, Smart Eurolyser and 
ABX Micros devices with CV values of greater than 10% reported in at least one primary care 
practice or at one of the specific concentration ranges assessed. High levels of imprecision were 
recorded with the ABX micros device (CV ≥24.6%) at CRP concentrations under 25mg/L; howev-
er, at CRP concentrations over 25mg/L the CV value was less than 3.2% (Table 23). 
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Table 23:  Summary range of the within-day and between-day imprecision values of the 
quantitative POCT devices 
 Laboratory Point-of--Care 
Device Studies 
(n) 
Within-Day  
CV (%) 
Between-Day 
CV (%) 
Studies 
(n) 
Within-Day 
CV (%) 
Between-Day  
CV (%) 
Afinion
™
 2  2.6
b
[16] - 
7.4
a
[18] 
4.6
a
 - 7.3
b
[18] 0 NR NR 
Ny-
coCard
™
 
1 1.876[170] NR 0 NR NR 
Ny-
coCard™ 
Reader II  
1 9.8
b
 to 
13.3
a
[18] 
6.0
b
 to 
16.9
a
[18] 
0 NR NR 
QuikRead 
go
®
  
2 1.1
b
 to 2.6
a
[18] 4.0
b
 to 
8.3
a
[18] 
0 NR NR 
QuikRead
®
 
101    
3 5.4
a
 to 5.7
b
[18] 
8-25mg/L: 6.1 
(5.0-7.8) 
25-100mg/L: 
2.4 (2.1-2.9) 
>100 mg/L: 1.7 
(1.4-2.3) 
Overall: 2.5 
(2.1-2.8)[20] 
3.4%[174] 
6.3
b
 - 9.3
a
[18] 2 Inter-assay: 
21mg/L: 8.7 
63mg/L: 4.5  
Intra-assay: 
25mg/L: 6.4 
70mg/L:3.6[176]  
3.4 - 6.0[20] 
2.5 (1.9 - 3.6) - 
2.6 (2.1 - 3.7) 
[20] 
Smart 
Eurolyser  
3 2.8
a
[16] 
to19.4
a
[18] 
18.0
b
 to 
30.5
a
[18] 
1 Overall CV: 8 
(6.8-9.7) 
7.4 - 12.1[23] 
21.0 – 25.7 
with control 
material[23] 
iChroma™ 2 3.3[22] - 
18.7
a
[16] 
NR 1 5.7 - 15.0[22] 16.1 – 24.1 
with control 
material[22] 
Microsemi  1 1.3
b
 - 3.0
a
[16] NR 0 NR NR 
spinit
®
 0 NR NR 1[171][1
72][174][
174][175
][175][17
5][176][1
77][178][
178][178
][179][17
9][179][1
80][180][
181][181
][181][18
2][182][1
84][185][
185][185
][186][18
6][187][1
88][189][
189][187
6.9[171] NR 
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][187][18
8][188][1
88][188][
188][188
][189][18
9][190][1
91][190][
190][190
][190][17
6][174](1
74)(174)(
174)(173
)(173) 
AQT90 
Flex  
1 3.5
a
 - 7.6
b
[16] NR 0 NR NR 
ABX Mi-
cros 
2[21, 
170] 
0.9160[170]  
<2mg/L: 57.7 
2-25mg/L: 3.9 
25-75mg/L: 5.3 
75-100mg/L: 
1.4 [21] 
NR 1 Initial Results: 
<2mg/L: 53.4-
103.6 
2-25mg/L: 24.6-
38.4 
25-75mg/L: 0.1-
3.1 
>75mg/L: 0.7  
Six month re-
sults: 1.4 - 
5.0[21] 
NR 
Notes:
 a,b
 Two studies reporting on precision measured imprecision at two different CRP concentrations. 
a
 represents the 
lower concentration range (16 -37 mg/L in Minnaard et al. and 57 to 82 mg/L in Brouwer et al.) and 
b
 represents the higher 
concentration range (82 to 160 g/L in Minnaard et al. and 77 to 120 mg/L in Brouwer et al.).  
 
[D1008] – What is known about the intra- and inter-observer variation in test 
interpretation? 
This outcome overlaps with D1001. Data on this outcome are limited to one study which evaluat-
ed two semi-quantitative tests (Actim
®
 and Cleartest
®
) [16]. As illustrated in Table 21, there was 
evidence of inter-observer variation for both devices. Inter-observer agreement values after five 
minutes were 0.81 and 0.55 for Actim
®
 and Cleartest
®
, respectively. When tests were re-read at 
15 minutes, the inter-observer agreement values were 0.83 and 0.74 for Actim
®
 and Cleartest
®
, 
respectively. 
In terms of intra-observer variation, as noted, tests were read at five minutes and re-read by the 
same two observers at 15 minutes. For the Actim
®
 device, the intra-observer agreement for ob-
servers one and two were 0.64 and 0.60, respectively. For the Cleartest
®
 device, these values 
were 0.40 and 0.20, respectively. Although the test was read twice by the same observer, the ten-
minute time lapse between the readings may account for the low intra-observer agreement as the 
test is known to be time critical, with five minutes being the optimal time to read the test. 
[D1007] – How does the analytical performance vary in different settings? 
This assessment element overlaps with D1001. While data comparing the accuracy of the POCT 
versus a laboratory standard in laboratory and primary care settings are available for eight devic-
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es, due to differences in the choice of comparator, it is only appropriate to evaluate the impact of 
setting if the device was tested in both settings (laboratory by trained laboratory personnel and in 
primary care by the intended users) within the same study. Data to inform this question are de-
rived from the external quality assurance reports by SKUP on the Smart Eurolyser, iChroma™, 
ABX Micros and QuikRead
®
 101 devices (Table 24). 
In terms of accuracy, SKUP set an allowable level of bias of +/- 1 mg/L or <26% from the compar-
ison method. A total of 98% of the results for the Smart Eurolyser fulfilled this goal for accuracy 
with venous EDTA samples in the hospital evaluation and with capillary samples at both primary 
health care centres. In the laboratory setting the Smart Eurolyser exhibited a negative bias at low 
concentrations <30 mg/L and a positive bias at higher concentrations (all <10%) while at the POC 
a negative bias was seen at low and high concentrations but it was more pronounced at lower 
concentrations (at low concentration bias 11.2% and 17.0%) in two primary care centres (Table 
24). In terms of precision, the Smart Eurolyser fulfilled the quality goals for imprecision in the la-
boratory setting and in primary care at CRP concentrations above 3.2 mg/L. However the mean 
CV was higher in the primary care setting (8%, 95% CI: 6.8–9.7) compared with the laboratory 
setting (4.9%, 95% CI: 4.3–5.7). The internal control material was used to assess reproducibility 
and was measured each day of the evaluation. In the laboratory setting an acceptable CV was 
reported (CV <10%), but at the point of care the CV was between 21% and 25.7% at different 
concentrations in the two centres, suggesting poor reproducibility with the control material in the 
primary care setting. It was unclear if this poor reproducibility was due to operator error or had to 
do with the control material. Overall, the Smart Eurolyser had acceptable performance (except for 
the control material) but the performance of the device was consistently better in the laboratory 
setting (Table 24). 
The iChroma™device was tested by SKUP in 2011. Accuracy was not accessed at the point of 
care as the blood taken for comparison to the laboratory method did not reach the laboratory with-
in the day of sampling. Precision was reported in both settings with acceptable within-day repeat-
ability reported in the laboratory for both capillary and venous blood samples. The internal quality 
control material was measured each day of the evaluation and used to measure between-day 
variation, this was also found to be acceptable in the laboratory setting (<10%). Precision meas-
ured in forty samples from two primary care health centres resulted in a CV of 5.7% in one centre 
and 15.0% in the other. The between-day variation measured using the quality control material 
resulted in unacceptable imprecision of 16% and 20% in the two primary health care centres. It 
was suggested that the colourless control material may not be ideal for use in the primary care 
setting.  
The QuikRead
®
 device was analysed by SKUP in 2001 in the laboratory using plasma samples 
and in three general practices using whole blood. Although the agreement was acceptable in the 
laboratory setting, when used at the POC, the device consistently underestimated the CRP levels 
compared with the reference method (<75 mg/L approx. -10%, >75 mg/L up to -20%). The au-
thors suggested the discrepancy was due to the use of whole blood at the point of care with no 
correction for haematocrit. Subsequent to this feedback, the company responded that the device 
would be recalibrated (3% at the lower end of the concentration range and 13% at the higher end) 
to correct these systematic differences. The data therefore may not be relevant to the current 
QuikRead
®
 technology. In terms of precision, overall precision was considered acceptable with 
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CV <10% in the laboratory and in two out of three general practices. One practice had a higher 
variation of 3% to 12%. The highest CV was with samples with CRP concentrations of <25 mg/L 
[20]. 
SKUP reported that the ABX Micros had acceptable levels of bias in the laboratory setting (< ± 
15%), but unacceptable high levels of bias when first measured in the primary care setting 
(around 28% lower than reference method). Accuracy improved after six months of use to -14%, 
suggesting that, with practice, operators made fewer mistakes. The device had acceptable preci-
sion in the laboratory setting at CRP concentrations above 2 mg/L and at concentrations above 25 
mg/L in the primary care setting. The overall precision in the primary care setting improved after 
six months of practice particularly, in the CRP 2-25 mg/L concentration range category. Impreci-
sion reduced from 24% to 5% in one primary care site and from 37.8% to 2.7% in the other.  
Table 24:  Accuracy and precision of the quantitative POCT tests compared with a 
reference standard when tested both in the laboratory and at the point-of-care 
 Laboratory Point-of-care 
Device Measures of 
accuracy 
Measures of 
precision 
Measures of 
accuracy 
Measures of 
precision 
QuikRea
d
®
 101 
[20] 
Regression equation: 
0.98x +0.32 
R
2
: 0.977 
Within day CV %: 
8-25mg/L: 6.1 
(5.0-7.8) 
25-100mg/L: 2.4 
(2.1-2.9) 
>100 mg/L: 1.7 
(1.4-2.3) 
20 
Overall: 2.5 (2.1-
2.8)  
 
Between day CV 
%: 
62.9 mg/L: 3.4% 
(2.3-6.4) 
<75mg/L: -10% 
>75 mg/L: -20% 
Stated as approxi-
mate results 
Within day CV %: 
Practice A: 
8-25 mg/L: 7.7 
25-100 mg/L:1.3 
>100 mg/L: 0.6 
Overall:3.4 
Practice B: 
8-25 mg/L: 5.9 
25-100 mg/L:2.0 
>100 mg/L: - 
Overall:2.8 
Practice C:: 
8-25 mg/L: 11.5 
25-100 mg/L:8.3 
>100 mg/L: 3.0 
Overall:6.0 
Between day CV %: 
Practice A: 
58.7 mg/L: 2.5 (1.9-
3.6) 
Practice B: 
58.5 mg/L: 2.6 (2.1-
3.7) 
 
Smart 
Eurolys-
er [23] 
Low (1.8-27,4 mg/L):           
-4.4% (-7.4;-1.4)                      
Medium (27.5-41.1 
mg/L) 5.5% (2.9;8.2)                          
High (41,7-280 mg/L): 
Within day CV %: 
Low(1.8-27.4): 
6.7% (5.4-8.9) 
Medium(27.5-
Primary Health Cen-
tre 1:                                      
Low (0.3-13.5mg/L):                         
-11.2% (-14.7;-7.8)                       
High (14.3-
Within day CV %: 
Primary Health Centre 
1:  
Low(0.3-13.5mg/L): 
8.3% (6.1;12.8)  
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9.6% (5.6;13.5)  
 
41.1): 4.1%(3.4-
5.4) 
High(41.7-281): 
3.3% (2.7-4.4) 
Overall: 4.9 (4.3-
5.7). 
 
Between day CV%: 
Low(9.7mg/L): 
7.9% 
High(75.5mg/L): 
3.7% 
148mg/L):                      
-8.6%(-12.9;-4.3)              
Overall: -9.8% (-
12.5;-6.9) 
Primary Health Cen-
tre 2: 
Low (0.3-9.0mg/L): -
17.0%  (-24.0;-9.6) 
High (9.7-109mg/L): 
-4.8%  (-9.9;0.3) 
Overall: -10.3%(-
15.1;-5.6)  
 
High (14.3-148mg/L): 
6.7% (6.0-9,6)   
Overall: -9.8% (-12.5;-
6.9)  
Primary Health Centre 
2:   
Low(0.3-9.0mg/L): 
15.4%  (11.3;24.3)  
High(9.7-109mg/L): 
8.6% (6.5-12.9)  
Overall:-12.1% 
(9.7;16.2) 
Overall: 8.0% 
(6.8;9.7) 
Between day CV%: 
Primary Care centre 1 
Low(9.7mg/L): 23.1% 
High(74.5mg/L): 
25.7% 
Primary Care Centre 
2: 
Low(11.3mg/L): 
25.4% 
High(79.1mg/L): 
21.0% 
iChro-
ma™[22
]  
Low (0.0-13.5mg/L): 
6.6% (2.8;10.4)                         
Medium (13.5-
56.4mg/L): 3.3% 
(1.0;7.6)                        
High (56.6-
264.6mg/L):        -
6.2%  (-10.2;2.2)                    
Overall: 0.4%(-
2.2;2.9)[22]                                  
 
Capillary samples 
within day CV %: 
Low: 4.5(3.5-6.6) 
Medium: 3.7 (3.0-
4.8) 
High:4.9 (4.0-6.4) 
All: 4.3 (3.8-5.1) 
Venous samples 
within day CV%: 
Low: 4.8 (3.7-4.8) 
Medium: 2.9 (2.4-
3.9)  
High: 4.3 (3.6-5.7)  
All: 3.9 (3.5-4.7)  
NR Within day CV %: 
5.7 - 15.0 
Between day CV%: 
Primary care centre 1: 
24.1% 
Primary care centre 
2:16.1%  
 
ABX 
Micros 
200 [21] 
NR Within day CV %: 
<2mg/L: 57.7 
2-25mg/L: 3.9 
25-75mg/L: 5.3 
75-100mg/L: 1.4  
10-135mg/L: -27.6% 
After 6 months use 
this decreased to -
14.7% 
R
2
: 0.81 to 0.98 for 4 
practices 
Within day CV %: 
Initial Results: 
<2mg/L: 53.4-103.6 
2-25mg/L: 24.6-38.4 
25-75mg/L: 0.1-3.1 
>75mg/L: 0.7  
Six month results: 1.4 
- 5.0 
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Ease of Use 
The ease of use of the C-reactive protein POCT devices was presented in some form in ten [16, 
18, 20-23, 170, 172, 176, 177] of the 18 studies. Often this was a note in the discussion without 
reference to the use of a validated tool to objectively measure the ease of use. In a number of the 
studies the operator was a trained laboratory technician rather than a healthcare professional and 
therefore may have a different view on ease of use of equipment. Of the ten studies included in 
this section, only seven used a questionnaire or other tool to obtain the information [16, 18, 20-23, 
177]. The information presented below is summarised in Table 25. 
Ease of use recorded by laboratory personnel  
Brouwer et al. compared six quantitative POCT devices (QuikRead go
®
, Smart Eurolyser, Af-
inion™, iChroma™, Microsemi) and two semi-quantitative methods to measure CRP. The authors 
carried out a practical evaluation of all of the POC devices in the laboratory setting evaluating the: 
minimum amount of material required, analytical range, pre-analytical handling of the samples 
and estimated pre-analytical time, if haematocrit (Ht) correction was required, size and weight of 
the analyser and the possibility of also measuring other analytes [16]. Details on pre-analytical 
handling time can be found in Table 25, other details on size, weight and analytical range of the 
devices can be found in Section 3, Table 7. The authors concluded that the Afinion™ device re-
quired the least pre-analytical handling. The Afinion™ and the Smart Eurolyser required less than 
a minute pre-analytical handling while the QuikRead go
®
, the iChroma™, the Actim
®
 and Cleart-
est
®
 semi-quantitative strips required two to three minutes of pre-analytical handling. These six 
devices all use capillary blood samples. AQT90 Flex required no additional pre-analytical han-
dling, but required a venous blood sample which is a disadvantage given the intended use of the 
equipment in the primary care setting. The Microsemi also required little pre-analytical handling 
but the size and weight of the device was noted as a possible issue. It was reported that a clear 
disadvantage of the semi-quantitative strips was the requirement that they be read after five 
minutes and that the results were time sensitive, which may be restrictive in a busy clinical envi-
ronment. The upper CRP cut point used by the strips was 80 mg/L; this is not consistent with the 
cut point of 100 mg/L identified in a number of national and European guidelines. The authors 
concluded that when combining analytical performance and practical evaluation, the Afinion™ and 
the Smart Eurolyser were the preferred analysers for CRP POCT. 
The practicality of a requirement to read the Actim
®
 strip at exactly five minutes was also ques-
tioned by Evrand and colleagues, who assessed the performance of this device in the laboratory 
setting [172].  
In the study by Clouth et al. [170], the authors used two point-of-care devices, the NycoCard™ 
and the Micros CRP. No questionnaire or survey was used, rather the authors provided a narra-
tive account that both tests were rapid and easy to perform and required no specialist training. 
They also noted that both are useful for use in POCT in a range of settings including general prac-
tice.  
Ease of use recorded by primary care personnel 
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Minnaard et al. compared five quantitative devices (Afinion™, NycoCard™ Reader II, Smart Euro-
lyser, QuikRead go
®
 and QuikRead
®
 101) using a standardised questionnaire published by 
Geersing et al. to assess user friendliness [18, 184]. The questionnaire was completed by 20 GPs 
and GP assistants who were unfamiliar with point-of-care testing. Two main items were reported 
for user friendliness: the time required for analysis (including warm-up time of the device, pre-
analytical handling, analysis time, blank measurement and time needed for calibration and/or 
internal quality control measurements) and susceptibility to flaws (blood application on test kit 
flaws, buffer application flaws, test kit placement in analyser flaws and loss of material flaws). 
Table 25 reports the pre-analytical handling time as reported by Minnaard et al. as well as the 
total time for assay with and without a warm-up period. For most devices the warm-up period is 
less than a minute and therefore adds little to the overall time; however, for the Afinion™ device it 
adds an additional four minutes to the assay time, which brings the total time to 8 minutes and 15 
seconds. The warm-up time would not be a factor in every consultation and if not taken into ac-
count the total time required varies between 3 minutes and 20 seconds (QuikRead
®
 101) and 6 
minutes and 50 seconds (NycoCard™ Reader II). In terms of susceptibility to flaws, Minnaard 
reported that the Afinion™ and the Smart Eurolyser were the least susceptible to flaws based on 
the opinion of 20 GPs and GP assistants. The Afinion™ was least susceptible to flaws in blood 
application, buffer application, placement in analyser and loss of material. The NycoCard™ 
Reader II scored poorly in each category, while QuikRead go
®
 and QuikRead
®
 101 were moder-
ate in overall liability to flaws. The Afinion™ and the Smart Eurolyser required the fewest separate 
actions minimising the chance of mistakes. The conclusion from this study was that four devices 
(not the Smart Eurolyser) showed adequate analytical performance and agreement and that Af-
inion™ and the Smart Eurolyser were the easiest to operate [18]. 
Verbakel et al. [177] evaluated the ease of use of the Afinion™ device by asking ten participating 
physicians who performed the CRP POCT to fill out a questionnaire, consisting of a five-point 
Likert scale to rate seven items (device start-up, handling of the capillary, filling of the capillary, 
placing the capillary in the cartridge, placing the test cartridge in the test device, duration of analy-
sis and display of results). Median scores of 4 to 5 were obtained for each item evaluated, indicat-
ing that GPs found it very user friendly. 
Seamark et al. [176] evaluated the QuikRead
®
 device. The study was funded by an educational 
grant by the supplier of the QuikRead
®
 system. Although no formal questionnaire or instrument 
was used to evaluate ease of use, the authors state that the QuikRead
®
 system was quick and 
simple to use in a routine phlebotomy clinic and that the capillary blood method was acceptable to 
patients. They also commented on the time taken for the assay as being six and eight minutes in 
a real-life situation and that there were no device failures during the testing period. 
SKUP (Scandinavian Evaluations of Laboratory Equipment for Primary Health Care) evalu-
ations 
SKUP carried out evaluations on four point-of-care devices (iChroma™, QuikRead
®
 101, Smart 
Eurolyser and ABX Micros systems) [20-23]. In each case, a questionnaire was used that asked 
the end user (either biomedical scientists or GPs) to evaluate the device based on a list of criteria 
within four domains: (i) the information provided by the user manual, (ii) the time factors in the 
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measurement and preparation of the test, (iii) the rating for the performance of the internal and 
external quality control and (iv) the rating of the operation facilities and how easy the system was 
to handle. Each area was graded as satisfactory, intermediate, or unsatisfactory.  
The smart Eurolyser was evaluated in the primary care setting by two nurses and two biomedical 
scientists. The manual provided with the device, time factors and the operation of the device were 
rated as satisfactory by the four evaluators. However, all evaluators reported having difficulties 
with the control material, and although acceptable precision (CV <10%) was reported in the hospi-
tal laboratory evaluation, high levels of imprecision (CV >20%) were reported in the two primary 
health care centres. There were also three technical errors (out of 86 samples measured in dupli-
cate) with the device reported during the evaluation. 
For the iChroma™, two evaluators rated the user friendliness of the device. According to both of 
the evaluators the instrument is best suited for users with laboratory experience. The preparation 
of instrument and sample as well as the number of steps involved were rated as intermediate, 
suggesting that these steps were not as straightforward as they could be. No invalid tests were 
reported during the testing. 
For the QuikRead
®
 101 device, three evaluators rated the device, one GP and two biomedical 
scientists in primary care centres. The overall assessment of the QuikRead
®
 instrument was that 
it was relatively easy to operate, but requires training. Some of the evaluators commented that 
there may be problems with putting the lid on the cuvettes. The analysis time of two to four 
minutes was acceptable to biomedical scientists but the GP commented it may be too long. 
The ABX micros system was assessed in primary care by a GP, a nurse and two biomedical sci-
entists. The questionnaire for this assessment asked about the manufacturer’s training, the man-
ual, the instrument and ability to operate the instrument. The device received an above average 
rating for connections, reagent storage, waste disposal and operation of the device. The device 
scored well overall, scoring 3.8 out of 4.0. Maintenance of the device was set as one to two 
minutes per day and five to ten minutes per week. The authors stated that the ABX required a 
very long training time as pre-analytical errors probably contributed to bias and uncertainty in their 
analysis. 
Table 25: Summary of the ease of use evidence for CRP POCT devices 
Analyser Pre-
analytica
l 
handling 
time and 
(total 
time)[16]
* 
Pre-
analytica
l 
handling 
time and 
(total 
time with 
warm up, 
without 
warm 
up)[18] 
Overall 
handling 
time[176] 
Overall 
Liability 
to 
flaws[18] 
SKUP 
evaluation 
Practical aspect of 
test[16] 
Semi quantitative tests  
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Analyser Pre-
analytica
l 
handling 
time and 
(total 
time)[16]
* 
Pre-
analytica
l 
handling 
time and 
(total 
time with 
warm up, 
without 
warm 
up)[18] 
Overall 
handling 
time[176] 
Overall 
Liability 
to 
flaws[18] 
SKUP 
evaluation 
Practical aspect of 
test[16] 
Actim
®
 2.5 min 
(7.5 min) 
    Relatively complex 
pre-analytical 
handling, cut off at 80 
mg/L. 
Cleartest
®
 2.5 min 
(7.5 min) 
    Relatively complex 
pre-analytical 
handling, cut of at 80 
mg/L. 
       
Quantitative tests 
QuikRead go
®
 2.5 min (4 
min) 
30 sec 
(4.83 min, 
4 min) 
 Moderate  Relatively complex 
pre-analytical 
handling, issues with 
cap on cuvette. 
Smart 
Eurolyser 
45 sec 
(5.25 
min) 
50 sec 
(5.25 min, 
5.17 min) 
 Small Satisfactory in 
terms of the 
manual, time 
factors and the 
operation of 
the device. 
Unsatisfactory 
for the control 
materials.  
No Ht correction, 
integrated capillary 
not always easy to fill 
with blood 
Afinion 30 sec 
(4.25 
min) 
35 sec 
(8.25 min, 
4.25 min) 
 Small  Not portable when 
on. Relatively often 
error codes due to 
small sample volume 
and sample drying 
out. 
iChroma 2 min (5 
min) 
   Better suited 
to users with 
laboratory 
experience as 
the 
preparation of 
the device and 
the number of 
steps involved 
rated as 
intermediate 
Relatively complex 
pre-analytical 
handling. No Ht 
correction 
CRP POCT to guide antibiotic prescribing in primary care settings for acute respiratory tract infections 
147 
 
 
 
 
Analyser Pre-
analytica
l 
handling 
time and 
(total 
time)[16]
* 
Pre-
analytica
l 
handling 
time and 
(total 
time with 
warm up, 
without 
warm 
up)[18] 
Overall 
handling 
time[176] 
Overall 
Liability 
to 
flaws[18] 
SKUP 
evaluation 
Practical aspect of 
test[16] 
Microsemi 30 sec 
(4.5 min) 
    CRP measurement 
only possible in 
combination with 
haematology 
parameters. Size of 
analyser may be 
issue as large and 
heavy. 
AQT90 Flex 30 sec 
(13.5 
min) 
    Needs venous blood 
sampling. Size of 
analyser may be 
issue as large and 
heavy. 
NycoCard™ 
Reader II 
 3.33 min 
(7.25 min, 
6.83 min) 
 Large   
QuikRead
®
 
101 
 1.83 min 
(3.83 min, 
3.33 min) 
6 to 8 
minutes 
in primary 
care 
setting 
Moderate Overall 
operation was 
satisfactory, 
but training 
was required. 
May be issue 
with cuvette 
lids. 
Biomedical 
scientists 
found timing 
acceptable but 
the GP 
thought it may 
be too long. 
 
ABX Micros     Score 3.8/4. 
However, may 
be issues with 
pre-analytical 
handling. 
 
Note: * The minutes and seconds listed by Brouwer et al. were recalculated into minutes. 
5.15 Discussion 
A total of 18 studies evaluated the analytical performance of two semi-quantitative POCT devices 
and 11 quantitative POCT devices. The literature regarding the analytical performance of quanti-
tative and semi-quantitative point of care tests varied widely in terms of the study design, reported 
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results and the quality of evidence presented. Analytical performance was presented as a meas-
ure of accuracy and/or precision. Ten studies also include information on the ease of use of the 
device. There were three methodologies used in the included studies, with methods differing in 
the origin of the blood sample, the operator performing the test or the setting for the test (laborato-
ry or primary care). All studies compared the CRP levels obtained when using a POCT device 
with those obtained using a standard laboratory technique; the most common methods of report-
ing accuracy were agreement from a Passing Bablok regression, correlation from a Pearson or 
Spearman correlation coefficient or a mean difference from Bland-Altman plots. The most com-
mon method of reporting precision was a coefficient of variation based on measuring samples a 
number of times in one day (within-day CV) or measuring samples a number of times over a 
number of days (between-day CV).  
Analytical performance refers to the ability of a laboratory assay to conform to predefined tech-
nical specifications [185]. Studies noted that there are few international guidelines that specify 
analytical quality requirements for CRP POCT devices. Two of the studies identified in this sys-
tematic review reported on acceptable levels of accuracy from three Scandinavian quality im-
provement schemes [17, 23]. Accuracy criteria used by the Norwegian EQAS scheme were noted 
to be as follows: good if the CRP value was +/- 8% of the target value; poor if it exceeded +/- 
15%; and adequate if it was between these two values [17]. The 2013 SKUP report [23] outlined 
the analytical performance requirements specified by a number of bodies including the National 
Danish Committee for General Practice Laboratory Testing. These criteria are based on consulta-
tion with GPs in Denmark who have highlighted that they want to be able to detect a CRP de-
crease from 40 mg/L to 20 mg/L and to be able to detect the difference between 35 mg/L and 50 
mg/L. The Danish analytical quality goals for CRP POCT in primary care (CRP >15mg/L) are: bias 
≤+/- 10% and imprecision (CV) ≤10%. In Sweden, the Equalis Expert group has recommended 
that a maximum deviation for a single result measured in whole blood should be within +/- 15% of 
hospital laboratory method (as measured by five agreeing hospitals) for CRP POCT used in pri-
mary care centres. SKUP themselves consider a deviation of +/- 1 mg/L or ≤+/- 26% (depending 
on the concentration range) acceptable for bias and a CV <10% for precision. Other studies 
specified criteria for accuracy as (r
2
 > 0.95 and 95% confidence interval (CI) of the slope and in-
tercept including 1.0 and 0.0, respectively). Correlation by itself is not generally recommended as 
a method for assessing comparability between methods and good correlation does not necessari-
ly mean good agreement between methods particularly when two methods are being used to 
measure the same analyte [183]. These differences in the assessment of analytical performance 
as well as differences in the study methodology, makes direct comparison of the study data diffi-
cult.  
The relevance of accuracy and precision of these devices in clinical decision-making can be seen 
by using the NICE guidelines for pneumonia as an example. These provide a recommendation 
that CRP POCT should be considered for patients with symptoms of LRTI in primary care if a 
diagnosis is unclear after clinical assessment, and that antibiotics should be prescribed based on 
the test result, that is, CRP <20 mg/L (no antibiotic required), a CRP ≥100 mg/L (immediate anti-
biotic prescription), and a CRP of 20–99 mg/L (consider a delayed antibiotic prescription These 
are broad concentration categories and it could be argued that we are only interested to know if 
the analytical performance using CRP POCT is sufficient to ensure that the categorisation of pa-
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tient samples is consistent with what can be achieved with laboratory-grade testing. Therefore 
while some of the devices have poorer performance in the lower (<2 mg/L) or upper (>100 mg/L) 
CRP concentrations, this may not be clinically relevant for use of these devices for patients pre-
senting with RTIs.  
There were very few studies (n=2) that evaluated semi-quantitative devices, the agreement be-
tween the reference test and the POCT was found to be moderate to good with Kappa values of 
0.53 to 0.93 for the Actim
®
 test [16, 172] and moderate for the Cleartest
®
 (Kappa values 0.56 to 
0.61) [16]. The interobserver variation was lower for the Actim
®
 test than the Cleartest
®
 (Table 
21). There was also evidence from one study that the test was time dependant and that accuracy 
decreased between reading the results at the optimal 5 minutes compared to 15 minutes [16]. The 
time-critical nature of these semi-quantitative tests may not be ideal in a busy clinic environment 
where it may be difficult to read a test at exactly five minutes. Both of the semi-quantitative tests 
were found to have complex pre-analytical handling and were difficult to interpret [16]. The main 
advantage of the strips was said to be the cost as no analyser was needed and the main disad-
vantages were the difficult pre-analytical handling, the accuracy, the time-critical nature of the 
strips and that the results are not automatically entered into the patient record. In addition, the 
semi-quantitative test included here (Actim
®
 and Cleartest
®
) have an upper limit of 80mg/L and 
are therefore of limited use in terms of a number of current guidelines for managing LRTIs where 
a cut-point of 100 mg/L is recommended for antibiotic prescribing.  
In the laboratory setting, the majority of the evidence suggested acceptable performance for all 
eleven quantitative devices. In comparison to a standard laboratory technique, the accuracy data 
showed that most devices had acceptable levels of accuracy except at the higher end of CRP 
concentration levels (CRP >100 mg/L). Although precision was also acceptable for most devices, 
CV values greater than 10% were reported in the laboratory setting in at least one study for the 
Smart Eurolyser, the NycoCard™ Reader II and the iChroma™devices. This suggests that under 
idealised circumstances most of the devices are accurate and precise.  
When used at the point of care (that is, the primary care setting) the data available for accuracy 
and precision were far more variable. In terms of accuracy, the Afinion™ (n=2) and the iChro-
ma™(n=1) devices both reported levels of bias <10%. Bias was variable or not available for the 
other devices. Very little data were available on precision in the primary care setting. Acceptable 
precision was reported for the QuikRead
®
 101 and the spinit
®
 devices, while the Smart Eurolyser 
and the iChroma™ devices had inconsistent results. The lack of data at the point of care and the 
variable results makes it difficult to draw conclusions about the suitability of many of these devices 
for the primary care setting.  
All data on the difference in analytical performance of the devices in the laboratory setting com-
pared to the primary care setting came from four SKUP reports (D1007) [20-23]. Four devices 
were analysed. The Smart Eurolyser had acceptable accuracy and precision in the laboratory and 
at the POC, but it had better performance in the laboratory. The other devices (ABX Micros, 
iChroma™ and QuikRead
®
) had acceptable levels of precision and accuracy in the laboratory but 
unacceptable levels of either precision or accuracy in at least one primary care centre. Based on 
the SKUP data, it appears that all four devices had acceptable analytical performance in the la-
boratory setting, but performance was more variable and poorer at the point of care. This may 
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have been caused by the type of material used in the analysis (whole blood versus plasma), the 
method of blood extraction (capillary versus venous sample) or related to the skill, experience or 
training of the operator (non-laboratory trained personnel versus trained laboratory technician) or 
the level of training received by the operator. There was evidence that analytical performance 
varied between primary care sites and improved over time, suggesting that thorough and ongoing 
training is necessary when using CRP POCT devices in the primary care setting. The difference in 
analytical performance was larger for some devices than others.  
Four of the studies provided a direct comparison of multiple devices either in the laboratory or 
point-of-care setting [16-19]. Minnaard et al. and Brouwer et al. compared multiple devices in the 
laboratory setting (Appendix 1, Table A8). The Afinion™ device was consistently found to be a 
preferred device based on analytical performance and ease of use both in the laboratory [16, 18] 
and at the point-of-care [17], Consistent evidence of acceptable analytical performance was also 
found for the QuikRead go
®
, and QuikRead
®
 101 devices both in the laboratory [16, 18] and at the 
POC [17] and for the NycoCard™ device [18, 19]. Evidence for the Smart Eurolyser device were 
conflicting with findings of unacceptably high imprecision [18] and that it was a preferred analyser 
[16]. The iChroma™ device was reported by Brouwer et al. to be the poorest in terms of accuracy 
and precision in the laboratory setting, while Bukve et al. reported the accuracy of the iChroma™ 
to be similar to the NycoCard™,   but poorer than the Afinion™ or QuikRead
®
 systems [16, 17]. 
Devices with less pre-analytical handling and that are designed in a way that they are less sus-
ceptible to flaws tend to be easier to use. Complex pre-analytical handling might introduce varia-
tion if the test is not performed on a regular basis, can lead to spills of biological materials, test 
errors and use of more than one set of consumables if the test fails [16]. The overall time taken for 
the test to be performed was an important factor, with times ranging from just over three minutes 
(QuikRead
®
) to over 13 mins (AQT90 Flex), but it is unclear from the literature what time period 
would be considered acceptable in the primary care setting. Two studies comparing multiple de-
vices and reporting on ease of use found the Afinion™ and the Smart Eurolyser to be the easiest 
to use [16, 18]. 
On the basis of these findings, it would appear that most of the devices could be used in the pri-
mary care setting, but training would need to be put in place to ensure healthcare personnel who 
are likely to use the devices in practice are thoroughly trained. In addition, an external quality 
assurance scheme would need to be established to ensure adequate levels of accuracy and pre-
cision are being maintained over time. Bukve et al. presented the results of the Norwegian EQAS 
scheme from 2006 to 2015 and reported that: participating in the EQAS scheme more than once, 
performing internal quality control at least weekly, the type of instrument used, having laboratory-
qualified personnel performing the tests and performing more than ten C-reactive protein tests per 
week were associated with good test performance. Core to a quality assurance scheme is the use 
of predefined levels for accuracy and precision so that those using CRP POCT in primary care 
can be assured that test results have an acceptable level of analytical performance. 
One of the limitations of any study of this type is selecting a suitable reference test. All included 
studies used an established laboratory method in a hospital setting as their reference standard, 
and although some studies reported details of the accuracy and precision of the device used, 
many provided no information beyond the name of the instrument. SKUP reports used the aver-
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age of more than one reference standard, which should provide a more reliable reference stand-
ard assuming the two methods are in agreement. In addition, the devices can be updated and 
improved and therefore some of the data included in this review may refer to the analytical per-
formance of a device that has since been improved by the manufacturer on the basis of user 
feedback.  
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6 SAFETY (SAF) 
6.1 Research questions 
Element ID Research question 
Safety 
C0008 
 
How safe is the use of CRP POCT in guiding antibiotic prescribing in 
comparison with standard care? 
Does the use of CRP POCT to guide antibiotic prescribing impact mortality in 
those presenting with symptoms of an acute RTI compared with standard care? 
How does CRP POCT to guide antibiotic prescribing affect the duration and 
severity of symptoms associated with an acute RTI compared with standard 
care? 
Does the use of C-reactive protein POCT to guide antibiotic prescribing impact 
reconsultation or hospitalisation rates in those presenting with symptoms of an 
acute RTI compared with standard care? 
C0005 
 
What are the susceptible patient groups that are more likely to be harmed 
through the use of CRP POCT to guide antibiotic prescribing for acute RTIs? 
C0007 As the skin will be broken to remove a small amount blood, is there a risk of 
harm to staff from blood-borne contamination? 
B0010 What kind of data/records and/or registry is needed to monitor  
the use of the technology and the comparator? 
 
6.2 Results 
Included studies 
Effectiveness and safety of using CRP POCT to guide antibiotic prescribing in patients with acute 
respiratory infections in primary care settings 
For the assessment of safety, all 12 studies identified for inclusion in systematic review 1 were 
considered. The main characteristics of individual studies as well as the risk of bias and the QoE 
of the studies retrieved can be found in the clinical effectiveness domain.  
 
Patient safety 
[C0008] – How safe is the use of CRP POCT in guiding antibiotic prescribing in comparison 
with standard care? This AE overlaps with D0011. 
Does the use of CRP POCT to guide antibiotic prescribing impact mortality in those presenting 
with symptoms of an acute RTI compared with standard care? 
None of the included RCTs or observational studies reported the death of a patient. Five of the 
included RCTs specifically stated that there were no deaths during the study period (n=7,165 
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patients, CRP test group n=3,696, usual care group n= 2,469) [127, 129, 130, 132, 135]. It is 
therefore unlikely that the use of CRP POCT will have any beneficial or detrimental effect on mor-
tality. However, it should be noted that the follow-up period for these studies was short (max of 28 
days) and most of the observational studies had no follow-up beyond the initial consultation. 
Adverse drug reactions (ADR), including number of patients reconsulting or hospitalised due to 
ADR  
This AE overlaps with D0011. There were no studies that reported specifically on reconsultations 
or hospitalisations due to an antibiotic-related ADR. Most papers that did report on hospitalisa-
tions or reconsultations did not state the reason for the hospitalisation. It is therefore conceivable 
that a number of the hospitalisations and reconsultations presented in the next section could have 
been due to ADRs, although it is noted that with the exception of anaphylactic reactions, antibiot-
ics are generally not associated with serious ADRs. 
Number of patients in need of hospitalisation  
In the RCTs, five studies reported on hospitalisations during the follow-up period [127, 129, 130, 
132, 135]. Three studies of these reported either no serious adverse events (defined as death or 
hospitalisation) [127, 129, 130] or patient recovery to some extent during the two-week follow-up 
period [127]. Two studies by Do et al. [132] and Little et al. [135] reported 14/1,775 and 30/4,264 
hospitalisations, respectively. In the study by Do et al. there was no significant difference between 
the CRP POCT group and the control group (RR 0.73, 95% CI: 0.25–2.09), but in the case of the 
study by Little et al. there were significantly more hospitalisations in the CRP POCT group than 
the control group (RR 2.52, 95% CI: 1.13–5.65). However, the authors state that after controlling 
for all potential confounders this difference was no longer significant (OR 2.91, 95% CI: 0.96–
8.85, p = 0.060). The reasons for hospitalisation were available for 15/30 patients and included 
cardiac problems (n=2), respiratory problems (n=8), generally unwell or pyrexia (n=2), gastroin-
testinal symptoms (n=2) and sinusitis (n=1). It is unclear whether these reasons are directly relat-
ed to the RTI the patients presented with and the prescribing or non-prescribing of an antibiotic, or 
if the hospitalisations were due to unrelated problems. 
[C0005] – What are the susceptible patient groups that are more likely to be harmed 
through the use of CRP POCT to guide antibiotic prescribing for acute RTIs? 
No studies were retrieved in the systematic reviews that reported on patient groups that were 
more susceptible to harm from the use of CRP POCT. 
 
[C0007] – As the skin will be broken to remove a small amount blood, is there a risk of 
harm to staff from blood-borne contamination? 
No studies were retrieved in the systematic reviews that reported on harms to staff (or patients) 
from blood-borne contamination. 
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[B0010] – What kind of data/records and/or registry is needed to monitor the use of the 
technology and the comparator? 
No studies were retrieved in the systematic reviews that reported on specific data records or reg-
istries that should be used to monitor use of CRP POCT. 
 
6.3 Discussion 
The reduction in antibiotic prescribing observed in Section 5 (Effectiveness domain) arising from 
the use of CRP POCT to inform antibiotic prescribing appears not to lead to an increase in mortal-
ity. For the majority of studies (five out of seven) there was no hospitalisations reported; two stud-
ies reported hospitalisations within the study period, but it was unclear if the events were directly 
related to the RTI or not. In the study by Do et al. there were a similar number of hospitalisations 
in both the CRP POCT group and in the usual care group, suggesting that CRP POCT had no 
influence on hospitalisations. The study by Little et al., on the other hand, had significantly more 
hospitalisations in the CRP POCT group than in the usual care arm. The authors investigated this 
finding further and state that after controlling for confounders the difference is no longer signifi-
cant, but more studies are needed that specifically look at the effect of using CRP POCT on hos-
pitalisation rates and to determine the main reasons for hospitalisation and if these are related to 
the under- or over-prescribing of antibiotics following a CRP POCT. 
Our study shows similar results to other published systematic reviews in the area in terms of safe-
ty [24, 48, 139, 142], which concluded that use of CRP POCT to inform antibiotic prescribing in 
primary care for acute RTIs leads to a significant reduction in antibiotic prescribing without com-
promising patient safety. 
It is noted, that the outcomes reported in the trials may not capture all safety concerns. While 
serious adverse events that result in substantial morbidity or mortality are rare, antibiotic-related 
adverse events are common and may impact short-term health-related quality of life. However, it 
is also recognised that changes in the incidence of rare serious suppurative complications of RTIs 
(e.g., peritonsillar abscess, empyema, and intracranial abscess) arising from a failure to provide 
timely antibiotic treatment cannot be evaluated precisely in clinical trials. These data are provided 
by large long term cohort studies which suggest that substantial reductions in antibiotic prescrib-
ing can be safely achieved, although caution may be required in subgroups at higher risk of 
pneumonia. (A0006) 
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7 CONCLUSION 
Based on a systematic review of the clinical effectiveness and safety of CRP POCT in patients 
presenting with acute RTIs in primary care, we are moderately certain that its use leads to a sig-
nificant reduction in the prescribing of antibiotics compared with usual care. Although some stud-
ies showed no significant difference, when combined, the pooled estimates suggest CRP POCT 
does have a significant effect on prescribing. We included both RCTs and observational studies in 
our review to ensure the review reflected the findings from a range of study types and not just 
clinical trials where GPs might be more motivated to follow the suggested algorithms and limit 
their antibiotic prescribing. This reduction in prescribing is achieved without compromising patient 
safety, with no evidence of an increase in hospitalisations or patient mortality. These findings are 
based on short-term data. It is not clear if the behavioural change is sustained over time or if the 
conditions in the trials (that is, ongoing use of CRP POCT to inform decision making) can be 
maintained. Further research is required to validate the efficacy and safety of CRP POCT in spe-
cific sub-populations such as children and in older adults (>65 years) and in different primary care 
settings (out-of-hours clinics and long-term care facilities) where the spectrum of patients present-
ing may differ. Given the very limited data regarding the effectiveness of CRP POCT by prescrip-
tion type (immediate versus deferred), further research on this outcome would be useful, including 
data on the relative rates of redemption of these prescriptions. Further research is also required to 
investigate the impact of CRP POCT on patient referral for other diagnostic testing and to deter-
mine its long-term effectiveness to change prescribing behaviour.  
Results from the systematic review of diagnostic test accuracy suggest that there is limited evi-
dence for the use of CRP testing in acute sinusitis. Even if a suitable threshold could be estab-
lished it is unclear based on current clinical guidelines what the aim of the test would be. In phar-
yngitis it is unclear if there is a difference in the mean CRP value of GAS compared with non-GAS 
infections. A cut-point of 35 mg/L CRP may be useful in discriminating bacterial from non-bacterial 
pharyngitis. One study suggests that at this threshold, CRP may be useful as part of a two-step 
clinical prediction rule in patients presenting with sore throats, for whom diagnosis is still inconclu-
sive after clinical examination; however, this score system required further validation. In contrast, 
at a threshold of 6 mg/L, the use of CRP in combination with a clinical prediction rule to rule out 
GAS could lead to unnecessary prescribing of antibiotics. Patients with pneumonia may present 
with low levels of CRP, therefore use of CRP levels in isolation may lead to cases of pneumonia 
being missed. At a CRP cut-point of 20 mg/L, three out of four studies found the sensitivity to be 
<0.75, and considered it too low to use as a rule-out threshold for pneumonia, while most studies 
found a CRP cut-point of 50 or 100 mg/L to be sufficiently specific to use as a rule-in threshold for 
the diagnosis of pneumonia and prescribing of antibiotics. Two studies found that at a cut-point of 
20 or 30 mg/L, the addition of CRP to a clinical prediction rule improved its performance com-
pared with a rule based on signs and symptoms only. While the value of CRP testing in addition to 
clinical signs and symptoms for the diagnosis of pneumonia in primary care is unclear, it appears 
most useful in identifying a group of low-risk patients who do not require antibiotics or to aid pri-
mary care physicians in the management of patients for whom there is still diagnostic uncertainty 
(that is, those considered at intermediate risk) after the review of signs and symptoms. Further 
research is, however, required to validate clinical algorithms that incorporate CRP POCT for spe-
cific RTIs. 
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Limited data were identified to support the analytical performance of two semi-quantitative CRP 
POCT devices in primary care, both of which were found to have complicated pre-analytical han-
dling and were difficult to interpret. The analytical performance of most of the CE marked quantita-
tive CRP POCT devices evaluated in this assessment are acceptable under the ideal conditions 
found in a laboratory. Performance may be poorer at extreme levels, but this is unlikely to impact 
decision-making in primary care where the decision to prescribe or not prescribe an antibiotic 
applies to all values above or below a threshold. There is evidence of greater variability in perfor-
mance when carried out by non-laboratory trained healthcare staff in primary care, with the varia-
tion most likely due to operator error. Devices that are easier to use may be associated with im-
proved performance. To minimise risk of operator error contributing to poor analytical perfor-
mance, adequate training is necessary to ensure devices are used correctly and appropriately 
along with the use of a quality assurance programme to ensure that test performance is main-
tained over time. Further research that directly compares the performance of different CRP POCT 
devices in their intended setting (primary care) is required as well as research on their ease of use 
in this setting (preferably collected using a validated survey) to inform decisions around preferred 
device(s). 
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE USED 
DOCUMENTATION OF THE SEARCH STRATEGIES 
 
Search strategy for systematic review 1 
Medline OVID – Date of search 19/04/2018 
51 34 and 50  
50 or/35-49  
49 exp Ciprofloxacin/  
48 ciprofloxacin*.tw,nm. 
47 quinolone*.tw,nm. 
46 exp Quinolones/ 
45 tetracycline*.tw,nm. 
44 exp Tetracyclines/ 
43 amoxacillin*.tw,nm. 
42 (amoxicillin* or amoxycillin*).tw,nm. 
41 exp Amoxicillin/ 
40 macrolide*.tw,nm. 
39 exp Macrolides/ 
38 penicillin*.tw. 
37 exp Penicillins/ 
36 antibiotic*.tw. 
35 exp Anti-Bacterial Agents/ 
34 18 and 33 
33 or/19-22 
22 (c reactive protein or c-reactive protein or C-reactive protein).tw,nm. 
21 c-reactive protein/ 
20 (("point of care" or "point-of-care" or "near patient" or poc or rapid or bedside) adj5 (test* or 
analys* or immunoassay* or technique* or immunofluorescence or "fluorescent antibody")).tw. 
19 Point-of-Care Systems/ 
18 or/1-17 
17 ((acute or exacerbation*) adj3 (copd or coad or chronic obstructive pulmonary disease or 
chronic obstructive airway* disease or chronic obstructive lung disease)).tw. 
16 Pulmonary Disease, Chronic Obstructive/ 
15 croup.tw. 
14 (severe acute respiratory syndrome or sars).tw. 
13 (influenza* or flu or ili).tw. 
12 ((acute or viral or bacter*) adj2 rhinit*).tw. 
11 (common cold* or coryza).tw. 
10 (sinusit* or rhinosinusit* or nasosinusit*).tw. 
9 (nasopharyngit* or rhinopharyngit*).tw. 
8 (pharyngit* or laryngit* or tonsillit* or sore throat* or cough*).tw. 
7 (bronchit* or bronchiolit*).tw. 
6 (otitis media or aom).tw. 
5 exp otitis media/ 
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4 (pneumon* or bronchopneumon* or pleuropneumon*).tw. 
3 (ari or urti or lrti).tw. 
2 (respiratory* adj3 (inflam* or infect*)).tw. 
1 exp Respiratory tract infections/ 
 
EMBASE Date of search: 19/04/2018 
#35#30 NOT #34 
#34#31 NOT #33 
#33#31 AND #32 
#32'human'/de 
#31'animal'/de OR 'animal experiment'/de OR 'nonhuman'/de 
#30#20 AND #24 AND #28 
#29#25 OR #26 OR #27 OR #27 
#28penicillin*:ab,ti OR macrolide*:ab,ti OR amoxicillin*:ab,ti OR amoxycillin*:ab,ti OR tetracy-
cline*:ab,ti OR quinolone*:ab,ti OR ciproﬂoxacin*:ab,ti 
#27'quinolone derivative'/exp OR 'ciproﬂoxacin'  
#26antibiotic*:ab,ti 
#25'antibiotic agent'/exp 
#24#21 OR #22 OR #23 
#23('c reactive protein':ab,ti OR 'c-reactive protein':ab,ti OR 'c reactive') AND protein:ab,ti 
#22'c reactive protein'/de 
#21(('point of care' OR 'point-of-care' OR 'near patient' OR poc OR rapid OR bedside) NEAR/5 
(test* OR analys* OR immunoassay* OR technique* OR immunofluores* OR 'fluorescent anti-
body' OR 'florescent antibodies')):ab,ti 
#20#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 
OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 
#19(((acute OR exacerbation*) NEAR/3 (copd OR coad OR 'chronic obstructive pulmonary dis-
ease' OR 'chronic obstructive airways disease' OR 'chronic obstructive lung disease')):ab,ti) OR 
aecb:ab,ti 
#18'chronic obstructive lung disease'/de 
#17croup:ab,ti 
#16'severe acute respiratory syndrome':ab,ti OR sars:ab,ti 
#15inﬂuenza*:ab,ti OR ﬂu:ab,ti OR ili:ab,ti 
#14((acute OR viral OR bacter*) NEAR/2 rhinit*):ab,ti 
#13'common cold':ab,ti OR 'common colds':ab,ti OR coryza:ab,ti 
#12rhinosinusit*:ab,ti OR nasosinusit*:ab,ti  
#11nasopharyngit*:ab,ti OR rhinopharyngit*:ab,ti  
#10'sore throat'/de 
#9phary AND ngit*:ab,ti OR laryngit*:ab,ti OR tonsillit*:ab,ti OR 'sore throat':ab,ti OR 'sore 
throats':ab,ti OR cough 
#8bronchit*:ab,ti OR bronchiolit*:ab,ti  
#7'otitis media':ab,ti OR aom:ab,ti  
#6'otitis media'/de OR 'acute otitis media'/exp 
#5pneumon*:ab,ti OR bronchopneumon*:ab,ti OR pleuropneumon*:ab,ti  
#4ari:ab,ti OR urti:ab,ti OR lrti:ab,ti 
#3(respiratory NEAR/2 (infect* OR inflam*)):ab,ti  
#2'respiratory tract inflammation'/exp  
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#1'respiratory tract infection'/exp  
 
CINAHL via EBSCOHOST 
 S29 S18 AND S23 AND S28  
 S28 S24 or S25 OR S26 OR S27  
 S27 TI (penicillin* or macrolide* or amoxicillin* or amoxycillin* or amoxacillin* or tetracyclin* or 
quinolon* or ciproﬂoxacin*) OR AB (penicillin* or macrolide* or amoxicillin* or amoxycillin* or 
amoxacillin* or tetracyclin* or quinolon* or ciproﬂoxacin*)  
 S26 (MH “Antiinfective Agents, Quinolone+”)  
 S25 TI antibiotic* OR AB antibiotic*  
 S24 (MH “Antibiotics+”)  
 S23 S19 or S20 or S21 or S22  
 S22 TI (“c reactive protein” or c-reactive protein or C-reactive protein) OR AB (“c reactive protein” 
or c-reactive protein or C-reactive protein)  
 S21 (MH “C-Reactive Protein”)  
 S20 TI ((“point of care” or point-of-care or poc or “near patient” or rapid or bedside*) N5 (test* or 
analys* or immunoass* or technique*or immunoﬂuores* or “ﬂuorescent antibody”)) OR AB ((“point 
of care” or point-of-care or poc or “near patient” or rapid or bedside* ) N5 (test* or analys* or im-
munoass* or technique* or immunoﬂuores* or “ﬂuorescent antibody”))  
 S19 (MH “Point-of-Care Testing”)  
 S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or 
S15 or S16 or S17  
 S17 TI ((acute or exacerbation) N3 (copd or coad or chronic obstructive pulmonary disease or 
chronic obstructive airway* disease or chronic obstructive lung disease)) OR AB ((acute or exac-
erbation) N3 (copd or coad or chronic obstructive pulmonary disease or chronic obstructive air-
way* disease or chronic obstructive lung disease))  
 S16 (MH “Pulmonary Disease, Chronic Obstructive+”) 
 S15 TI croup OR AB croup   
S14 TI (severe acute respiratory syndrome or sars) OR AB (severe acute respiratory syndrome or 
sars)  
 S13 TI (inﬂuenza* or ﬂu or ili) OR AB (inﬂuenza* or ﬂu or ili)  
 S12 TI ((acute or viral or bacter*) N2 rhinit*) OR AB ((acute or viral or bacter*) N2 rhinit*)  
 S11 TI (common cold* or coryza) OR AB (common cold* or coryza)  
 S10 TI (sinusit* or rhinosinusit* or nasosinusit*) OR AB (sinusit* or rhinosinusit* or nasosinusit*)  
 S9 TI (nasopharyngit* or rhinopharyngit*) OR AB (nasopharyngit* or rhinopharyngit*)  
 S8 TI (pharyngit* or laryngit* or tonsillit* or sore throat* or cough*) OR AB (pharyngit* or laryngit* 
or tonsillit* or sore throat* or cough*)  
 S7 TI (otitis media or aom) OR AB (otitis media or aom)  
 S6 (MH “Otitis Media+”)  
 S5 TI (bronchit* or bronchiolit*) OR AB (bronchit* or bronchiolit*)  
 S4 TI (pneumon* or bronchopneumon* or pleuropneumon*) OR AB (pneumon* or bronchopneu-
mon* or pleuropneumon)  
 S3 TI (ari OR arti OR urti OR lrti) OR AB (ari OR arti OR urti OR lrti)  
 S2 TI (respiratory N3 (inﬂam* or infect* )) OR AB (respiratory N3 (inﬂam* or infect*))  
 S1 (MH “Respiratory Tract Infections+”)  
 
COCHRANE LIBRARY  Date of search: 19/04/2018 
#1 (respiratory* near/3 (inﬂam* or infect*))  
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#2 Respiratory Tract Infections  
#3 (ari or urti or lrti)  
#4 (pneumon* or bronchopneumon* or pleuropneumon*)   
#5 Otitis media   
#6 (otitis media or aom)  
#7 (bronchit* or bronchiolit*)  
#8 (pharyngit* or laryngit* or tonsillit* or sore throat* or cough*)  
#9 (nasopharyngit* or rhinopharyngit*)  
#10 (sinusit* or rhinosinusit* or nasosinusit*)  
#11 (common cold* or coryza)  
#12 ((acute or viral or bacter*) near/2 rhinit*)  
#13 (inﬂuenza* or ﬂu or ili)  
#14 (severe acute respiratory syndrome or sars)  
#15 croup  
#16 Chronic Obstructive Pulmonary disease   
#17 ((acute or exacerbation*) near/3 (copd or coad or chronic obstructive pulmonary disease or 
chronic obstructive airway* disease or chronic obstructive lung disease))  
#18 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 
or #16 or #17  
#19 Point-of-Care Systems  
#20 (("point of care" or "point-of-care" or "near patient" or poc or rapid or bedside) near/5 (test* 
or analys* or immunoassay* or technique*or immunoﬂuorescence or "ﬂuorescent antibody"))  
#21 C-Reactive Protein  
#22 (c reactive protein or c-reactive protein or C-reactive protein)  
#23 #19 or #20 or #21 or #22 
#24 Anti-Bacterial Agents 
#25 antibiotic*  
#26 Penicillins  
#27 penicillin* 
#28 Macrolides 
#29 macrolide* 
#30 Amoxicillin  
#31 (amoxicillin* or amoxycillin*) 
#32 amoxacillin*  
#33 Tetracyclines   
#34 tetracycline*   
#35 Quinolones   
#36 quinolone*   
#37 ciprofloxacin*   
#38 ciprofloxacin   
#39 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or 
#37 or #38  
#40 #18 and #23 and #39  
 
Search strategy for systematic review 2   
Embase search: Date of search: 17/05/18 
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No. Query Results 
40. #33 NOT #39                                               2,602   
39. #34 NOT #36                                           5,840,761   
38. #33 NOT #37                                                 462 
37. #35 NOT #36                                          17,556,070   
36. #34 AND #35                                           1,732,020   
35 'human'/de                                           19,288,090   
34. 'animal'/de OR 'animal experiment'/de OR 'nonhuman'/de 7,572,781   
33. #32 AND [embase]/lim NOT ([embase]/lim AND [medline]/lim) 2,621   
32. #27 AND #31                                               6,193   
31. #28 OR #30                                            7,371,204   
30. 'diagnostic accuracy' OR 'diagnostic test accuracy' OR 'dta' 292,693   
29. #27 AND #28                                               6,193   
28. sensitiv* OR detect* OR accura* OR specific* OR reliab* 7,366,875   
27. #20 AND #24                                              19,694   
26. #25 AND #24 AND #20 14,685   
25. sensitiv* OR detect* OR accura* OR specific* OR reliab* OR positive OR 
negative OR diagnos* 
12,746,185   
24. #21 OR #22 OR #23                                       174,668   
23. crp:ab,ti 77,014   
22. ('c reactive protein':ab,ti OR 'c-reactive protein':ab,ti OR 'c reactive') AND pro-
tein:ab,ti 
86,282   
21. 'c reactive protein'/de  142,108   
20. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 
OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 
1,098,229   
19. (((acute OR exacerbation*) NEAR/3 (copd OR coad OR 'chronic obstructive 
pulmonary disease' OR      'chronic obstructive airways disease' OR 'chronic 
obstructive lung disease')):ab,ti) OR aecb:ab,ti       
11,916 
18. 'chronic obstructive lung disease'/de 108,899   
17. croup:ab,ti 1,729   
16. 'severe acute respiratory syndrome':ab,ti OR sars:ab,ti 9,484   
15. influenza*:ab,ti OR flu:ab,ti OR ili:ab,ti 134,361   
14. ((acute OR viral OR bacter*) NEAR/2 rhinit*):ab,ti 361 
13. 'common cold':ab,ti OR 'common colds':ab,ti OR coryza:ab,ti OR coryza:ab,ti 5,105   
12. rhinosinusit*:ab,ti OR nasosinusit*:ab,ti 9,318   
11. nasopharyngit*:ab,ti OR rhinopharyngit*:ab,ti 2,216   
10. 'sore throat'/de 13,685   
9. pharyngit*:ab,ti OR laryngit*:ab,ti OR tonsillit*:ab,ti OR 'sore throat':ab,ti OR 
'sore throats':ab,ti OR cough* 
137,640   
8. bronchit*:ab,ti OR bronchiolit*:ab,ti 41,697   
7. 'otitis media':ab,ti OR aom:ab,ti                        26,302   
6. 'otitis media'/de OR 'acute otitis media'/exp   26,423   
5. pneumon*:ab,ti OR bronchopneumon*:ab,ti OR pleuropneumon*:ab,ti 234,837   
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4. ari:ab,ti OR urti:ab,ti OR lrti:ab,ti                     6,126   
3. (respiratory NEAR/2 (infect* OR inflam*)):ab,ti   59,010   
2. 'respiratory tract inflammation'/exp 485,474 
1. 'respiratory tract infection'/exp 409,603   
 
Cochrane library:  Date of search: 17/05/18  
ID Search Hits 
1. MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] this term only 3395 
2. (copd or coad or "chronic obstructive pulmonary disease" or "chronic obstruc-
tive airway disease" or "chronic obstructive airways disease" or "chronic ob-
structive lung disease"):ti,ab,kw  (Word variations have been searched) 
14023 
3. #1 or #2 14211 
4. "severe acute respiratory syndrome" or sars 141 
5. croup 210 
6. inﬂuenza* or ﬂu or ili 2283 
7. common cold* or coryza 2160 
8. sinusit* or rhinosinusit* or nasosinusit* 3035 
9. nasopharyngit* or rhinopharyngit* 2942 
10. pharyngit* or laryngit* or tonsillit* or sore throat* or cough*   13359 
11. bronchit* or bronchiolit* 4962 
12. otitis media or aom 2708 
13. MeSH descriptor: [Otitis Media] this term only 714 
14. pneumon* or bronchopneumon* or pleuropneumon* 15364 
15. ari or urti or lrti 6655 
16. MeSH descriptor: [Respiratory Tract Infections] explode all trees 11801 
17. #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or 
#15 or #16 
57737 
18. MeSH descriptor: [C-Reactive Protein] this term only 4259 
19. "c reactive protein" or "c-reactive protein" or "C-reactive protein" or CRP 14874 
20. #18 or #19 14874 
21. "Diagnostic test accuracy" or "diagnostic accuracy" or dta 10166 
22. MeSH descriptor: [Sensitivity and Specificity] this term only 12095 
23. predict* or diagnose* or diagnosi* or diagnosti* or accura* 237612 
24. #21 or #22 or #23 240077 
25. #24 and #20 and #17 680 
 
CINAHL ( via EBSCOhost):  Date of search: 17/5/18 
No.  Query Results 
S28 s27 and s22 and s19 611 
S27 s23 or s24 or s26 1,077,841 
S26 (MH "Sensitivity and Specificity") 70,314 
S25 "predict* or diagnose* or diagnosi* or diagnosti* or accura*" 0 
S24 predict* or diagnose* or diagnosi* or diagnosti* or accura*" 1,056,784 
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S23 "Diagnostic test accuracy" or "diagnostic accuracy" or dta" 8,815 
S22 s20 or s21 18,378 
S21 TI (“c reactive protein” or c-reactive protein or C-reactive protein) OR AB (“c 
reactive protein” or c-reactive protein or C-reactive protein) 
12,993 
S20 (MH “C-Reactive Protein”) 12,758 
S19 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or 
S13 or S14 or S15 or S16 or S17 
115,467 
S18 TI ((acute or exacerbation) N3 (copd or coad or chronic obstructive pulmonary 
disease or chronic obstructive airway* disease or chronic obstructive lung 
disease)) OR AB ((acute or exacerbation) N3 (copd or coad or chronic ob-
structive pulmonary disease or chronic obstructive airway* disease or chronic 
obstructive lung disease)) 
1,980 
S17 (MH “Pulmonary Disease, Chronic Obstructive+”) 15,507 
S16 TI croup OR AB croup 384 
S15 TI (severe acute respiratory syndrome or sars) OR AB (severe acute respira-
tory syndrome or sars) 
1,412 
S14 TI (severe acute respiratory syndrome or sars) OR AB (severe acute respira-
tory syndrome or sars) 
2,550 
S13 TI (inﬂuenza* or ﬂu or ili) OR AB (inﬂuenza* or ﬂu or ili) 21,505 
S12 TI ((acute or viral or bacter*) N2 rhinit*) OR AB ((acute or viral or bacter*) N2 
rhinit*) 
50 
S11 TI (common cold* or coryza) OR AB (common cold* or coryza) 997 
S10 TI (sinusit* or rhinosinusit* or nasosinusit*) OR AB (sinusit* or rhinosinusit* or 
nasosinusit*) 
3,663 
S9 TI (nasopharyngit* or rhinopharyngit*) OR AB (nasopharyngit* or rhi-
nopharyngit*) 
220 
S8 TI (pharyngit* or laryngit* or tonsillit* or sore throat* or cough*) OR AB (phar-
yngit* or laryngit* or tonsillit* or sore throat* or cough*) 
11,162 
S7 TI (otitis media or aom) OR AB (otitis media or aom) 3,582 
S6 (MH “Otitis Media+”) 4,416 
S5 TI (bronchit* or bronchiolit*) OR AB (bronchit* or bronchiolit*) 3,781 
S4 TI (pneumon* or bronchopneumon* or pleuropneumon*) OR AB (pneumon* or 
bronchopneumon* or pleuropneumon) 
25,341 
S3 TI (ari or arti or urti or lrti) OR AB (ari or arti or urti or lrti) 1,310 
S2 TI (respiratory N3 (inﬂam* or infect* )) OR AB (respiratory N3 (inﬂam* or in-
fect*)) 
8,504 
S1 (MH “Respiratory Tract Infections+” 62,810 
 
Search strategy for systematic review 3  
 
 
Embase:  Date of search: 14/06/2018 
No. Query 
#23 AND ‘HUMAN’ 
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#22 #10 AND #14 AND #21 
#21 #15 OR #16 OR #17 OR #18 OR #19 OR #20 
#20 ‘bedside’ 
#19 ‘near patient’ 
#18 ‘point of care system’ 
#17 ‘point of care testing’ 
#16 POC 
#15 POCT 
#14 #11 OR #12 OR #13 
#13 ‘CRP’ 
#12 ‘c-reactive protein’ 
#11 ‘c reactive protein’ 
#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
#9 ‘Quality control’ 
#8 ‘User friendliness’ 
#7 ‘Ease of use’ 
#6 Variability 
#5 ‘coefficient of variation’ 
#4 Agreement 
#3 Accuracy 
#2 Precision 
#1 ‘analytical performance’ 
 
 
EBSCO Host (Cinhal):  Date of search: 14/06/2018 
No. Query 
#22 #10 AND #14 AND #21 
#21 #15 OR #16 OR #17 OR #18 OR #19 OR #20 
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#20 ‘bedside’ 
#19 ‘near patient’ 
#18 ‘point of care system’ 
#17 ‘point of care testing’ 
#16 POC 
#15 POCT 
#14 #11 OR #12 OR #13 
#13 ‘CRP’ 
#12 ‘c-reactive protein’ 
#11 ‘c reactive protein’ 
#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
#9 ‘Quality control’ 
#8 ‘User friendliness’ 
#7 ‘Ease of use’ 
#6 Variability 
#5 ‘coefficient of variation’ 
#4 Agreement 
#3 Accuracy 
#2 Precision 
#1 ‘analytical performance’ 
 
 
PubMed:  Date of search: 14/06/2018 
No. Query 
#22 #10 AND #14 AND #21 
#21 #15 OR #16 OR #17 OR #18 OR #19 OR #20 
#20 ‘bedside’ 
#19 ‘near patient’ 
#18 ‘point of care system’ 
#17 ‘point of care testing’ 
#16 POC 
#15 POCT 
#14 #11 OR #12 OR #13 
#13 ‘CRP’ 
#12 ‘c-reactive protein’ 
#11 ‘c reactive protein’ 
#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
#9 ‘Quality control’ 
#8 ‘User friendliness’ 
#7 ‘Ease of use’ 
#6 Variability 
#5 ‘coefficient of variation’ 
#4 Agreement 
#3 Accuracy 
#2 Precision 
#1 ‘analytical performance’ 
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Cochrane Library: Date of search: 14/06/2018 
No.    Query 
#22 #10 AND #14 AND #21 
#21 #15 OR #16 OR #17 OR #18 OR #19 OR #20 
#20 ‘bedside’ 
#19 ‘near patient’ 
#18 ‘point of care system’ 
#17 ‘point of care testing’ 
#16 POC 
#15 POCT 
#14 #11 OR #12 OR #13 
#13 ‘CRP’ 
#12 ‘c-reactive protein’ 
#11 ‘c reactive protein’ 
#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
#9 ‘Quality control’ 
#8 ‘User friendliness’ 
#7 ‘Ease of use’ 
#6 Variability 
#5 ‘coefficient of variation’ 
#4 Agreement 
#3 Accuracy 
#2 Precision 
#1 ‘analytical performance’  
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Table A1: Studies excluded at full-text review for systematic review 1 
Reason for exclusion* Study reference 
1 Inappropriate patient group De La Flor[186], Lemiengre 2018[187], Llor 2013[188], André 
2005[189], Takemura 2005,[190] Van den Bruel 2016[50], Takemura 
2005[191], Diar 2012[192], Verbakel 2016[193] 
2. Not set in primary care Chauhan 2013[194], Gotta 2017[195], Fagan 2001[143], Gonzales 
2011[144] 
3. Not CRP POCT Atlas 2005[196], Christakis 2001[197], Llor 2017[198], Llor 2011[199], 
Hopstaken 2003[13] 
4. No relevant comparator Lindstrom 2015[200], Muszyńska 2007[201], Neumark 2010[202], 
André 2004[203], Salwan 2015[204], Haldrup 2017[205], Schuijta 
2018[206], Engstrom[207], Boonman De Winter 2016[208], Steurer 
2011[209], Minnaard 2016[46], Yebyo 2016[210], Streit 2015[211], 
Hoffmann 2013[212], Davidson 2017[213] 
5. Inappropriate study design  Clinical laboratory news 2017[214], Schwartz 2017[215], Bjerrum 
2010[216], Oppong 2013[217], Cals 2011[218] 
6. Study protocol Altiner 2012[219] 
7. Conference abstract Keitel 2016[220], Andreeva 2012 [221], Moreno 2014[222], Harmans 
2015[223], Demir 2014[224], Herman 2015[225] 
8. Not original study The Netherlands Organisation for Health Research and Development 
2005[226], Andre 2008[227], Aabenhus 2016[228] 
9. Duplicate Cals 2009[123], Diederichersen 2001[125], Strykowski 2015[126], 
Bjerrum 2005[122] 
10. Cannot extract outcome data Llor 2013[229], Rebnord 2016[230], Bjerrum 2011[231], Rebnord 
2017[232], Hughes 2016[53], Llor 2014,[233] Bjerrum 2006[234]  
*Studies may have been excluded for more than one reason. For studies with more than one reason for exclusion, the first 
reason identified is listed.  
 
Table A2: Studies excluded at full-text review for systematic review 2 
Reason for exclusion* Study reference 
1. Not set in primary care Almirall 2014[235], Chen 2006 [236], Elsammak 2006[237], Flanders 
2004[238], Gan 2017[239], Garcia Vazquez[240], Higdon 2017[241], 
Hu 2010[242], Isaacman 2002[243], Kang 2009[244], Kaur 2013[245], 
Kerttula 1987[246], McCarthy 1978[247], Melbye 1992[248], Peng 
2013[249], Poyrazoğlu 2003[250], Prat 2003[251], Principi 1986[252], 
Requejo 2003[253], Stolz 2006[254], Shapiro 2018[163], Self 2017 
2. Study irretrievable Babu 1989[255], Hu 2003[256], Khomerki 1966[257], Udovicki 
1980[258] 
3. Study outcomes not relevant Broekhuizen 2012[259]  
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to current systematic review 
4. Inappropriate study design Schaaf 2006[260], Searle-Barnes 2017[261], Tomas 2015[262] 
5 Abstract only Rautakorpi 2008[263] 
6. Duplicate Hopstaken 2004[264] 
7. Inappropriate patient popula-
tion 
Bielsa 2014[265] 
8. Data irretrievable Young 2003 
*Studies may have been excluded for more than one reason. For studies with more than one reason for exclusion,only one 
reason is listed. 
 
Table A3: Studies excluded at full-text review for systematic review 3 
Reason for exclusion* Study reference 
1. Inappropriate patient group Davis and Bigelow 2001[266], Grisales et al 2016[267],Inaba et al 
2015[268],Inaba et al 2016 [269] 
2. No outcome of interest Albersen et al 2013[270], Albersen et al 2014[271], Bustinduy et al 
2017[272], Demir et al 2014[224], Hopstaken et al 2012[273], Kotani 
et al 2014[274], Shapiro et al 2018[163] 
3. Inappropriate study design  Minnaard et al 2015[11], Rogers and Bayston 1991[275] 
4. Inappropriate setting Esposito et al 2005[276],Fernandes et al 2016 [277], Hernandez-Bou 
et al 2017[278], Papaevangelou et al 2006[279] 
5. Conference abstract Hofmans et al 2015[280], Kratochvila and Budina 2013[281], Min-
naard et al 2015[282], Ono et al 2010[283], Scwanzar et al 2013[284], 
Van Aelst et a 2015al[285],Van Aelst et al 2015b [286], Venkatesh et 
al 2017[287] 
6. No sufficient translation Rim et al 2016[167] 
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DESCRIPTION OF THE EVIDENCE USED  
Table A4:  Acute respiratory tract infections (RTIs) – definition and symptoms of conditions, burden of disease and natural course in the individual 
 patient [288, 289] 
Type of RTI Definition  Symptoms and burden of disease Natural course of illness 
Upper Respiratory Tract Infections 
Common cold 
 
 
The common cold is a viral infectious disease of the upper 
respiratory tract that is marked by inflammation of the mucous 
membranes of the nose, throat, eyes, and eustachian tubes 
and by a watery then purulent discharge and is caused by any 
of several viruses (such as a rhinovirus or an adenovirus). The 
condition is associated with more than 200 virus subtypes. 
The condition is rarely characterised by a discrete set of spe-
cific symptoms, with the illness varying according to individual 
and causative pathogen. Occasionally, there is spread to the 
lower respiratory tract. 
Symptoms include: blocked or runny nose; sore throat; 
headaches; muscle aches; coughs; sneezing; a raised 
temperature; pressure in ears and face; loss of taste and 
smell; malaise. 
 
Most of the population experience at least one episode per 
year; these are usually self-limiting illnesses and resolve 
within a few days. 
One and a half weeks[93] 
Acute sore 
throat/pharyn
gitis 
 
 
Pharyngitis is inflammation of the pharynx, also known as a 
sore throat, and can be caused by viral or bacterial illnesses. 
 
 
Symptoms include: swollen tonsils; enlarged and tender 
lymph nodes (glands) in the neck; a painful, tender feeling 
at the back of the throat; discomfort when swallowing. 
82% of cases resolve in 7 days, and pain is only reduced 
by 16 hours[290]. 
One week[93] 
 
 
Acute tonsilli-
tis 
 
 
Tonsillitis is inflammation of the tonsils. The main symptom is 
a sore throat, and it can be caused by viral or bacterial illness-
es – although most cases are viral. The viruses that cause 
tonsillitis include the flu virus, parainfluenza virus (which also 
causes laryngitis and croup), adenovirus, enterovirus and 
rhinovirus. Bacterial tonsillitis may be caused by a number of 
different bacteria, but is usually caused by group 
A streptococcus bacteria. 
Symptoms include: red and swollen tonsils; pain when 
swallowing; high temperature (fever) over 38°C (100.4°F); 
coughing; headache; tiredness; pain in ears or neck; white 
pus-filled spots on the tonsils; and swollen lymph nodes 
(glands) in the neck. 
 
Illness comes on suddenly and gets worse during the first 
3 days. Most cases are viral and resolve within a few days. 
One week[93] 
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Type of RTI Definition  Symptoms and burden of disease Natural course of illness 
Acute laryngi-
tis 
 
 
Laryngitis refers to inflammation of the larynx. This can lead 
to oedema of the true vocal folds, resulting in hoarseness. 
Laryngitis can be acute or chronic, infectious or non-infectious. 
Accompanying signs of infectious laryngitis include pain on 
swallowing foods or liquids, cough, fever, and respiratory dis-
tress. The most common variant is acute viral laryngitis, which 
is self-limiting and usually related to an upper respiratory infec-
tion such as the common cold. Bacterial laryngitis often 
caused by Haemophilus influenza, and can be life threatening. 
Other causes can include tuberculosis (TB), diphtheria, syphi-
lis, and fungi.  
Symptoms include: hoarse (croaky) voice; sometimes los-
ing the ability to speak; sore throat, cough, difficulty swal-
lowing, and fever. 
Most patients make a full recovery within three weeks 
without developing complications. 
 
One to two weeks  
Acute otitis 
media  
 
 
Acute otitis media (AOM) is defined as an infection of the 
middle-ear space and is a common complication of viral res-
piratory illnesses. It is associated with rapid onset of signs and 
symptoms (<48 hours) of inflammation, such as otalgia, fever, 
irritability, anorexia, vomiting, and otorrhoea. Otoscopic find-
ings include a yellow–red exudate behind the tympanic mem-
brane (TM).  
 
 
Symptoms include: severe earache (caused by the pres-
sure of mucous on the eardrum); a high temperature (fe-
ver) of 38°C (100.4°F) or above; flu-like symptoms in chil-
dren, such as vomiting and lethargy (a lack of energy); 
slight deafness.  
Most common in young children, with more than 75% of 
episodes occurring in children under 10 years of age. 
AOM resolves in 60% of cases in 24 hours without antibiot-
ics[290] . 
Four days[93] 
 
 
 
Acute rhi-
nosinusitis 
 
 
Acute sinusitis (also commonly known as acute rhinosinusi-
tis) is defined as symptomatic inflammation of the mucosal 
lining of the nasal cavity and paranasal sinuses for less than 4 
weeks. This swelling of the sinuses is usually caused by either 
a viral or a bacterial infection.  
 
 
Symptoms include: pain, swelling and tenderness around 
cheeks, eyes or forehead; a blocked nose; reduced sense 
of smell; green or yellow mucous from the nose; a sinus 
headache; a high temperature of 38C or above; toothache 
and/or bad breath. 
Most infections resolve in 14 days without treatment and 
antibiotics only offer marginal benefit after 7 days.[290]  
Two and a half weeks[93]  
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Type of RTI Definition  Symptoms and burden of disease Natural course of illness 
Lower Respiratory Tract Infections 
Acute bron-
chitis/cough 
 
 
An acute illness, occurring in a patient without chronic lung 
disease, with symptoms including cough, which may or may 
not be productive and associated with other symptoms or clini-
cal signs that suggest LRTI (sputum production, dyspnoea, 
wheeze or chest discomfort /pain) and no alternative explana-
tion (e.g. sinusitis or asthma). 
Symptoms include: Cough with sputum production, dysp-
noea, wheeze or chest discomfort/pain. 
Three weeks[93] 
Influenza  
 
 
An acute illness, usually with fever, together with the presence 
of one or more of headache, myalgia, cough or sore throat. 
 
 
The illness can be categorised into uncomplicated or com-
plicated influenza.[291]  
Uncomplicated influenza: Influenza presenting with fever, 
coryza, generalised symptoms (headache, malaise, myal-
gia, arthralgia) and sometimes gastrointestinal symptoms, 
but without any features of complicated influenza. Symp-
toms peak after two to three days and most patients begin 
to feel much better within five to eight days. 
Complicated influenza: Influenza requiring hospital ad-
mission and/or with symptoms and signs of lower respira-
tory tract infection (hypoxaemia, dyspnoea, lung infiltrate), 
central nervous system involvement and/or a significant 
exacerbation of an underlying medical condition. 
Immunocompromised patients and young children can 
experience prolonged durations of infection and/or greater 
viral burden, compared to other groups.  
Elderly patients may also develop pneumonia. While preg-
nant women are more likely to have complications if they 
become ill with influenza. 
One week (if uncomplicated) 
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Community-
acquired 
pneumonia 
(CAP) 
 
 
Suspected CAP  
An acute illness with cough and at least one of new focal chest 
signs, fever >4 days or dyspnoea/tachypnoea, and without 
other obvious cause.  
 
Definite CAP 
As above, but supported by chest radiograph findings of lung 
shadowing that is likely to be new. In the elderly, the presence 
of chest radiograph shadowing accompanied by acute clinical 
illness (unspecified) without other obvious cause.  
Symptoms include: cough (dry or with thick mucous 
that is yellow, green, brownish or blood-stained); difficul-
ty breathing; tachycardia; fever; feeling generally unwell; 
sweating and shivering; loss of appetite; chest pain. 
Every year between 0.5% and 1% of adults in the UK will 
have community-acquired pneumonia. It is diagnosed in 
5–12% of adults who present to GPs with symptoms of 
lower respiratory tract infection, and 22–42% of these 
are admitted to hospital, where the mortality rate is be-
tween 5% and 14%. Between 1.2% and 10% of adults 
admitted to hospital with community-acquired pneumonia 
are managed in an intensive care unit, and for these 
patients the risk of dying is more than 30%. More than 
half of pneumonia-related deaths occur in people older 
than 84 years.[42] 
  
After starting treatment for 
community-acquired pneumo-
nia, the symptoms of patients 
should steadily improve, alt-
hough the rate of improvement 
will vary with the severity of the 
pneumonia, and most people 
can expect that by:  
• 1 week: fever should have 
resolved; 
• 4 weeks: chest pain and 
sputum production should have 
substantially reduced; 
• 6 weeks: cough and breath-
lessness should have substan-
tially reduced; 
• 3 months: most symptoms 
should have resolved but fatigue 
may still be present; 
• 6 months: most people will 
feel back to normal.[42] 
Acute exac-
erbation of 
COPD 
(AECOPD) 
 
 
An event in the natural course of the disease (COPD) charac-
terised by a worsening of the patient’s baseline dyspnoea, 
cough and/or sputum beyond day-to-day variability sufficient to 
warrant a change in management. If chest radiograph shadow-
ing, consistent with infection, is present the patient is consid-
ered to have CAP.[58] 
On the day of onset, symptoms can increase sharply 
with symptoms of dyspnoea (64%), increased sputum 
volume (26%), sputum purulence (42%), colds (35%), 
wheeze (35%), sore throat (12%) and cough (20%).[87] 
Recovery of Peak Expiratory 
Flow (PEF) was achieved in only 
75.2% of exacerbations within 35 
days, and 7.1% of exacerbations 
had still not returned to baseline 
after 91 days.[87]  
Definitions extracted from: the 2011 European Respiratory Society (ERS) in collaboration with The European Society for Clinical Microbiology and Infectious Disease (ESCMID) Guidelines for the 
management of adult lower respiratory tract infections, the 2017 Public Health England Antibiotic Guidance for primary care on the management and treatment of common infections, 2017 Public 
Health England guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza HSE Health A-Z and other resources (NHS choices, HSE A-Z and BMJ best practice 
guidance). 
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Guidelines for diagnosis and management  
Table A5: Overview of guidelines 
Name of society/organisation issuing 
guidance 
Date 
of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation Level of 
evidence 
(A,B,C)/ class 
of 
recommendatio
n (I, IIa, IIb, III) 
Upper Respiratory Tract Infections  
Common cold 
[93]  
 
2008 UK A no antibiotic prescribing strategy or a delayed antibiotic prescribing strategy 
should be agreed for patients with the common cold. 
Offer all patients advice about the usual natural history of the illness and aver-
age total illness length of one and a half weeks. 
Advice about managing symptoms including fever (particularly analgesics and 
antipyretics).  
 
Acute sore throat/ pharyngitis /tonsillitis 
European Society for Clinical Micro-
biology and Infectious Diseases 
(ESCMID) guideline for acute sore 
throats[292] 
2012 Europe The Centor clinical scoring system can help to identify those patients who have 
a higher likelihood of group A streptococcal infection. However, its utility in 
children appears lower than in adults because of the different clinical 
presentation of sore throat in the first years of life. 
A-3 
 
  Throat culture is not necessary for routine diagnosis of acute sore throat to 
detect group A Streptococci. 
C-3 
  If rapid antigen testing (RAT) is performed, throat culture is not necessary after 
a negative RAT for the diagnosis of group A streptococci in both children and 
adults. 
B-2 
   In patients with high likelihood of streptococcal infections (e.g. 3–4 Centor 
criteria) physicians can consider the use of RATs. In patients with lower 
likelihood of streptococcal infections (e.g. 0–2 Centor criteria) there is no need 
to routinely use RATs. 
B-3 
   It is not necessary to routinely use biomarkers in the assessment of acute sore 
throat. 
Clinical scoring systems and rapid tests can be helpful in targeting antibiotic 
use. 
C-3 
 
B-2 
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Name of society/organisation issuing 
guidance 
Date 
of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation Level of 
evidence 
(A,B,C)/ class 
of 
recommendatio
n (I, IIa, IIb, III) 
   Either ibuprofen or paracetamol are recommended for relief of acute sore throat 
symptoms. 
A-1 
   Use of corticosteroids in conjunction with antibiotic therapy is not routinely 
recommended for treatment of sore throat. It can however be considered in 
adult patients with more severe presentations, e.g. 3–4 Centor criteria. 
A-1 
   Zinc gluconate is not recommended for use in sore throat. B-2 
   There is inconsistent evidence of herbal treatments and acupuncture as 
treatments for sore throat. 
C-1 to C-3 
   Sore throat should not be treated with antibiotics to prevent the development of 
rheumatic fever and acute glomerulonephritis in low-risk patients (e.g. patients 
with no previous history of rheumatic fever. 
A-1 
   The prevention of suppurative complications is not a specific indication for 
antibiotic therapy in sore throat. 
A-1 
   Clinicians do not need to treat most cases of acute sore throat to prevent 
quinsy, acute otitis media, cervical lymphadenitis, mastoiditis and acute 
sinusitis. 
A-3 
   Antibiotics should not be used in patients with less severe presentation of sore 
throat, e.g. 0–2 Centor criteria, to relieve symptoms. 
A-1 
   In patients with more severe presentations, e.g. 3–4 Centor criteria, physicians 
should consider discussion of the likely benefits with patients. Modest benefits 
of antibiotics, which have been observed in group A b-haemolytic 
Streptococcus-positive patients and patients with 3–4 Centor criteria, have to be 
weighed against side effects, the effect of antibiotics on the microbiota, 
increased antibacterial resistance, medicalization and costs. 
A-1 
   If antibiotics are indicated, penicillin V, twice or three times daily for 10 days, is 
recommended. 
There is not enough evidence that indicates shorter treatment length. 
A-1 
 
Finnish Medical Society Duodecim, 
the Finnish Association for Central 
Practice, the Finnish Otolaryngologi-
cal Society, Infectious Diseases Soci-
ety of Finland and the Clinical Micro-
biologists Society: Current care guide-
2012 Finland Sore throat (pharyngitis) is typically a viral infection. Patients should be informed 
that pharyngitis is usually a mild, self-healing disease. Throat swab is recom-
mended for adults with two or more symptoms: fever over 38°C, swollen sub-
mandibular lymph nodes, tonsillar exudate and no cough. Children under 15 
years of age with any of these symptoms should be tested. If antibiotic is indi-
cated, penicillin is the preferred choice, whereas first generation cephalosporins 
are recommended for those with penicillin allergy. Antibiotics can be started for 
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Name of society/organisation issuing 
guidance 
Date 
of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation Level of 
evidence 
(A,B,C)/ class 
of 
recommendatio
n (I, IIa, IIb, III) 
lines for sore throat  patients with high fever before culture results are available. Adequate pain med-
ication is important. 
http://www.kaypahoito.fi/web/english/guidelineabstracts/guideline?id=ccs
00095 
Diagnostics and non-surgical man-
agement of tonsillitis (2016)[107] 
 
2016 Germany Diagnosis 
To estimate the probability of tonsillitis caused by β-haemolytic Streptococci, a 
diagnostic scoring system according to Centor or McIsaac is suggested. If ther-
apy is considered, a positive score of ≥3 should lead to pharyngeal swab or 
rapid test or culture in order to identify β-haemolytic streptococci. Routinely per-
formed blood tests for acute tonsillitis are not indicated. After acute streptococ-
cal tonsillitis, there is no need to repeat a pharyngeal swab or any other routine 
blood tests, urine examinations or cardiological diagnostics such as ECG. The 
determination of the antistreptolysin O-titer (ASLO titer) and other antistrepto-
coccal antibody titers do not have any value in relation to acute tonsillitis with or 
without pharyngitis and should not be performed. 
Management 
First-line therapy of β-hemolytic streptococci consists of oral penicillin. Instead 
of phenoxymethylpenicillin–potassium (penicillin V potassium), also phe-
noxymethlpenicillin–benzathine with a clearly longer half-life can be used. Oral 
intake for 7 days of one of both the drugs is recommended. Alternative treat-
ment with oral cephalosporins (e.g. cefadroxil, cefalexin) is indicated only in 
cases of penicillin failure, frequent recurrences, and whenever a more reliable 
eradication of β-hemolytic streptococci is desirable. In cases of allergy or in-
compatibility of penicillin, cephalosporins or macrolides (e.g. Erythromycin-
estolate) are valuable alternatives.  
 
German Society of General Practice 
and Family Medicine guidelines for 
the management of sore throat [106] 
 
2011 Germany Management 
Routine antibiotic treatment of sore throat for the prevention of complications is 
currently not indicated. The effect of antibiotics on symptoms and duration of 
disease is, at best, moderate. It is more pronounced in patients with typical clin-
ical symptoms and signs of pharyngitis caused by group A Streptococci (GAS) 
and slightly more pronounced again in cases of additional positive throat swab 
for GAS. An algorithm for decision-making is proposed. Rapid testing for strep-
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guidance 
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tococcal antigen or a culture for GAS is only recommended if the result is likely 
to influence therapeutic decision-making. Patients with more severe illness and 
signs of GAS pharyngitis can be given antibiotic therapy for symptomatic relief. 
HAS guidelines for acute naso-
pharyngitis and strep throat in chil-
dren and adults 
2017 France No antibiotics in adults with: 
 an acute nasopharyngitis;  
 an acute strep throat with a McIsaac score < 2 or with a McIsaac score ≥ 2 
and a  negative rapid diagnostic test (RDT). 
In case of acute strep throat with a McIsaac score ≥ 2 and a positive RDT: 
amoxicillin, 2g per day for 6 days. https://www.has-
sante.fr/portail/upload/docs/application/pdf/2017-05/dir82/memo_sheet_-
_acute_nasopharyngitis_and_acute_strep_throat_in_adults.pdf 
No antibiotics in a child with: 
 an acute nasopharyngitis;  
 under the age of 3 years with an acute strep throat 
 ≥3 years with an acute strep throat with a negative RDT. 
In a child ≥3 years with an acute strep throat and a positive RDT amoxicillin, 
50mg/kg/days for 6 days.  
https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-
05/dir82/memo_sheet_-
_acute_nasopharyngitis_and_acute_strep_throat_in_children.pdf 
 
ISKRA guidelines on sore throat: di-
agnostic and therapeutic approach 
[104] 
 
2009 Croatia For streptococcal sore throat diagnostics, the Working Group recommends 
evaluation of clinical presentation according to Centor criteria and for patients 
with Centor score 0-1, antibiotic therapy is not recommended nor bacteriological 
testing, while for patients with Centor score 2-4 bacteriological testing is rec-
ommended (rapid test or culture) as well as antibiotic therapy in case of positive 
result.  
The drug of choice for the treatment of streptococcal tonsillopharyngitis is oral 
penicillin taken for ten days (penicillin V) or in case of poor patient compliance 
benzathine penicillin G can be administered parenterally in a single dose. Other 
antibiotics (macrolides, clindamycin, cephalosporins, co-amoxiclav) are adminis-
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tered only in case of hypersensitivity to penicillin or in recurrent infections.  
Tonsillectomy is a widely accepted surgical procedure that decreases the num-
ber of sore throats in children and should be performed only if indications for 
this procedure are established. Absolute indications include five or more strep-
tococcal infections per year, tonsillitis complications, permanent respiratory tract 
obstruction, obstructive sleep apnoea syndrome and suspected tonsillar malig-
nancy. Relative indications include chronic tonsillitis and occlusion disturbances. 
National Institute of Health Guide-
lines: Management of acute pharyngi-
tis in Children  
2012 Italy None of the available scoring systems are sufficiently accurate to identify group 
A β-hemolytic Streptococci (GABHS) pharyngitis in settings with low prevalence 
for rheumatic disease. RADT should be performed by trained personnel in every 
child with a history and signs/symptoms suggestive of GABHS pharyngitis. 
RADT is not recommended in children with a McIsaac score of 0 or 1 with ≥2 
signs/symptoms suggestive of viral infection. Backup culture in children with 
negative RADT result is not recommended. Culture test with antibiotic suscepti-
bility assay should be performed exclusively for epidemiologic purposes. Strep-
tococcal antibody titers are of no value in diagnosing acute pharyngitis.  
Antibiotic therapy is recommended in microbiologically documented GABHS 
pharyngitis. Because penicillin V is not available in Italy, amoxicillin (50 mg/kg/d 
in 2–3 doses orally) for 10 days is the first choice of treatment. In noncompliant 
cases, benzathine penicillin may be administered. Although not routinely rec-
ommended due to the high cost and wide spectrum of activity, a 5-day course 
with a second-generation cephalosporin may be used in noncompliant cases. 
Macrolides should be limited to children with demonstrated type I hypersensitivi-
ty to penicillin. Ibuprofen or paracetamol is recommended for relief of pain or 
fever associated with discomfort. Because the carrier state is not associated 
with increased risk of suppurative complications and risk of GABHS transmis-
sion to contacts is minimal, the carrier state should never be investigated and 
treated.  
 
NICE: Sore throat (acute): antimicro-
bial prescribing(2018)[93, 164]  
 
2018 
 
UK Use FeverPAIN or Centor criteria to identify people who are more likely to bene-
fit from an antibiotic  
People who are unlikely to benefit from an antibiotic (FeverPAIN score of 0 
or 1, or Centor score of 0, 1 or 2) : Do not offer an antibiotic prescription. 
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People who may be more likely to benefit from an antibiotic (FeverPAIN 
score of 2 or 3): Consider no antibiotic prescription or a back-up antibiotic pre-
scription taking account of: evidence that antibiotics make little difference to how 
long symptoms last (on average, they shorten symptoms by about 16 hours); 
evidence that most people feel better after 1 week, with or without antibiotics; 
the unlikely event of complications if antibiotics are withheld; possible adverse 
effects, particularly diarrhoea and nausea. 
When a back-up antibiotic prescription is given, give advice about: an antibiotic 
not being needed immediately; using the back-up prescription if symptoms do 
not start to improve within 3 to 5 days or if they worsen rapidly or significantly at 
any time; seeking medical help if symptoms worsen rapidly or significantly or the 
person becomes systemically very unwell.  
People who are most likely to benefit from an antibiotic (FeverPAIN 
score of 4 or 5, or Centor score of 3 or 4): Consider an immediate antibiotic 
prescription or a back-up antibiotic prescription with advice taking account of: 
the unlikely event of complications if antibiotics are withheld; possible adverse 
effects, particularly diarrhoea and nausea. 
People who are systemically very unwell, have symptoms and signs of a 
more serious illness or condition, or are at high-risk of complications: 
Offer an immediate antibiotic prescription with advice or further appropriate in-
vestigation and management. 
Refer people to hospital if they have acute sore throat associated with any of 
the following: a severe systemic infection; severe suppurative complications 
(such as quinsy [peri-tonsillar abscess] or cellulitis, parapharyngeal abscess or 
retropharyngeal abscess or Lemierre syndrome). 
 
Give advice about seeking medical help if symptoms worsen rapidly or signifi-
cantly, do not start to improve after 1 week, or the person becomes systemically 
very unwell. 
Self-help: All people with acute sore throat: Consider paracetamol for pain or 
fever, or if preferred and suitable, ibuprofen; advise about the adequate intake 
of fluids; explain that some adults may wish to try medicated lozenges contain-
ing either a local anaesthetic, a non-steroidal anti-inflammatory drug (NSAID) or 
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an antiseptic. However, they may only help to reduce pain by a small amount; 
be aware that no evidence was found on non-medicated lozenges, mouthwash-
es, or local anaesthetic mouth spray used on its own. 
Reassess at any time if symptoms worsen rapidly or significantly, taking ac-
count of: other possible diagnoses; any symptoms or signs suggesting a more 
serious illness or condition; previous antibiotic use, which may lead to resistant 
organisms. 
First line antibiotic treatment: phenoxymethylpenicillin (dose age-dependent) 
two or four times a day for 5 to 10 days. 
 
. 
Acute otitis media (AOM) 
Finnish Medical Society Duodecim, 
the Finnish association of otorhino-
laryngology and head and neck sur-
gery, the Finnish Paediatric Society, 
the Finnish Otolaryngological Society 
and the Finnish Association for Gen-
eral Practice: Current care guideline for 
acute otitis media 
2017 Finland The diagnosis of acute otitis media is based on the presence of middle-ear effu-
sion, signs of inflammation of the tympanic membrane, and signs and symptoms 
of an acute infection. Effective treatment of ear pain is crucial in the manage-
ment of the disease. Antibiotic treatment for 5–7 days with amoxicillin or amoxi-
cillin/clavulanate is recommended as a rule, because antibiotics shorten the time 
to resolution of illness, and no individually applicable criteria to guide antibiotic 
use are available. The follow-up of children with acute otitis media should be 
tailored individually.  
http://www.kaypahoito.fi/web/english/guidelineabstracts/guideline?id=ccs00071  
 
NICE Otitis media (acute: antimicrobi-
al prescribing) [93]  
https://www.nice.org.uk/guidance/ng91/e
vidence/evidence-review-pdf-
4787286589  
 
 
 
 
2018 
 
 
 
 
 
 
 
UK 
 
 
 
 
 
 
Patients should be given advice that: acute otitis media is a self-limiting infection 
that mainly affects children; acute otitis media can be caused by viruses and 
bacteria, and it is difficult to distinguish between these (both are often present at 
the same time); symptoms last for about 3 days, but can last for up to 1 week; 
most children and young people get better within 3 days without antibiotics. Of-
fer regular pain-relief at right dose, time; use maximum dose for severe pain. 
 
Consider no antibiotic prescription or a back-up antibiotic prescription, 
taking account of: evidence that antibiotics make little difference to symptoms 
(no improvement in pain at 24 hours, and after that the number of children im-
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proving is similar to the number with adverse effects); evidence that antibiotics 
make little difference to the development of common complications (such as 
short-term hearing loss [measured by tympanometry], perforated eardrum or 
recurrent infection); evidence that acute complications such as mastoiditis are 
rare with or without antibiotics; possible adverse effects of antibiotics, particular-
ly diarrhoea and nausea. 
 
Children and young people who may be more likely to benefit from antibi-
otics (those of any age with otorrhoea or those under 2 years with infection in 
both ears): Consider no antibiotic or a back-up antibiotic prescription with advice 
to commence the back-up prescription (if provided) or to seek medical help if 
symptoms worsen rapidly or significantly, do not start to improve after 3 days, or 
if becomes systemically very unwell) 
 
Children and young people who are systemically very unwell, have symp-
toms and signs of a more serious illness or condition, or are at high-risk 
of complications: Offer an immediate antibiotic prescription with advice or fur-
ther appropriate investigation and management. 
Refer children and young people to hospital if they have acute otitis media as-
sociated with: a severe systemic infection; acute complications, including mas-
toiditis, meningitis, intracranial abscess, sinus thrombosis or facial nerve paraly-
sis. 
First choice antibiotic (<18 years): Amoxicillin 3 times daily for 5 to 7 days. 
Antibiotic compared with placebo (children): 
Pain reduction at 2-3 days RR: 0.7, 95%CI: 0.58-0.86; NNT=24 [95%CI: 15-
70])), at 4-7 days (RR 076 [0.63-0.91], NNT= 16 [95% CI: 10-44].  
Abnormal tympanometry: RR 0.82, 95% CI 0.74 to 0.90; NNT 12 [95% CI 8 to 
21]; 
Tympanic membrane perforation: RR 0.37, 95% CI 0.18 to 0.76; NNT 33 [95% 
CI 20 to 100] 
NNT to prevent mastoiditis = 4,831 
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NNH (vomiting, diarrhoea, rash) =13 (95%CI: 5-19). 
HAS guidelines for purulent acute otitis 
media in children (> 3 months) and 
adults 
2017 France Adults: In a case of purulent acute otitis media confirmed by visualisation of the 
tympanic membranes: amoxicillin: 3 g/day for 5 days. If conjunctivitis-otitis syn-
drome (Haemophilus influenzae): amoxicillin-clavulanic acid, 3 g/day, for 5 days. 
https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-
05/dir82/memo_sheet_-_purulent_acute_otitis_media_in_adults.pdf  
Children: 
In case of congestive or seromucinous acute otitis media: no antibiotics 
If purulent acute otitis media: 
Children <2 years: amoxicillin 80-90mg/kg/day for 8-10 days. If conjunctivitis-
otitis syndrome (Haemophilus influenzae): amoxicillin-clavulanic acid, 
80mg/kg/day, for 8-10 days 
https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-
05/dir82/memo_sheet_-_purulent_acute_otitis_media_in_adults.pdf  
Children >2 years with mild symptoms: no antibiotics 
Children > 2 years with severe symptoms: 80-90mg/kg/day for 5days. If conjunc-
tivitis-otitis syndrome (Haemophilus influenzae): amoxicillin-clavulanic acid, 
80mg/kg/day, for 8-10 days 
https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-
05/dir82/memo_sheet_-
_purulent_acute_otitis_media_in_children_over_3_months.pdf  
 
 
Acute rhinosinusitis 
Current Care Guidelines/Finnish Med-
ical Society Duodecim: Current care 
guidelines for sinusitis 
2018 Finland Patients with common cold have often symptoms similar to sinusitis. Mild or 
moderate symptoms often resolve in time, but symptomatic treatment (e.g. anal-
gesics, decongestants) may be used. If the patient has severe pain (unilateral), 
purulent excretion in nose and/or pharynx, pain radiating to teeth or fever, bacte-
rial sinusitis should be suspected. Diagnosis is based on clinical findings. Symp-
tomatic treatment is recommended for patients with mild or moderate symptoms. 
Those with purulent excretion may benefit from antibiotics. First line treatment for 
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patients with chronic or recurrent sinusitis is conservative. 
http://www.kaypahoito.fi/web/english/guidelineabstracts/guideline?id=ccs00022  
HAS guidelines for sinusitis 2016 France In case of maxillary sinusitis: 
• acute purulent, uncomplicated with suspected bacterial infection with at least 2 
of the following 3 criteria: persistent or increased infraorbital sinus pain despite a 
prescribed symptomatic treatment for at least 48 hours; unilateral nature of pain 
and/or its increase when the head is tilted forward, and/or its pulsating nature 
and/or its peak in late afternoon and at night; increased rhinorrhoea and contin-
ued purulence. These signs are all the more significant because they are unilat-
eral; amoxicillin, 3 g/day, for 7 days. 
• unilateral maxillary sinusitis associated with an obvious dental infection of the 
upper dental arch: amoxicillin clavulanic acid, 3 g/day, for 7 days. 
In case of frontal, ethmoid, sphenoid sinusitis: amoxicillin-clavulanic acid, 3 g/day, 
for 7 days. 
 
AWMF Association of Scientific Medi-
cal Societies 
2017 Germany Not in English  
NHG Dutch College of General Practi-
tioners 
2014 Netherlands Not in English  
NICE sinusitis (acute) (2017)[98]  
 
2017 UK People presenting with symptoms for around 10 days or less 
Do not offer an antibiotic prescription. 
Give advice about: 
 the usual course of acute sinusitis (2 to 3 weeks) 
 an antibiotic not being needed 
 managing symptoms, including fever, with self-care (see the rec-
ommendations on self-care) 
 seeking medical help if symptoms worsen rapidly or significantly, 
do not improve after 3 weeks, or they become systemically very 
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unwell. 
Reassess if symptoms worsen rapidly or significantly, taking account of:  
 alternative diagnoses such as a dental infection 
 any symptoms or signs suggesting a more serious illness or condi-
tion. 
People presenting with symptoms for around 10 days or more with no im-
provement 
Consider prescribing a high-dose nasal corticosteroid
[1]
 for 14 days for adults 
and children aged 12 years and over, being aware that nasal corticosteroids:  
 may improve symptoms but are not likely to affect how long they last 
 could cause systemic effects, particularly in people already taking an-
other corticosteroid 
 may be difficult for people to use correctly. 
Consider no antibiotic prescription or a back-up antibiotic prescription (see the 
recommendations on choice of antibiotic), taking account of: 
 evidence that antibiotics make little difference to how long symptoms 
last, or the proportion of people with improved symptoms 
 withholding antibiotics is unlikely to lead to complications 
 possible adverse effects, particularly diarrhoea and nausea 
 factors that might make a bacterial cause more likely (see symptoms 
and signs). 
When a back-up antibiotic prescription is given, give verbal and written advice 
about: 
 managing symptoms, including fever, with self-care (see the recom-
mendations on self-care) 
 an antibiotic not being needed immediately 
 using the back-up prescription if symptoms do not improve within 7 days 
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or if they worsen rapidly or significantly at any time 
 seeking medical help if symptoms worsen rapidly or significantly despite 
taking the antibiotic, or the antibiotic has been stopped because it was not toler-
ated. 
People presenting at any time who are systemically very unwell, have symp-
toms and signs of a more serious illness or condition, or are at high risk of 
complications 
Offer an immediate antibiotic prescription (see the recommendations on choice 
of antibiotic) or further appropriate investigation and management in line with the 
NICE guideline on respiratory tract infections (self-limiting): prescribing antibiot-
ics. 
 Refer people to hospital if they have symptoms and signs of acute sinusitis as-
sociated with any of the following: 
 a severe systemic infection (see the NICE guideline on sepsis) 
 intraorbital or periorbital complications, including periorbital oedema or 
cellulitis, a displaced eyeball, double vision, ophthalmoplegia, or newly reduced 
visual acuity 
 intracranial complications, including swelling over the frontal bone, 
symptoms or signs of meningitis, severe frontal headache, or focal neurological 
signs. 
 
Lower Respiratory Tract Infections 
Acute bronchitis/cough 
The Dutch College of General Practi-
tioners (NHG) guideline for acute 
cough (2011)[111] 
 
2011 Netherlands The guideline covers the diagnosis, treatment, and education of patients with 
cough, pneumonia, bronchiolitis, croup, whooping cough, and Q-fever. Acute 
cough is defined as cough lasting less than 3 weeks at presentation. It is im-
portant to distinguish an uncomplicated respiratory tract infection from a compli-
cated respiratory tract infection that requires antibiotic treatment. In most cases, 
cough is caused by an uncomplicated respiratory tract infection (viral or bacteri-
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al) A patient with an uncomplicated respiratory tract infection has no risk factors 
for complications (age > 3 months and < 75 years, no relevant comorbidity), is 
not very ill, doesn't have signs of a complicated respiratory tract infection and 
has a fever < 7 days. The symptoms (cough) can last up to 4 weeks. There is no 
effective therapy. There are two groups of patients with a complicated respirato-
ry tract infection.  
1 Patients with a pneumonia (severely ill [tachypnea, tachycardia, hypotension 
or confusion] OR moderately ill and one-sided auscultatory findings, CRP > 100 
mg/l [a CRP of 20-100 mg/l doesn't exclude a pneumonia, [management de-
pends on presentation and risk-factors], infiltrate on chest X-ray or sick > 7 days 
with fever and a cough). These patients are prescribed an antibiotic.  
2 Patients with other risk factors for complications (age < 3 months or > 75 
years and/or relevant comorbidity [in children cardiac and pulmonary disease 
not being asthma, in adults congestive heart failure, severe chronic obstructive 
pulmonary disease, diabetes mellitus, neurological disorders, severe renal fail-
ure, compromised immunity]). In these patients, the decision to prescribe antibi-
otics is based on the presentation, supported, if necessary, by measurement of 
CRP.  
The measurement of C-reactive protein can help differentiate between pneumo-
nia and mild respiratory tract infection in moderately ill adults with general and/ 
or local symptoms. This recommendation does not apply to children. 
Specific management recommendations are made for croup, bronchiolitis and 
whooping cough. In cases of moderate croup, a single dose of corticosteroid 
(e.g. dexamethasone, 0.15 mg/kg, oral or intramuscular, or 2 mg of nebulized 
budesonide) should be given. Mild croup is self-limiting; children with severe 
croup should be referred to a paediatrician. Children with bronchiolitis and dysp-
noea should be monitored regularly during the first few days. Use of medication 
has not proven to be effective. In whooping cough antibiotics might be useful in 
preventing secondary cases only Additional investigations should be performed 
if there is suspicion of whooping cough in a patient from a family with unvac-
cinated or incomplete vaccinated children younger than 1 year or with a preg-
nant woman of more than 34 weeks gestation. 
The increasing resistance to doxycycline and macrolide antibiotics makes amox-
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icillin (for 5 days) the drug of first choice for pneumonia, with doxycycline as 
second choice. Doxycycline remains the first-choice drug if there is an increased 
risk of pneumonia caused by Coxiella burnetii (Q-fever) or Legionella. Because 
of lack of evidence on the effectiveness of noscapine and codeine and their 
known side effects these drugs are not recommended. 
NICE diagnosis and management of 
pneumonia in adults (2014)[42] 
 
2014 UK For people presenting with symptoms of lower respiratory tract infection in 
primary care, consider a point of care C-reactive protein test if after clinical as-
sessment a diagnosis of pneumonia has not been made and it is not clear 
whether antibiotics should be prescribed.  
Use the results of the C-reactive protein test to guide antibiotic prescribing in 
people without a clinical diagnosis of pneumonia as follows: 
1 Do not routinely offer antibiotic therapy if the C-reactive protein concentration 
is less than 20 mg/litre. 
2 Consider a delayed antibiotic prescription (a prescription for use at a later date 
if symptoms worsen) if the C-reactive protein concentration is between 
20 mg/litre and 100 mg/litre. 
3 Offer antibiotic therapy if the C-reactive protein concentration is greater than 
100 mg/litre. 
 
ESCMID/ERS guidelines for adult LRTI 
(2011)[58] 
 
2011 Europe Elderly LRTI patients with relevant co-morbidity should be followed-up 2 days 
after the first visit. All patients with LRTI should be advised to return to the doc-
tor if the symptoms take longer than 3 weeks to disappear. 
Antibiotic treatment should also be considered for patients with LRTI and seri-
ous co-morbidity such as: 
1 selected exacerbations of COPD (see section ‘acute exacerbation 
of COPD’); 
2 cardiac failure; 
3 insulin-dependent diabetes mellitus; or 
4 a serious neurological disorder (stroke, etc.). 
Cough suppressants, expectorants, mucolytics, antihistamines, inhaled cortico-
steroids and bronchodilators should not be prescribed in acute LRTI in primary 
 
 
 
 
 
 
 
 
 
 C3 
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care. 
Finnish Medical Society Duodecim, 
the Finnish Respiratory Society, Infec-
tious Diseases Society of Finland and 
the Finnish Association for General 
Practice: Current care guidelines for 
acute lower respiratory tract infection 
in adults 
2015 Finland Adults: 
Pneumonia is recognised in patients suffering from acute cough or deteriorated 
general condition. Patients with acute cough without pneumonia-related symp-
toms or clinical findings do not benefit from antimicrobial treatment. Those with 
suspected or confirmed pneumonia are treated with antibiotics, amoxicillin being 
the first choice. Most patients with pneumonia can be treated at home. Those 
with severe symptoms are referred to hospital. Patients are always encouraged 
to contact his/her physician if the symptoms worsen or do not ameliorate within 
2–3 days. Patients aged 50 years or older and smokers are controlled by thorac-
ic radiography in 6–8 weeks. 
http://www.kaypahoito.fi/web/english/guidelineabstracts/guideline?id=ccs00108 
 
 
Finnish Medical Society Duodecim, 
the Finnish Society of Pediatrics and 
the Finnish Society of General Medi-
cine: Current care guidelines for low-
er respiratory tract infections in chil-
dren 
2014 Finland Children: 
All respiratory viruses are capable of causing lower respiratory tract infections. 
Active testing of influenza viruses during influenza epidemics is recommended. 
Antitussive medications are ineffective and should not be used. Croup present-
ing with inspiratory stridor is recommended to be treated with oral corticoster-
oids and inhaled racemic adrenalin. Corticosteroids and inhaled racemic 
adrenalin are ineffective for the treatment of bronchiolitis. Inhaled salbutamol 
administered by a spacer (with a mask) is recommended for wheezy bronchitis. 
Amoxicillin is recommended for treating pneumonia at home and intravenous 
penicillin in hospital (combined with macrolide if mycoplasma is suspected). 
Pertussis is treated with azithromycin or clarithromycin. 
 
Community acquired pneumonia 
ESCMID/ERS guidelines for adult LRTI 
(2011)[58] 
 
2011 Europe To differentiate between pneumonia and other respiratory tract infections: 
A patient should be suspected of having pneumonia when one of the following 
signs and symptoms are present: new focal chest signs, dyspnoea, tachypnoea, 
pulse rate >100 or fever >4 days. In patients with a suspected pneumonia a test 
for serum-level of C-reactive protein (CRP) can be done. A level of CRP <20mg/L 
at presentation, with symptoms for >24 h, makes the presence of pneumonia 
B-1 
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highly unlikely; a level of >100 mg/L makes pneumonia likely. In case of persisting 
doubt after CRP testing, a chest X-ray should be considered to confirm or reject 
the diagnosis.  
  Should the primary care physician test for a possible microbiological aetiology of 
LRTI? 
Microbiological tests such as cultures and gram stains are not recommended  
 
 
B-1 
  Biomarkers to assess the presence of a bacterial pathogen are not recommended 
in primary care 
A-1 
   Patients with an elevated risk of complications should be monitored carefully and 
referral should be considered. In patients over 65 years of age the following 
characteristics are associated with a complicated course: presence of COPD, 
diabetes or heart failure, previous hospitalization in the past year, taking oral 
glucosteroids, antibiotic use in the previous month, general malaise, absence of 
upper respiratory symptoms, confusion/diminished consciousness, pulse >100, 
temperature >38, respiratory rate >30, blood pressure <90/60, and when the 
primary care physician diagnoses pneumonia. 
A-3 
   In patients under 65 the working group thinks that diabetes, a diagnosis of pneu-
monia and possibly also asthma are risk factors for complications. For all age 
groups, serious conditions such as active malignant disease, liver and renal 
disease and other disorders that are relatively rare in primary care but affect 
immunocompetence, do also increase risk of complications. 
C-3 
   Cough suppressants, expectorants, mucolytics, antihistamines, inhaled cortico-
steroids and bronchodilators should not be prescribed in acute LRTI in primary 
care. 
A-1 
   Antibiotic treatment should be prescribed in patients with suspected or definite 
pneumonia. 
C-1 
   Antibiotic treatment should be considered for patients with LRTI and serious 
comorbidity such as: selected exacerbations of COPD; (see below) 2 cardiac 
failure; 3 insulin-dependent diabetes mellitus; 4 a serious neurological disorder 
(stroke etc.) . 
C-3 
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   An antibiotic should be given in exacerbations of COPD in patients with all three 
of the following symptoms: increased dyspnoea, sputum volume and sputum 
purulence. In addition, antibiotics should be considered for exacerbations in 
patients with severe COPD. 
C-1 
   Amoxicillin or tetracycline should be used as the antibiotic of first choice based 
on least chance of harm and wide experience in clinical practice. In the case of 
hypersensitivity, a tetracycline or macrolide such as azithromycin, clarithromy-
cin, erythromycin or roxithromycin is a good alternative in countries with low 
pneumococcal macrolide resistance. National/local resistance rates should be 
considered when choosing a particular antibiotic. When there are clinically rele-
vant bacterial resistance rates against all first choice agents, treatment with 
levofloxacin or moxifloxacin may be considered. 
C-1 
   The empirical use of antiviral treatment in patients suspected of having influenza 
is usually not recommended. 
B-1 
   Only in high-risk patients who have typical influenza symptoms (fever, muscle 
ache, general malaise and respiratory tract infection), for <2 days and during a 
known influenza epidemic, can antiviral treatment be considered 
A-1 
   A patient should be advised to return if the symptoms take longer than 3 weeks 
to disappear’. ‘Clinical effect of antibiotic treatment should be expected within 3 
days and patients should be instructed to contact their doctor if this effect is not 
noticeable. Seriously ill patients, meaning those with suspected pneumonia and 
elderly with relevant co-morbidity, should be followed-up 2 days after the first 
visit’. ‘All patients or persons in their environment should be advised to contact 
their doctor again if fever exceeds 4 days, dyspnoea gets worse, patients stop 
drinking or consciousness is decreasing. 
C-3 
   In the following categories of patients, referral to hospital should be considered. 
1 Severely ill patients with suspected pneumonia (the following signs and symp-
toms are especially relevant here: tachypnoea, tachycardia, hypotension and 
confusion). 2 Patients with pneumonia who fail to respond to antibiotic treat-
ment. 3 Elderly patients with pneumonia and elevated risk of complications, 
notably those with relevant co-morbidity (diabetes, heart failure, moderate and 
C-3 
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severe COPD, liver disease, renal disease or malignant disease). 4 Patients 
suspected of pulmonary embolism. 5 Patients suspected of malignant disease of 
the lung. 
NICE diagnosis and management of 
pneumonia in adults (2014)[42]  
 
2014 UK Management 
When a clinical diagnosis of community-acquired pneumonia is made in primary 
care, determine whether patients are at low, intermediate or high risk of death 
using the CRB65 score. The CRB65 score assesses the mortality risk, and 
guides place of care and use of antibiotics. Each CRB65 parameter scores one: 
Confusion (AMT<8 or new disorientation in person, place or time); Respiratory 
rate >30/min; BP systolic <90, or diastolic <60; age >65.  
Use clinical judgement in conjunction with the CRB65 score to inform decisions 
about whether patients need hospital assessment as follows: 
Stratify patients presenting with community-acquired pneumonia into those with 
low-, moderate- or high-severity disease. The grade of severity will usually cor-
respond to the risk of death. 
Score 0: low risk, consider home-based care; 1-2: intermediate risk, consider 
hospital assessment; 3-4: high risk, urgent hospital admission. 
Treatment 
Put in place processes to allow diagnosis (including X-rays) and treatment of 
community-acquired pneumonia within 4 hours of presentation to hospital. 
Offer antibiotic therapy as soon as possible after diagnosis, and certainly within 
4 hours to all patients with community-acquired pneumonia who are admitted 
to hospital. 
 Low-severity CAP: 
Offer a 5-day course of a single antibiotic to patients with low-severity 
community-acquired pneumonia. 
Consider amoxicillin in preference to a macrolide or a tetracycline for patients 
with low-severity community-acquired pneumonia. Consider a macrolide or a 
tetracycline for patients who are allergic to penicillin. 
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Consider extending the course of the antibiotic for longer than 5 days as a 
possible management strategy for patients with low-severity 
community-acquired pneumonia whose symptoms do not improve as expected 
after 3 days. 
Explain to patients with low-severity community-acquired pneumonia treated 
in the community, and when appropriate their families or carers, that they 
should seek further medical advice if their symptoms do not begin to improve 
within 3 days of starting the antibiotic, or earlier if their symptoms are 
worsening. 
Do not routinely offer patients with low-severity community-acquired 
pneumonia: a fluoroquinolone or dual antibiotic therapy. 
Moderate and high severity CAP:  
Consider a 7- to 10-day course of antibiotic therapy for patients with moderate 
or high-severity community-acquired pneumonia. 
Consider dual antibiotic therapy with amoxicillin and a macrolide for patients 
with moderate-severity community-acquired pneumonia. 
Consider dual antibiotic therapy with a beta-lactamase stable beta-lactam and 
a macrolide for patients with high-severity community-acquired pneumonia. 
 
Give safety-net advice and likely duration of different symptoms, e.g. cough 
present for up to 6 weeks. 
 
Hospital-acquired infections can be caused by highly resistant pathogens that 
need treatment with extended-spectrum antibiotics (for example, extended-
spectrum penicillins, third-generation cephalosporins, aminoglycosides, car-
bapenems, linezolid, vancomycin, or teicoplanin), as recommended by British 
Society of Antimicrobial Chemotherapy guidance. 
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Name of society/organisation issuing 
guidance 
Date 
of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation Level of 
evidence 
(A,B,C)/ class 
of 
recommendatio
n (I, IIa, IIb, III) 
Influenza 
ESCMID/ERS guidelines for adult LRTI 
(2011)[58] 
 
2011 Europe The empirical use of antiviral treatment in patients suspected of having influenza 
is usually not recommended.  
 
Only in high-risk patients who have typical influenza symptoms (fever, muscle 
ache, general malaise and respiratory tract infection), for <2 days and during a 
known influenza epidemic, can antiviral treatment can be considered. 
 
B-1 
 
 
A-1 
 
National Institutes for Health (Italy) 
guidelines for the management of 
influenza in children [294] 
2002 Italy Management 
Rapid diagnostic tests are not recommended due to insufficient sensitivity and 
specificity. Etiological treatment with neuraminidase inhibitors or other antiviral 
agents is not recommended. Symptomatic treatment should be based on acet-
aminophen or ibuprofen. Antibiotics are not recommended unless fever persists 
for more than 7 days and signs of lower respiratory tract infection are present. 
Admission to hospital should be limited to cases with pre-existing risk conditions, 
young infants with bronchiolitis, cases with respiratory distress and oxygen de-
saturation, or cases where home management is difficult due to social reasons. 
 
Public Health England (2017)  
Management and treatment of com-
mon infections (Antibiotic guidance 
for primary care: For consultation and 
local adaptation) 
 
With reference to: NICE influenza 
prophylaxis (2008)[73] and treatment 
(2009)[295]  
 
2017 
 
 
 
 
 
2008/
9 
England 
 
 
 
 
 
UK 
At risk: pregnant (including up to two weeks post-partum); children under six 
months; adults 65 years or older; chronic respiratory disease (including COPD 
and asthma); significant cardiovascular disease (not hypertension); severe im-
munosuppression; diabetes mellitus; chronic neurological, renal or liver disease; 
morbid obesity (BMI>40). 
Annual vaccination is essential for all those “at risk” of influenza. Antivirals 
are not recommended for healthy adults.  
Treat “at risk” patients with five days oseltamivir 75mg BD, when influenza is 
circulating in the community, and ideally within 48 hours of onset (36 hours for 
zanamivir treatment in children), or in a care home where influenza is likely. See 
PHE Influenza guidance for the treatment of patients under 13 years of age. 
At risk: In severe immunosuppression, or oseltamivir resistance, use zanamivir 
10mg BD (two inhalations by diskhaler for up to 10 days) and seek advice.  
 
Abbreviations:  
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Evidence tables of individual studies included for clinical effectiveness and safety 
 
Table A6: Characteristics of included studies for effectiveness and safety of using C reactive protein POCT to guide antibiotic prescribing in 
patients with acute RTIs in primary care settings (Systematic Review 1) 
Author 
(Year) 
Country  Study 
design  
Number 
of 
participa
nts 
Lengt
h of 
follow
-up 
Gender Inclusion criteria Exclusion  
criteria 
Funding 
source 
Non 
responders/ 
loss to 
follow-up 
Device 
type 
Randomised controlled trials (cluster and individually randomised) 
Andreeva 
2014 
Russia RCT clus-
ter 
179 2 weeks 72% 
female in 
CRP arm 
and 74% 
female in 
Usual 
care 
group. 
Adult patients (≥18 
years). Patients with 
acute cough/LRTI (includ-
ing acute bronchitis, 
pneumonia, and infec-
tious exacerbations of 
COPD or asthma) were 
included. An illness of 
less than 28 days dura-
tion, first consultation for 
the illness episode, being 
seen in a physician’s 
office, and written con-
sent to participate. 
Exclusion criteria 
were an inability 
to fill out study 
documentation, 
being previously 
included in the 
study, immuno-
compromised 
status (HIV pa-
tients, immuno-
suppressive 
treatment), and 
ongoing treatment 
with oral cortico-
steroids. 
None stated 
but authors 
declared no 
competing 
interests 
99 out of 101 
in CRP group 
completed 
follow-up. 77 
out of 78 in 
usual group 
completed 
follow-up. 20 
patients ex-
cluded from 
analysis as 2 
GPs not com-
pleting forms 
Afinion™ 
test sys-
tem (Axis 
Shield) 
Cals 
2009 
Nether-
lands 
RCT clus-
ter 
431 pa-
tients, 40 
GPs from 
20 practic-
es 
28 days CRP 
group 
59% 
female; 
no CRP 
test arm 
64% 
female. 
Patients were eligible if 
they had a suspected 
lower respiratory tract 
infection with a cough 
lasting less than four 
weeks together with one 
focal and one systemic 
symptom 
(from protocol) 
Immediate hospi-
talisation, previ-
ous hospitalisa-
tion within last 6 
weeks, previous 
participation in the 
study, current or 
within past 2 
weeks antibiotic 
use, insufficient 
understanding of 
Netherlands 
Organisation 
for Health Re-
search and 
Development 
(grant 945-
04010) 
90% complet-
ed 
Ny-
coCard™ 
II reader 
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Dutch language 
Cals 
2010 
Nether-
lands 
RCT 258 28 days CRP 
group 
68.2% 
female, 
control 
group 
70.1% 
female. 
Adult ( ≥18+ years) pre-
senting with current epi-
sode of 1) LRTI or 2) 
rhinosinusitis. 1) For 
LRTI, cough duration <4 
weeks with at least 1 
focal sign and 1 systemic 
sign or symptom. 2) For 
rhinosinusitis, duration <4 
weeks with at least 2 
symptoms or signs. 
1. Immediate 
requirement of 
admission to a 
hospital, 2. No 
understanding of 
the Dutch lan-
guage, 3. Previ-
ous participation 
in the study, 4. 
Antibiotic use or 
hospitalisation in 
the past 2 weeks, 
5. Immunocom-
promised status. 
Orion Diagnos-
tica. Cals sup-
ported by grant 
of the Nether-
lands Organi-
zation for 
Health Re-
search and 
Development. 
100% for 
antibiotic 
follow-up data. 
91% (CRP 
arm) and 97% 
(control arm) 
for patient 
reported out-
comes. 
QuikRead
®
 
CRP ana-
lyser (Ori-
on Diag-
nostica) 
Diederich
sen 2000 
Denmark RCT 812 7 days 57% 
female 
Patients: Children and 
adults. Patients who con-
sulted their GP during 
normal working hours 
because of respiratory 
infections, and who be-
longed to the National 
Health Insurance Group 
1, were eligible for partic-
ipation. Practices: All 
GP's in single handed 
practices in the County of 
Fenen 
Patients: Patients 
who had previ-
ously been seen 
by a GP as a 
result of the infec-
tion in question, 
patients who had 
a Streptococcus 
test carried out, 
and patients 
known to have 
chronic inflamma-
tory disease were 
excluded Practic-
es: GP's already 
using the CRP 
test 
NR 792 (98%) 
follow-up 
Ny-
coCard™ 
reader 
Do 
2016 
Vietnam RCT 2,037 14 days 60% (of 
2036) 
female 
Children and adults aged 
1-65 years with at least 
one focal and one sys-
temic symptom lasting for 
less than 2 weeks for a 
non-severe acute respira-
tory tract infection. 
Patients with 
severe acute 
respiratory tract 
infection were 
excluded. Pa-
tients were also 
excluded if al-
ready taking anti-
Wellcome 
Trust, UK, and 
Global Antibi-
otic Resistance 
Partnership, 
USA. Alere 
Technologies 
provided rea-
Out of 1019 in 
usual care 
arm (139 
missed 14 day 
follow-up). Out 
of 1017 in the 
CRP POCT 
arm(123 
Ny-
coCard™ 
analyser 
used with 
Ny-
coCard™ 
II reader 
(Alere 
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biotics, convul-
sions, confusion, 
chronic disease 
e.g. Liver disease, 
cancer. No ac-
cess to a tele-
phone, not able to 
come for follow-
up visit. 
gents missed 14 
days follow-
up) 
Technolo-
gies) 
Little 
2013 
Europe-
an (Bel-
gium, 
Spain, 
Wales, 
Poland, 
UK and 
Nether-
lands) 
RCT clus-
ter 
4,264 
patients 
372 GPs in 
228 prac-
tices 
4 weeks CRP arm 
64% 
female; 
no CRP 
arm 64% 
female 
Practices needed to re-
cruit more than 10 pa-
tients in baseline audit. 
Patients Adults (≥18 
years). First consultation 
for acute cough of up to 
28 days’ duration or what 
the clinician believed to 
be an acute lower-
respiratory-tract infection, 
despite cough not being 
the most prominent symp-
tom; and diagnosis 
judged by the physician to 
be an acute upper-
respiratory-tract infection 
(e.g., sore throat, otitis 
media, sinusitis, influen-
za, and coryzal illness) 
Exclusion criteria 
were a working 
diagnosis of a 
non-infective 
disorder (e.g., 
pulmonary embo-
lus, heart failure, 
oesophageal 
reflux, or allergy); 
use of antibiotics 
in the previous 
month; inability to 
provide informed 
consent (e.g., 
because of de-
mentia, psycho-
sis, or severe 
depression); 
pregnancy; and 
immunological 
deficiencies.  
European 
Commission 
Framework 6 
Programme 
and the Na-
tional Institute 
for Health Re-
search and the 
Research 
Foundation 
Flanders. 
For primary 
outcome 
100% follow-
up. For patient 
diaries more 
than 95% 
follow-up. 18 
GPs excluded 
as not enough 
patients re-
cruited. 
QuikRead
®
 
CRP kits 
Melbye 
1995 
Norway  RCT 239 21 days 63% 
female 
Adults (≥18 years). Pa-
tients presenting with 
suspected pneumonia, 
bronchitis or asthma 
during normal office hours 
were included as well as 
those who presented the 
symptoms cough or 
shortness of breath, chest 
pain on deep inspiration 
or cough 
Patients with sore 
throat, blocked 
nose or pain in 
ears or sinuses 
were excluded. 
Patients with 
angina or myo-
cardial infarction 
like chest pain 
Nycomed 
Pharma funded 
study. Melbye 
had scholarship 
from Norwe-
gian Research 
council 
For antibiotic 
prescribing 
100% follow-
up over 3 
weeks. For 
symptoms 
98/108 (91%) 
in CRP arm 
and 121/131 
(92%) in usual 
care arm 
Ny-
coCard™ 
Reader 
(Axis 
Shield) 
 
 
214 
 
Non randomised studies 
Bjerrum 
2004 
Denmark Observa-
tional 
study 
367 GPs none CRP arm 
56% (55 
to 57) 
female, 
No CRP 
arm 59% 
(57 to 
60) fe-
male 
All ages, adults and chil-
dren presenting with 
acute sinusitis, acute 
tonsillitis or acute otitis 
not reported Grant from The 
Health Insur-
ance Founda-
tion of Den-
mark 
No follow-up 
period 
Not re-
ported 
Jakobsen 
2010 
Norway, 
Sweden 
and 
Wales 
Observa-
tional 
study 
803 none CRP arm 
males = 
37%, No 
CRP use 
arm 
males = 
34%, no 
access to 
CRP arm 
males = 
38% 
Adults (≥18 years). Con-
secutive patients present-
ing for consultation with 
first episode of acute 
cough. Duration of epi-
sode less than 28 days 
since onset of symptoms. 
Anyone who is 
immunocompro-
mised 
Funded 
through the 
GRACE study 
by the 6th 
Framework 
Program of the 
European 
Commission 
no follow-up 
period 
Ny-
coCard™ 
CRP Sin-
gle Test 
(Axis-
Shield) 
and 
QuikRead
®
 
CRP (Ori-
on Diag-
nostica) 
Kavanagh 
2011 
Ireland Pilot non 
random-
ised study 
120 28 days Not re-
ported 
Adults (≥18 years). Partic-
ipants presented with 
acute cough and/or sore 
throat with duration ≤1 
month. Informed consent. 
Not reported Research Bur-
sary funded by 
MSD 
CRP arm 3/60 
(5%) missing 
patient ques-
tionnaire, 1 
patient com-
pleted ques-
tionnaire but 
refused CRP 
test. Usual 
care arm 3/60 
(5%) missing 
patient ques-
tionnaire and 
1 doctors 
questionnaire. 
Quik-Read 
CRP kit 
(Orion 
Diagnosti-
ca) 
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Llor(a) 
2012 
Spain Non-
random-
ised be-
fore–after 
study 
Patients: 
3,356 in 
full inter-
vention 
group. 280 
GPs 
None Not stat-
ed 
Patient presenting with 
LRTI 
None stated  European 
Commission: 
DG SANCO 
under the 
Frame Program 
6 
No follow-up 
but 14 physi-
cians didn't 
complete the 
intervention 
Ny-
coCard™ 
CRP appa-
ratus (Ax-
is-Shield)  
Llor(b) 
2012 
Spain Non-
random-
ised be-
fore–after 
study 
Patients: 
560 in full 
interven-
tion group. 
GPs 175 
None 2008 
(pre) 
36.1% 
men. 
2009 
(post) 
34.2% 
men. 
Patients presenting with 
acute rhinosinusitis 
Not reported European 
Commission: 
DG SANCO 
under the 
Frame Program 
6 
No follow-up, 
but 14 physi-
cians did not 
complete 
intervention.  
Ny-
coCard™ 
CRP appa-
ratus (Ax-
is-Shield) 
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Table A7: Characteristics of included studies for diagnostic test accuracy of C reactive protein POCT to guide antibiotic prescribing in patients 
with acute RTIs in primary care settings (Systematic Review 2) 
Author  
year 
Country 
and 
setting 
Population Reference test CRP test Other diagnostic 
/prognostic tests 
/clinical 
prediction rule 
Groups (size) CRP 
cut-off 
used 
(mg/L) 
Sinusitis 
Ebell 
2017 
General 
practice 
in Den-
mark 
Adult patients aged 18-
65 with suspected 
acute rhinosinusitis 
Acute rhinosinusitis: 
 Abnormal CT finding 
OR  
 Abnormal CT finding + 
+ purulent antral punc-
ture fluid 
Acute bacterial rhinosi-
nusitis: 
 Abnormal CT finding 
+purulent antral punc-
ture fluid + positive bac-
terial culture of antral 
fluid 
Blood test None Acute rhinosinusitis (n=91)  
Not acute rhinosinusitis 
(n=84) 
>15 
Hansen 
1995 
General 
practice 
in Den-
mark 
Patients 18-65 years 
suspected of having 
acute maxillary sinusitis 
CT + aspiration + labor-
atory culture 
NycoCard™ 
CRP whole 
blood  
Erythrocyte sedi-
mentation rate 
Acute maxillary sinusitis (n= 
89) 
Not acute maxillary sinusitis 
(n=79) 
10 
Pharyngitis/tonsillitis 
Christensen 2014 General 
practice 
in Den-
mark 
Acute tonsillitis patients 
aged 15-40 years with 
a Centor score of 1-4 
Laboratory culture Laboratory 
test 
 GAS (n=29) 
Non-GAS (n=71)  
6 
Calvino 2014 Primary 
care in 
Spain 
Adults >18 years old 
with acute pharyngitis 
and the presence of the 
Microbiologic culture 
confirmed with posterior 
serogrouping 
QuikRead
®
/G
o
®
 devices  
None GAS (n=83) 
GBS (n=8) 
None 
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4 Centor criteria GCS (n=13) 
GGS (n=5) 
Other Streptococcus (n=10) 
No bacteria (n=29) 
Gulich 
2002 
General 
practice 
in Ger-
many 
Patients aged ≥16 with 
newly developed sore 
throat 
Microbiological culture 
of throat swabs 
NycoCard™ 
CRP Whole 
Blood test 
Clinical score of 4 
parameters (throat 
mucosa, uvula, soft 
palate, tonsils), 2 
points per criterion:  
High=6-8 
Ambiguous=4-5  
Low=0-3 . 
CRP test only in 
patients in ambigu-
ous category 
GAS (n=73)  
non-GAS (n=192) 
≥35 
Gulich 
1999 
General 
practice 
in South-
ern Ger-
many 
Patients 16-75 years 
presenting with sore 
throat 
Microbiological culture 
of a throat swab. 
GPs clinical diagnosis 
NycoCard™ 
CRP Whole 
Blood test 
Routine physical 
exam 
Bacterial pharyngitis (n=38) 
Non-bacterial pharyngitis 
(n=123) 
≥35 
Pneumonia 
Heiskanen-Kosma 
2000 
Primary 
care in 
Finland 
Children with radiologi-
cally confirmed pneu-
monia 
EIA and immune com-
plex assays (bacterial) 
Routine complement 
fixation (viral and myco-
plasma)  
Immunoturbi-
dometric 
method (LKB 
8600 Reac-
tion rate ana-
lyser) 
None Pneumococcal (n=57) Myco-
plasmal /chlamydial (n=43) 
Viral (n=29) 
Unknown (n=64) 
None 
Holm 
2007 
Primary 
care in 
Denmark 
Adults diagnosed with 
community-acquired 
LRTI  
Chest radiography + 
laboratory culture 
Laboratory 
test 
None Pneumonia (n=48) 
Non-Pneumonia (n=316) 
20 
Hopstaken 
2003 
GP sur-
geries in 
southern 
part of 
Adults presenting with 
LRTI  
 
Chest radiograph Laboratory 
test 
Signs and symp-
toms 
Pneumonia (n=32) 
Non-Pneumonia (n=211) 
10 
20 
50 
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The 
Nether-
lands 
Hopstaken 
2009 
General 
practice 
in The 
Nether-
lands 
Patients presenting 
with signs and symp-
toms of LRTI 
Chest radiograph (lat-
eral and postero-
anterior) + laboratory 
tests 
Laboratory 
test 
None Pneumonia (n=11)  
No pneumonia (n=84)  
10 
50 
100 
Lagerström 2006 Primary 
care in 
Sweden 
Adults with radiological-
ly confirmed CAP 
Chest X-ray Laboratory 
based Ny-
coCard™ 
reader  
None Pneumonia (n=82)  
Non-pneumonia (n=95) 
None 
Melbye 
1988 
General 
practices 
in Nor-
way 
Patients aged ≥15 
years treated with 
antibiotics for clinically 
suspected pneumonia 
Chest X-ray (postero-
anterior and lateral 
projections) 
Laboratory 
blood test 
None Pneumonia (n=11)  
Non-pneumonia (n=58) 
> 11 
> 50 
Minnaard 
2015 
Primary 
care in 
12 Euro-
pean 
countries 
Adult out-patients pre-
senting with acute 
cough 
Chest radiograph + 
Laboratory culture 
Afinion™  
Nyco-Card 
Reader II  
Eurolyser 
Smart 
700|340  
QuikRead go
®
 
QuikRead
®
 
101  
Signs and symp-
toms 
Pneumonia (n=100 )  
No pnuemonia (n=100) 
20 
100 
Teepe 2016 GPs in 
16 prima-
ry care 
research 
networks 
in 12 
Europe-
an coun-
tries 
(GRACE 
consorti-
At least 18 years of age 
presenting for the first 
time with the main 
symptom of acute or 
deteriorating cough 
(duration ≤ 28 days) or 
any clinical 
presentation 
considered by the GP 
to be caused by LRTI 
Bacterial LRTI: The 
presence of prespecified 
bacteria in respiratory 
samples. Bacterial 
pneunomia: Chest 
radiography within 7 
days of presentation in 
combination with the 
presence of prespecified 
bacteria from sputum or 
nasopharyngeal swab 
Laboratory 
test 
LRTI bacterial 
infection (CRP at 30 
mg/l reported in 
combination with 
discoloured sputum) 
Bacterial pneumonia 
(CRP at 30 mg/L 
reported in 
combination with 
comorbidity, 
temperature greater 
All Patients (n=3,104) 
LRTI bacterial infection 
(n=539) 
Radiologically confirmed 
pneumonia (n=141) 
Bacterial pneumonia (n=38) 
> 20 
> 30 
>100 
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um) or equal to 38 
degrees centrigrade 
and crackles on lung 
ausculation) 
Van Vugt 
2013 
Primary 
care 
centres 
in 12 
Europe-
an coun-
tries 
(GRACE 
consorti-
um) 
Adults presenting with 
acute cough 
Chest radiograph Laboratory 
test 
Signs and symp-
toms 
No pneumonia: CRP level 
≤20 (n=2039; 76.1%) 
21-30 (n=214, 8%) 
31-50 (n=230; 8.6%) 
51-100: (n=135; 5%) 
>100 (n=62; 2.3%). 
 
Pneumonia: CRP level 
≤20 (n=55; 39.3%) 
21-30 (n=11, 7.9%) 
31-50 (n=16; 11.4%) 
51-100: (n=24; 17.1%) 
>100 (n=34; 24.3%). 
 
Diagnostic risk group*: 
Low: (n=1,556; 55.2%) 
Intermediate: (n=1132 
40.1%) 
High: (n= 132; 4.7%) 
> 30 
Abbreviations: CAP – community acquired pneumonia CRP – C reactive protein; CT – computed tomography; GAS - group A Streptococcus; GBS - group B Streptococcus; GCS - group C 
Streptococcus; GGS - group G Streptococcus; GP – General Practitioner; LRTI – Lower respiratory tract infection;. 
* Risk of radiologically confirmed pneumonia based on prediction model using signs and symptoms only. Risks defined a priori: low = <2.5%; intermediate = 2.5-20%; high = >20%. 
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Table A8: Characteristics of included studies for analytical performance of CRP POCT devices (Systematic Review 3) 
Author 
(Year) 
Study Type 
& Country  
Test 
setting(s) and 
operator(s)  
Sample source(s) 
(n) 
Population / 
Inclusion 
criteria 
POCT device Comparator 
device 
Blood 
sample 
type(s) 
Funding 
source 
Bains 
(2017)[168] 
UK – AP Laboratory – 
Lab technician 
Hospital Samples 
(n=44) 
NR iChroma Architect 
ci8200 
Venous NR 
Brouwer 
(2014)[16] 
Netherlands –
AP 
Laboratory – 
Lab technicians 
Primary Care Sam-
ples (n=100) 
Adults aged >18 
years. GP's pa-
tients, CRP con-
centrations from 5 
to 200 mg/L 
QuikRead
®
 101 Synchron Venous None – analys-
ers were provid-
ed for free Smart Eurolyser Venous 
Afinion Venous 
iChroma Venous 
Microsemi Venous 
AQT Flex 90 Venous 
Actim
®
 Venous 
Cleartest
®
 Venous 
Bukve 
(2016)[17] 
Norway – EQA Primary Care – 
GP & Nurses 
Laboratory Samples 
(n=3) 
Primary Care Sam-
ples (n=2134) 
Hospital samples 
(n=22) 
Healthy volun-
teers, blood 
stored in K2-
EDTA and spiked 
with recombinant 
CRP (range 8-92 
mg/L) 
ABX Micros 200 Cobas 600 Venous None 
Afinion 
iChroma 
NycoCard 
QuikRead go
®
 
QuikRead
®
 101 
Ciftci 
(2014)[169] 
Turkey – AP Laboratory – 
Lab technicians 
Hospital Blood 
Sample (n=96) 
NR iChroma Immage 800 Venous None 
 
 
221 
 
Author 
(Year) 
Study Type & 
Country  
Test setting(s) 
and operator(s)  
Sample source(s) 
(n) 
Population / 
Inclusion criteria 
POCT device Comparator 
device 
Blood sample 
type(s) 
Funding source 
Clouth 
(2009)[170] 
Germany – AP Laboratory – 
Not stated 
Hospital Blood 
Samples (n=200)  
NR NycoCard Tina Quant Venous NR 
Micros CRP 
De Graaf 
(2017)[171] 
Netherlands – 
AP 
Primary Care – 
GP 
NR (n=100) NR spinit
®
 Roche Cobas 
8000 
EDTA anti 
coagulated 
whole blood 
Device provided 
for free by manu-
facturer 
Evrard 
(2005)[172] 
France – AP Laboratory – 
Lab technicians 
(n=43) NR Actim
®
 Modular P900 Venous NR 
Ivaska 
(2015)[173] 
Finland – AP Laboratory – 
Lab technicians 
Clinical blood sam-
ples (n=48) 
NR Afinion Modular P Serum from 
EDTA venous 
blood 
Turku University 
Research grant 
Matheeu-
sen  
(2018)[174] 
12 European 
Countries – 
AP 
Laboratory – 
Lab technicians 
Primary Care 
(n=2922) 
Adults >18 years 
of age. Symptoms 
of LRTI, acute 
cough lasting less 
than 28 days, 
presenting to 
primary care 
QuikRead
®
 101 Dimension 
Vista 
Plasma from 
venous blood 
EU funding 
Kits provided by 
manufacturers 
  
 
 
222 
 
Author 
(Year) 
Study Type & 
Country  
Test setting(s) 
and operator(s)  
Sample source(s) 
(n) 
Population / Inclu-
sion criteria 
POCT device Comparator 
device 
Blood sample 
type(s) 
Funding source 
Minnaard 
(2013)[18] 
Netherlands –
AP 
Laboratory 
samples – Lab 
technicians 
Hospital Samples NR Afinion Olyumpus AU 
2700 
Venous  None  
NycoCard™ Reader 
II 
Smart Eurolyser 
QuikRead go
®
 
QuikRead
®
 101 
Monteny 
(2006)[19] 
Netherlands – 
AP 
Primary care – 
GP 
Primary Care 
(n=61) 
Any child attend-
ing out-of-hours 
primary care ser-
vice with a fever 
 
NycoCard 
 
Tina Quant Capillary 
Venous 
ZonMW – health 
research/ devel-
opment funding 
Distributor pro-
vided equipment 
 
QuikRead
®
 CRP 
Nomura 
(2014)[175] 
Japan – AP Unclear Hospital Samples 
(n=244) 
NR Microsemi Hitachi 7600 Venous Authors em-
ployed by Horiba 
– manufacturers 
of Microsemi 
Semark 
(2003)[176] 
UK – AP Primary Care – 
Practice Nurse 
Primary Care 
(n=124) 
NR QuikRead
®
 101 Vitros 950 dry 
slide 
Venous & 
Capillary 
Grant from Bio-
Stat Ltd – supply 
QuikRead sys-
tem 
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Author 
(Year) 
Study Type & 
Country  
Test setting(s) 
and operator(s)  
Sample source(s) 
(n) 
Population / 
Inclusion criteria 
POCT device Comparator 
device 
Blood sample 
type(s) 
Funding source 
SKUP 
(2001)[20] 
Denmark –
EQA 
Hospital Labora-
tory – Lab 
Technicians & 
Primary Care 
Centres 
Primary Care 
(n=40) Hospital 
samples (n=40) 
Each hospital 
chose 40 samples 
with concentration 
of CRP in required 
range. Each GP 
selected 40 pa-
tients 
QuikRead
®
 101 Bayon, Cobas 
Integra, Hita-
chi 
Venous SKUP 
SKUP 
(2002)[21] 
Denmark – 
EQA 
Hospital Labora-
tory – Lab 
Technicians & 
General Prac-
tice 
Primary Care 
(n=160) 
160 patients gen-
eral practice and 
laboratory sam-
ples 
ABX Micros Vitros 250, 
Axon, Cobas 
Integra 700, 
Vitros 950 
Venous 
 
 
SKUP 
SKUP 
(2011)[22] 
Denmark – 
EQA 
Hospital Labora-
tory – Lab 
Technicians & 
Primary Care 
Centres 
Hospital (n=109) 
venous (n=114) 
capillary Primary 
Care (n=80) 
109 venous and 
114 capillary 
bloods from same 
patients in hospi-
tal laboratory, 80 
capillary blood in 
primary care 
Smart Eurolyser Cobas Integra 
800 
Capillary and 
Venous 
SKUP 
SKUP 
(2013)[23] 
Denmark – 
EQA 
Hospital Labora-
tory – Lab 
Technicians & 
Primary Care 
Centres 
Hospital (n=100) 
Primary Care 
(n=86) 
100 venous whole 
blood EDTA pa-
tient samples in a 
hospital laboratory 
and capillary 
samples from 86 
patients in two 
primary health 
care centres  
iChroma Cobas Integra Capillary and 
Venous 
SKUP 
Verbakel  
(2014) [177] 
Belgium – AP GP carried out 
the test in pri-
mary care 
Primary care (n=35 
adults) 
(Adults aged 18-
65 years attending 
a general practice 
surgery  
Afinion Cobas c702 Capillary 
 
Fund for Scien-
tific Research 
(FWO) devices 
were provided by 
the manufacturer 
Abbreviations: AP – analytical performance; EQA – external quality assurance; GP – general practitioner; NR – not reported.
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Table A9: Systematic review 2 (diagnostic test accuracy) - likelihood ratios from included 
studies 
Author 
Year  
CRP Threshold (mg/L) + Clinical Criteria Likelihood Ratios 
LR (+) LR (-) 
Sinusitis 
Hansen 
1995 
10 1.83 0.45 
25  2.36 0.62 
50  3.3 0.74 
Pharyngitis or tonsillitis  
Christensen  
2014 
6 + Centor Score 1-4* 1.64 0.22 
6 + Centor Score 2-4* 2.77 0.24 
Gulich  
2002 
35 + derivation strepto-score** 17.6 0.13 
35 + validation strepto-score** 14.8 0.27 
Gulich  
1999 
35 + clinical assessment 4.33 0.27 
Pneumonia 
Holm  
2007 
20  2.09 0.42 
20 + clinical pneumonia 3.06 0.61 
Hopstaken  
2009 
10  1.56 0 
20  2.02 0 
100  5.21 0.22 
Lagerstrom 
2006 
20  2.26 0.32 
50  3.69 0.49 
Melbye  
1988 
11  2.05 0.3 
50  18.5 0.27 
Minnaard  
2015 
Table A10 Table A10 Table A10 
Van Vugt  
2013 
30 + low probability of pneumonia*** 0.39 1.81 
30 + high probability of pneumonia*** 9.67 0.73 
Abbreviations: LR (+) – positive likelihood ratio; LR (-) – negative likelihood ratio.  
Notes: 
a
 These likelihood ratios were calculated using an online calculator based on the sensitivity and specificity data reported 
in the paper (http://getthediagnosis.org/calculator.htm ) 
*The Centor criteria (tonsillar exudate, tender anterior cervical lymphadenopathy or lymphadenitisk, history of fever (over 38°C), 
and/or absence of cough) are an algorithm to estimate the probability of group A β-haemolytic Streptococcus (GABHS) as the 
origin of sore throat. Each of the Centor criteria score 1 point (maximum score of 4).  
**The clinical strepto-score (throat mucosa, uvula, tonsils, soft palate) was based on clinical examination. Each criterion was 
scored 0-2 points (total score 0-8 points).  
*** Probability of pneumonia based on signs and symptoms (breathlessness, absence of runny nose, diminished vesicular 
breathing, crackles, tachycardia, temperature (>37.8°C)). 
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Table A10:  Systematic review 2 (diagnostic test accuracy) likelihood ratios from Minnaard et 
  al 2015 
Author 
Year 
CRP test CRP Threshold 
(mg/L) 
Likelihood Ratios 
LR (+) LR (-) 
Minnaard 
 
2015 
Laboratory analyser 20 2.56 0.51 
100  10.57 0.77 
Afinion 20  2.04 0.62 
100  20 0.81 
NycoCard™ Reader II 20  2.16 0.61 
100  10 0.82 
Eurolyser Smart 20  2.29 0.66 
100  19 0.82 
QuikRead go
®
 20  1.86 0.67 
100  20 0.81 
QuikRead
®
 101 20  1.88 0.69 
100  19 0.82 
Abbreviations: LR (+) – positive likelihood ratio; LR (-) – negative likelihood ratio.  
Notes: 
a
 These likelihood ratios were calculated using an online calculator based on the sensitivity and specificity data reported 
in the paper (http://getthediagnosis.org/calculator.htm ) 
 
  
 
 
226 
 
Figure A1: Systematic Review 2 (Diagnostic test accuracy) examples of Nomograms  
a. Nomogram for clinical diagnosis without CRP (Gulich et al. 1999) 
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b. Nomogram for diagnosis with CRP (Gulich et al. 1999) 
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List of ongoing and planned studies 
The following sites were searched in January 2019: ClinicalTrials.gov and International Clinical Trials 
Registry Platform (ICTRP). Feedback was also obtained from a manufacturer during the factual accu-
racy check confirmed One planned or ongoing studies in relation to the use of CRP POCT to inform 
antibiotic prescribing in primary care was identified (Table A11). Feedback was also obtained from the 
trial sponsor to confirm the details of the trial protocol. 
Table A11: List of planned and ongoing studies with CRP POCT  
Study 
Identifier 
Estima
ted 
start 
date 
Study type Numb
er  
of 
patien
ts 
Interve
ntion 
Comparator Patient 
populatio
n 
Endpoints 
NCT020181
98 
‘DIStinguish 
Respiratory 
Underlying 
Pathogen 
associaTed 
host 
response in 
Upper 
Respiratory 
Infection: An 
Evaluation 
of FebriDx
®
 
POC 
Test’(FebriD
x
®
 DISRUPT 
URI Trial)’ 
04/201
9 
Prospective 
observation
al study 
1,225 FebriDx
®
 
Expert 
clinical 
reviewers' 
evaluation in 
conjunction 
with the 
results of 
clinical 
standardised 
microbiologic 
and 
laboratory 
testing 
Clinical 
Reference 
Algorithm) 
Patients 
(one year 
and older) 
presenting 
with 
reported 
fever and 
acute 
respiratory 
symptoms 
to primary 
care and 
urgent care 
outpatient 
offices and 
emergency 
department
s 
The primary analysis 
will determine 
performance 
characteristics of 
FebriDx
®
 test by 
assessing negative 
and positive 
agreement of 
FebriDx
®
 results in 
determining the 
presence of a 
bacterial associated 
systemic host 
immune response or 
viral associated 
systemic host 
immune response 
compared with a 
Clinical Reference 
Algorithm 
(comparator method) 
that is supervised by 
clinical experts. 
Source: www.clinicaltrials.gov and RPS Diagnostics 
 
Risk of bias tables 
 
Figure A2 shows an overview of the risk of bias of the RCTs included in systematic review 1 (effec-
tiveness and safety). Most of the RCTs had adequate randomisation procedures [127, 129, 130, 132, 
135]. In two studies it was unclear how the randomisation was done as no details were provided in the 
paper [131, 138]. It was often unclear from the description of the randomisation process if steps had 
been taken to ensure allocation concealment in the studies. All the RCTs had a high risk of perfor-
mance bias as it was not possible to blind clinicians as to which group a patient was in as they had to 
know the CRP level when it was available in order for it to influence their management of a patient. It 
would also be difficult to blind patients to which group they were in as a placebo (sham) procedure 
would need to be carried out instead of the CRP measurement. For the primary outcome of antibiotic 
prescribing, most of the outcome data were gathered from electronic databases or from forms filled 
out by the clinician and were judged to be at low risk of bias. Symptom duration and patient satisfac-
tion were often recorded in patient diaries or by interview and it was often unclear how the data were 
 
 
229 
 
extracted and if it was open to bias. For the primary outcome of antibiotic prescribing at index consul-
tation, the data were complete and at low risk of attrition bias. For other outcomes, where data was 
collected up to 28 days later, the follow-up was good for most of the studies. When a protocol was 
available it was usually clear that there was no or low risk of reporting bias; however, a few older stud-
ies had no available protocol [131, 138]. Other sources of bias included the cluster randomised con-
trolled design [127, 129, 135], stopping the study early [138], and the method used to recruit patients 
[131]. 
Figure A2:  Risk of bias of included RCTs in systematic review 1 (clinical effectiveness and 
 safety) 
 
Key 
 Low risk of bias  High risk of bias  Unclear risk of bias 
Table A12 shows an overview of the risk of bias of included non-randomised studies in systematic re-
view 1. All of the studies scored either a four or a five out of a possible seven, or in the case of Ka-
vanagh et al. [134], five out of a possible nine (as this study included a follow-up period). All of the stud-
ies scored a star for the representativeness of the cohort that underwent the CRP POCT. All bar the 
study by Jakobson et al. [133] also scored a star for selection of the control group. In the study by Jak-
obson et al., the CRP POCT group included patients from Norway and Sweden, with Wales in the UK 
used as the control group as CRP POCT was not available in Wales at the time. The authors justified 
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this choice stating that the countries have similar characteristics. However as these countries have very 
different health systems and the presenting characteristics of the patients were different between the 
intervention and control groups, the suitability of the control group is questionable. For most studies it 
was unclear if antibiotics had been prescribed to any of the patients before the start of the study. Only 
the study by Jakcobsen et al. stated that patients were only included if it was their first visit for the cur-
rent RTI episode, suggesting that the outcome had not been present before the start of the study. For 
assessment of the outcome; in four out of five of the studies the antibiotic information was recorded by 
the clinician at the time of consultation which means these studies do not score a star based on the 
Newcastle Ottawa scale, as a point is only scored for this domain if the assessment of the outcome is 
done independently and blinded or by record linkage. However, as the clinician must know the outcome 
of the CRP POCT for it to influence antibiotic prescribing, it seems unlikely that this would be a source of 
bias in this type of study. Also, it seems unlikely that there would be inherent bias in the clinician record-
ing the antibiotic prescribing either in the medical records or on a form.  
Table A12: Quality rating of included non-randomised studies (systematic review 1 – 
effectiveness and safety) 
Study, 
Year 
Selection  Comparability  Outcome Overall quality 
score (Max. 
=9) 
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Bjerrum 
2004 
* * * X * X X N/A N/A 4 out of 7 
Jakobsen 
2010 
* X * * * X * N/A N/A 5 out of 7 
Kavanagh 
2011 
* * * X X X X * * 5 out of 9 
Llor 
2012(b) 
* * * X * * X N/A N/A 5 out of 7 
Llor 
2012(a)  
* * * X * * X N/A N/A 5 out of 7 
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Figure A3: Risk of bias of included studies in systematic review 2 (diagnostic test accuracy) 
Study RISK OF BIAS APPLICABILITY CONCERNS 
PATIENT 
SELEC-
TION 
INDEX 
TEST 
REFER-
ENCE 
STAND-
ARD 
FLOW 
AND 
TIMING 
PATIENT 
SELEC-
TION 
 
INDEX 
TEST 
REFER-
ENCE 
STAND-
ARD 
Calvino 
2014 
Low Low Low Low Low Low Low 
Christen-
sen 2014 
Low Unclear Low Low Low High Low 
Ebell 
2017 
Unclear Unclear Low Low Unclear High Low 
Gulich 
2002 
Low Low Low Low Low Low Low 
Gulich 
1999 
Low Low High Low Low Low High 
Hansen 
1995 
Low Low Low Low Low Low Low 
Heiskanen
-Kosma 
2000 
Low High Low Low Low High Low 
Holm 
2007 
Low Unclear Low Low Low High Low 
Hopstak-
en 2003 
Low Low Low High Low High Low 
Hopstak-
en 2009 
Low Unclear Low Unclear Low High Low 
Lager-
strom 
2006 
Low Unclear Low Unclear High Unclear Low 
Melbye 
1988 
High Unclear Low Low High High Low 
Minnaard 
2015 
Low Unclear Low High Low High High 
Teepe 
2016 
Low Low Low High Low High Low 
Van Vugt 
2013 
Low Low Low High Low High Low 
 
A tabular presentation of the QUADAS-2 quality assessment of the 15 studies included in systematic 
review 2 is shown in Figure A3. All studies reported clearly defined selection criteria. The majority of 
studies included either all patients presenting with symptoms of RTI or consecutive patients, therefore 
risk of bias and concerns regarding applicability were generally low. Potential risk of bias or applicabil-
ity concerns were identified regarding patient selection in five studies. Exclusion of patients living in 
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nursing homes by Lagerstrom et al. may reduce the applicability of the findings to the target popula-
tion identified in our review question as this patient group is of particular interest due to high antibiotic 
prescribing rates in long term care facilities in Europe [149]. Melbye et al. included only patients treat-
ed with antibiotics by a general practitioner for a suspected pneumonia [10]. Failure to include pa-
tients not treated with antibiotics introduces a potential risk of bias. Furthermore, patients who were 
too ill to attend the outpatient clinic for analysis of CRP levels were excluded which could lead to un-
derestimation of diagnostic test accuracy. Van Vugt et al. reports that not all consecutive eligible pa-
tients were recruited [14]. The authors state that sequential recruitment was impossible given the high 
volume of patients presenting with LRTI during the winter period, and the time required to recruit and 
assess each patient. Given the large sample size in this study, clinically important selection bias was 
considered to be unlikely. Ebell et al. state that a large proportion of eligible patients declined to par-
ticipate and data on nonparticipants were not available, introducing potential selection bias[3]. 
In all included studies patients received both the index and reference standard tests. The risk of bias 
and applicability of a number of included studies was judged to be unclear in terms of the index test. 
Insufficient information was provided in the majority of cases in order to determine if the results of the 
reference standard were available prior to interpretation of the index test. In studies where a POC 
CRP test was used, it was assumed that interpretation of the index test result was carried out during 
the consultation, eliminating the potential for the reference standard to influence interpretation of the 
test. Gulich et al. defined evidence of bacterial pharyngitis as throat swabs growing bacteria caused 
by group A- and C-β-haemolytic Streptococci and Haemophilus Influenzae [5]. This has the potential 
to underestimate the prevalence of bacterial pharyngitis as infections may be attributable to other 
types of bacteria. 
Variation in test technology or execution may affect estimates of diagnostic test accuracy. This sys-
tematic review aimed to evaluate the diagnostic test accuracy of CRP testing at the POC. An im-
portant limitation to the study conducted by Minnaard and colleagues was noted [11]. All tests were 
carried out in a laboratory setting by laboratory analysts, which may not be representative of the pri-
mary care setting where CRP POCTs are intended for use. A number of studies used laboratory-
based CRP testing and the findings of these studies may not be directly transferable to the primary 
care setting [3, 6, 10, 12, 14, 150-152]. Studies for which CRP testing was carried out in a laboratory 
setting rated high in terms of concerns regarding the applicability of these findings to the primary care 
setting. 
Four studies rated poorly in terms of patient flow and timing. Ideally, results of the index test and ref-
erence standard should be collected at the same time. The studies by Minnaard et al. and Teepe et 
al. reported that blood samples were taken on day one for analysis of CRP levels, however chest 
radiographs were obtained within seven days [11, 15]. Similarly, Hopstaken et al. reports that blood 
samples were taken for analysis of CRP levels on the day of presentation to the GP, while chest radi-
ographs were not obtained until three days after inclusion in the study [152]. The time interval be-
tween the execution of the index test and reference standard has the potential to introduce bias as a 
result of misclassification due to changes in patient condition or the potential of the results of one test 
to influence the results of another. A graphical summary of the overall quality assessment for each of 
the QUADAS-2 domains is illustrated in Figure A4. 
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Figure A4: Graphical overview of the overall quality rating of included studies in systematic 
review 2 (diagnostic test accuracy) for each of the key domains using the QUADAS-2 quality 
appraisal tool 
 
Overall, studies included in systematic review 3 were of low or unclear risk of bias by QUADAS 2 
(Figure A5 and A6). However, there were three clear areas where bias was of concern. It was not 
clear if operators were blinded to the results of the POCT or had prior information regarding the CRP 
concentration of the sample being tested. This could introduce bias, particularly in the laboratory set-
ting where the same individual could be performing both the POCT and laboratory reference test. 
Another potential source of bias related to the lack of clarity around the length of time the samples 
were stored prior to their use or the time interval between performance of the POCT and reference 
tests. The absence of a clear explanation of the experimental design of these studies limits the inter-
pretation of the results. Finally, in several of the studies, the population samples were not specific to 
patients presenting to primary care with symptoms of RTI with samples also taken from hospital inpa-
tient and outpatient settings in addition to stored laboratory samples for which little if any detail of the 
patient population from which they were derived provided. Therefore the spectrum of patients was 
often not the same as those who would receive the test in practice. In many studies, principally those 
where multiple devices were compared with each other, frozen or EDTA-treated venous samples 
were taken from laboratory stores. The advantage of this approach is that the samples are of a known 
concentration allowing a range of CRP concentrations to be analysed. This method also eliminates 
bias that could be introduced due to heterogeneity of the operator at the point of care, which is im-
portant when comparing devices with each other. The disadvantage of the approach is that laboratory 
venous blood samples that have been frozen or treated with EDTA or heparin are not the same as 
capillary blood samples tested at the point of care, thereby introducing a potential source of bias. By 
controlling the sample and operator variables, these studies also create an artificial environment that 
does not reflect the intended use of these POCT devices, that is, in primary care by non-laboratory 
trained health care professionals. 
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An additional potential source of bias is the source of funding of the studies. One study was spon-
sored by the manufacturer [176] and in a further two studies, the equipment and training was funded 
by the manufacturer.[171, 177] Research in one of the studies was undertaken by company employ-
ees.[175] Four studies were recipients of educational grants.[19, 173, 174, 177] 
 
Figure A5: QUADAS 2 – Risk of bias of included studies systematic review 3 (analytical 
performance) 
 
0% 20% 40% 60% 80% 100% 120%
Was the operator of the POCT representative of
operators that would carry the test out in practice?
Were withdrawals from the study explained? i.e. were
reasons given for missing samples due to logistics or
time degredation?
Were uninterpretable/intermediate rest results
reported?
Were the reference standard results interpreted without
knowledge of the reults of the index test?
Were the index rest results interpreted without
knowledge of the results of the reference?
Was the exection of the reference standard described in
sufficient detail to permit its replication?
Was the execution of the index test described in
sufficicent detail to perit replication of the test?
Did patients receive the same reference standard
regardless of the index test result?
Is the time period between reference standard and index
test short enough to be resonably sure that samples did
not degrade between the two tests?
Is the reference standard appropriate?
Were selection criteria clearly described?
Was the spectrum of patients representative of the
patients who will receive the test in practice?
Yes Unclear No
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Figure A6: Risk of bias of included studies in systematic review 3 (analytical performance) 
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Were with-
drawals 
from the 
study ex-
plained? 
Was the 
operator of 
the POCT 
representa-
tive of 
operator in 
practice? 
Bains High High Low Unclear Low Low High Unclear Unclear Low Low High 
Brouwer Unclear High Low Low Low High High High Unclear Unclear High High 
Bukve High High Low Low Low Unclear High Unclear Low Unclear Unclear Low 
Ciftci High High Low Low Low High High Low Low Unclear High High 
Clouth High High Low Low Low Low High Unclear Low Unclear Unclear High 
De Graaf Unclear High Low Unclear Low High High Unclear Unclear High High Unclear 
Evrard High High Low Unclear Low Low Low Low Unclear Low Unclear High 
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Ivaska High High Low Low Low Unclear High Low Unclear High High Low 
Matheeussen Low Low Low Unclear Low High High Low Low Unclear Low High 
Minnaard High High Low Unclear Low Low High Low Low High High High 
Monteny Unclear High Low Unclear Low High High Low Low Unclear Low Low 
Nomura High Low Low Unclear Low High High Unclear Unclear Unclear Low High 
Seamark Unclear Low Low Unclear Low Low High Low Unclear High High Unclear 
SKUP Smart 
Eurolyser 
Unclear High Low Low Low Low High Low Unclear Low Low Low 
SKUP iChro-
ma 
Unclear Low Low Unclear Low High High Low Unclear Low Low Low 
SKUP      ABX 
Micros 
Unclear High Low Low Low Low High Low Unclear Low Low Low 
SKUP 
QuikRead
® 
101 
Unclear High Low Low Low Low High Low Unclear Low Low Low 
Verbakel High High Low Low Low Low High Low Unclear Low High Low 
Notes: * Two-part study involving initial testing of samples in laboratory and then at the point of care. 
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Applicability tables 
 
Table A13: Summary table characterising the applicability of the body of studies – 
systematic review 1 (effectiveness and safety) 
Domain Description of applicability of evidence 
Population As mentioned in the PICO question, patients of all ages who present with symptoms of 
acute RTI in primary care were considered relevant to this systematic review. Subgroups of 
particular interest included: patients presenting with upper versus lower RTI, children, older 
adults (≥65 years of age), patients attending OOH services and those in LTC facilities. 
Most studies only included adults, while three included adults and children. No study re-
ported data that could be extracted for a population restricted to older adults (>65 years). 
Subgroup analysis was performed for upper versus lower RTI for the outcome of antibiotic 
prescribing at index consultation. No further planned subgroup analysis was performed due 
to retrieval of insufficient data to facilitate analysis.  
Of the eleven studies retrieved in the systematic review, nine were carried out in EU coun-
tries, one in Russia and one in Vietnam. Therefore, the findings of this systematic review 
are believed to be transferable to the majority of European primary care settings given that 
the findings of the review are largely based on European data. 
 
Intervention The intervention of interest was any CE marked CRP POC quantitative or semi-quantitative 
test designed for use in the primary care setting.  
The identified studies included in this systematic review related to only three of the 15 CE 
marked devices (QuikRead
®
 CRP kit/QuikRead
®
 101, Alere Afinion™ CRP, and Ny-
coCard™ CRP for use with NycoCard™ II Readers). All three of these devices are quanti-
tative devices. No data were retrieved in relation to the clinical effectiveness and safety of 
semi-quantitative CRP POC devices. Therefore, there is no evidence to suggest that the 
findings of the systematic review of clinical effectiveness and safety are applicable to semi-
quantitative devices.  
A number of RCTs [129, 135, 137] included an educational component or communication 
skills training as part of the intervention arm alongside CRP POCT. This may have 
enhanced the effect of CRP POCT on antibiotic prescribing. However, removal of Little 
2013 and Cals 2009 from the RCT meta-analysis resulted in only a minor change in the 
pooled RR and still suggests that CRP POCT leads to a significant reduction in antibiotic 
prescribing. In this way, the findings should be applicable to primary care settings in which 
healthcare workers carrying out CRP POCT have not received additional education or 
communication skills training beyond that necessary to conduct the test.  
Comparators The comparison of interest was standard care, which is the case of two of the trials (Little 
2013 and Cals 2009) also included either an educational or communication component. For 
the majority of included studies, standard care comprised clinical assessment only with no 
access to CRP POCT. The usual care arms are therefore thought to be representative of a 
typical primary care setting prior to the introduction of CRP POCT.  
Some of the cluster RCTs [129, 135] identified in this systematic review included 
educational components or communication skills training as part of standard care which 
may not be representative of the current standard of care across Europe. However, as both 
intervention and control groups were exposed to the educational or communications 
component in these studies, it is likely that any observed effect is due to CRP POCT. 
Exposure of the usual care arm to education or communication skills training is therefore 
not thought to reduce the applicability of the evidence. A study by Jakobsen et al. used 
patients presenting to primary care settings in Wales as the usual care group, due to the 
fact that standard care in Scandinavian countries already involves the use of CRP POCT, 
therefore it was not possible to use a control population from the same region. Removal of 
this study from the meta-analysis led to a decrease in heterogeneity, but CRP POCT was 
still associated with a significant reduction in antibiotic prescribing at index consultation. 
Therefore, the lack of a suitable comparator in this study does not reduce the applicability 
of the evidence. 
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Domain Description of applicability of evidence 
Outcomes While no deaths were reported in any of the studies identified, there was limited evidence 
retrieved in relation to safety outcomes. No evidence was retrieved to answer the following 
assessment elements: C0005, C0007, B0010. Therefore the results should be interpreted 
and applied to relevant healthcare settings in the context of the limited evidence base in 
relation to safety. Very few studies reported on the number of antibiotics prescribed as a 
delayed prescription, It may be that delayed prescriptions are common in cases where CRP 
levels are between 20 and 99 mg/L this could mean that our effect estimate is lower than 
would be seen in practice as a portion of delayed prescriptions may not be redeemed.  
Setting All studies included in the primary analysis were carried out in primary care settings with 
nine of the 11 included studies undertaken in European countries. They were therefore 
considered to be applicable to the settings in which CRP POCT will typically be used in 
Europe. The study by Do et al was carried out in Vietnam and may not be as applicable as 
the Vietnam healthcare system would differ to most European countries, However removal 
of this study decreased erogeneity but did not substantially change the overall pooled 
estimate. 
Abbreviations: CRP POCT – C-reactive protein point-of-care testing; LTC – long-term care; RTI – respiratory tract 
infection. 
 
Table A14: Summary table characterising the applicability of the body of studies retrieved 
for systematic review 2 (diagnostic test accuracy) 
Domain Description of applicability of evidence 
Population Patients of all ages who present with symptoms of acute RTI in primary care were 
considered relevant to this systematic review. Subgroups of particular interest included: 
children, older adults (≥65 years of age), patients attending out-of-hours (OOH) services 
and those in Long Term Care (LTC) facilities. If sufficient data were retrieved, it was 
intended that subgroup analysis would be carried out for the following subgroups: children 
versus adults; and older adults (≥65 years) versus younger adults (<65 years). The body of 
evidence retrieved did not contain sufficient information to facilitate analysis of the 
aforementioned subgroups. Only one study included children aged between 3 months to 15 
years of age[150]. No study reported on the DTA of CRP POCT in older adults (>65 years). 
Therefore this systematic review cannot draw conclusions on the DTA of CRP POCT in 
these specific subgroups. All results should be interpreted in terms of the general 
population. 
Studies included in this systematic review contained evidence regarding the DTA of CRP 
POCT in relation to a number of types of RTI. Evidence was retrieved and evaluated with 
regard to the following RTI types: Pharyngitis and tonsillitis; sinusitis; and LRTI and 
pneumonia. The DTA of CRP POCT differed by RTI type, therefore, the findings of this 
review may be CRP POCT may be of limited applicability to patients presenting with signs 
and symptoms of other URTI in primary care. 
Intervention The intervention of interest was any CE marked C-reactive protein POC quantitative or 
semi-quantitative method designed for use in the primary care setting.  
No relevant studies were identified that used semi-quantitative CRP POCT devices. 
Therefore, this systematic review cannot draw conclusions on the applicability of semi-
quantitative CRP POCT to the primary care setting. 
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Domain Description of applicability of evidence 
Comparators A number of comparators were considered relevant in this systematic review given the 
absence of a universal reference standard for the diagnosis of RTI requiring antibiotics. The 
diagnostic standard used depended on the type of RTI under consideration.  
 
For studies investigating the DTA of CRP POCT in patients presenting with LRTI or 
pneumonia, the conclusive finding of an infiltrate on a chest radiograph was regarded as 
evidence of pneumonia. Chest radiography is not typically performed in the primary care 
setting. However, given the absence of a more appropriate comparator, chest radiography 
was considered to be a suitable comparator to identify patients with pneumonia. Culture of 
throat swab was used as the gold standard to diagnose tonsillar bacterial infection and is 
considered to be applicable to the primary care setting. Reference standards for acute 
sinusitis were abnormal finding on a CT scan, the presence of purulent or mucopurulent 
fluid from an antral puncture of the maxillary sinus, and, for acute bacterial sinusitis, 
positive bacterial culture of antral fluid. Antral puncture is the preferred reference standard 
test, but is not widely used in primary care due to the discomfort it causes and a lack of 
expertise in performing antral puncture in the primary care setting. 
Outcomes Outcomes of interest were measures of diagnostic test accuracy including; Sensitivity and 
specificity; PPV and NPV; likelihood ratio, AUC; and DOR. A variety of statistical measures 
were used to report on diagnostic test accuracy across the studies. Three studies reported 
measures of DTA of CRP POCT for the combination of signs and symptoms and CRP 
testing at a threshold of 20 mg/L, however the signs and symptoms included in the clinical 
examination were either inconsistent [14, 152] or not reported[8]. Some studies did not 
report typical measures of DTA, and reported only mean or median CRP concentrations 
(mg/L) in the patient groups. In such studies, the best available measures of DTA were 
extracted, however such measures are not typically considered informative in determining 
the DTA of an intervention.  
Meta-analysis of data was not possible due to considerable heterogeneity among studies 
therefore it is difficult to comment on the accuracy of CRP POCT for the body of evidence.  
Setting All studies were carried out in primary care settings in European countries and were 
considered to be reflective of the settings in which CRP POCT will typically be used.  
Eight of the included studies used standardised laboratory testing for CRP. In the context of 
this systematic review, the intended user is healthcare staff who are non-laboratory 
specialists working in the primary care setting. The inclusion of studies where CRP testing 
was carried out by laboratory specialists in a laboratory setting may reduce the applicability 
of the findings to the primary care setting due to the potential of variation in user’s 
technique and the environment to impact the results of the CRP test, and thereby possibly 
lead to variation in clinical diagnoses. Therefore, the applicability of the findings of this 
review are dependent on the analytical performance of the CRP POCT as determined in 
the systematic review of analytical performance. 
Abbreviations: AUC – area under the curve; CRP – C-reactive protein; DOR – Diagnostic odds ratio; DTA – diagnostic 
test accuracy; LTC – Long-term care; NPV – negative predictive value; OOH – out-of-hours; PICO – Population, 
Intervention, Comparator, Control; POCT – point-of-care testing; PPV – positive predictive value; RTI – respiratory tract 
infection. 
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Table A15: Summary table characterising the applicability of the body of studies retrieved 
for systematic review 3 (analytical performance) 
Domain Description of applicability of evidence 
Population As mentioned in the PICO question, patients of all ages who present with symptoms of 
acute RTI in primary care were considered relevant to this systematic review.  
 
This inclusion criteria was expanded to include blood samples from any setting as long as 
the CRP measurement was likely to be within a similar range to that found in patients with 
RTIs. Studies set in primary care did not specifically target patients suffering from RTI and 
often included any patient who required a blood sample to be taken and sent to the labora-
tory. One laboratory-based study did specify that samples used were obtained from patients 
suffering from RTI. The origin of the blood samples for other laboratory studies was either 
primary care or unspecified. The findings of the current systematic review are based on 
samples obtained from patients presenting with a variety of symptoms, rather than the target 
population only (patients presenting with symptoms of acute RTI in primary care). However, 
it is not believed that the origin of the sample would significantly impact measures of accu-
racy or precision, therefore the impact in terms of applicability is considered minimal. 
  
Intervention The intervention of interest was any CE marked C-reactive protein POC quantitative or 
semi-quantitative method designed for use in the primary care setting.  
 
Only two studies evaluated semi-quantitative CRP POCT. Due to this limited data for semi-
quantitative CRP POCT this systematic review cannot draw conclusions on the applicability 
of these devices to the primary care setting.  
 
Ten quantitative devices were evaluated in seventeen studies. These studies provided sub-
stantial data on the quantitative CRP POCT however there was no standardised testing 
method used to evaluate the devices.  
  
Two laboratory based studies compared multiple devices reporting detailed results enabling 
a direct comparison of a number of quantitative CRP POC devices. However as they were 
carried out in a laboratory setting by trained technicians the applicability of the data to use in 
primary care settings is more limited.  
 
Comparators In each study the CRP result recorded by the POCT device was compared to a laboratory 
analyser. Laboratory analysers are currently utilised to measure the level of CRP in blood. 
Most of these analysers were based in a hospital and are a robust comparator against 
which the devices were evaluated. Many of the studies had limited information on the 
comparator, however the studies did state what the comparator was and in general there 
are no concerns regarding the applicability of the evidence in terms of the comparator given 
that in all studies the comparator used was representative of the current standard of care.  
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Domain Description of applicability of evidence 
Outcomes The outcomes of interest for analytical performance of CRP POCT were the accuracy, 
precision and the ease of use. 
 
No standardised assay or universally agreed acceptable levels of accuracy and precision for 
CRP POCT devices exists. For accuracy the POC CRP level was compared to a hospital 
analyser and for precision samples were measured numerous times in a day (within day 
precision) or measured once a day over a number of days (between day precision). 
 
There were three indicators of the accuracy of POCT devices stated in the literature: 
agreement, bias and correlation. The agreement was predominantly reported as the slope of 
a Passing-Bablok regression comparing the POCT device to the reference standard. Bias 
was reported as the mean difference between the POCT device and the reference standard. 
The correlation between the reference standard and result of the POCT device was stated 
as a Spearman or Pearson correlation coefficient. All included studies presented one or 
more of these measures of accuracy. The applicability of the accuracy data depended on 
the setting and the method used for comparison with the reference standard.  
 
Precision was reported as a coefficient of variation (CV). The CV value was calculated by 
testing the same sample multiple times with the aim of obtaining the same result. There was 
no standardised assay for determining precision. Studies differed in the number of samples 
tested, the CRP concentration of the sample, the number of times the sample was meas-
ured and the time period the samples where tested for. These factors ensured that it was 
difficult to directly compare the reported precision. There is no universally acceptable level 
of precision, however, imprecision <10% was generally considered to be acceptable in the 
literature.   
 
The ease of use was reported in studies from the perspective of laboratory technicians and 
healthcare professionals. In some cases a standardised questionnaire was used and in 
others the author had made a comment on ease of use often without any justification around 
their statement. Many components of ease of use are subjective and are likely to be influ-
enced by the users opinions and experience of POC testing and therefore, the reported 
ease of use may not be representative of the users who are likely to use the devices in 
practice.  
 
Setting All studies included in the primary analysis were carried out in primary care or laboratory 
settings. Seventeen studies were conducted in European countries and one in Japan. 
Studies that took place in an emergency department were omitted as the operators in emer-
gency departments may not be representative of healthcare professionals in primary care.  
 
The inclusion criteria were expanded to include laboratory based studies as these studies 
present analytical performance of the devices in an ideal environment where operator error 
is less likely to be a factor. While studies conducted in primary care give us an insight into 
user variability, when the operators are likely to be similar as those who will use the devices 
in practice (Laboratory based studies n=8, Primary care based studies n=5). Four studies 
were part of an external quality assurance programme and tested devices in the laboratory 
and at the point-of-care. One study did not state the setting where the analysis took place. 
 
In the context of this systematic review, the intended user is healthcare staff who are non-
laboratory specialists working in the primary care setting. The inclusion of studies where 
CRP testing was carried out by laboratory specialists in a laboratory setting may reduce the 
applicability of the findings to the primary care setting due to the potential of variation in 
user’s technique and the environment to impact the results of the CRP test.  
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APPENDIX 2: REGULATORY AND REIMBURSEMENT STATUS 
 
Table A16: Regulatory status 
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Quantitative CRP analysers 
QuikR
ead 
go
®
 
CRP 
assay   
and 
QuikR
ead 
go
®
 
instru
ment 
 
 
Valvira, 
Finland 
 
 
 
CE 
mark 
Yes QuikRead go
®
 CRP (Cat.No. 
135171) 
The QuikRead go
®
 CRP test 
is intended for quantitative 
determination of CRP (C-
reactive protein) in whole 
blood, serum and plasma 
using the QuikRead go
®
 
instrument. For in vitro 
diagnostic use only. 
 
 
Diagnostic 
and treat-
ment 
decisions 
must al-
ways be 
made by 
the 
healthcare 
profes-
sional in 
the light of 
all clinical 
infor-
mation on 
the pa-
tient, nev-
er on the 
QuikRead
®
 test 
result 
only. 
2010 
 
 
 
Yes 
 
 
QuikR
ead 
go
®
 
CRP 
assay   
and 
QuikR
ead 
go
®
 
instru
ment 
USA FDA 
 
 QuikRead go
®
 CRP (Cat.No. 
145215) 
The QuikRead go
®
 CRP test 
is an immunoturbidimetric 
assay for the in vitro quanti-
tative determination of C-
reactive protein (CRP) in K2-
EDTA and lithium heparin 
whole blood, K2-EDTA and 
lithium heparin plasma and 
in serum samples. The test 
is carried out by means of 
the QuikRead go
®
 instru-
ment. Measurement of C-
reactive protein aids in the 
evaluation of injury to body 
tissues, and infection and 
inflammatory disorders. The 
instrument and assay are for 
use by trained professionals 
in the clinical laboratory. For 
in vitro diagnostic use only. 
Not for point-of-care use. 
 2016 Yes  
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QuikR
ead 
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CRP+H
b 
assay 
and 
QuikR
ead go 
Instru
ment 
Valvira, 
Finland 
CE 
mark 
 
 QuikRead go
®
 CRP+Hb 
(Cat. No. 140068) 
The QuikRead go
®
 CRP+Hb 
test is intended for quantita-
tive determination of CRP 
(C-reactive protein) in whole 
blood, serum and plasma 
and for quantitative determi-
nation of haemoglobin (Hb) 
in whole blood using the 
QuikRead go
®
 instrument. 
For in vitro diagnostic use 
only. 
 2012 Yes  
QuikR
ead
®
 
CRP 
assay 
and 
QuikR
ead
®
 
101 
Instru
ment 
Valvira, 
Finland 
CE 
mark 
 QuikRead
®
 CRP (Cat. No. 
67961) 
For quantitative determina-
tion of CRP (C-reactive 
protein) in whole blood, 
serum or plasma, using the 
QuikRead
®
 101 Instrument. 
For in vitro diagnostic use. 
 2003 Yes  
QuikR
ead
®
 
CRP 
assay 
and 
QuikR
ead
®
 
101 
Instru
ment 
Valvira, 
Finland 
CE 
mark 
 
 QuikRead
®
 CRP with pre-
filled cuvettes (Cat. No. 
134192) 
For quantitative determina-
tion of CRP (C-reactive 
protein) in whole blood, 
serum or plasma, using the 
QuikRead
®
 101 instrument. 
For in vitro diagnostic use. 
 2003 Yes  
NycoC
ard™ 
CRP 
assay 
and 
NycoC
ard™ 
Reader 
II 
Norway CE 
mark 
Yes NycoCard™ CRP is an in 
vitro diagnostic test for the 
quantitative determination of 
C-reactive protein (CRP) in 
human whole blood and in 
human serum and plasma. 
The measurement of CRP 
provides information for the 
detection and evaluation of 
infection, tissue injury, in-
flammatory disorders and 
associated diseases. 
Not avail-
able 
 Yes  
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Alere 
Afinion
™ CRP 
assay 
and 
Alere 
Afinion
™ 
AS100
*
 
or 
Alere 
Afinion
™ 2
**
 
Analys
er 
Norway CE 
mark 
Yes Alere Afinion™ CRP is an in 
vitro diagnostic test for the 
quantitative determination of 
C-reactive protein (CRP) in 
human whole blood and in 
human serum and plasma. 
The measurement of CRP 
provides information for the 
detection and evaluation of 
infection, tissue injury, in-
flammatory disorders and 
associated diseases. 
 
Not avail-
able 
May 
2005 
Yes Not 
availabl
e 
Euroly
ser 
CRP 
assay 
and  
Cube 
Analys
er 
Austria CE 
mark 
Yes  Not avail-
able 
10-03-
2010 
Yes  
Euroly
ser 
CRP 
assay 
and  
Cube S 
Analys
er 
Austria CE 
mark 
Yes  Not avail-
able 
10-03-
2010 
Yes  
Euroly
ser 
CRP 
assay 
and 
Euroly
ser 
smart 
700/34
0 
Austria CE 
mark 
Yes  Not avail-
able 
04-05-
2008 
Yes  
Euroly
ser 
CRP 
assay 
and 
Euroly
ser 
smart 
700/54
6 
Austria CE 
mark 
Yes The Eurolyser smart (single 
method automated reading 
technology 546 is intended 
to provide a precise, user-
friendly measurement sys-
tem for rapid, direct ascer-
tainment of CRP /hsCRP 
concentrations from whole 
blood and serum, as a true 
point-of-care system. 
Not avail-
able 
10-03-
2010 
Yes  
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iChro
ma™ 
CRP 
test 
car-
tridge 
and 
iChro
ma™ 
Reader 
UK CE 
mark 
Yes Not available  Not avail-
able 
04-11-
2014 
Expiry 
date: 
02/11/2
019 
Yes  
iChro
ma™ 
CRP 
test 
car-
tridge 
and 
iChro
ma™ 
Reader 
US FDA  Yes Not available Not avail-
able 
13-07-
2007 
Yes  
AQT90 
Flex 
CRP 
assay 
and 
AQT90 
Flex™ 
analys
er 
Denma
rk 
CE 
mark 
Yes The AQT90 FLEX analyzer 
is an immunoassay instru-
ment based on the quantita-
tive determination of time-
resolved fluorescence to 
estimate the concentrations 
of clinically relevant markers 
on whole-blood and plasma 
specimens to which a rele-
vant anticoagulant has been 
added. It is intended for use 
in point-of-care and laborato-
ry settings. 
 01-
2008 
Yes  
Micros
emi™ 
CRP 
Reage
nt Unit 
 CE 
mark 
Yes    Yes  
spinit
®
 
CRP 
dispos
able 
disc 
and 
spinit
®
 
instru
ment 
Portug
al 
CE 
mark  
Yes spinit
®
 is a fully automated 
Point-of-Care diagnostics 
solution designed to deliver 
quantitative measurement of 
blood parameters to 
physicians in minutes. spinit
®
 
CRP disposable disk is used 
with the spinit
®
 instrument as 
a quantitative assay for the 
measurement of CRP 
concentration in whole blood 
(venous and capillary), 
serum and plasma samples. 
Not avail-
able 
06-
2016 
Yes Not 
availabl
e 
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This type of assay is used 
for the detection and 
evaluation of infection, tissue 
injuries, inflammatory 
responses and associated 
diseases. 
CRP 
IS™ 
test 
kits 
and 
Innova
star™a
nalyse
r 
 CE 
mark 
Yes   21-07-
2016 
  
Semi-quantitative CRP tests 
Actim
®
 
CRP 
dip 
sticks 
Finlan
d 
CE 
mark  
Yes The Actim
®
 CRP test is a 
visually interpreted, semi 
quantitative immunochroma-
tographic dipstick test, which 
is used for determination 
and monitoring of CRP con-
centrations in whole blood 
samples. The test is intend-
ed for professional use. 
Not avail-
able 
01-06-
2015 
  
Clearte
st
® 
CRP 
strips 
        
FebriD
x
®
 
US CE 
Mark 
 
Yes FebriDx
®
 is a rapid immuno-
assay for the visual, qualita-
tive, in vitro detection of 
elevated levels of both MxA 
and CRP directly from pe-
ripheral whole blood. The 
test measures a clinically 
significant immune response 
to a suspected invasive viral 
and/or bacterial infection in 
patients older than 1 years 
that present within 3 days of 
an acute onset fever (exhib-
ited or reported) and within 7 
days of new onset respirato-
ry symptoms consistent with 
a community-acquired upper 
respiratory infection. 
The FebriDx
®
 test aids in the 
The fol-
lowing 
conditions 
could lead 
to errone-
ous re-
sults: 
● Current 
immuno-
suppres-
sive state 
or use of 
immuno-
suppres-
sive drugs. 
● Current 
use of 
oral anti-
infective 
October 
2014 
Ap-
proval; 
Updat-
ed 
regis-
tration 
July 
2018 
No 
launch 
yet. 
Anticipa
ted 
Europe
an 
launch 
Septem
ber 
2018. 
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clinical identification of pa-
tients with an underlying 
acute respiratory viral infec-
tion from either Influenza 
A/B, Adenovirus, Respiratory 
Syncytial Virus, Metapneu-
movirus, Parainfluenza Vi-
rus, Rhinovirus, Coronavirus, 
Cytomegalovirus, Herpes 
Simplex Virus, and Epstein-
Barr Virus; and/or patients 
with a clinically significant 
immune response consistent 
with an underlying bacterial 
infection. 
The test is intended for pro-
fessional use in an outpa-
tient setting and should be 
used in conjunction with 
other clinical evidence in-
cluding laboratory, radio-
graphic, and epidemiological 
information. 
Negative results do not pre-
clude respiratory infection 
(e.g. rhinovirus, coronavirus) 
and should not be used as 
the sole basis for diagnosis, 
treatment, or other clinical 
and patient management 
decisions. In addition to 
utilizing radiography and 
clinical presentation to aid in 
diagnosis, additional labora-
tory testing (e.g. bacterial 
and viral culture, immunoflu-
orescence, and polymerase 
chain reaction [PCR]) may 
be used to confirm whether 
a specific respiratory patho-
gen exists. 
drugs. 
● Current 
use of 
interferon 
therapy 
(e.g. for 
multiple 
sclerosis, 
HIV, 
hepatitis 
B/C). 
● Live 
viral 
immun-
ization 
within the 
last 14 
days. 
● Major 
trauma, 
major 
surgical 
interven-
tion, and 
severe 
burns 
within the 
preced-
ing 14 
days. 
● Chronic 
fevers 
lasting 
more 
than 7 
days. 
Sources: Dossier submissions from Orion, Abbott, Medix Biochemica and RPS Diagnostics, and available 
information from manufacturers’ websites. 
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Table A17:  Summary of (reimbursement) recommendations in European countries for CRP 
 POCT 
Country  Implementation of CRP 
POCT 
Status of recommendation 
(positive/negative/ongoing/not-
assessed/no detail available) 
If positive, level of 
reimbursement* 
Belgium Yes [99] No details available No details available 
Czech 
Republic
 b
 
Yes[52] No details available No details available 
Denmark 
b
 Yes[131] Positive about DKK 65-77 per 
test 
b
 
Estonia Yes[52, 128] No details available No details available 
Finland Yes[296]  No details available No details available 
Germany 
a,
 
b
 Yes[52] (ambulatory care 
setting only) 
a
  
Positive, also under assessment 
appears to be ambulatory care 
setting only) 
a
 
€1.15 per test 
in general laboratory, 
€4.90 in special 
laboratory 
a
 
Hungary
a b
 Yes Positive (reimbursed regardless of 
test product)
 a
 
No price available 
Ireland No Not assessed Not relevant 
Italy 
a
 Yes (inpatient & 
outpatient settings only)
 a
 
Positive (tests are performed and 
reimbursed in the NHS, but this 
may vary between regions. CRP 
POCT is not reimbursed by the 
NHS in primary care) 
About €3.87/test 
a
 
 
Lithuania
 a
 Yes (inpatient & 
outpatient settings only)
 a 
 
Positive (inpatient and out-patient 
only) 
 
No price available 
Netherlands 
a 
b
 
Yes[52]
 
 Positive (depending on the indica-
tion (e.g. pneumonia))
 a
 
About €3.90/test 
b
 
Norway
 a b
 Yes[52] Positive (CRP tests are reim-
bursed; CRP POCT are the most 
widely used) 
NOK 42/test 
b
 
Poland 
a b
 Yes (primary care, 
ambulatory & hospital 
setting)
a
  
Positive No price available 
Slovakia
 b
 Yes No details available No details available 
Slovenia
 a
 Yes (emergency and 
primary care settings)
 
 
Positive (higher costs for CRP 
POCT than lab test) 
a
 
No details available 
Spain  No details available  No details available  No details available 
Sweden Yes[52] No details available No details available 
Switzerland
 a 
b
 
Yes[52] Positive (regardless of setting; 
fixed price per test)
 a
 
CHF 10 
b
  
United 
Kingdom
 a
 
Yes[42, 44]  Negative (non-mandatory recom-
mendation in guideline) 
No price available 
Abbreviations: CHF – Swiss Franc; DKK – Danish Krone; NHS – National Health Service; NOK – Norwegian Krone. 
Sources: a. Feedback from WP4 partners; b. Dossier submission from Orion on availability of QuikRead
®
 (and price if 
available) in European countries. 
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APPENDIX 3:  CHECKLIST FOR POTENTIAL ETHICAL, ORGANISATIONAL, 
 PATIENT AND SOCIAL AND LEGAL ASPECTS 
 Ethical  
o Does the introduction of the new technology and its potential use/non-use 
instead of the defined, existing comparator(s) give rise to any new ethical issues? 
Yes 
As the skin will be broken to remove a small amount blood, there is a small risk of harm to patient or 
staff from blood borne contamination. 
o Does comparing the new technology to the defined, existing comparators point to 
any differences that may be ethically relevant? 
Yes 
As the skin will be broken to remove a small amount blood, there is a small risk of harm to patient or 
staff from blood borne contamination. 
 Organisational  
o Does the introduction of the new technology and its potential use/non-use 
instead of the defined, existing comparator(s) require organisational changes? 
Yes 
Yes, it requires the use of a test and therefore the time taken to collect the blood sample and run the 
test would need to be incorporated into the care pathway. It is currently unclear who would administer 
the test (GP/practice nurse/ other staff member) and it may differ between practices based on the their 
availability. In either case, use of CRP POCT is likely to prolong the consultation period, even when the 
time take to run the test is short. The reimbursement for the cost of purchasing and administering the 
technology would need to be considered. Those involved in testing with require training in the use of the 
device and the interpretation of the findings. To ensure the accuracy and reliability of testing, all testing 
should be ISO-accreditable, including meeting requirements in relation to internal quality control, quality 
assurance and the recording of training and test results. Careful planning including of a quality 
management system is required to support implementation at a regional or national level. 
o Does comparing the new technology to the defined, existing comparator(s) point 
to any differences that may be organisationally relevant? 
Yes 
Introduction of CRP POCT may lead to changes in the patient care pathway depending on by whom the 
test is administered and who communicates the test results to the patient. Introduction of delayed 
prescriptions for patients with equivocal results may be considered which could represent a change in 
practice. 
 Social  
o Does the introduction of the new technology and its potential use/non-use 
instead of the defined, existing comparator(s) give rise to any new social issues? 
Yes 
Yes, the introduction of CRP POCT could potentially lead to inequality of care for different patient 
groups (e.g. public and private patients) depending on how and for whom the test is reimbursed. 
o Does comparing the new technology to the defined, existing comparator(s) point 
to any differences that may be socially relevant? 
Yes 
Given wide variation between countries in prescribing guidelines, patient access 
and pathways, and cultures, availability of CRP POCT could be used to change 
the conversation between clinician and patient, rather than reduce diagnostic 
uncertainty and subsequent management. Clinicians may already have high 
clinical certainty of diagnosis, the value of the CRP POCT may be around patient 
education rather than just clinician behaviour change 
 
 Legal  
o Does the introduction of the new technology and its potential use/non-use 
instead of the defined, existing comparator(s) give rise to any legal issues? 
No 
o Does comparing the new technology to the defined, existing comparator(s) point 
to any differences that may be legally relevant? 
No 
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For the purpose of transparency, a separate document with comments on the 2
nd
 draft as-
sessment from external experts and the MAH/manufacturer(s) (fact check), as well as re-
sponses from authors, is available on the EUnetHTA website. 
